Patent Publication Number: US-2004054156-A1

Title: Method and reagent for inhibiting hepatitis B viral replication

Description:
[0001] This patent application is a continuation-in-part of Draper et al., U.S. Ser. No. (09/877,478), filed Jun. 8, 2001, entitled “METHOD AND REAGENT FOR INHIBITING HEPATITIS B VIRUS REPLICATION”, which is a continuation-in-part of Draper et al., U.S. Ser. No. (09/696,347), filed Oct. 24, 2000, entitled “METHOD AND REAGENT FOR INHIBITING HEPATITIS B VIRUS REPLICATION”, which is a continuation-in-part of Draper et al., U.S. Ser. No. (09/636,385), filed Aug. 9, 2000, entitled “METHOD AND REAGENT FOR INHIBITING HEPATITIS B VIRUS REPLICATION”, which is a continuation in part of Draper et al., U.S. Ser. No. (09/531,025), filed Mar. 20, 2000, entitled “METHOD AND REAGENT FOR INHIBITING HEPATITIS B VIRUS REPLICATION”, which is a continuation in part of Draper, U.S. Ser. No. (09/436,430), filed Nov. 8, 1999, entitled “METHOD AND REAGENT FOR INHIBITING HEPATITIS B VIRUS REPLICATION”, which is a continuation of U.S. Ser. No. (08/193,627), filed Feb. 7, 1994, now U.S. Pat. No. 6,017,756, which is a continuation of U.S. Ser. No. (07/882,712), filed May 14, 1992, entitled “METHOD AND REAGENT FOR INHIBITING HEPATITIS B VIRUS REPLICATION”, now abandoned. These applications are hereby incorporated by reference herein in their entireties, including the drawings. 
    
    
     
       BACKGROUND OF THE INVENTION  
       [0002] The present invention concerns compounds, compositions, and methods for the study, diagnosis, and treatment of degenerative and disease states related to hepatitis B virus (HBV) replication and gene expression. Specifically, the invention relates to nucleic acid molecules used to inhibit expression of HBV.  
       [0003] The following is a discussion of relevant art pertaining to hepatitis B virus (HBV). The discussion is not meant to be complete and is provided only for understanding of the invention that follows. The summary is not an admission that any of the work described below is prior art to the claimed invention.  
       [0004] Chronic hepatitis B is caused by an enveloped virus, commonly known as the hepatitis B virus or HBV. HBV is transmitted via infected blood or other body fluids, especially saliva and semen, during delivery, sexual activity, or sharing of needles contaminated by infected blood. Individuals may be “carriers” and transmit the infection to others without ever having experienced symptoms of the disease. Persons at highest risk are those with multiple sex partners, those with a history of sexually transmitted diseases, parenteral drug users, infants born to infected mothers, “close” contacts or sexual partners of infected persons, and healthcare personnel or other service employees who have contact with blood. Transmission is also possible via tattooing, ear or body piercing, and acupuncture; the virus is also stable on razors, toothbrushes, baby bottles, eating utensils, and some hospital equipment such as respirators, scopes and instruments. There is no evidence that HBsAg positive food handlers pose a health risk in an occupational setting, nor should they be excluded from work. Hepatitis B has never been documented as being a food-borne disease. The average incubation period is 60 to 90 days, with a range of 45 to 180; the number of days appears to be related to the amount of virus to which the person was exposed. However, determining the length of incubation is difficult, since onset of symptoms is insidious. Approximately 50% of patients develop symptoms of acute hepatitis that last from 1 to 4 weeks. Two percent or less of these individuals develop fulminant hepatitis resulting in liver failure and death.  
       [0005] The determinants of severity include: (1) The size of the dose to which the person was exposed; (2) the person&#39;s age with younger patients experiencing a milder form of the disease; (3) the status of the immune system with those who are immunosuppressed experiencing milder cases; and (4) the presence or absence of co-infection with the Delta virus (hepatitis D), with more severe cases resulting from co-infection. In symptomatic cases, clinical signs include loss of appetite, nausea, vomiting, abdominal pain in the right upper quadrant, arthralgia, and tiredness/loss of energy. Jaundice is not experienced in all cases, however, jaundice is more likely to occur if the infection is due to transfusion or percutaneous serum transfer, and it is accompanied by mild pruritus in some patients. Bilirubin elevations are demonstrated in dark urine and clay-colored stools, and liver enlargement may occur accompanied by right upper-quadrant pain. The acute phase of the disease may be accompanied by severe depression, meningitis, Guillain-Barré syndrome, myelitis, encephalitis, agranulocytosis, and/or thrombocytopenia.  
       [0006] Hepatitis B is generally self-limiting and will resolve in approximately 6 months. Asymptomatic cases can be detected by serologic testing, since the presence of the virus leads to production of large amounts of HBsAg in the blood. This antigen is the first and most useful diagnostic marker for active infections. However, if HBsAg remains positive for 20 weeks or longer, the person is likely to remain positive indefinitely and is now a carrier. While only 10% of persons over age 6 who contract HBV become carriers, 90% of infants infected during the first year of life do so.  
       [0007] Hepatitis B virus (HBV) infects over 300 million people worldwide (Imperial, 1999,  Gastroenterol. Hepatol.,  14 (suppl), S1-5). In the United States approximately 1.25 million individuals are chronic carriers of HBV as evidenced by the fact that they have measurable hepatitis B virus surface antigen HBsAg in their blood. The risk of becoming a chronic HBsAg carrier is dependent upon the mode of acquisition of infection as well as the age of the individual at the time of infection. For those individuals with high levels of viral replication, chronic active hepatitis with progression to cirrhosis, liver failure and hepatocellular carcinoma (HCC) is common, and liver transplantation is the only treatment option for patients with end-stage liver disease from HBV.  
       [0008] The natural progression of chronic HBV infection over a 10 to 20 year period leads to cirrhosis in 20-to-50% of patients and progression of HBV infection to hepatocellular carcinoma has been well documented. There have been no studies that have determined sub-populations that are most likely to progress to cirrhosis and/or hepatocellular carcinoma, thus all patients have equal risk of progression.  
       [0009] It is important to note that the survival for patients diagnosed with hepatocellular carcinoma is only 0.9 to 12.8 months from initial diagnosis (Takahashi et al., 1993,  American Journal of Gastroenterology,  88, 240-243). Treatment of hepatocellular carcinoma with chemotherapeutic agents has not proven effective and only 10% of patients will benefit from surgery due to extensive tumor invasion of the liver (Trinchet et al., 1994, Presse Medicine,  23, 831-833). Given the aggressive nature of primary hepatocellular carcinoma, the only viable treatment alternative to surgery is liver transplantation (Pichlmayr et al., 1994,  Hepatology.,  20, 33S-40S).  
       [0010] Upon progression to cirrhosis, patients with chronic HCV infection present with clinical features, which are common to clinical cirrhosis regardless of the initial cause (D&#39;Amico et al., 1986,  Digestive Diseases and Sciences,  31, 468-475). These clinical features may include: bleeding esophageal varices, ascites, jaundice, and encephalopathy (Zakim D, Boyer TD.  Hepatology a textbook of liver disease,  Second Edition Volume 1. 1990 W. B. Saunders Company. Philadelphia). In the early stages of cirrhosis, patients are classified as compensated, meaning that although liver tissue damage has occurred, the patient&#39;s liver is still able to detoxify metabolites in the blood-stream. In addition, most patients with compensated liver disease are asymptomatic and the minority with symptoms report only minor symptoms such as dyspepsia and weakness. In the later stages of cirrhosis, patients are classified as decompensated meaning that their ability to detoxify metabolites in the bloodstream is diminished and it is at this stage that the clinical features described above will present.  
       [0011] In 1986, D&#39;Amico et al. described the clinical manifestations and survival rates in 1155 patients with both alcoholic and viral associated cirrhosis (D&#39;Amico supra). Of the 1155 patients, 435 (37%) had compensated disease although 70% were asymptomatic at the beginning of the study. The remaining 720 patients (63%) had decompensated liver disease with 78% presenting with a history of ascites, 31% with jaundice, 17% had bleeding and 16% had encephalopathy. Hepatocellular carcinoma was observed in six (0.5%) patients with compensated disease and in 30 (2.6%) patients with decompensated disease.  
       [0012] Over the course of six years, the patients with compensated cirrhosis developed clinical features of decompensated disease at a rate of 10% per year. In most cases, ascites was the first presentation of decompensation. In addition, hepatocellular carcinoma developed in 59 patients who initially presented with compensated disease by the end of the six-year study.  
       [0013] With respect to survival, the D&#39;Amico study indicated that the five-year survival rate for all patients on the study was only 40%. The six-year survival rate for the patients who initially had compensated cirrhosis was 54% while the six-year survival rate for patients who initially presented with decompensated disease was only 21%. There were no significant differences in the survival rates between the patients who had alcoholic cirrhosis and the patients with viral related cirrhosis. The major causes of death for the patients in the D&#39;Amico study were liver failure in 49%; hepatocellular carcinoma in 22%; and, bleeding in 13% (D&#39;Amico supra).  
       [0014] Hepatitis B virus is a double-stranded circular DNA virus. It is a member of the Hepadnaviridae family. The virus consists of a central core that contains a core antigen (HBcAg) surrounded by an envelope containing a surface protein/surface antigen (HBsAg) and is 42 nm in diameter. It also contains an e antigen (HBeAg) which, along with HBcAg and HBsAg, is helpful in identifying this disease  
       [0015] In HBV virions, the genome is found in an incomplete double-stranded form. HBV uses a reverse transcriptase to transcribe a positive-sense full length RNA version of its genome back into DNA. This reverse transcriptase also contains DNA polymerase activity and thus begins replicating the newly synthesized minus-sense DNA strand. However, it appears that the core protein encapsidates the reverse-transcriptase/polymerase before it completes replication.  
       [0016] From the free-floating form, the virus must first attach itself specifically to a host cell membrane. Viral attachment is one of the crucial steps which determines host and tissue specificity. However, currently there are no in vitro cell-lines that can be infected by HBV. There are some cells lines, such as HepG2, which can support viral replication only upon transient or stable transfection using HBV DNA.  
       [0017] After attachment, fusion of the viral envelope and host membrane must occur to allow the viral core proteins containing the genome and polymerase to enter the cell. Once inside, the genome is translocated to the nucleus where it is repaired and cyclized.  
       [0018] The complete closed circular DNA genome of HBV remains in the nucleus and gives rise to four transcripts. These transcripts initiate at unique sites but share the same 3′-ends. The 3.5-kb pregenomic RNA serves as a template for reverse transcription and also encodes the nucleocapsid protein and polymerase. A subclass of this transcript with a 5′-end extension codes for the precore protein that, after processing, is secreted as HBV e antigen. The 2.4-kb RNA encompasses the pre-S1 open reading frame (ORF) that encodes the large surface protein. The 2.1-kb RNA encompasses the pre-S2 and S ORFs that encode the middle and small surface proteins, respectively. The smallest transcript (˜0.8-kb) codes for the X protein, a transcriptional activator.  
       [0019] Multiplication of the HBV genome begins within the nucleus of an infected cell. RNA polymerase II transcribes the circular HBV DNA into greater-than-full length mRNA. Since the mRNA is longer than the actual complete circular DNA, redundant ends are formed. Once produced, the pregenomic RNA exits the nucleus and enters the cytoplasm.  
       [0020] The packaging of pregenomic RNA into core particles is triggered by the binding of the HBV polymerase to the 5′ epsilon stem-loop. RNA encapsidation is believed to occur as soon as binding occurs. The HBV polymerase also appears to require associated core protein in order to function. The HBV polymerase initiates reverse transcription from the 5′ epsilon stem-loop three to four base pairs at which point the polymerase and attached nascent DNA are transferred to the 3′ copy of the DR1 region. Once there, the (−)DNA is extended by the HBV polymerase while the RNA template is degraded by the HBV polymerase RNAse H activity. When the HBV polymerase reaches the 5′ end, a small stretch of RNA is left undigested by the RNAse H activity. This segment of RNA is comprised of a small sequence just upstream and including the DR1 region. The RNA oligomer is then translocated and annealed to the DR2 region at the 5′ end of the (−)DNA. It is used as a primer for the (+)DNA synthesis which is also generated by the HBV polymerase. It appears that the reverse transcription as well as plus strand synthesis may occur in the completed core particle.  
       [0021] Since the pregenomic RNA is required as a template for DNA synthesis, this RNA is an excellent target for enzymatic nucleic acid cleavage. Nucleoside analogues that have been documented to inhibit HBV replication target the reverse transcriptase activity needed to convert the pregenomic RNA into DNA. Enzymatic nucleic acid cleavage of the pregenomic RNA template is expected to result in a similar inhibition of HBV replication. Further, targeting the 3′-end of the pregenomic RNA that is common to all HBV transcripts can result in reduction of all HBV gene products and an additional level of inhibition of HBV replication.  
       [0022] Cell Culture Models  
       [0023] As previously mentioned HBV does not infect cells in culture. However, transfection of HBV DNA (either as a head-to-tail dimer or as an “overlength” genome of &gt;100%) into HuH7 or Hep G2 hepatocytes results in viral gene expression and production of HBV virions released into the media. Thus, HBV replication competent DNA can be co-transfected with enzymatic nucleic acids in cell culture. Such an approach has been used to report intracellular ribozyme activity against HBV (zu Putlitz, et al., 1999,  J. Virol.,  73, 5381-5387, and Kim et al., 1999,  Biochem. Biophys. Res. Commun.,  257, 759-765). In addition, stable hepatocyte cell lines have been generated that express HBV. Enzymatic nucleic acid can be delivered to these cell lines; however, such assays require the performance of a delivery screen.  
       [0024] Phenotypic Assays  
       [0025] Intracellular HBV gene expression can be assayed by a Taqman® assay for HBV RNA or by ELISA for HBV protein. Extracellular virus can be assayed by PCR for DNA or ELISA for protein. Antibodies are commercially available for HBV surface antigen and core protein. A secreted alkaline phosphatase expression plasmid can be used to normalize for differences in transfection efficiency and sample recovery.  
       [0026] Animal Models  
       [0027] There are several small animal models to study HBV replication. One is the transplantation of HBV-infected liver tissue into irradiated mice. Viremia (as evidenced by measuring HBV DNA by PCR) is first detected 8 days after transplantation and peaks between 18-25 days (Ilan et al., 1999,  Hepatology,  29, 553-562).  
       [0028] Transgenic mice that express HBV have also been used as a model to evaluate potential anti-virals. HBV DNA is detectable in both liver and serum (Morrey et al., 1999,  Antiviral Res.,  42, 97-108).  
       [0029] An additional model is to establish subcutaneous tumors in nude mice with Hep G2 cells transfected with HBV. Tumors develop in about 2 weeks after inoculation and express HBV surface and core antigens. HBV DNA and surface antigen is also detected in the circulation of tumor-bearing mice (Yao et al., 1996,  J. Viral Hepat.,  3, 19-22).  
       [0030] Woodchuck hepatitis virus (WHV) is closely related to HBV in its virus structure, genetic organization, and mechanism of replication. As with HBV in humans, persistent WHV infection is common in natural woodchuck populations and is associated with chronic hepatitis and hepatocellular carcinoma (HCC). Experimental studies have established that WHV causes HCC in woodchucks and woodchucks chronically infected with WHV have been used as a model to test a number of anti-viral agents. For example, the nucleoside analogue 3T3 was observed to cause dose dependent reduction in virus (50% reduction after two daily treatments at the highest dose) (Hurwitz et al., 1998.  Antimicrob. Agents Chemother.,  42, 2804-2809).  
       [0031] Therapeutic Approaches  
       [0032] Current therapeutic goals of treatment are three-fold: to eliminate infectivity and transmission of HBV to others, to arrest the progression of liver disease and improve the clinical prognosis, and to prevent the development of hepatocellular carcinoma (HCC).  
       [0033] Interferon alpha use is the most common therapy for HBV; however, recently Lamivudine (3TC®) has been approved by the FDA. Interferon alpha (IFN-alpha) is one treatment for chronic hepatitis B. The standard duration of IFN-alpha therapy is 16 weeks, however, the optimal treatment length is still poorly defined. A complete response (HBV DNA negative HBeAg negative) occurs in approximately 25% of patients. Several factors have been identified that predict a favorable response to therapy including: High ALT, low HBV DNA, being female, and heterosexual orientation.  
       [0034] There is also a risk of reactivation of the hepatitis B virus even after a successful response, this occurs in around 5% of responders and normally occurs within 1 year.  
       [0035] Side effects resulting from treatment with type 1 interferons can be divided into four general categories including: Influenza-like symptoms, neuropsychiatric, laboratory abnormalities, and other miscellaneous side effects. Examples of influenza-like symptoms include, fatigue, fever; myalgia, malaise, appetite loss, tachycardia, rigors, headache and arthralgias. The influenza-like symptoms are usually short-lived and tend to abate after the first four weeks of dosing (Dusheiko et al., 1994,  Journal of Viral Hepatitis,  1, 3-5). Neuropsychiatric side effects include irritability, apathy, mood changes, insomnia, cognitive changes, and depression. Laboratory abnormalities include the reduction of myeloid cells, including granulocytes, platelets and to a lesser extent, red blood cells. These changes in blood cell counts rarely lead to any significant clinical sequellae. In addition, increases in triglyceride concentrations and elevations in serum alaine and aspartate aminotransferase concentration have been observed. Finally, thyroid abnormalities have been reported. These thyroid abnormalities are usually reversible after cessation of interferon therapy and can be controlled with appropriate medication while on therapy. Miscellaneous side effects include nausea, diarrhea, abdominal and back pain, pruritus, alopecia, and rhinorrhea. In general, most side effects will abate after 4 to 8 weeks of therapy (Dushieko et al., supra ).  
       [0036] Lamivudine (3TC®) is a nucleoside analogue, which is a very potent and specific inhibitor of HBV DNA synthesis. Lamivudine has recently been approved for the treatment of chronic Hepatitis B. Unlike treatment with interferon, treatment with 3TC® does not eliminate the HBV from the patient. Rather, viral replication is controlled and chronic administration results in improvements in liver histology in over 50% of patients. Phase III studies with 3TC®, showed that treatment for one year was associated with reduced liver inflammation and a delay in scarring of the liver. In addition, patients treated with Lamivudine (100 mg per day) had a 98 percent reduction in hepatitis B DNA and a significantly higher rate of seroconversion, suggesting disease improvements after completion of therapy. However, stopping of therapy resulted in a reactivation of HBV replication in most patients. In addition recent reports have documented 3TC® resistance in approximately 30% of patients.  
       [0037] Current therapies for treating HBV infection, including interferon and nucleoside analogues, are only partially effective. In addition, drug resistance to nucleoside analogues is now emerging, making treatment of chronic Hepatitis B more difficult. Thus, a need exists for effective treatment of this disease which utilizes antiviral inhibitors which work by mechanisms other than those currently utilized in the treatment of both acute and chronic hepatitis B infections.  
       [0038] Draper, U.S. Pat. No. 6,017,756, describes the use of enzymatic nucleic acids for the inhibition of Hepatitis B Virus.  
       [0039] Passman et al, 2000,  Biochem. Biophys. Res. Commun.,  268(3), 728-733.; Gan et al., 1998,  J. Med. Coll. PLA,  13(3), 157-159.; Li et al., 1999,  Jiefangjun Yixue Zazhi,  24(2), 99-101.; Putlitz et al., 1999,  J. Virol.,  73(7), 5381-5387.; Kim et al., 1999,  Biochem. Biophys. Res. Commun.,  257(3), 759-765.; Xu et al., 1998, Bingdu Xuebao, 14(4), 365-369.; Welch et al., 1997,  Gene Ther.,  4(7), 736-743.; Goldenberg et al, 1997, International PCT publication No. WO 97/08309, Wands et al., 1997,  J. of Gastroenterology and Hepatology,  12(suppl.), S354-S369.; Ruiz et al., 1997,  BioTechniques,  22(2), 338-345.; Gan et al., 1996,  J. Med. Coll. PLA,  11(3), 171-175.; Beck and Nassal, 1995,  Nucleic Acids Res.,  23(24), 4954-62.; Goldenberg, 1995, International PCT publication No. WO 95/22600.; Xu et al., 1993,  Bingdu Xuebao,  9(4), 331-6.; Wang et al., 1993,  Bingdu Xuebao,  9(3), 278-80, all describe ribozymes that are targeted to cleave a specific HBV target site.  
       SUMMARY OF THE INVENTION  
       [0040] This invention relates to enzymatic nucleic acid molecules directed to disrupt the function of RNA species of hepatitis B virus (HBV) and/or encoded by the HBV. In particular, applicant describes the selection and function of enzymatic nucleic acid molecules capable of specifically cleaving HBV RNA. Such enzymatic nucleic acid molecules may be used to treat diseases and disorders associated with HBV infection.  
       [0041] In one embodiment, the invention features an enzymatic nucleic acid molecule that specifically cleaves RNA derived from hepatitis B virus (HBV), wherein the enzymatic nucleic acid molecule comprises sequence defined as Seq. ID No. 6346.  
       [0042] In another embodiment, the invention features a pharmaceutical composition comprising an enzymatic nucleic acid molecule of the invention in a pharmaceutically acceptable carrier.  
       [0043] In another embodiment, the invention features a mammalian cell, for example a human cell, including an enzymatic nucleic acid molecule contemplated by the invention.  
       [0044] In one embodiment, the invention features a method for treatment of cirrhosis, liver failure or hepatocellular carcinoma comprising administering to a patient an enzymatic nucleic acid molecule the invention under conditions suitable for the treatment.  
       [0045] In another embodiment, the invention features a method of treatment of a patient having a condition associated with HBV infection, comprising contacting cells of said patient with an enzymatic nucleic acid molecule of the invention, and further comprising the use of one or more drug therapies, for example type I interferon or 3TC® (lamivudine), under conditions suitable for said treatment. In another embodiment, the other therapy is administered simultaneously with or separately from the enzymatic nucleic acid molecule.  
       [0046] In another embodiment, the invention features a method for inhibiting HBV replication in a mammalian cell comprising administering to the cell an enzymatic nucleic acid molecule of the invention under conditions suitable for the inhibition.  
       [0047] In yet another embodiment, the invention features a method of cleaving a separate RNA molecule comprising, contacting an enzymatic nucleic acid molecule of the invention with the separate RNA molecule under conditions suitable for the cleavage of the separate RNA molecule.  
       [0048] In one embodiment, cleavage by an enzymatic nucleic acid molecule of the invention is carried out in the presence of a divalent cation, for example Mg2+.  
       [0049] In another embodiment, an enzymatic nucleic acid molecule of the invention is chemically synthesized.  
       [0050] In another embodiment, the type I interferon contemplated by the invention is interferon alpha, interferon beta, polyethylene glycol interferon, polyethylene glycol interferon alpha 2a, polyethylene glycol interferon alpha 2b, polyethylene glycol consensus interferon.  
       [0051] In one embodiment, the invention features a pharmaceutical composition comprising type I interferon and an enzymatic nucleic acid molecule of the invention, in a pharmaceutically acceptable carrier.  
       [0052] In another embodiment, the invention features a method of administering to a cell, for example a mammalian cell or human cell, an enzymatic nucleic acid molecule of the invention independently or in conjunction with other therapeutic compounds such as type I interferon or 3TC® (lamivudine), comprising contacting the cell with the enzymatic nucleic acid molecule under conditions suitable for the administration.  
       [0053] In another embodiment, administration of an enzymatic nucleic acid molecule of the invention is in the presence of a delivery reagent, for example a lipid, cationic lipid, phospholipid, or liposome.  
       [0054] In a preferred embodiment, the invention features novel nucleic acid-based techniques such as enzymatic nucleic acid molecules and antisense molecules and methods for their use to down regulate or inhibit the expression of HBV RNA and/or replication of HBV.  
       [0055] In a preferred embodiment, the invention features the use of one or more of the enzymatic nucleic acid-based techniques to inhibit the expression of the genes encoding HBV viral proteins. Specifically, the invention features the use of enzymatic nucleic acid-based techniques to specifically inhibit the expression of the HBV viral genome.  
       [0056] In another preferred embodiment, the invention features nucleic acid-based inhibitors (e.g., enzymatic nucleic acid molecules (ribozymes), antisense nucleic acids, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups) and methods for their use to down regulate or inhibit the expression of RNA (e.g., HBV) capable of progression and/or maintenance of hepatitis, hepatocellular carcinoma, cirrhosis, and/or liver failure.  
       [0057] In one embodiment, nucleic acid molecules of the invention are used to treat HBV infected cells or a HBV infected patient wherein the HBV is resistant or the patient does not respond to treatment with 3TC® (Lamivudine), either alone or in combination with other therapies under conditions suitable for the treatment.  
       [0058] In another embodiment, nucleic acid molecules of the invention are used to treat HBV infected cells or a HBV infected patient wherein the HBV is resistant or the patient does not respond to treatment with Interferon, for example Infergen®, either alone or in combination with other therapies under conditions suitable for the treatment.  
       [0059] In yet another preferred embodiment, the invention features the use of an enzymatic nucleic acid molecule, preferably in the hammerhead, NCH (Inozyme), G-cleaver, amberzyme, zinzyme, and/or DNAzyme motif, to inhibit the expression of HBV RNA.  
       [0060] By “inhibit” it is meant that the activity of HBV or level of RNAs or equivalent RNAs encoding one or more protein subunits of HBV is reduced below that observed in the absence of the nucleic acid. In one embodiment, inhibition with enzymatic nucleic acid molecule preferably is below that level observed in the presence of an enzymatically inactive or attenuated molecule that is able to bind to the same site on the target RNA, but is unable to cleave that RNA. In another embodiment, inhibition with antisense oligonucleotides is preferably below that level observed in the presence, of for example, an oligonucleotide with scrambled sequence or with mismatches. In another embodiment, inhibition of HBV RNA with the nucleic acid molecule of the instant invention is greater than in the presence of the nucleic acid molecule than in its absence.  
       [0061] These enzymatic nucleic acid molecules exhibit a high degree of specificity for only the viral mRNA in infected cells. Nucleic acid molecules of the instant invention targeted to highly conserved sequence regions allow the treatment of many strains of human HBV with a single compound. No treatment presently exists which specifically attacks expression of the viral gene(s) that are responsible for transformation of hepatocytes by HBV.  
       [0062] The methods of this invention can be used to treat human hepatitis B virus infections, which include productive virus infection, latent or persistent virus infection, and HBV-induced hepatocyte transformation. The utility can be extended to other species of HBV which infect non-human animals where such infections are of veterinary importance.  
       [0063] Preferred target sites are genes required for viral replication, a non-limiting example includes genes for protein synthesis, such as the 5′ most 1500 nucleotides of the HBV pregenomic mRNAs. For sequence references, see Renbao et al., 1987,  Sci. Sin.,  30, 507. This region controls the translational expression of the core protein (C), X protein (X) and DNA polymerase (P) genes and plays a role in the replication of the viral DNA by serving as a template for reverse transcriptase. Disruption of this region in the RNA results in deficient protein synthesis as well as incomplete DNA synthesis (and inhibition of transcription from the defective genomes). Target sequences 5′ of the encapsidation site can result in the inclusion of the disrupted 3′ RNA within the core virion structure and targeting sequences 3′ of the encapsidation site can result in the reduction in protein expression from both the 3′ and 5′ fragments.  
       [0064] Alternative regions outside of the 5′ most 1500 nucleotides of the pregenomic mRNA also make suitable targets of enzymatic nucleic acid mediated inhibition of HBV replication. Such targets include the mRNA regions that encode the viral S gene. Selection of particular target regions will depend upon the secondary structure of the pregenomic mRNA. Targets in the minor mRNAs can also be used, especially when folding or accessibility assays in these other RNAs reveal additional target sequences that are unavailable in the pregenomic mRNA species.  
       [0065] A desirable target in the pregenomic RNA is a proposed bipartite stem-loop structure in the 3′-end of the pregenomic RNA which is believed to be critical for viral replication (Kidd and Kidd-Ljunggren, 1996.  Nuc. Acid Res.  24:3295-3302). The 5′ end of the HBV pregenomic RNA carries a cis-acting encapsidation signal, which has inverted repeat sequences that are thought to form a bipartite stem-loop structure. Due to a terminal redundancy in the pregenomic RNA, the putative stem-loop also occurs at the 3′-end. While it is the 5′ copy which functions in polymerase binding and encapsidation, reverse transcription actually begins from the 3′ stem-loop. To start reverse transcription, a 4 nt primer which is covalently attached to the polymerase is made, using a bulge in the 5′ encapsidation signal as template. This primer is then shifted, by an unknown mechanism, to the DR1 primer binding site in the 3′ stem-loop structure, and reverse transcription proceeds from that point. The 3′ stem-loop, and especially the DR1 primer binding site, appear to be highly effective targets for enzymatic nucleic acid intervention.  
       [0066] Sequences of the pregenomic RNA are shared by the mRNAs for surface, core, polymerase, and X proteins. Due to the overlapping nature of the HBV transcripts, all share a common 3′-end. Enzymatic nucleic acid targeting of this common 3′-end will thus cleave the pregenomic RNA as well as all of the mRNAs for surface, core, polymerase and X proteins.  
       [0067] By “enzymatic nucleic acid molecule” it is meant a nucleic acid molecule which has complementarity in a substrate binding region to a specified gene target, and also has an enzymatic activity which is active to specifically cleave target RNA. That is, the enzymatic nucleic acid molecule is able to intermolecularly cleave RNA and thereby inactivate a target RNA molecule. These complementary regions allow sufficient hybridization of the enzymatic nucleic acid molecule to the target RNA and thus permit cleavage. One hundred percent complementarity is preferred, but complementarity as low as 50-75% may also be useful in this invention (see for example Werner and Uhlenbeck, 1995,  Nucleic Acids Research,  23, 2092-2096; Hammann et al., 1999,  Antisense and Nucleic Acid Drug Dev.,  9, 25-31). The nucleic acids may be modified at the base, sugar, and/or phosphate groups. The term enzymatic nucleic acid is used interchangeably with phrases such as ribozymes, catalytic RNA, enzymatic RNA, catalytic DNA, aptazyme or aptamer-binding ribozyme, regulatable ribozyme, catalytic oligonucleotides, nucleozyme, DNAzyme, RNA enzyme, endoribonuclease, endonuclease, minizyme, leadzyme, oligozyme or DNA enzyme. All of these terminologies describe nucleic acid molecules with enzymatic activity. The specific enzymatic nucleic acid molecules described in the instant application are not meant to be limiting and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it have a specific substrate binding site which is complementary to one or more of the target nucleic acid regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart a nucleic acid cleaving activity to the molecule (Cech et al., U.S. Pat. No. 4,987,071; Cech et al., 1988, JAMA 260:20 3030-4).  
       [0068] By “nucleic acid molecule” as used herein is meant a molecule having nucleotides. The nucleic acid can be single, double, or multiple stranded and may comprise modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof.  
       [0069] By “enzymatic portion” or “catalytic domain” is meant that portion/region of the enzymatic nucleic acid molecule essential for cleavage of a nucleic acid substrate (for example see FIGS.  1 - 5 ).  
       [0070] By “substrate binding arm” or “substrate binding domain” is meant that portion/region of an enzymatic nucleic acid which is complementary to (i.e., able to base-pair with) a portion of its substrate. Generally, such complementarity is 100%, but can be less if desired. For example, as few as 10 bases out of 14 may be base-paired (see for example Werner and Uhlenbeck, 1995,  Nucleic Acids Research,  23, 2092-2096; Hammann et al., 1999,  Antisense and Nucleic Acid Drug Dev.,  9, 25-31). Such arms are shown generally in FIGS.  1 - 5 . That is, these arms contain sequences within an enzymatic nucleic acid which are intended to bring enzymatic nucleic acid and target RNA together through complementary base-pairing interactions. The enzymatic nucleic acid of the invention can have binding arms that are contiguous (e.g., representing a single binding arm) or non-contiguous (e.g., representing two or more binding arms) and can be of varying lengths. The length of the binding arm(s) are preferably greater than or equal to four nucleotides and of sufficient length to stably interact with the target RNA; specifically 12-100 nucleotides; more specifically 14-24 nucleotides long (see for example Werner and Uhlenbeck, supra; Hamman et al., supra; Hampel et al., EP0360257; Berzal-Herrance et al., 1993,  EMBO J.,  12, 2567-73). If two binding arms are chosen, the design is such that the length of the binding arms are symmetrical (i.e., each of the binding arms is of the same length; e.g., five and five nucleotides, six and six nucleotides or seven and seven nucleotides long) or asymmetrical (i.e., the binding arms are of different length; e.g., six and three nucleotides; three and six nucleotides long; four and five nucleotides long; four and six nucleotides long; four and seven nucleotides long; and the like).  
       [0071] By “NCH” or “Inozyme” motif is meant, an enzymatic nucleic acid molecule comprising a motif as described in Ludwig et al., U.S. Ser. No. 09/406,643, filed Sep. 27, 1999, entitled “COMPOSITIONS HAVING RNA CLEAVING ACTIVITY”, and International PCT publication Nos. WO 98/58058 and WO 98/58057, all incorporated by reference herein in their entirety, including the drawings.  
       [0072] By “G-cleaver” motif is meant, an enzymatic nucleic acid molecule comprising a motif as described in Eckstein et al., International PCT publication No. WO 99/16871, incorporated by reference herein in its entirety, including the drawings.  
       [0073] By “zinzyme” motif is meant, a class II enzymatic nucleic acid molecule comprising a motif as described in Beigelman et al., International PCT publication No. WO 99/55857, incorporated by reference herein in its entirety, including the drawings.  
       [0074] By “amberzyme” motif is meant, a class I enzymatic nucleic acid molecule comprising a motif as described in Beigelman et al., International PCT publication No. WO 99/55857, incorporated by reference herein in its entirety, including the drawings.  
       [0075] By ‘DNAzyme’ is meant, an enzymatic nucleic acid molecule lacking a ribonucleotide (2′-OH) group or an enzymatic nucleic acid molecule that does not require the presence of a ribonucleotide (2′-OH) group in the molecule for its activity. In particular embodiments, the enzymatic nucleic acid molecule may have an attached linker(s) or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2′-OH groups. A DNAzyme can be synthesized chemically or can be expressed by means of a single stranded DNA vector or equivalent thereof.  
       [0076] By “sufficient length” is meant an oligonucleotide of greater than or equal to 3 nucleotides that is of a length great enough to provide the intended function under the expected condition. For example, for binding arms of enzymatic nucleic acid “sufficient length” means that the binding arm sequence is long enough to provide stable binding to a target site under the expected binding conditions. Preferably, the binding arms are not so long as to prevent useful turnover.  
       [0077] By “stably interact” is meant, interaction of the oligonucleotides with target nucleic acid (e.g., by forming hydrogen bonds with complementary nucleotides in the target under physiological conditions).  
       [0078] By “equivalent” RNA to HBV is meant to include those naturally occurring RNA molecules having homology (partial or complete) to HBV proteins or encoding for proteins with similar function as HBV in various organisms, including human, rodent, primate, rabbit, pig, protozoans, fungi, plants, and other microorganisms and parasites. The equivalent RNA sequence also includes in addition to the coding region, regions such as 5′-untranslated region, 3′-untranslated region, introns, intron-exon junction and the like.  
       [0079] By “homology” is meant the nucleotide sequence of two or more nucleic acid molecules is partially or completely identical.  
       [0080] By “antisense nucleic acid”, it is meant a non-enzymatic nucleic acid molecule that binds to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al., 1993  Nature  365, 566) interactions and alters the activity of the target RNA (for a review, see Stein and Cheng, 1993  Science  261, 1004 and Woolf et al, U.S. Pat. No. 5,849,902). Typically, antisense molecules will be complementary to a target sequence along a single contiguous sequence of the antisense molecule. However, in certain embodiments, an antisense molecule may bind to substrate such that the substrate molecule forms a loop, and/or an antisense molecule may bind such that the antisense molecule forms a loop. Thus, the antisense molecule may be complementary to two (or even more) non-contiguous substrate sequences or two (or even more) non-contiguous sequence portions of an antisense molecule may be complementary to a target sequence or both. For a review of current antisense strategies, see Schmajuk et al., 1999,  J. Biol. Chem.,  274, 21783-21789, Delihas et al., 1997,  Nature,  15, 751-753, Stein et al., 1997,  Antisense N. A. Drug Dev.,  7, 151, Crooke, 1998,  Biotech. Genet. Eng. Rev.,  15, 121-157, Crooke, 1997,  Ad. Pharmacol.,  40, 1-49. In addition, antisense DNA can be used to target RNA by means of DNA-RNA interactions, thereby activating RNase H, which digests the target RNA in the duplex. The antisense oligonucleotides can comprise one or more RNAse H activating region, which is capable of activating RNAse H cleavage of a target RNA. Antisense DNA can be synthesized chemically or expressed via the use of a single stranded DNA expression vector or equivalent thereof.  
       [0081] By “RNase H activating region” is meant a region (generally greater than or equal to 4-25 nucleotides in length, preferably from 5-11 nucleotides in length) of a nucleic acid molecule capable of binding to a target RNA to form a non-covalent complex that is recognized by cellular RNase H enzyme (see for example Arrow et al., U.S. Pat. No. 5,849,902; Arrow et al., U.S. Pat. No. 5,989,912). The RNase H enzyme binds to the nucleic acid molecule-target RNA complex and cleaves the target RNA sequence. The RNase H activating region comprises, for example, phosphodiester, phosphorothioate (preferably at least four of the nucleotides are phosphorothiote substitutions; more specifically, 4-11 of the nucleotides are phosphorothiote substitutions); phosphorodithioate, 5′-thiophosphate, or methylphosphonate backbone chemistry or a combination thereof. In addition to one or more backbone chemistries described above, the RNase H activating region can also comprise a variety of sugar chemistries. For example, the RNase H activating region can comprise deoxyribose, arabino, fluoroarabino or a combination thereof, nucleotide sugar chemistry. Those skilled in the art will recognize that the foregoing are non-limiting examples and that any combination of phosphate, sugar and base chemistry of a nucleic acid that supports the activity of RNase H enzyme is within the scope of the definition of the RNase H activating region and the instant invention.  
       [0082] By “2-5A antisense chimera” it is meant, an antisense oligonucleotide containing a 5′-phosphorylated 2′-5′-linked adenylate residue. These chimeras bind to target RNA in a sequence-specific manner and activate a cellular 2-5A-dependent ribonuclease which, in turn, cleaves the target RNA (Torrence et al, 1993  Proc. Natl. Acad. Sci. USA  90, 1300).  
       [0083] By “triplex DNA” it is meant an oligonucleotide that can bind to a double-stranded DNA in a sequence-specific manner to form a triple-strand helix. Formation of such triple helix structure has been shown to inhibit transcription of the targeted gene (Duval-Valentin et al., 1992,  Proc. Natl. Acad. Sci. USA,  89, 504).  
       [0084] By “gene” it is meant a nucleic acid that encodes an RNA.  
       [0085] By “complementarity” is meant that a nucleic acid can form hydrogen bond(s) with another RNA sequence by either traditional Watson-Crick or other non-traditional types. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its target or complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., enzymatic nucleic acid cleavage, antisense or triple helix inhibition. Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner et al., 1987,  CSH Symp. Quant. Biol.  LII pp.123-133; Frier et al., 1986,  Proc. Nat. Acad. Sci. USA  83:9373-9377; Turner et al., 1987,  J. Am. Chem. Soc.  109:3783-3785). A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). “Perfectly complementary” means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.  
       [0086] At least seven basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds in trans (and thus can cleave other RNA molecules) under physiological conditions. Table I summarizes some of the characteristics of these enzymatic nucleic acids. In general, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets. Thus, a single enzymatic nucleic acid molecule is able to cleave many molecules of target RNA. In addition, the enzymatic nucleic acid is a highly specific inhibitor of gene expression, with the specificity of inhibition depending not only on the base-pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a enzymatic nucleic acid.  
       [0087] The enzymatic nucleic acid molecule that cleave the specified sites in HBV-specific RNAs represent a novel therapeutic approach to treat a variety of pathologic indications, including, HBV infection, hepatitis, hepatocellular carcinoma, tumorigenesis, cirrhosis, liver failure and others.  
       [0088] In one of the preferred embodiments of the inventions described herein, the enzymatic nucleic acid molecule is formed in a hammerhead or hairpin motif, but may also be formed in the motif of a hepatitis delta virus, group I intron, group II intron or RNase P RNA (in association with an RNA guide sequence), Neurospora VS RNA, DNAzymes, NCH cleaving motifs, or G-cleavers. Examples of such hammerhead motifs are described by Dreyfus, supra, Rossi et al., 1992,  AIDS Research and Human Retroviruses  8, 183. Examples of hairpin motifs are described by Hampel et al., EP0360257, Hampel and Tritz, 1989  Biochemistry  28, 4929, Feldstein et al., 1989,  Gene  82, 53, Haseloff and Gerlach, 1989,  Gene,  82, 43, Hampel et al., 1990  Nucleic Acids Res.  18, 299; and Chowrira &amp; McSwiggen, U.S. Pat. No. 5,631,359. The hepatitis delta virus motif is described by Perrotta and Been, 1992  Biochemistry  31, 16. The RNase P motif is described by Guerrier-Takada et al., 1983  Cell  35, 849; Forster and Altman, 1990,  Science  249, 783; and Li and Altman, 1996,  Nucleic Acids Res.  24, 835. The Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, 1990  Cell  61, 685-696; Saville and Collins, 1991  Proc. Natl. Acad. Sci. USA  88, 8826-8830; Collins and Olive, 1993  Biochemistry  32, 2795-2799; and Guo and Collins, 1995,  EMBO. J.  14, 363). Group II introns are described by Griffin et al., 1995,  Chem. Biol.  2, 761; Michels and Pyle, 1995,  Biochemistry  34, 2965; and Pyle et al., International PCT Publication No. WO 96/22689. The Group I intron is described by Cech et al., U.S. Pat. No. 4,987,071. DNAzymes are described by Usman et al., International PCT Publication No. WO 95/11304; Chartrand et al., 1995,  NAR  23, 4092; Breaker et al., 1995,  Chem. Bio.  2, 655; and Santoro et al., 1997,  PNAS  94, 4262. NCH cleaving motifs are described in Ludwig &amp; Sproat, International PCT Publication No. WO 98/58058; and G-cleavers are described in Kore et al., 1998,  Nucleic Acids Research  26, 4116-4120 and Eckstein et al., International PCT Publication No. WO 99/16871. Additional motifs include the Aptazyme (Breaker et al., WO 98/43993), Amberzyme (Class I motif; FIG. 3; Beigelman et al., International PCT publication No. WO 99/55857) and Zinzyme (Beigelman et al., International PCT publication No. WO 99/55857), all these references are incorporated by reference herein in their totalities, including drawings and can also be used in the present invention. These specific motifs are not limiting in the invention. and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule (Cech et al., U.S. Pat. No. 4,987,071).  
       [0089] In preferred embodiments of the present invention, a nucleic acid molecule, e.g., an antisense molecule, a triplex DNA, or an enzymatic nucleic acid, is 13 to 100 nucleotides in length, e.g., in specific embodiments 35, 36, 37, or 38 nucleotides in length (e.g., for particular enzymatic nucleic acids or antisense). In particular embodiments, the nucleic acid molecule is 15-100, 17-100, 20-100, 21-100, 23-100, 25-100, 27-100, 30-100, 32-100, 35-100, 40-100, 50-100, 60-100, 70-100, or 80-100 nucleotides in length. Instead of 100 nucleotides being the upper limit on the length ranges specified above, the upper limit of the length range can be, for example, 30, 40, 50, 60, 70, or 80 nucleotides. Thus, for any of the length ranges, the length range for particular embodiments has lower limit as specified, with an upper limit as specified which is greater than the lower limit. For example, in a particular embodiment, the length range can be 35-50 nucleotides in length. All such ranges are expressly included. Also in particular embodiments, a nucleic acid molecule can have a length which is any of the lengths specified above, for example, 21 nucleotides in length.  
       [0090] Exemplary enzymatic nucleic acid molecules of the invention are shown in Tables V-XI. For example, enzymatic nucleic acid molecules of the invention are preferably between 15 and 50 nucleotides in length, more preferably between 25 and 40 nucleotides in length, e.g., 34, 36, or 38 nucleotides in length (for example see Jarvis et al., 1996,  J. Biol. Chem.,  271, 29107-29112). Exemplary DNAzymes of the invention are preferably between 15 and 40 nucleotides in length, more preferably between 25 and 35 nucleotides in length, e.g., 29, 30, 31, or 32 nucleotides in length (see for example Santoro et al., 1998,  Biochemistry,  37, 13330-13342; Chartrand et al., 1995, Nucleic Acids Research, 23, 4092-4096). Exemplary antisense molecules of the invention are preferably between 15 and 75 nucleotides in length, more preferably between 20 and 35 nucleotides in length, e.g., 25, 26, 27, or 28 nucleotides in length (see for example Woolf et al., 1992,  PNAS.,  89, 7305-7309; Milner et al., 1997,  Nature Biotechnology,  15, 537-541). Exemplary triplex forming oligonucleotide molecules of the invention are preferably between 10 and 40 nucleotides in length, more preferably between 12 and 25 nucleotides in length, e.g., 18, 19, 20, or 21 nucleotides in length (see for example Maher et al., 1990,  Biochemistry,  29, 8820-8826; Strobel and Dervan, 1990,  Science,  249, 73-75). Those skilled in the art will recognize that all that is required is for the nucleic acid molecule are of length and conformation sufficient and suitable for the nucleic acid molecule to catalyze a reaction contemplated herein. The length of the nucleic acid molecules of the instant invention are not limiting within the general limits stated.  
       [0091] In a preferred embodiment, the invention provides a method for producing a class of nucleic acid-based gene inhibiting agents which exhibit a high degree of specificity for the RNA of a desired target. For example, the enzymatic nucleic acid molecule is preferably targeted to a highly conserved sequence region of target RNAs encoding HBV proteins (specifically HBV RNA) such that specific treatment of a disease or condition can be provided with either one or several nucleic acid molecules of the invention. Such nucleic acid molecules can be delivered exogenously to specific tissue or cellular targets as required. Alternatively, the nucleic acid molecules (e.g., enzymatic nucleic acids and antisense) can be expressed from DNA and/or RNA vectors that are delivered to specific cells.  
       [0092] As used in herein “cell” is used in its usual biological sense, and does not refer to an entire multicellular organism, e.g., specifically does not refer to a human. The cell may be present in an organism which may be a human but is preferably a non-human multicellular organism, e.g., birds, plants and mammals such as cows, sheep, apes, monkeys, swine, dogs, and cats. The cell may be prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian or plant cell).  
       [0093] By “HBV proteins” is meant, a protein or a mutant protein derivative thereof, comprising sequence expressed and/or encoded by the HBV genome.  
       [0094] By “highly conserved sequence region” is meant a nucleotide sequence of one or more regions in a target gene does not vary significantly from one generation to the other or from one biological system to the other.  
       [0095] The enzymatic nucleic acid-based inhibitors of HBV expression are useful for the prevention of the diseases and conditions including HBV infection, hepatitis, cancer, cirrhosis, liver failure, and any other diseases or conditions that are related to the levels of HBV in a cell or tissue.  
       [0096] By “related” is meant that the reduction of HBV expression (specifically HBV gene) RNA levels and thus reduction in the level of the respective protein will relieve, to some extent, the symptoms of the disease or condition.  
       [0097] The nucleic acid-based inhibitors of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues ex vivo, or in vivo through injection, infusion pump or stent, with or without their incorporation in biopolymers. In preferred embodiments, the enzymatic nucleic acid inhibitors comprise sequences, which are complementary to the substrate sequences in Tables IV to XI. Examples of such enzymatic nucleic acid molecules also are shown in Tables V to XI. Examples of such enzymatic nucleic acid molecules consist essentially of sequences defined in these tables.  
       [0098] In yet another embodiment, the invention features antisense nucleic acid molecules including sequences complementary to the substrate sequences shown in Tables IV to XI. Such nucleic acid molecules can include sequences as shown for the binding arms of the enzymatic nucleic acid molecules in Tables V to XI. Similarly, triplex molecules can be provided targeted to the corresponding DNA target regions, and containing the DNA equivalent of a target sequence or a sequence complementary to the specified target (substrate) sequence. Typically, antisense molecules will be complementary to a target sequence along a single contiguous sequence of the antisense molecule. However, in certain embodiments, an antisense molecule may bind to substrate such that the substrate molecule forms a loop, and/or an antisense molecule may bind such that the antisense molecule forms a loop. Thus, the antisense molecule may be complementary to two (or even more) non-contiguous substrate sequences or two (or even more) non-contiguous sequence portions of an antisense molecule may be complementary to a target sequence or both.  
       [0099] In another aspect, the invention provides mammalian cells containing one or more nucleic acid molecules and/or expression vectors of this invention. The one or more nucleic acid molecules may independently be targeted to the same or different sites.  
       [0100] By “consists essentially of” is meant that the active nucleic acid molecule of the invention, for example, an enzymatic nucleic acid molecule, contains an enzymatic center or core equivalent to those in the examples, and binding arms able to bind RNA such that cleavage at the target site occurs. Other sequences can be present which do not interfere with such cleavage. Thus, a core region can, for example, include one or more loop, stem-loop structure, or linker which does not prevent enzymatic activity. Thus, the underlined regions in the sequences in Tables V and VI can be such a loop, stem-loop, nucleotide linker, and/or non-nucleotide linker and can be represented generally as sequence “X”. For example, a core sequence for a hammerhead enzymatic nucleic acid can comprise a conserved sequence, such as 5′-CUGAUGAG-3′ and 5′-CGAA-3′ connected by “X”, where X is 5′- GCCGUUAGGC -3′ (SEQ ID NO 6586), or any other Stem II region known in the art, or a nucleotide and/or non-nucleotide linker. Similarly, for other nucleic acid molecules of the instant invention, such as Inozyme, G-cleaver, amberzyme, zinzyme, DNAzyme, antisense, 2-5A antisense, triplex forming nucleic acid, and decoy nucleic acids, other sequences or non-nucleotide linkers can be present that do not interfere with the function of the nucleic acid molecule.  
       [0101] In another aspect of the invention, enzymatic nucleic acids or antisense molecules that interact with target RNA molecules and inhibit HBV (specifically HBV RNA) activity are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Enzymatic nucleic acid or antisense expressing viral vectors could be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the enzymatic nucleic acids or antisense are delivered as described above, and persist in target cells. Alternatively, viral vectors may be used that provide for transient expression of enzymatic nucleic acids or antisense. Such vectors might be repeatedly administered as necessary. Once expressed, the enzymatic nucleic acids or antisense bind to the target RNA and inhibit its function or expression. Delivery of enzymatic nucleic acid or antisense expressing vectors could be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell. Antisense DNA can be expressed via the use of a single stranded DNA intracellular expression vector.  
       [0102] By RNA is meant a molecule comprising at least one ribonucleotide residue. By “ribonucleotide” is meant a nucleotide with a hydroxyl group at the 2′ position of a β-D-ribofuranose moiety.  
       [0103] By “vectors” is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid.  
       [0104] By “patient” is meant an organism, which is a donor or recipient of explanted cells or the cells themselves. “Patient” also refers to an organism to which the nucleic acid molecules of the invention can be administered. Preferably, a patient is a mammal or mammalian cells. More preferably, a patient is a human or human cells.  
       [0105] The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed above. For example, to treat a disease or condition associated with HBV, the patient may be treated, or other appropriate cells may be treated, as is evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable for the treatment.  
       [0106] In a further embodiment, the described molecules, such as antisense or enzymatic nucleic acids, can be used in combination with other known treatments to treat conditions or diseases discussed above. For example, the described molecules could be used in combination with one or more known therapeutic agents to treat HBV infection, hepatitis, hepatocellular carcinoma, cancer, cirrhosis, and liver failure. Such therapeutic agents may include, but are not limited to nucleoside analogs selected from the group comprising Lamivudine (3TC®), L-FMAU, and/or adefovir dipivoxil (for a review of applicable nucleoside analogs, see Colacino and Staschke, 1998,  Progress in Drug Research,  50, 259-322). Immunomodulators selected from the group comprising Type 1 Interferon, Therapeutic vaccines, steriods, and 2′-5′ oligoadenylates (for a review of 2′-5′ Oligoadenylates, see Charubala and Pfleiderer, 1994,  Progress in Molecular and Subcellular Biology,  14, 113-138).  
       [0107] In another preferred embodiment, the invention features nucleic acid-based inhibitors (e.g., enzymatic nucleic acid molecules (ribozymes), antisense nucleic acids, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups) and methods for their use to down regulate or inhibit the expression of RNA (e.g., HBV) capable of progression and/or maintenance of liver disease and failure.  
       [0108] In another preferred embodiment, the invention features nucleic acid-based techniques (e.g., enzymatic nucleic acid molecules (ribozymes), antisense nucleic acids, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups) and methods for their use to down regulate or inhibit the expression of HBV RNA expression.  
       [0109] In preferred embodiments, the invention features a method for the analysis of HBV proteins. This method is useful in determining the efficacy of HBV inhibitors. Specifically, the instant invention features an assay for the analysis of HBsAg proteins and secreted alkaline phosphatase (SEAP) control proteins to determine the efficacy of agents used to modulate HBV expression.  
       [0110] The method consists of coating a micro-titer plate with an antibody such as anti-HBsAg Mab (for example, Biostride B88-95-31ad,ay) at 0.1 to 10 μg/ml in a buffer (for example, carbonate buffer, such as Na 2 CO 3  15 mM, NaHCO 3  35 mM, pH 9.5) at 4° C. overnight. The microtiter wells are then washed with PBST or the equivalent thereof, (for example, PBS, 0.05% Tween 20) and blocked for 0.1-24 hr at 37° C. with PBST, 1% BSA or the equivalent thereof. Following washing as above, the wells are dried (for example, at 37° C. for 30 min). Biotinylated goat anti-HBsAg or an equivalent antibody (for example, Accurate YVS1807) is diluted (for example at 1:1000) in PBST and incubated in the wells (for example, 1 hr. at 37° C.). The wells are washed with PBST (for example, 4×). A conjugate, (for example, Streptavidin/Alkaline Phosphatase Conjugate, Pierce 21324) is diluted to 10-10,000 ng/ml in PBST, and incubated in the wells (for example, 1 hr. at 37° C.). After washing as above, a substrate (for example, p-nitrophenyl phosphate substrate, Pierce 37620) is added to the wells, which are then incubated (for example, 1 hr. at 37° C.). The optical density is then determined (for example, at 405 nm). SEAP levels are then assayed, for example, using the Great EscAPe® Detection Kit (Clontech K2041-1), as per the manufacturers instructions. In the above example, incubation times and reagent concentrations may be varied to achieve optimum results, a non-limiting example is described in Example 6.  
       [0111] Comparison of this HBsAg ELISA method to a commercially available assay from World Diagnostics, Inc. 15271 NW 60 th  Ave, #201, Miami Lakes, Fla. 33014 (305) 827-3304 (Cat. No. EL10018) demonstrates an increase in sensitivity (signal:noise) of 3-20 fold.  
       [0112] Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.  
       BRIEF DESCRIPTION OF THE DRAWINGS  
       [0113]FIG. 1 shows the secondary structure model for seven different classes of enzymatic nucleic acid molecules. Arrow indicates the site of cleavage. --------- indicate the target sequence. Lines interspersed with dots are meant to indicate tertiary interactions. - is meant to indicate base-paired interaction. Group I Intron: P1-P9.0 represent various stem-loop structures (Cech et al., 1994,  Nature Struc. Bio.,  1, 273). RNase P (M1RNA): EGS represents external guide sequence (Forster et al., 1990,  Science,  249, 783; Pace et al., 1990,  J. Biol. Chem.,  265, 3587). Group II Intron: 5′SS means 5′ splice site; 3′SS means 3′-splice site; IBS means intron binding site; EBS means exon binding site (Pyle et al., 1994,  Biochemistry,  33, 2716). VS RNA: I-VI are meant to indicate six stem-loop structures; shaded regions are meant to indicate tertiary interaction (Collins, International PCT Publication No. WO 96/19577). HDV Ribozyme: I-IV are meant to indicate four stem-loop structures (Been et al, U.S. Pat. No. 5,625,047). Hammerhead Ribozyme: I-III are meant to indicate three stem-loop structures; stems I-III can be of any length and may be symmetrical or asymmetrical (Usman et al., 1996,  Curr. Op. Struct. Bio.,  1, 527). Hairpin Ribozyme: Helix 1, 4 and 5 can be of any length; Helix 2 is between 3 and 8 base-pairs long; Y is a pyrimidine; Helix 2 (H2) is provided with a least 4 base pairs (i.e., n is 1, 2, 3 or 4) and helix 5 can be optionally provided of length 2 or more bases (preferably 3-20 bases, i.e., m is from 1-20 or more). Helix 2 and helix 5 may be covalently linked by one or more bases (i.e., r is ≧1 base). Helix 1, 4 or 5 may also be extended by 2 or more base pairs (e.g., 4-20 base pairs) to stabilize the ribozyme structure, and preferably is a protein binding site. In each instance, each N and N′ independently is any normal or modified base and each dash represents a potential base-pairing interaction. These nucleotides may be modified at the sugar, base or phosphate. Complete base-pairing is not required in the helices, but is preferred. Helix 1 and 4 can be of any size (i.e., o and p is each independently from 0 to any number, e.g., 20) as long as some base-pairing is maintained. Essential bases are shown as specific bases in the structure, but those in the art will recognize that one or more may be modified chemically (abasic, base, sugar and/or phosphate modifications) or replaced with another base without significant effect. Helix 4 can be formed from two separate molecules, i.e., without a connecting loop. The connecting loop when present may be a ribonucleotide with or without modifications to its base, sugar or phosphate. “q”≧is 2 bases. The connecting loop can also be replaced with a non-nucleotide linker molecule. H refers to bases A, U, or C. Y refers to pyrimidine bases. “ ————— ” refers to a covalent bond. (Burke et al., 1996,  Nucleic Acids  &amp;  Mol. Biol.,  10, 129; Chowrira et al., U.S. Pat. No. 5,631,359).  
       [0114]FIG. 2 shows examples of chemically stabilized enzymatic nucleic acid motifs. HH Rz, represents hammerhead ribozyme motif (Usman et al., 1996,  Curr. Op. Struct. Bio.,  1, 527); NCH Rz represents the NCH ribozyme motif (Ludwig &amp; Sproat, International PCT Publication No. WO 98/58058); G-Cleaver, represents G-cleaver ribozyme motif (Kore et al., 1998,  Nucleic Acids Research,  26, 4116-4120). N or n, represent independently a nucleotide which may be same or different and have complementarity to each other; rI, represents ribo-Inosine nucleotide; arrow indicates the site of cleavage within the target. Position 4 of the HH Rz and the NCH Rz is shown as having 2′-C-allyl modification, but those skilled in the art will recognize that this position can be modified with other modifications well known in the art, so long as such modifications do not significantly inhibit the activity of the ribozyme.  
       [0115]FIG. 3 shows an example of the Amberzyme enzymatic nucleic acid motif that is chemically stabilized (see, for example, Beigelman et al., International PCT publication No. WO 99/55857; also referred to as Class I Motif). The Amberzyme motif is a class of enzymatic nucleic acid molecules that do not require the presence of a ribonucleotide (2′-OH) group for activity.  
       [0116]FIG. 4 shows an example of the Zinzyme A enzymatic nucleic acid motif that is chemically stabilized (see, for example, International PCT publication No. WO 99/55857; also referred to as Class A Motif). The Zinzyme motif is a class of enzymatic nucleic acid molecules that do not require the presence of a ribonucleotide (2′-OH) group for activity.  
       [0117]FIG. 5 shows an example of a DNAzyme motif described by Santoro et al., 1997,  PNAS,  94, 4262.  
       [0118]FIG. 6 is a bar graph showing the percent change in serum HBV DNA levels following fourteen days of enzymatic nucleic acid treatment in HBV transgenic mice. Enzymatic nucleic acids targeting sites 273 (RPI.18341) and 1833 (RPI.18371) of HBV RNA administerd via continuous s.c. infusion at 10, 30, and 100 mg/kg/day are compared to continuous s.c. infusion administration of scrambled attenuated core enzymatic nucleic acid and saline controls, and orally administered 3TC® (300 mg/kg/day) and saline controls.  
       [0119]FIG. 7 is a bar graph showing the mean serum HBV DNA levels following fourteen days of enzymatic nucleic acid treatment in HBV transgenic mice. Enzymatic nucleic acids targeting sites 273 (RPI.18341) and 1833 (RPI.18371) of HBV RNA administerd via continuous s.c. infusion at 10, 30, and 100 mg/kg/day are compared to continuous s.c. infusion administration of scrambled attenuated core enzymatic nucleic acid and saline controls, and orally administered 3TC® (300 mg/kg/day) and saline controls.  
       [0120]FIG. 8 is a bar graph showing the decrease in serum HBV DNA (log) levels following fourteen days of enzymatic nucleic acid treatment in HBV transgenic mice. Enzymatic nucleic acids targeting sites 273 (RPI.18341) and 1833 (RPI.18371) of HBV RNA administerd via continuous s.c. infusion at 10, 30, and 100 mg/kg/day are compared to continuous s.c. infusion administration of scrambled attenuated core enzymatic nucleic acid and saline controls, and orally administered 3TC® (300 mg/kg/day) and saline controls.  
       [0121]FIG. 9 is a bar graph showing the decrease in HBV DNA in HepG2.2.15 cells after treatment with enzymatic nucleic acids targeting sites 273 (RPI.18341), 1833 (RPI.18371), 1874 (RPI.18372), and 1873 (RPI.18418) of HBV RNA as compared to a scrambled attenuated core enzymatic nucleic acid (RPI.20995).  
       [0122]FIG. 10 is a bar graph showing reduction in HBsAg levels following treatment of HepG2 cells with anti-HBV arm, stem, and loop-variant enzymatic nucleic acids (RPI.18341, RPI.22644, RPI.22645, RPI.22646, RPI.22647, RPI.22648, RPI.22649, and RPI.22650) targeting site 273 of the HBV pregenomic RNA as compared to a scrambled attenuated core enzymatic nucleic acid (RPI.20599).  
       [0123]FIG. 11 is a bar graph showing reduction in HBsAg levels following treatment of HepG2 cells with RPI 18341 alone or in combination with Infergen®. At either 500 or 1000 units of Infergen®, the addition of 200 nM of RPI.18341 results in a 75-77% increase in anti-HBV activity as judged by the level of HBsAg secreted from the treated Hep G2 cells. Conversely, the anti-HBV activity of RPI.18341(at 200 nM) is increased 31-39% when used in combination of 500 or 1000 units of Infergen®.  
       [0124]FIG. 12 is a bar graph showing reduction in HBsAg levels following treatment of HepG2 cells with RPI 18341 alone or in combination with Lamivudine. At 25 nM Lamivudine (3TC®), the addition of 100 nM of RPI.18341 results in a 48% increase in anti-HBV activity as judged by the level of HBsAg secreted from treated Hep G2 cells. Conversely, the anti-HBV activity of RPI.18341 (at 100 nM) is increased 31% when used in combination with 25 nM Lamivudine.  
       [0125]FIG. 13 is a bar graph showing reduction of HBsAg levels following treatment of HepG2 cells with RPI 18341 (at 125 nM) in HepG2 cells expressing wild-type HBV and HepG2-DM2 cells expressing lamividine resistant HBV.  
       [0126]FIG. 14 shows a non-limiting example of an enzymatic nucleic acid molecule of the invention lacking ribonucleotides. FIG. 15 shows a bar graph comparing the activity of a “no-ribo” enzymatic nucleic acid molecule (RPI 25516) to matched binding attenuated (BAC, RPI 25535) and scrambled attenuated (SAC, RPI 25536) controls, and to an enzymatic nucleic acid molecule having 5 ribonucleotides (RPI 18341) and its matched scrambed attenuated control (RPI 24588) in a HBsAg assay. The concentration of all nucleic acid molecules is 200 nM. 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION  
     [0127] Mechanism of Action of Nucleic Acid Molecules of the Invention  
     [0128] Antisense: Antisense molecules may be modified or unmodified RNA, DNA, or mixed polymer oligonucleotides and primarily function by specifically binding to matching sequences resulting in inhibition of peptide synthesis (Wu-Pong, November 1994,  BioPharm,  20-33). The antisense oligonucleotide binds to target RNA by Watson Crick base-pairing and blocks gene expression by preventing ribosomal translation of the bound sequences either by steric blocking or by activating RNase H enzyme. Antisense molecules may also alter protein synthesis by interfering with RNA processing or transport from the nucleus into the cytoplasm (Mukhopadhyay &amp; Roth, 1996,  Crit. Rev. in Oncogenesis  7, 151-190).  
     [0129] In addition, binding of single stranded DNA to RNA may result in nuclease degradation of the heteroduplex (Wu-Pong, supra; Crooke, supra). To date, the only backbone modified DNA chemistry which will act as substrates for RNase H are phosphorothioates, phosphorodithioates, and borontrifluoridates. Recently, it has been reported that 2′-arabino and 2′-fluoro arabino-containing oligos can also activate RNase H activity.  
     [0130] A number of antisense molecules have been described that utilize novel configurations of chemically modified nucleotides, secondary structure, and/or RNase H substrate domains (Woolf et al., International PCT Publication No. WO 98/13526; Thompson et al., U.S. Ser. No. 60/082,404 which was filed on Apr. 20, 1998; Hartmann et al., U.S. Ser. No. 60/101,174 which was filed on Sep. 21, 1998) all of these are incorporated by reference herein in their entirety.  
     [0131] Antisense DNA can be used to target RNA by means of DNA-RNA interactions, thereby activating RNase H, which digests the target RNA in the duplex. Antisense DNA can be chemically synthesized or can be expressed via the use of a single stranded DNA intracellular expression vector or the equivalent thereof.  
     [0132] Triplex Forming Oligonucleotides (TFO): Single stranded DNA may be designed to bind to genomic DNA in a sequence specific manner. TFOs are comprised of pyrimidine-rich oligonucleotides which bind DNA helices through Hoogsteen Base-pairing (Wu-Pong, supra). The resulting triple helix composed of the DNA sense, DNA antisense, and TFO disrupts RNA synthesis by RNA polymerase. The TFO mechanism may result in gene expression or cell death since binding may be irreversible (Mukhopadhyay &amp; Roth, supra)  
     [0133] 2′-5′ Oligoadenylates: The 2-5 A system is an interferon-mediated mechanism for RNA degradation found in higher vertebrates (Mitra et al., 1996,  Proc Nat Acad Sci USA  93, 6780-6785). Two types of enzymes, 2-5A synthetase and RNase L, are required for RNA cleavage. The 2-5A synthetases require double stranded RNA to form 2′-5′ oligoadenylates (2-SA). 2-5A then acts as an allosteric effector for utilizing RNase L which has the ability to cleave single stranded RNA. The ability to form 2-5A structures with double stranded RNA makes this system particularly useful for inhibition of viral replication.  
     [0134] (2′-5′) oligoadenylate structures may be covalently linked to antisense molecules to form chimeric oligonucleotides capable of RNA cleavage (Torrence, supra). These molecules putatively bind and activate a 2-5A dependent RNase, the oligonucleotide/enzyme complex then binds to a target RNA molecule which can then be cleaved by the RNase enzyme. The covalent attachment of 2′-5′ oligoadenylate structures is not limited to antisense applications, and can be further elaborated to include attachment to nucleic acid molecules of the instant invention.  
     [0135] Enzymatic Nucleic Acid: Seven basic varieties of naturally-occurring enzymatic RNAs are presently known. In addition, several in vitro selection (evolution) strategies (Orgel, 1979,  Proc. R. Soc. London,  B 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing cleavage and ligation of phosphodiester linkages (Joyce, 1989,  Gene,  82, 83-87; Beaudry et al., 1992,  Science  257, 635-641; Joyce, 1992,  Scientific American  267, 90-97; Breaker et al., 1994,  TIBTECH  12, 268; Bartel et al.,1993,  Science  261:1411-1418; Szostak, 1993,  TIBS  17, 89-93; Kumar et al., 1995,  FASEB J.,  9, 1183; Breaker, 1996,  Curr. Op. Biotech.,  7, 442; Santoro et al., 1997,  Proc. Natl. Acad. Sci.,  94, 4262; Tang et al., 1997,  RNA  3, 914; Nakamaye &amp; Eckstein, 1994, supra; Long &amp; Uhlenbeck, 1994, supra; Ishizaka et al., 1995, supra; Vaish et al., 1997,  Biochemistry  36, 6495; all of these are incorporated by reference herein). Each can catalyze a series of reactions including the hydrolysis of phosphodiester bonds in trans (and thus can cleave other RNA molecules) under physiological conditions.  
     [0136] Nucleic acid molecules of this invention will block to some extent HBV protein expression and can be used to treat disease or diagnose disease associated with the levels of HBV.  
     [0137] The enzymatic nature of an enzymatic nucleic acid has significant advantages, such as the concentration of enzymatic nucleic acid necessary to affect a therapeutic treatment is low. This advantage reflects the ability of the enzymatic nucleic acid to act enzymatically. Thus, a single enzymatic nucleic acid molecule is able to cleave many molecules of target RNA. In addition, the enzymatic nucleic acid is a highly specific inhibitor, with the specificity of inhibition depending not only on the base-pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can be chosen to completely eliminate catalytic activity of an enzymatic nucleic acid.  
     [0138] Nucleic acid molecules having an endonuclease enzymatic activity are able to repeatedly cleave other separate RNA molecules in a nucleotide base sequence-specific manner. Such enzymatic nucleic acid molecules can be targeted to virtually any RNA transcript, and achieve efficient cleavage in vitro (Zaug et al., 324,  Nature,  429 1986 ; Uhlenbeck, 1987  Nature,  328, 596; Kim et al., 84  Proc. Natl. Acad. Sci. USA,  8788, 1987; Dreyfus, 1988,  Einstein Quart. J. Bio. Med.,  6, 92; Haseloff and Gerlach, 334  Nature,  585, 1988; Cech, 260  JAMA,  3030, 1988; Jefferies et al., 17  Nucleic Acids Research,  1371, 1989; and Santoro et al., 1997 supra).  
     [0139] Because of their sequence specificity, trans-cleaving enzymatic nucleic acids show promise as therapeutic agents for human disease (Usman &amp; McSwiggen, 1995  Ann. Rep. Med. Chem.  30, 285-294; Christoffersen and Marr, 1995  J. Med. Chem.  38, 2023-2037). Enzymatic nucleic acids can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the RNA non-functional and abrogates protein expression from that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited (Warashina et al., 1999,  Chemistry and Biology,  6, 237-250.  
     [0140] The nucleic acid molecules of the instant invention are also referred to as GeneBloc™ reagents, which are essentially nucleic acid molecules (e.g.; enzymatic nucleic acids, antisense) capable of down-regulating gene expression.  
     [0141] Target Sites  
     [0142] Targets for useful enzymatic nucleic acids and antisense nucleic acids can be determined as disclosed in Draper et al., WO 93/23569; Sullivan et al., WO 93/23057; Thompson et al., WO 94/02595; Draper et al., WO 95/04818; McSwiggen et al., U.S. Pat. No. 5,525,468, and all hereby incorporated in their entirites by reference herein. Other examples include the following PCT applications, which concern inactivation of expression of disease-related genes: WO 95/23225, WO 95/13380, WO 94/02595, all incorporated by reference herein. Rather than repeat the guidance provided in those documents here, below are provided specific examples of such methods, not limiting to those in the art. Enzymatic nucleic acids and antisense to such targets are designed as described in those applications and synthesized to be tested in vitro and in vivo, as also described. The sequence of human HBV RNAs (for example, accession AF100308.1; HBV strain 2-18; additionally, other HBV strains can be screened by one skilled in the art, see Table III for other possible strains) were screened for optimal enzymatic nucleic acid and antisense target sites using a computer-folding algorithm. Antisense, hammerhead, DNAzyme, NCH (Inozyme), amberzyme, zinzyme or G-Cleaver enzymatic nucleic acid binding/cleavage sites were identified. These sites are shown in Tables V to XI (all sequences are 5′ to 3′ in the tables; X can be any base-paired sequence, the actual sequence is not relevant here). The nucleotide base position is noted in the Tables as that site to be cleaved by the designated type of enzymatic nucleic acid molecule. Table IV shows substrate positions selected from Renbo et al., 1987,  Sci. Sin.,  30, 507, used in Draper, U.S. Ser. No. (07/882,712), filed May 14, 1992, entitled “METHOD AND REAGENT FOR INHIBITING HEPATITIS B VIRUS REPLICATION” and Draper et al., International PCT publication No. WO 93/23569, filed Apr. 29, 1993, entitled “METHOD AND REAGENT FOR INHIBITING VIRAL REPLICATION”. While human sequences can be screened and enzymatic nucleic acid molecule and/or antisense thereafter designed, as discussed in Stinchcomb et al., WO 95/23225, mouse targeted enzymatic nucleic acids may be useful to test efficacy of action of the enzymatic nucleic acid molecule and/or antisense prior to testing in humans.  
     [0143] Antisense, hammerhead, DNAzyme, NCH (Inozyme), amberzyme, zinzyme or G-Cleaver enzymatic nucleic acid binding/cleavage sites were identified, as discussed above. The nucleic acid molecules were individually analyzed by computer folding (Jaeger et al., 1989  Proc. Natl. Acad. Sci. USA,  86, 7706) to assess whether the sequences fold into the appropriate secondary structure. Those nucleic acid molecules with unfavorable intramolecular interactions such as between the binding arms and the catalytic core were eliminated from consideration. Varying binding arm lengths can be chosen to optimize activity.  
     [0144] Antisense, hammerhead, DNAzyme, NCH, amberzyme, zinzyme or G-Cleaver enzymatic nucleic acid binding/cleavage sites were identified and were designed to anneal to various sites in the RNA target. The binding arms are complementary to the target site sequences described above. The nucleic acid molecules were chemically synthesized. The method of synthesis used follows the procedure for normal DNA/RNA synthesis as described below and in Usman et al., 1987  J. Am. Chem. Soc.,  109, 7845; Scaringe et al., 1990  Nucleic Acids Res.,  18, 5433; Wincott et al., 1995  Nucleic Acids Res.  23, 2677-2684; and Caruthers et al., 1992,  Methods in Enzymology  211,3-19.  
     [0145] Synthesis of Nucleic Acid Molecules  
     [0146] Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs (“small” refers to nucleic acid motifs no more than 100 nucleotides in length, preferably no more than 80 nucleotides in length, and most preferably no more than 50 nucleotides in length; e.g., antisense oligonucleotides, hammerhead or the NCH enzymatic nucleic acids) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of RNA structure. Exemplary molecules of the instant invention are chemically synthesized, and others can similarly be synthesized.  
     [0147] Oligonucleotides (e.g.; antisense GeneBlocs) are synthesized using protocols known in the art as described in Caruthers et al., 1992,  Methods in Enzymology  211, 3-19, Thompson et al., International PCT Publication No. WO 99/54459, Wincott et al., 1995, Nucleic Acids Res. 23, 2677-2684, Wincott et al., 1997,  Methods Mol. Bio.,  74, 59, Brennan et al., 1998,  Biotechnol Bioeng.,  61, 33-45, and Brennan, U.S. Pat. No. 6,001,311. All of these references are incorporated herein by reference. The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μmol scale protocol with a 2.5 min coupling step for 2′-O-methylated nucleotides and a 45 sec coupling step for 2′-deoxy nucleotides. Table II outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 μmol scale can be performed on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, Calif.) with minimal modification to the cycle. A 33-fold excess (60 μL of 0.11 M=6.6 μmol) of 2′-O-methyl phosphoramidite and a 105-fold excess of S-ethyl tetrazole (60 μL of 0.25 M=15 μmol) can be used in each coupling cycle of 2′-O-methyl residues relative to polymer-bound 5′-hydroxyl. A 22-fold excess (40 μL of 0.11 M=4.4 μmol) of deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40 μL of 0.25 M=10 μmol) can be used in each coupling cycle of deoxy residues relative to polymer-bound 5′-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); and oxidation solution is 16.9 mM I 2 , 49 mM pyridine, 9% water in THF (PERSEPTIVE™). Burdick &amp; Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in acetonitrile) is used.  
     [0148] Deprotection of the antisense oligonucleotides is performed as follows: the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65° C. for 10 min. After cooling to −20° C., the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H2O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder.  
     [0149] The method of synthesis used for normal RNA including certain enzymatic nucleic acid molecules follows the procedure as described in Usman et al., 1987,  J. Am. Chem. Soc.,  109, 7845; Scaringe et al., 1990,  Nucleic Acids Res.,  18, 5433; and Wincott et al., 1995,  Nucleic Acids Res.  23, 2677-2684 Wincott et al., 1997,  Methods Mol. Bio.,  74, 59, and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μmol scale protocol with a 7.5 min coupling step for alkylsilyl protected nucleotides and a 2.5 min coupling step for 2′-O-methylated nucleotides. Table II outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 μmol scale can be done on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, Calif.) with minimal modification to the cycle. A 33-fold excess (60 μL of 0.11 M=6.6 μmol) of 2′-O-methyl phosphoramidite and a 75-fold excess of S-ethyl tetrazole (60 μL of 0.25 M=15 μmol) can be used in each coupling cycle of 2′-O-methyl residues relative to polymer-bound 5′-hydroxyl. A 66-fold excess (120 μL of 0.11 M=13.2 μmol) of alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess of S-ethyl tetrazole (120 μL of 0.25 M=30 μmol) can be used in each coupling cycle of ribo residues relative to polymer-bound 5′-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution is 16.9 mM I 2 , 49 mM pyridine, 9% water in THF (PERSEPTIVE™). Burdick &amp; Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide0.05 M in acetonitrile) is used.  
     [0150] Deprotection of the RNA is performed using either a two-pot or one-pot protocol. For the two-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65° C. for 10 min. After cooling to −20° C., the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H2O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The base deprotected oligoribonucleotide is resuspended in anhydrous TEA/HF/NMP solution (300 μL of a solution of 1.5 mL N-methylpyrrolidinone, 750 μL TEA and 1 mL TEA·3HF to provide a 1.4 M HF concentration) and heated to 65° C. After 1.5 h, the oligomer is quenched with 1.5 M NH 4 HCO 3 .  
     [0151] Alternatively, for the one-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 33% ethanolic methylamine/DMSO: 1/1 (0.8 mL) at 65° C. for 15 min. The vial is brought to r.t. TEA·3HF (0.1 mL) is added and the vial is heated at 65° C. for 15 min. The sample is cooled at −20° C. and then quenched with 1.5 M NH 4 HCO 3 .  
     [0152] For purification of the trityl-on oligomers, the quenched NH 4 HCO 3  solution is loaded onto a C-18 containing cartridge that had been prewashed with acetonitrile followed by 50 mM TEAA. After washing the loaded cartridge with water, the RNA is detritylated with 0.5% TFA for 13 min. The cartridge is then washed again with water, salt exchanged with 1 M NaCl and washed with water again. The oligonucleotide is then eluted with 30% acetonitrile.  
     [0153] Inactive hammerhead enzymatic nucleic acids or binding attenuated control (BAC) oligonucleotides) are synthesized by substituting a U for G 5  and a U for A 14  (numbering from Hertel, K. J., et al., 1992,  Nucleic Acids Res.,  20, 3252). Similarly, one or more nucleotide substitutions can be introduced in other enzymatic nucleic acid molecules to inactivate the molecule and such molecules can serve as a negative control.  
     [0154] The average stepwise coupling yields are typically &gt;98% (Wincott et al., 1995  Nucleic Acids Res.  23, 2677-2684). Those of ordinary skill in the art will recognize that the scale of synthesis can be adapted to be larger or smaller than the example described above including but not limited to 96-well format, all that is important is the ratio of chemicals used in the reaction.  
     [0155] Alternatively, the nucleic acid molecules of the present invention can be synthesized separately and joined together post-synthetically, for example, by ligation (Moore et al., 1992,  Science  256, 9923; Draper et al., International PCT publication No. WO 93/23569; Shabarova et al., 1991,  Nucleic Acids Research  19, 4247; Bellon et al., 1997,  Nucleosides  &amp;  Nucleotides,  16, 951; Bellon et al., 1997,  Bioconjugate Chem.  8, 204).  
     [0156] The nucleic acid molecules of the present invention are modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2′-amino, 2′-C-allyl, 2′-flouro, 2′-O-methyl, 2′-H (for a review see Usman and Cedergren, 1992,  TIBS  17, 34; Usman et al., 1994,  Nucleic Acids Symp. Ser.  31, 163). Enzymatic nucleic acids are purified by gel electrophoresis using general methods or are purified by high pressure liquid chromatography (HPLC; see Wincott et al., supra, the totality of which is hereby incorporated herein by reference) and are re-suspended in water.  
     [0157] The sequences of the enzymatic nucleic acids and antisense constructs that are chemically synthesized, useful in this study, are shown in Tables IV to IX. Those in the art will recognize that these sequences are representative only of many more such sequences where the enzymatic portion of the enzymatic nucleic acid (all but the binding arms) is altered to affect activity. The enzymatic nucleic acid and antisense construct sequences listed in Tables IV to IX may be formed of ribonucleotides or other nucleotides or non-nucleotides. Such enzymatic nucleic acids with enzymatic activity are equivalent to the enzymatic nucleic acids described specifically in the Tables.  
     [0158] Optimizing Activity of the Nucleic Acid Molecule of the Invention  
     [0159] Chemically synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) that prevent their degradation by serum ribonucleases may increase their potency (see e.g., Eckstein et al., International Publication No. WO 92/07065; Perrault et al., 1990  Nature  344, 565; Pieken et al., 1991,  Science  253, 314; Usman and Cedergren, 1992,  Trends in Biochem. Sci.  17, 334; Usman et al., International Publication No. WO 93/15187; Rossi et al., International Publication No. WO 91/03162; Sproat, U.S. Pat. No. 5,334,711; and Burgin et al., supra; all of these describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of the nucleic acid molecules herein and are all hereby incorporated by reference herein). Modifications which enhance their efficacy in cells, and removal of bases from nucleic acid molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired.  
     [0160] There are several examples in the art describing sugar, base and phosphate modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2′-amino, 2′-C-allyl, 2′-flouro, 2′-O-methyl, 2′-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992,  TIBS.  17, 34; Usman et al., 1994,  Nucleic Acids Symp. Ser.  31, 163; Burgin et al., 1996,  Biochemistry,  35, 14090). Sugar modification of nucleic acid molecules have been extensively described in the art (see Eckstein et al., International Publication PCT No. WO 92/07065; Perrault et al.  Nature,  1990, 344, 565-568; Pieken et al.  Science,  1991, 253, 314-317; Usman and Cedergren,  Trends in Biochem. Sci.,  1992, 17, 334-339; Usman et al. International Publication PCT No. WO 93/15187; Sproat, U.S. Pat. No. 5,334,711 and Beigelman et al., 1995,  J. Biol. Chem.,  270, 25702; Beigelman et al., International PCT publication No. WO 97/26270; Beigelman et al., U.S. Pat. No. 5,716,824; Usman et al., U.S. Pat. No. 5,627,053; Woolf et al., International PCT Publication No. WO 98/13526; Thompson et al., U.S. Ser. No. 60/082,404 which was filed on Apr. 20, 1998; Karpeisky et al., 1998,  Tetrahedron Lett.,  39, 1131; Earnshaw and Gait, 1998,  Biopolymers  ( Nucleic Acid Sciences ), 48, 39-55; Verma and Eckstein, 1998,  Annu. Rev. Biochem.,  67, 99-134; and Burlina et al., 1997,  Bioorg. Med. Chem.,  5, 1999-2010; all of the references are hereby incorporated in their totality by reference herein). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into enzymatic nucleic acids without inhibiting catalysis, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein to modify the nucleic acid molecules of the instant invention.  
     [0161] While chemical modification of oligonucleotide internucleotide linkages with phosphorothioate, phosphorothioate, and/or 5′-methylphosphonate linkages improves stability, too many of these modifications may cause some toxicity. Therefore, when designing nucleic acid molecules, the amount of these internucleotide linkages should be minimized. The reduction in the concentration of these linkages should lower toxicity resulting in increased efficacy and higher specificity of these molecules.  
     [0162] Nucleic acid molecules having chemical modifications which maintain or enhance activity are provided. Such nucleic acid molecules are also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or in vivo the activity may not be significantly lowered. Therapeutic nucleic acid molecules delivered exogenously must optimally be stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Clearly, nucleic acid molecules must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of RNA and DNA (Wincott et al., 1995  Nucleic Acids Res.  23, 2677; Caruthers et al., 1992,  Methods in Enzymology  211,3-19 (are incorporated by reference herein) have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above.  
     [0163] Use of these the nucleic acid-based molecules of the invention will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple antisense or enzymatic nucleic acid molecules targeted to different genes, nucleic acid molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations of molecules (including different motifs) and/or other chemical or biological molecules). The treatment of patients with nucleic acid molecules may also include combinations of different types of nucleic acid molecules.  
     [0164] Therapeutic nucleic acid molecules (e.g., enzymatic nucleic acid molecules and antisense nucleic acid molecules) delivered exogenously must optimally be stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Clearly, these nucleic acid molecules must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of nucleic acid molecules described in the instant invention and in the art have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above.  
     [0165] By “enhanced enzymatic activity” is meant to include activity measured in cells and/or in vivo where the activity is a reflection of both catalytic activity and enzymatic nucleic acid stability. In this invention, the product of these properties is increased or not significantly (less than 10-fold) decreased in vivo compared to an all RNA enzymatic nucleic acid or all DNA enzyme.  
     [0166] In yet another preferred embodiment, nucleic acid catalysts having chemical modifications which maintain or enhance enzymatic activity is provided. Such nucleic acid catalysts are also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or in vivo the activity may not be significantly lowered. As exemplified herein such enzymatic nucleic acids are useful in a cell and/or in vivo even if activity over all is reduced 10 fold (Burgin et al., 1996,  Biochemistry,  35, 14090). Such enzymatic nucleic acids herein are said to “maintain” the enzymatic activity of an all RNA enzymatic nucleic acid.  
     [0167] In another aspect the nucleic acid molecules comprise a 5′ and/or a 3′-cap structure.  
     [0168] By “cap structure” is meant chemical modifications, which have been incorporated at either terminus of the oligonucleotide (see, for example, Wincott et al., WO 97/26270, incorporated by reference herein). These terminal modifications protect the nucleic acid molecule from exonuclease degradation, and may help in delivery and/or localization within a cell. The cap may be present at the 5′-terminus (5′-cap) or at the 3′-terminal (3′-cap) or may be present on both termini. In non-limiting examples: the 5′-cap is selected from the group comprising inverted abasic residue (moiety); 4′,5′-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide, 4′-thio nucleotide; carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3′-3′-inverted nucleotide moiety; 3′-3′-inverted abasic moiety; 3′-2′-inverted nucleotide moiety; 3′-2′-inverted abasic moiety; 1,4-butanediol phosphate; 3′-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3′-phosphate; 3′-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety (for more details, see Wincott et al., International PCT publication No. WO 97/26270, incorporated by reference herein).  
     [0169] In yet another preferred embodiment, the 3′-cap is selected from a group comprising, 4′,5′-methylene nucleotide; 1-(beta-D-erythrofuranosyl) nucleotide; 4′-thio nucleotide, carbocyclic nucleotide; 5′-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate; 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; threo-pentofuranosyl nucleotide; acyclic 3′,4′-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5′-5′-inverted nucleotide moiety; 5′-5′-inverted abasic moiety; 5′-phosphoramidate; 5′-phosphorothioate; 1,4-butanediol phosphate; 5′-amino; bridging and/or non-bridging 5′-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5′-mercapto moieties (for more details see Beaucage and Tyer, 1993,  Tetrahedron  49, 1925; incorporated by reference herein).  
     [0170] By the term “non-nucleotide” is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine.  
     [0171] An “alkyl” group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, ═O, ═S, NO 2  or N(CH 3 ) 2 , amino, or SH. The term also includes alkenyl groups which are unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, ═O, ═S, NO 2 , halogen, N(CH 3 ) 2 , amino, or SH. The term “alkyl” also includes alkynyl groups which have an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, ═O, ═S, NO 2  or N(CH 3 ) 2 , amino or SH.  
     [0172] Such alkyl groups may also include aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester groups. An “aryl” group refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The preferred substituent(s) of aryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups. An “alkylaryl” group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above). Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted. Heterocyclic aryl groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted. An “amide” refers to an —C(O)—NH—R, where R is either alkyl, aryl, alkylaryl or hydrogen. An “ester” refers to an —C(O)—OR′, where R is either alkyl, aryl, alkylaryl or hydrogen.  
     [0173] By “nucleotide” as used herein is as recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1′ position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, nonnatural nucleotides, non-standard nucleotides and other; see, for example, Usman and McSwiggen, supra; Eckstein et al., International PCT Publication No. WO 92/07065; Usman et al., International PCT Publication No. WO 93/15187; Uhlman &amp; Peyman, supra, all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach et al., 1994,  Nucleic Acids Res.  22, 2183. Some of the non-limiting examples of base modifications that can be introduced into nucleic acid molecules include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, and others (Burgin et al., 1996,  Biochemistry,  35, 14090; Uhlman &amp; Peyman, supra). By “modified bases” in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1′ position or their equivalents; such bases may be used at any position, for example, within the catalytic core of an enzymatic nucleic acid molecule and/or in the substrate-binding regions of the nucleic acid molecule.  
     [0174] In a preferred embodiment, the invention features modified enzymatic nucleic acids with phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, morpholino, amidate carbamate, carboxymethyl, acetamidate, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioforrnacetal, and/or alkylsilyl, substitutions. For a review of oligonucleotide backbone modifications, see Hunziker and Leumann, 1995,  Nucleic Acid Analogues: Synthesis and Properties,  in  Modern Synthetic Methods,  VCH, 331-417, and Mesmaeker et al., 1994,  Novel Backbone Replacements for Oligonucleotides,  in  Carbohydrate Modifications in Antisense Research,  ACS, 24-39. These references are hereby incorporated by reference herein.  
     [0175] By “abasic” is meant sugar moieties lacking a base or having other chemical groups in place of a base at the 1′ position, (for more details, see Wincott et al., International PCT publication No. WO 97/26270).  
     [0176] By “unmodified nucleoside” is meant one of the bases adenine, cytosine, guanine, thymine, uracil joined to the 1′ carbon of β-D-ribo-furanose.  
     [0177] By “modified nucleoside” is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate.  
     [0178] In connection with 2′-modified nucleotides as described for the present invention, by “amino” is meant 2′-NH 2  or 2′-O-NH 2 , which may be modified or unmodified. Such modified groups are described, for example, in Eckstein et al., U.S. Pat. No. 5,672,695 and Matulic-Adamic et al., WO 98/28317, which are both incorporated by reference in their entireties.  
     [0179] Various modifications to nucleic acid (e.g., antisense and enzymatic nucleic acid) structure can be made to enhance the utility of these molecules. Such modifications will enhance shelf-life, half-life in vitro, stability, and ease of introduction of such oligonucleotides to the target site, e.g., to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.  
     [0180] Use of these molecules will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple enzymatic nucleic acids targeted to different genes, enzymatic nucleic acids coupled with known small molecule inhibitors, or intermittent treatment with combinations of enzymatic nucleic acids (including different enzymatic nucleic acid motifs) and/or other chemical or biological molecules). The treatment of patients with nucleic acid molecules may also include combinations of different types of nucleic acid molecules. Therapies may be devised which include a mixture of enzymatic nucleic acids (including different enzymatic nucleic acid motifs), antisense and/or 2-5A chimera molecules to one or more targets to alleviate symptoms of a disease.  
     [0181] Administration of Nucleic Acid Molecules  
     [0182] Methods for the delivery of nucleic acid molecules are described in Akhtar et al., 1992,  Trends Cell Bio.,  2, 139; and  Delivery Strategies for Antisense Oligonucleotide Therapeutics,  ed. Akhtar, 1995 which are both incorporated herein by reference. Sullivan et al., PCT WO 94/02595, further describes the general methods for delivery of enzymatic RNA molecules. These protocols may be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, nucleic acid molecules may be directly delivered ex vivo to cells or tissues with or without the aforementioned vehicles. Alternatively, the nucleic acid/vehicle combination is locally delivered by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of nucleic acid delivery and administration are provided in Sullivan et al., supra, Draper et al., PCT WO93/23569; Beigelman et al., PCT WO99/05094, and Klimuk et al., PCT WO99/04819 all of which are incorporated by reference herein.  
     [0183] The molecules of the instant invention can be used as pharmaceutical agents. Pharmaceutical agents prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a patient.  
     [0184] The negatively charged polynucleotides of the invention can be administered (e.g., RNA, DNA or protein) and introduced into a patient by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can be followed. The compositions of the present invention may also be formulated and used as tablets, capsules or elixirs for oral administration; suppositories for rectal administration; sterile solutions; suspensions for injectable administration; and the other compositions known in the art.  
     [0185] The present invention also includes pharmaceutically acceptable formulations of the compounds described. These formulations include salts of the above compounds, e.g., acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid.  
     [0186] A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, e.g., systemic administration, into a cell or patient, preferably a human. Suitable forms, in part, depend upon the use or the route of entry, for example, oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell (i.e., a cell to which the negatively charged polymer is desired to be delivered to). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms which prevent the composition or formulation from exerting its effect.  
     [0187] By “systemic administration” is meant in vivo systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include, without limitations: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes expose the desired negatively charged polymers, e.g., nucleic acids, to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation which can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach may provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as cancer cells.  
     [0188] By pharmaceutically acceptable formulation is meant, a composition or formulation that allows for the effective distribution of the nucleic acid molecules of the instant invention in the physical location most suitable for their desired activity. Nonlimiting examples of agents suitable for formulation with the nucleic acid molecules of the instant invention include: P-glycoprotein inhibitors (such as Pluronic P85) which can enhance entry of drugs into the CNS (Jolliet-Riant and Tillement, 1999,  Fundam. Clin. Pharmacol.,  13, 16-26); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after intracerebral implantation (Emerich, DF et al, 1999,  Cell Transplant,  8, 47-58) Alkermes, Inc. Cambridge, Mass.; and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which can deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms ( Prog Neuropsychopharmacol Biol Psychiatry,  23, 941-949, 1999). Other non-limiting examples of delivery strategies for the nucleic acid molecules of the instant invention include material described in Boado et al., 1998,  J. Pharm. Sci.,  87, 1308-1315; Tyler et al., 1999,  FEBS Lett.,  421, 280-284; Pardridge et al., 1995,  PNAS USA.,  92, 5592-5596; Boado, 1995,  Adv. Drug Delivery Rev.,  15, 73-107; Aldrian-Herrada et al., 1998,  Nucleic Acids Res.,  26, 4910-4916; and Tyler et al., 1999,  PNAS USA.,  96, 7053-7058.  
     [0189] The invention also features the use of the composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic et al.  Chem. Rev.  1995, 95, 2601-2627; Ishiwata et al.,  Chem. Pharm. Bull.  1995, 43, 1005-1011). Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic et al.,  Science  1995, 267, 1275-1276; Oku et al., 1995,  Biochim. Biophys. Acta,  1238, 86-90). The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu et al.,  J. Biol. Chem.  1995, 42, 24864-24870; Choi et al., International PCT Publication No. WO 96/10391; Ansell et al., International PCT Publication No. WO 96/10390; Holland et al., International PCT Publication No. WO 96/10392; all of which are incorporated by reference herein). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen.  
     [0190] The present invention also includes compositions prepared for storage or administration which include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in  Remington&#39;s Pharmaceutical Sciences,  Mack Publishing Co. (A. R. Gennaro edit. 1985) hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents may be provided. These include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. In addition, antioxidants and suspending agents may be used.  
     [0191] A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors which those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer.  
     [0192] The nucleic acid molecules of the present invention may also be administered to a patient in combination with other therapeutic compounds to increase the overall therapeutic effect. The use of multiple compounds to treat an indication may increase the beneficial effects while reducing the presence of side effects.  
     [0193] Alternatively, certain of the nucleic acid molecules of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985,  Science,  229, 345; McGarry and Lindquist, 1986,  Proc. Natl. Acad. Sci., USA  83, 399; Scanlon et al., 1991,  Proc. Natl. Acad. Sci. USA,  88, 10591-5; Kashani-Sabet et al., 1992,  Antisense Res. Dev.,  2, 3-15; Dropulic et al., 1992,  J. Virol.,  66, 1432-41; Weerasinghe et al., 1991,  J. Virol.,  65, 5531-4; Ojwang et al., 1992,  Proc. Natl. Acad. Sci. USA,  89, 10802-6; Chen et al., 1992,  Nucleic Acids Res.,  20, 4581-9; Sarver et al., 1990  Science,  247, 1222-1225; Thompson et al., 1995,  Nucleic Acids Res.,  23, 2259; Good et al., 1997,  Gene  Therapy, 4, 45; all of these references are hereby incorporated in their totalites by reference herein). Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a ribozyme (Draper et al., PCT WO 93/23569, and Sullivan et al., PCT WO 94/02595; Ohkawa et al., 1992,  Nucleic Acids Symp. Ser.,  27, 15-6; Taira et al., 1991,  Nucleic Acids Res.,  19, 5125-30; Ventura et al., 1993,  Nucleic Acids Res.,  21, 3249-55; Chowrira et al., 1994,  J. Biol. Chem.,  269, 25856; all of these references are hereby incorporated in their totality by reference herein).  
     [0194] In another aspect of the invention, RNA molecules of the present invention are preferably expressed from transcription units (see, for example, Couture et al., 1996,  TIG.,  12, 510) inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Enzymatic nucleic acid expressing viral vectors could be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the nucleic acid molecules are delivered as described above, and persist in target cells. Alternatively, viral vectors may be used that provide for transient expression of nucleic acid molecules. Such vectors might be repeatedly administered as necessary. Once expressed, the nucleic acid molecule binds to the target mRNA. Delivery of nucleic acid molecule expressing vectors could be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell (for a review see Couture et al., 1996,  TIG.,  12, 510).  
     [0195] In one aspect, the invention features an expression vector comprising a nucleic acid sequence encoding at least one of the nucleic acid molecules of the instant invention is disclosed. The nucleic acid sequence encoding the nucleic acid molecule of the instant invention is operable linked in a manner which allows expression of that nucleic acid molecule.  
     [0196] In another aspect the invention features an expression vector comprising: a) a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); c) a nucleic acid sequence encoding at least one of the nucleic acid catalyst of the instant invention; and wherein said sequence is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. The vector may optionally include an open reading frame (ORF) for a protein operably linked on the 5′ side or the 3′-side of the sequence encoding the nucleic acid catalyst of the invention; and/or an intron (intervening sequences).  
     [0197] Transcription of the nucleic acid molecule sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990,  Proc. Natl. Acad. Sci. USA,  87, 6743-7; Gao and Huang 1993,  Nucleic Acids Res.,  21, 2867-72; Lieber et al., 1993,  Methods Enzymol.,  217, 47-66; Zhou et al., 1990,  Mol. Cell. Biol.,  10, 4529-37). All of these references are incorporated by reference herein. Several investigators have demonstrated that nucleic acid molecules, such as enzymatic nucleic acids expressed from such promoters can function in mammalian cells (e.g. Kashani-Sabet et al., 1992,  Antisense Res. Dev.,  2, 3-15; Ojwang et al., 1992,  Proc. Natl. Acad. Sci. USA,  89, 10802-6; Chen et al., 1992,  Nucleic Acids Res.,  20, 4581-9; Yu et al., 1993,  Proc. Natl. Acad. Sci. USA,  90, 6340-4; L&#39;Huillier et al., 1992,  EMBO J.,  11, 4411-8; Lisziewicz et al., 1993,  Proc. Natl. Acad. Sci. U.S.A.,  90, 8000-4; Thompson et al., 1995,  Nucleic Acids Res.,  23, 2259; Sullenger &amp; Cech, 1993,  Science,  262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as enzymatic nucleic acids in cells (Thompson et al., supra; Couture and Stinchcomb, 1996, supra; Noonberg et al., 1994,  Nucleic Acid Res.,  22, 2830; Noonberg et al., U.S. Pat. No. 5,624,803; Good et al., 1997,  Gene Ther.,  4, 45; Beigelman et al., International PCT Publication No. WO 96/18736; all of these publications are incorporated by reference herein. The above enzymatic nucleic acid transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review see Couture and Stinchcomb, 1996, supra).  
     [0198] In yet another aspect, the invention features an expression vector comprising nucleic acid sequence encoding at least one of the nucleic acid molecules of the invention, in a manner which allows expression of that nucleic acid molecule. The expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; c) a nucleic acid sequence encoding at least one said nucleic acid molecule; and wherein said sequence is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another preferred embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; d) a nucleic acid sequence encoding at least one said nucleic acid molecule, wherein said sequence is operably linked to the 3′-end of said open reading frame; and wherein said sequence is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In yet another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) a nucleic acid sequence encoding at least one said nucleic acid molecule; and wherein said sequence is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; e) a nucleic acid sequence encoding at least one said nucleic acid molecule, wherein said sequence is operably linked to the 3′-end of said open reading frame; and wherein said sequence is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.  
     EXAMPLES  
     [0199] The following are non-limiting examples showing the selection, isolation, synthesis and activity of nucleic acids of the instant invention.  
     [0200] The following examples demonstrate the selection and design of Antisense, Hammerhead, DNAzyme, NCH, Amberzyme, Zinzyme or G-Cleaver enzymatic nucleic acid molecules and binding/cleavage sites within HBV RNA.  
     Example 1  
     Identification of Potential Target Sites in Human HBV RNA  
     [0201] The sequence of human HBV was screened for accessible sites using a computer-folding algorithm. Regions of the RNA that did not form secondary folding structures and contained potential enzymatic nucleic acid and/or antisense binding/cleavage sites were identified. The sequences of these cleavage sites are shown in Tables IV-XI.  
     Example 2  
     Selection of Enzymatic Nucleic Acid Cleavage Sites in Human HBV RNA  
     [0202] Enzymatic nucleic acid target sites were chosen by analyzing sequences of Human HBV (accession number: AF100308.1) and prioritizing the sites on the basis of folding. Enzymatic nucleic acids were designed that could bind each target and were individually analyzed by computer folding (Christoffersen et al., 1994  J. Mol. Struc. Theochem,  311, 273; Jaeger et al., 1989,  Proc. Natl. Acad. Sci. USA,  86, 7706) to assess whether the enzymatic nucleic acid sequences fold into the appropriate secondary structure. Those enzymatic nucleic acids with unfavorable intramolecular interactions between the binding arms and the catalytic core were eliminated from consideration. As noted herein, varying binding arm lengths can be chosen to optimize activity. Generally, at least 5 bases on each arm are able to bind to, or otherwise interact with, the target RNA.  
     Example 3  
     Chemical Synthesis and Purification of Enzymatic Nucleic Acids and Antisense for Efficient Cleavage and/or Blocking of HBV RNA  
     [0203] Enzymatic nucleic acids and antisense constructs were designed to anneal to various sites in the RNA message. The binding arms of the enzymatic nucleic acids are complementary to the target site sequences described above, while the antisense constructs are fully complementary to the target site sequences described above. The enzymatic nucleic acids and antisense constructs were chemically synthesized. The method of synthesis used followed the procedure for normal RNA synthesis as described above and in Usman et al., (1987  J. Am. Chem. Soc.,  109, 7845), Scaringe et al., (1990  Nucleic Acids Res.,  18, 5433) and Wincott et al., supra, and made use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5′-end, and phosphoramidites at the 3′-end. The average stepwise coupling yields were typically &gt;98%.  
     [0204] Enzymatic nucleic acids and antisense constructs were also synthesized from DNA templates using bacteriophage T7 RNA polymerase (Milligan and Uhlenbeck, 1989,  Methods Enzymol.  180, 51). Enzymatic nucleic acids and antisense constructs were purified by gel electrophoresis using general methods or were purified by high pressure liquid chromatography (HPLC; see Wincott et al., supra; the totality of which is hereby incorporated herein by reference) and were resuspended in water. The sequences of the chemically synthesized enzymatic nucleic acids used in this study are shown below in Table XI.  
     Example 4  
     Enzymatic Nucleic Acid Cleavage of HBV RNA Target in vitro  
     [0205] Enzymatic nucleic acids targeted to the human HBV RNA are designed and synthesized as described above. These enzymatic nucleic acids can be tested for cleavage activity in vitro, for example using the following procedure. The target sequences and the nucleotide location within the HBV RNA are given in Tables IV-XI.  
     [0206] Cleavage Reactions: Full-length or partially full-length, internally-labeled target RNA for enzymatic nucleic acid cleavage assay is prepared by in vitro transcription in the presence of [α- 32 P] CTP, passed over a G 50 Sephadex® column by spin chromatography and used as substrate RNA without further purification. Alternately, substrates are 5′- 32 P-end labeled using T4 polynucleotide kinase enzyme. Assays are performed by pre-warming a 2× concentration of purified enzymatic nucleic acid in enzymatic nucleic acid cleavage buffer (50 mM Tris-HCl, pH 7.5 at 37° C., 10 mM MgCl 2 ) and the cleavage reaction was initiated by adding the 2× enzymatic nucleic acid mix to an equal volume of substrate RNA (maximum of 1-5 nM) that was also pre-warmed in cleavage buffer. As an initial screen, assays are carried out for 1 hour at 37° C. using a final concentration of either 40 nM or 1 mM enzymatic nucleic acid, i.e., enzymatic nucleic acid excess. The reaction is quenched by the addition of an equal volume of 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol after which the sample is heated to 95° C. for 2 minutes, quick chilled and loaded onto a denaturing polyacrylamide gel. Substrate RNA and the specific RNA cleavage products generated by enzymatic nucleic acid cleavage are visualized on an autoradiograph of the gel. The percentage of cleavage is determined by Phosphor Imager® quantitation of bands representing the intact substrate and the cleavage products.  
     Example 5  
     Transfection of HepG2 Cells with psHBV-1 and Enzymatic Nucleic Acids  
     [0207] The human hepatocellular carcinoma cell line Hep G2 was grown in Dulbecco&#39;s modified Eagle media supplemented with 10% fetal calf serum, 2 mM glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 25 mM Hepes, 100 units penicillin, and 100 μg/ml streptomycin. To generate a replication competent cDNA, prior to transfection the HBV genomic sequences are excised from the bacterial plasmid sequence contained in the psHBV-1 vector (Those skilled in the art understand that other methods may be used to generate a replication competent cDNA). This was done with an EcoRI and Hind III restriction digest. Following completion of the digest, a ligation was performed under dilute conditions (20 μg/ml) to favor intermolecular ligation. The total ligation mixture was then concentrated using Qiagen spin columns.  
     [0208] Secreted alkaline phosphatase (SEAP) was used to normalize the HBsAg levels to control for transfection variability. The pSEAP2-TK control vector was constructed by ligating a Bgl II-Hind III fragment of the pRL-TK vector (Promega), containing the herpes simplex virus thymidine kinase promoter region, into Bgl II/Hind III digested pSEAP2-Basic (Clontech). Hep G2 cells were plated (3×10 4  cells/well) in 96-well microtiter plates and incubated overnight. A lipid/DNA/enzymatic nucleic acid complex was formed containing (at final concentrations) cationic lipid (15 μg/ml), prepared psHBV-1 (4.5 μg/ml), pSEAP2-TK (0.5 μg/ml), and enzymatic nucleic acid (100 μM). Following a 15 min. incubation at 37° C., the complexes were added to the plated Hep G2 cells. Media was removed from the cells 96 hr. post-transfection for HBsAg and SEAP analysis.  
     [0209] Transfection of the human hepatocellular carcinoma cell line, Hep G2, with replication competent HBV DNA results in the expression of HBV proteins and the production of virions. To investigate the potential use of enzymatic nucleic acids for the treatment of chronic HBV infection, a series of enzymatic nucleic acids that target the 3′ terminus of the HBV genome have been synthesized. Enzymatic nucleic acids targeting this region have the potential to cleave all four major HBV RNA transcripts as well as the potential to block the production of HBV DNA by cleavage of the pregenomic RNA. To test the efficacy of these HBV enzymatic nucleic acids, they were co-transfected with HBV genomic DNA into Hep G2 cells, and the subsequent levels of secreted HBV surface antigen (HBsAg) were analyzed by ELISA. To control for variability in transfection efficiency, a control vector which expresses secreted alkaline phosphatase (SEAP), was also co-transfected. The efficacy of the HBV enzymatic nucleic acids was determined by comparing the ratio of HBsAg:SEAP and/or HBeAg:SEAP to that of a scrambled attenuated control (SAC) enzymatic nucleic acid. Twenty-five enzymatic nucleic acids (RPI18341, RPI18356, RPI18363, RPI18364, RPI18365, RPI18366, RPI18367, RPI18368, RPI18369, RPI18370, RPI18371, RPI18372, RPI18373, RPI18374, RPI18303, RPI18405, RPI18406, RPI18407, RPI18408, RPI18409, RPI18410, RPI18411, RPI18418, RPI18419, and RPI18422) have been identified which cause a reduction in the levels of HBsAg and/or HBeAg as compared to the corresponding SAC enzymatic nucleic acid. In addition, loop variant anti-HBV enzymatic nucleic acids targeting site 273 were tested using this system, the results of this study are summarized in FIG. 10. As indicated in the figure, the enzymatic nucleic acids tested demonstrate significant reduction in HepG2 HBsAg levels as compared to a scrambled attenuated core enzymatic nucleic acid control, with RPI 22650 and RPI 22649 showing the greatest decrease in HBsAg levels.  
     Example 6  
     Analysis of HBsAg and SEAP Levels Following Enzymatic Nucleic Acid Treatment  
     [0210] Immulon 4 (Dynax) microtiter wells were coated overnight at 4° C. with anti-HBsAg Mab (Biostride B88-95-31ad,ay) at 1 μg/ml in Carbonate Buffer (Na2CO3 15 mM, NaHCO3 35 mM, pH 9.5). The wells were then washed 4× with PBST (PBS, 0.05% Tween® 20) and blocked for 1 hr at 37° C. with PBST, 1% BSA. Following washing as above, the wells were dried at 37° C. for 30 min. Biotinylated goat ant-HBsAg (Accurate YVS1807) was diluted 1:1000 in PBST and incubated in the wells for 1 hr. at 37° C. The wells were washed 4× with PBST. Streptavidin/Alkaline Phosphatase Conjugate (Pierce 21324) was diluted to 250 ng/ml in PBST, and incubated in the wells for 1 hr. at 37° C. After washing as above, p-nitrophenyl phosphate substrate (Pierce 37620) was added to the wells, which were then incubated for 1 hr. at 37° C. The optical density at 405 nm was then determined. SEAP levels were assayed using the Great EscAPe® Detection Kit (Clontech K2041-1), as per the manufacturers instructions.  
     Example 7  
     X-gene Reporter Assay  
     [0211] The effect of enzymatic nucleic acid treatment on the level of transactivation of a SV40 promoter driven firefly luciferase gene by the HBV X-protein was analyzed in transfected Hep G2 cells. As a control for variability in transfection efficiency, a Renilla luciferase reporter driven by the TK promoter, which is not transactivated by the X protein, was used. Hep G2 cells were plated (3×10 4  cells/well) in 96-well microtiter plates and incubated overnight. A lipid/DNA/enzymatic nucleic acid complex was formed containing (at final concentrations) cationic lipid (2.4 μg/ml), the X-gene vector pSBDR(2.5 μg/ml), the firefly reporter pSV40HCVluc (0.5 μg/ml), the Renilla luciferase control vector pRL-TK (0.5 μg/ml), and enzymatic nucleic acid (100 μM). Following a 15 min. incubation at 37° C., the complexes were added to the plated Hep G2 cells. Levels of firefly and Renilla luciferase were analyzed 48 hr. post transfection, using Promega&#39;s Dual-Luciferase Assay System.  
     [0212] The HBV X protein is a transactivator of a number of viral and cellular genes. Enzymatic nucleic acids which target the X region were tested for their ability to cause a reduction in X protein transactivation of a firefly luciferase gene driven by the SV40 promoter in transfected Hep G2 cells. As a control for transfection variability, a vector containing the Renilla luciferase gene driven by the TK promotor, which is not activated by the X protein, was included in the co-transfections. The efficacy of the HBV enzymatic nucleic acids was determined by comparing the ratio of firefly luciferase: Renilla luciferase to that of a scrambled attenuated control (SAC) enzymatic nucleic acid. Eleven enzymatic nucleic acids (RPI18365, RPI18367, RPI18368, RPI18371, RPI18372, RPI18373, RPI18405, RPI18406, RPI18411, RPI18418, RPI18423) were identified which cause a reduction in the level of transactivation of a reporter gene by the X protein, as compared to the corresponding SAC enzymatic nucleic acid.  
     Example 8  
     HBV Transgenic Mouse Study A  
     [0213] A transgenic mouse strain (founder strain 1.3.32 with a C57B1/6 background) that expresses HBV RNA and forms HBV viremia (Morrey et al., 1999,  Antiviral Res.,  42, 97-108; Guidotti et al., 1995,  J. Virology,  69, 10, 6158-6169) was utilized to study the in vivo activity of enzymatic nucleic acids (RPI.18341, RPI.18371, RPI.18372, and RPI.18418) of the instant invention. This model is predictive in screening for anti-HBV agents. Enzymatic nucleic acid or the equivalent volume of saline was administered via a continuous s.c. infusion using Alzet® mini-osmotic pumps for 14 days. Alzet® pumps were filled with test material(s) in a sterile fashion according to the manufacturer&#39;s instructions. Prior to in vivo implantation, pumps were incubated at 37° C. overnight (≧18 hours) to prime the flow modulators. On the day of surgery, animals were lightly anesthetized with a ketamine/xylazine cocktail (94 mg/kg and 6 mg/kg, respectively; 0.3 ml, IP). Baseline blood samples (200 μl) were obtained from each animal via a retro-orbital bleed. For animals in groups 1-5 (Table XII), a 2 cm area near the base of the tail was shaved and cleansed with betadine surgical scrub and sequentially with 70% alcohol. A 1 cm incision in the skin was made with a #15 scalpel blade or a blunt pair of scissors near the base of the tail. Forceps were used to open a pocket rostrally (i.e., towards the head) by spreading apart the subcutaneous connective tissue. The pump was inserted with the delivery portal pointing away from the incision. Wounds were closed with sterile 9-mm stainless steel clips or with sterile 4-0 suture. Animals were then allowed to recover from anesthesia on a warm heating pad before being returned to their cage. Wounds were checked daily. Clips or sutures were replaced as needed. Incisions typically healed completely within 7 days post-op. Animals were then deeply anesthetized with the ketamine/xylazine cocktail (150 mg/kg and 10 mg/kg, respectively; 0.5 ml, IP) on day 14 post pump implantation. A midline thoracotomy/laparatomy was performed to expose the abdominal cavity and the thoracic cavity. The left ventricle was cannulated at the base and animals exsanguinated using a 23G needle and 1 ml syringe. Serum was separated, frozen and analyzed for HBV DNA and antigen levels. Experimental groups were compared to the saline control group in respect to percent change from day 0 to day 14. HBV DNA was assayed by quantitative PCR.  
     RESULTS  
     [0214] Table XII is a summary of the group designation and dosage levels used in this HBV transgenic mouse study. Baseline blood samples were obtained via a retroorbital bleed and animals (N=10/group) received anti-HBV enzymatic nucleic acids (100 mg/kg/day) as a continuous SC infusion. After 14 days, animals treated with a enzymatic nucleic acid targeting site 273 (RPI.18341) of the HBV RNA showed a significant reduction in serum HBV DNA concentration, compared to the saline treated animals as measured by a quantitative PCR assay. More specifically, the saline treated animals had a 69% increase in serum HBV DNA concentrations over this 2-week period while treatment with the 273 enzymatic nucleic acid (RPI.18341) resulted in a 60% decrease in serum HBV DNA concentrations. Enzymatic nucleic acids directed against sites 1833 (RPI.18371), 1873 (RPI.18418), and 1874 (RPI.18372) decreased serum HBV DNA concentrations by 49%, 15% and 16%, respectively.  
     Example 9  
     HBV Transgenic Mouse Study B  
     [0215] A transgenic mouse strain (founder strain 1.3.32 with a C57B1/6 background) that expresses HBV RNA and forms HBV viremia (Morrey et al, 1999,  Antiviral Res.,  42, 97-108; Guidotti et al., 1995,  J. Virology,  69, 10, 6158-6169) was utilized to study the in vivo activity of enzymatic nucleic acids (RPI.18341 and RPI.18371) of the instant invention. This model is predictive in screening for anti-HBV agents. Enzymatic nucleic acid or the equivalent volume of saline was administered via a continuous s.c. infusion using Alzet® mini-osmotic pumps for 14 days. Alzet® pumps were filled with test material(s) in a sterile fashion according to the manufacturer&#39;s instructions. Prior to in vivo implantation, pumps were incubated at 37° C. overnight (≧18 hours) to prime the flow modulators. On the day of surgery, animals were lightly anesthetized with a ketamine/xylazine cocktail (94 mg/kg and 6 mg/kg, respectively; 0.3 ml, IP). Baseline blood samples (200 μl) were obtained from each animal via a retro-orbital bleed. For animals in groups 1-10 (Table XIII), a 2 cm area near the base of the tail was shaved and cleansed with betadine surgical scrub and sequentially with 70% alcohol. A 1 cm incision in the skin was made with a #15 scalpel blade or a blunt pair of scissors near the base of the tail. Forceps were used to open a pocket rostrally (i.e., towards the head) by spreading apart the subcutaneous connective tissue. The pump was inserted with the delivery portal pointing away from the incision. Wounds were closed with sterile 9-mm stainless steel clips or with sterile 4-0 suture. Animals were then allowed to recover from anesthesia on a warm heating pad before being returned to their cage. Wounds were checked daily. Clips or sutures were replaced as needed. Incisions typically healed completely within 7 days post-op. Animals were then deeply anesthetized with the ketamine/xylazine cocktail (150 mg/kg and 10 mg/kg, respectively; 0.5 ml, IP) on day 14 post pump implantation. A midline thoracotomy/laparatomy was performed to expose the abdominal cavity and the thoracic cavity. The left ventricle was cannulated at the base and animals exsanguinated using a 23G needle and 1 ml syringe. Serum was separated, frozen and analyzed for HBV DNA and antigen levels. Experimental groups were compared to the saline control group in respect to percent change from day 0 to day 14. HBV DNA was assayed by quantitative PCR. Additionally, mice treated with 3TC® by oral gavage at a dose of 300 mg/kg/day for 14 days (group 11, Table XIII) were used as a positive control.  
     RESULTS  
     [0216] Table XIII is a summary of the group designation and dosage levels used in this HBV transgenic mouse study. Baseline blood samples were obtained via a retroorbital bleed and animals (N=15/group) received anti-HBV enzymatic nucleic acids (100 mg/kg/day, 30 mg/kg/day, 10 mg/kg/day) as a continuous SC infusion. The results of this study are summarized in FIGS. 6, 7, and  8 . As FIGS. 6, 7, and  8  demonstrate, Enzymatic nucleic acids directed against sites 273 (RPI.18341) and 1833 (RPI.18371) demonstrate reduction in the serum HBV DNA levels following 14 days of enzymatic nucleic acid treatment in HBV transgenic mice, as compared to scrambled attenuated core (SAC) enzymatic nucleic acid and saline controls. Furthermore, these enzymatic nucleic acids provide similar, and in some cases, greater reduction of serum HBV DNA levels, as compared to the 3TC® positive control, at lower doses than the 3TC® positive control.  
     Example 10  
     HBV DNA Reduction in HepG2.2.15 cells  
     [0217] Enzymatic nucleic acid treatment of HepG2.2.15 cells was performed in a 96-well plate format, with 12 wells for each different enzymatic nucleic acid tested (RPI.18341, RPI.18371, RPI.18372, RPI.18418, RPI.20599SAC). HBV DNA levels in the media collected between 120 and 144 hours following transfection was determined using the Roche Amplicor HBV Assay. Treatment with RPI.18341 targeting site 273 resulted in a significant (P&lt;0.05) decrease in HBV DNA levels of 62% compared to the SAC (RPI.20599). Treatment with RPI.18371 (site 1833) or RPI.18372 (site 1874) resulted in reductions in HBV DNA levels of 55% and 58% respectively, as compared to treatment with the SAC RPI.20599 (see FIG. 9).  
     Example 11  
     RPI 18341 Combination Treatment with Lamivudine/Infergen® 
     [0218] The therapeutic use of nucleic acid molecules of the invention either alone or in combination with current therapies, for example lamivudine or type 1 IFN, can lead to improved HBV treatment modalities. To assess the potential of combination therapy, HepG2 cells transfected with a replication competent HBV cDNA, were treated with RPI 18341(HepBzyme™), Infergen® (Amgen, Thousand Oaks Calif.), and/or Lamivudine (Epivir®: GlaxoSmithKline, Research Triangle Park N.C.) either alone or in combination. Results indicated that combination treatment with either RPI 18341 plus Infergen® or combination of RPI 18341 plus lamivudine results in additive down regulation of HBsAg expression (P&lt;0.001). These studies can be applied to the treatment of lamivudine resistant cells to further assses the potential for combination therapy of RPI 18341 plus currently available therapies for the treatment of chronic Hepatitis B.  
     [0219] Hep G2 cells were plated (2×104 cells/well) in 96-well microtiter plates and incubated overnight. A cationic lipid/DNA/enzymatic nucleic acid complex was formed containing (at final concentrations) lipid (11-15 μg/mL), re-ligated psHBV-1 (4.5 μg/mL) and enzymatic nucleic acid (100-200 nM) in growth media. Following a 15 min incubation at 37° C., 20 μL of the complex was added to the plated Hep G2 cells in 80 μL of growth media minus antibiotics. For combination treatment with interferon, interferon (Infergen®, Amgen, Thousand Oaks Calif.) was added at 24 hr post-transfection and then incubated for an additional 96 hr. In the case of co-treatment with Lamivudine (3TC®), the enzymatic nucleic acid-containing cell culture media was removed at 120 hr post-transfection, fresh media containing Lamivudine (Epivir®: GlaxoSmithKline, Research Triangle Park N.C.) was added, and then incubated for an additional 48 hours. Treatment with Lamivudine or interferon individually was done on Hep G2 cells transfected with the pSHBV-1 vector alone and then treated identically to the co-treated cells. All transfections were performed in triplicate. Analysis of HBsAg levels was performed using the Diasorin HBsAg ELISA kit.  
     RESULTS  
     [0220] At either 500 or 1000 units of Infergen®, the addition of 200 nM of RPI.18341 results in a 75-77% increase in anti-HBV activity as judged by the level of HBsAg secreted from the treated Hep G2 cells. Conversely, the anti-HBV activity of RPI.18341 (at 200 nM) is increased 31-39% when used in combination of 500 or 1000 units of Infergen® (FIG. 11).  
     [0221] At 25 nM Lamivudine (3TC®), the addition of 100 nM of RPI.18341 results in a 48% increase in anti-HBV activity as judged by the level of HBsAg secreted from treated Hep G2 cells. Conversely, the anti-HBV activity of RPI.18341 (at 100 nM) is increased 31% when used in combination with 25 nM Lamivudine (FIG. 12).  
     Example 12  
     RPI 18341 Treatment in Cells Expressing Lamivudine Resistant HBV  
     [0222] Antiviral therapy with Lamivudine can lead to development of viral resistance and subsequent viral rebound in patients with HBV infention. Viral resistance has been seen in 15% to 30% of HBV patients undergoing Lamivudine treatment for a period of one year. HBV resistance to Lamivudine is associated with characteristic mutations in the conserved tyrosine, methionine, aspartate, aspartate (YMDD) amino acid motif of viral polymerase. The most frequently described mutation leading to Lamivudine resistance is the substitution of valine or isoleucine for methionine at residue 552. Additional mutations in adjacent areas, including mutations at residues 528 and 555, have been detected and may also be involved in Lamivudine and/or other nucleoside resistance  
     [0223] To assess the efficacy of enzymatic nucleic acid molecules against Lamivudine resistant HBV, cells that express Lamivudine resistant HBV, Hep G2DM2 cells, (see for example Fu and Cheng, 2000 , Antimicrobial Agents and Chemotherapy,  44, 3402-3407) were treated with RPI 18341 (HepBzyme™) at a concentration of 150 nM. Treatment with RPI 18341 results in down regulation of HBsAg expression similar to that observed in Heg G2 cells expressing wildtype HBV (FIG. 13). This data indicates that enzymatic nucleic acid molecules, whether used alone or in combination with Lamivudine, are active against HBV resistance mutations that develop in nearly one third of patients within one year of beginning treatment with lamivudine. These results indicate that treatment with enzmatic nucleic acid molecules can be a potential new therapeutic option for patients with chronic hepatitis B infection.  
     Example 13  
     “No-ribo” Enzymatic Nucleic Acid Molecule Targeting HBV  
     [0224] To improve stability, efficacy and pharmacokinetic properties of enzymatic nucleic acid molecules targeting HBV, an enzymatic nucleic acid molecule targeting site 273 of the HBV pregenomic RNA was designed such that the enzymatic nucleic acid molecule completely lacked any ribonucleotides (RPI 25516 in Table XI, see also FIG. 14) by substituting ribonucleotides with 2′-O-methyl ribonucleotides. This enzymatic nucleic acid molecule lacking ribonucleotides demonstrates high levels of anti-HBV activity in the HBsAg ELISA cell culture system compared to binding attenuated (BAC, RPI 25535) and scrambled attenuated (SAC, RPI 25536) controls (see FIG. 15). In addition, the no-ribo enzymatic nucleic acid molecule demonstrates improved activity in the HBsAg ELISA cell culture system compared to HepBzyme (RPI 18341) which has 5 ribonucleotides.  
     Cell Culture Models  
     [0225] As previously mentioned, HBV does not infect cells in culture. However, transfection of HBV DNA (either as a head-to-tail dimer or as an “overlength” genome of &gt;100%) into HuH7 or Hep G2 hepatocytes results in viral gene expression and production of HBV virions released into the media. Thus, HBV replication competent DNA can be co-transfected with enzymatic nucleic acids in cell culture. Such an approach has been used to report intracellular enzymatic nucleic acid activity against HBV (zu Putlitz, et al., 1999,  J. Virol.,  73, 5381-5387, and Kim et al., 1999,  Biochem. Biophys. Res. Commun.,  257, 759-765). In addition, stable hepatocyte cell lines have been generated that express HBV. Enzymatic nucleic acid is delivered to these cell lines; however, such an assay requires the performance of a delivery screen. Intracellular HBV gene expression can be assayed by a Taqman® assay for HBV RNA or by ELISA for HBV protein. Extracellular virus can be assayed by PCR for DNA or ELISA for protein. Antibodies are commercially available for HBV surface antigen and core protein. A secreted alkaline phosphatase expression plasmid can be used to normalize for differences in transfection efficiency and sample recovery.  
     [0226] Animal Models  
     [0227] There are several small animal models to study HBV replication. One is the transplantation of HBV-infected liver tissue into irradiated mice. Viremia (as evidenced by measuring HBV DNA by PCR) is first detected 8 days after transplantation and peaks between 18-25 days (Ilan et al., 1999,  Hepatology,  29, 553-562).  
     [0228] Transgenic mice that express HBV have also been used as a model to evaluate potential anti-virals. HBV DNA is detectable in both liver and serum (Guidotti et al., 1995, J. Virology, 69, 10, 6158-6169; Morrey et al., 1999,  Antiviral Res.,  42, 97-108).  
     [0229] An additional model is to establish subcutaneous tumors in nude mice with Hep G2 cells transfected with HBV. Tumors develop in about 2 weeks after inoculation and express HBV surface and core antigens. HBV DNA and surface antigen is also detected in the circulation of tumor-bearing mice (Yao et al., 1996,  J. Viral Hepat.,  3, 19-22).  
     [0230] Woodchuck hepatitis virus (WHV) is closely related to HBV in its virus structure, genetic organization, and mechanism of replication. As with HBV in humans, persistent WHV infection is common in natural woodchuck populations and is associated with chronic hepatitis and hepatocellular carcinoma (HCC). Experimental studies have established that WHV causes HCC in woodchucks and woodchucks chronically infected with WHV have been used as a model to test a number of anti-viral agents. For example, the nucleoside analogue 3T3 was observed to cause dose dependent reduction in virus (50% reduction after two daily treatments at the highest dose) (Hurwitz et al., 1998.  Antimicrob. Agents Chemother.,  42, 2804-2809).  
     [0231] Indications  
     [0232] Particular degenerative and disease states that can be associated with HBV expression modulation include but are not limited to, HBV infection, hepatitis, cancer, tumorigenesis, cirrhosis, liver failure and others.  
     [0233] The present body of knowledge in HBV research indicates the need for methods to assay HBV activity and for compounds that can regulate HBV expression for research, diagnostic, and therapeutic use.  
     [0234] Lamivudine (3TC®), L-FMAU, adefovir dipivoxil, type 1 Interferon, therapeutic vaccines, steriods, and 2′-5′ Oligoadenylates are non-limiting examples of pharmaceutical agents that can be combined with or used in conjunction with the nucleic acid molecules (e.g. enzymatic nucleic acids and antisense molecules) of the instant invention. Those skilled in the art will recognize that other drugs or other therapies can similarly and readily be combined with the nucleic acid molecules of the instant invention (e.g. enzymatic nucleic acids and antisense molecules) and are, therefore, within the scope of the instant invention.  
     Diagnostic Uses  
     [0235] The nucleic acid molecules of this invention (e.g., enzymatic nucleic acids) can be used as diagnostic tools to examine genetic drift and mutations within diseased cells or to detect the presence of HBV RNA in a cell. The close relationship between enzymatic nucleic acid activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple enzymatic nucleic acids described in this invention, one can map nucleotide changes which are important to RNA structure and function in vitro, as well as in cells and tissues. Cleavage of target RNAs with enzymatic nucleic acids can be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease. In this manner, other genetic targets can be defined as important mediators of the disease. These experiments will lead to better treatment of the disease progression by affording the possibility of combinational therapies (e.g., multiple enzymatic nucleic acids targeted to different genes, enzymatic nucleic acids coupled with known small molecule inhibitors, or intermittent treatment with combinations of enzymatic nucleic acids and/or other chemical or biological molecules). Other in vitro uses of enzymatic nucleic acids of this invention are well known in the art, and include detection of the presence of mRNAs associated with HBV-related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a enzymatic nucleic acid using standard methodology.  
     [0236] In a specific example, enzymatic nucleic acids which cleave only wild-type or mutant forms of the target RNA are used for the assay. The first enzymatic nucleic acid is used to identify wild-type RNA present in the sample and the second enzymatic nucleic acid is used to identify mutant RNA in the sample. As reaction controls, synthetic substrates of both wild-type and mutant RNA are cleaved by both enzymatic nucleic acids to demonstrate the relative enzymatic nucleic acid efficiencies in the reactions and the absence of cleavage of the “non-targeted” RNA species. The cleavage products from the synthetic substrates also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus each analysis involves two enzymatic nucleic acids, two substrates and one unknown sample which is combined into six reactions. The presence of cleavage products is determined using an RNAse protection assay so that full-length and cleavage fragments of each RNA is analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain insight into the expression of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype (i.e., HBV) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels is adequate and decreases the cost of the initial diagnosis. Higher mutant form to wild-type ratios is correlated with higher risk whether RNA levels are compared qualitatively or quantitatively.  
     [0237] Additional Uses  
     [0238] Potential usefulness of sequence-specific enzymatic nucleic acid molecules of the instant invention might have many of the same applications for the study of RNA that DNA restriction endonucleases have for the study of DNA (Nathans et al., 1975  Ann. Rev. Biochem.  44:273). For example, the pattern of restriction fragments can be used to establish sequence relationships between two related RNAs, and large RNAs can be specifically cleaved to fragments of a size more useful for study. The ability to engineer sequence specificity of the enzymatic nucleic acid molecule is ideal for cleavage of RNAs of unknown sequence. Applicant describes the use of nucleic acid molecules to down-regulate gene expression of target genes in bacterial, microbial, fungal, viral, and eukaryotic systems including plant, or mammalian cells.  
     [0239] All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.  
     [0240] One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.  
     [0241] It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims.  
     [0242] The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.  
     [0243] In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.  
     [0244] Other embodiments are within the following claims.  
               TABLE I                       I.       Characteristics of naturally occurring enzymatic nucleic acids                                    Group I Introns       Size: ˜150 to &gt;1000 nucleotides.       Requires a U in the target sequence immediately 5′ of the cleavage site.       Binds 4-6 nucleotides at the 5′-side of the cleavage site.       Reaction mechanism: attack by the 3′-OH of guanosine to generate       cleavage products with 3′-OH and 5′-guanosine.       Additional protein cofactors required in some cases to help folding and       maintainance of the active structure.       Over 300 known members of this class. Found as an intervening sequence       in  Tetrahymena thermophila  rRNA, fungal mitochondria, chloroplasts,       phage T4, blue-green algae, and others.       Major structural features largely established through phylogenetic       comparisons, mutagenesis, and biochemical studies [ i , ii ].       Complete kinetic framework established for one ribozyme [ iii , iv , v , vi ].       Studies of ribozyme folding and substrate docking underway [ vii , viii , ix ].       Chemical modification investigation of important residues well estab-       lished [ x , xi ].       The small (4-6 nt) binding site may make this ribozyme too non-specific       for targeted RNA cleavage, however, the Tetrahymena group I intron       has been used to repair a “defective” β-galactosidase message by the       ligation of new β-galactosidase sequences onto the defective mes-       sage [ xii ].       Size: ˜290 to 400 nucleotides.       RNA portion of a ubiquitous ribonucleoprotein enzyme.       Cleaves tRNA precursors to form mature tRNA [ xiii ].       Reaction mechanism: possible attack by M 2+ -OH to generate cleavage       products with 3′-OH and 5′-phosphate.       RNAse P is found throughout the prokaryotes and eukaryotes. The RNA       subunit has been sequenced from bacteria, yeast, rodents, and primates.       Recruitment of endogenous RNAse P for therapeutic applications is pos-       sible through hybridization of an External Guide Sequence (EGS) to the       target RNA [ xiv , xv ]       Important phosphate and 2′ OH contacts recently identified [ xvi , xvii ]       Group II Introns       Size: &gt;1000 nucleotides.       Trans cleavage of target RNAs recently demonstrated [ xviii , xix ].       Sequence requirements not fully determined.       Reaction mechanism: 2′-OH of an internal adenosine generates cleavage       products with 3′-OH and a “lariat” RNA containing a 3′-5′ and a       2′-5′ branch point.       Only natural ribozyme with demonstrated participation in DNA cleav-       age [ xx , xxi ] in addition to RNA cleavage and ligation.       Major structural features largely established through phylogenetic       comparisons [ xxii ].       Important 2′ OH contacts beginning to be identified [ xxiii ]       Kinetic framework under development [ xxiv ]       Neurospora VS RNA       Size: ˜144 nucleotides.       Trans cleavage of hairpin target RNAs recently demonstrated [ xxv ].       Sequence requirements not fully determined.       Reaction mechanism: attack by 2′-OH 5′ to the scissile bond to generate       cleavage products with 2′,3′-cyclic phosphate and 5′-OH ends.       Binding sites and structural requirements not fully determined.       Only 1 known member of this class. Found in Neurospora VS RNA.       Hammerhead Ribozyme       (see text for references)       Size: ˜13 to 40 nucleotides.       Requires the target sequence UH immediately 5′ of the cleavage site.       Binds a variable number nucleotides on both sides of the cleavage site.       Reaction mechanism: attack by 2′-OH 5′ to the scissile bond to generate       cleavage products with 2′,3′-cyclic phosphate and 5′-OH ends.       14 known members of this class. Found in a number of plant pathogens       (virusoids) that use RNA as the infectious agent.       Essential structural features largely defined, including 2 crystal struc-       tures [ xxvi , xxvii ]       Minimal ligation activity demonstrated (for engineering through in vitro       selection) [ xxviii ]       Complete kinetic framework established for two or more ribozymes [ xxix ].       Chemical modification investigation of important residues well estab-       lished [ xxx ].       Hairpin Ribozyme       Size: ˜50 nucleotides.       Requires the target sequence GUC immediately 3′ of the cleavage site.       Binds 4-6 nucleotides at the 5′-side of the cleavage site and a variable       number to the 3′-side of the cleavage site.       Reaction mechanism: attack by 2′-OH 5′ to the scissile bond to       generate cleavage products with 2′,3′-cyclic phosphate and 5′-OH ends.       3 known members of this class. Found in three plant pathogen (satellite       RNAs of the tobacco ringspot virus, arabis mosaic virus and chicory       yellow mottle virus) which uses RNA as the infectious agent.       Essential structural features largely defined [ xxxi , xxxii , xxxiii , xxxiv ]       Ligation activity (in addition to cleavage activity) makes ribozyme       amenable to engineering through in vitro selection [ xxxv ]       Complete kinetic framework established for one ribozyme [ xxxvi ].       Chemical modification investigation of important residues       begun [ xxxvii , xxxviii ].       Hepatitis Delta Virus (HDV) Ribozyme       Size: ˜60 nucleotides.       Trans cleavage of target RNAs demonstrated [ xxxix ].       Binding sites and structural requirements not fully determined, although no       sequences 5′ of cleavage site are required. Folded ribozyme contains a       pseudoknot structure [ xl ].       Reaction mechanism: attack by 2′-OH 5′ to the scissile bond to generate       cleavage products with 2′,3′-cyclic phosphate and 5′-OH ends.       Only 2 known members of this class. Found in human HDV.         xli Circular form of HDV is active and shows increased nuclease stabil-       ity [xlii]                                                                                                                                                                                                                                                                                                                                                                  
 
     [0245]               TABLE II                          A. 2.5 μmol Synthesis Cycle ABI 394 Instrument                                     Reagent   Equivalents   Amount   Wait Time* DNA   Wait Time* 2′-O-methyl   Wait Time*RNA               Phosphoramidites     6.5    163 μL    45 sec    2.5 min    7.5 min       S-Ethyl Tetrazole    23.8    238 μL    45 sec    2.5 min    7.5 min       Acetic Anhydride    100    233 μL    5 sec    5 sec    5 sec       N-Methyl    186    233 μL    5 sec    5 sec    5 sec       Imidazole       TCA    176    2.3 mL    21 sec    21 sec    21 sec       Iodine    11.2    1.7 mL    45 sec    45 sec    45 sec       Beaucage    12.9    645 μL   100 sec   300 sec   300 sec       Acetonitrile   NA   6.67 mL   NA   NA   NA                 B. 0.2 μmol Synthesis Cycle ABI 394 Instrument                                     Phosphoramidites    15     31 μL    45 sec   233 sec   465 sec       S-Ethyl Tetrazole    38.7     31 μL    45 sec   233 min   465 sec       Acetic Anhydride    655    124 μL    5 sec    5 sec    5 sec       N-Methyl   1245    124 μL    5 sec    5 sec    5 sec       Imidazole       TCA    700    732 μL    10 sec    10 sec    10 sec       Iodine    20.6    244 μL    15 sec    15 sec    15 sec       Beaucage     7.7    232 μL   100 sec   300 sec   300 sec       Acetonitrile   NA   2.64 mL   NA   NA   NA                         C. 0.2 μmol Synthesis Cycle 96 well Instrument                                         Equivalents:DNA/   Amount: DNA/2′-O-       Wait Time* 2′-O-           Reagent   2′-O-methyl/Ribo   methyl/Ribo   Wait Time* DNA   methyl   Wait Time* Ribo               Phosphoramidites   22/33/66      40/60/120 μL    60 sec   180 sec   360 sec       S-Ethyl Tetrazole   70/105/210      40/60/120 μL    60 sec   180 min   360 sec       Acetic Anhydride   265/265/265      50/50/50 μL    10 sec    10 sec    10 sec       N-Methyl   502/502/502      50/50/50 μL    10 sec    10 sec    10 sec       Imidazole       TCA   238/475/475     250/500/500 μL    15 sec    15 sec    15 sec       Iodine   6.8/6.8/6.8      80/80/80 μL    30 sec    30 sec    30 sec       Beaucage   34/51/51     80/120/120   100 sec   200 sec   200 sec       Acetonitrile   NA   1150/1150/1150 μL   NA   NA   NA                            
     [0246]               TABLE III                          HBV Strains and Accession numbers                     Accession Number   NAME               AF100308.1   AF100308  Hepatitis B virus strain 2-18, complete       AB026815.1   AB026815  Hepatitis B virus DNA, complete genome,       AH033559.1   AB033559  Hepatitis B virus DNA, complete genome,       AB033558.1   AB033558  Hepatitis B virus DNA, complete genome,       AB033557.1   AB033557  Hepatitis B virus DNA, complete genome,       AB033556.1   AB033556  Hepatitis B virus DNA, complete genome,       AB033555.1   AB033555  Hepatitis B virus DNA, complete genome,       AB033554.1   AB033554  Hepatitis B virus DNA, complete genome,       AB033553.1   AB033553  Hepatitis B virus DNA, complete genome,       AB033552.1   AB033552  Hepatitis B virus DNA, complete genome,       AB033551.1   AB033551  Hepatitis B virus DNA, complete genome,       AB033550.1   AB033550  Hepatitis B virus DNA, complete genome       AF143308.1   AF143308  Hepatitis B virus clone WB1254, complete       AF1433O7.1   AF143307  Hepatitis B virus clone RM518, complete       AF143306.1   AF143306  Hepatitis B virus clone RMS17, complete       AF143305.1   AF143305  Hepatitis B virus clone RM501, complete       AF143304.1   AF143304  Hepatitis B virus clone HD319, complete       AF143303.1   AF143303  Hepatitis B virus clone HD1406, complete       AF143302.1   AF143302  Hepatitis B virus clone HD1402, complete       AF143301.1   AF143301  Hepatitis B virus clone BW1903, complete       AF143300.1   AF143300  Hepatitis B virus clone 7832-G4, complete       AF143299.1   AF143299  Hepatitis B virus clone 7744-G9, complete       AF143298.1   AF143298  Hepatitis B virus clone 7720-G8, complete       AB026814.1   AB026814  Hepatitis B virus DNA, complete genome,       AB026813.1   AB026813  Hepatitis B virus DNA, complete genome,       AB026812.1   AB026812  Hepatitis B virus DNA, complete genome,       AB026811.1   AB026811  Hepatitis B virus DNA, complete genome,       AJ131956.1   HBV131956 Hepatitis B virus complete genome,       AF151735.1   AF151735  Hepatitis B virus, complete genome       AF090842.1   AF090842  Hepatitis B virus strain G5.27295, complete       AF090841.1   AF090841  Hepatitis B virus strain G4.27241, complete       AF090840.1   AF090840  Hepatitis B virus strain G3.27270, complete       AF090839.1   AF090839  Hepatitis B virus strain G2.27246, complete       AF090838.1   AF090838  Hepatitis B virus strain P1.27239, complete       Y18858.1   HBV18858  Hepatitis B virus complete genome, isolate       Y18857.1   HBV18857  Hepatitis B virus complete genome, isolate       D12980.1   HPBCG     Hepatitis B virus subtype adr (SRADR) DNA,       Y18856.1   HBV18856  Hepatitis B virus complete genome, isolate       Y18855.1   HBV18855  Hepatitis B virus complete genome, isolate       AJ131133.1   HBV131133 Hepatitis H virus, complete genome, strain       X80925.1   HBVP6PCXX Hepatitis B virus (patient 6) complete       X80926.1   HBVP5PCXX Hepatitis B virus (patient 5) complete       X80924.1   HBVP4PCXX Hepatitis B virus (patient 4) complete       AF100309.1   Hepatitis B virus strain 56, complete genome       AF068756.1   AF068756  Hepatitis B virus, complete genome       AF043593.1   AF043593  Hepatitis B virus isolate 6/89, complete       Y07587.1   HBVAYWGEN Hepatitis B virus, complete genome       D28880.1   D28880    Hepatitis B virus DNA, complete genome, strain       X98076.1   HBVDEFVP3 Hepatitis B virus complete genome with       X98075.1   HBVDEFVP2 Hepatitis B virus complete genome with       X98074.1   HBVDEFVP1 Hepatitis B virus complete genome with       X98077.1   HBVCGWITY Hepatitis B virus complete genome, wild type       X98072.1   HBVCGINSC Hepatitis B virus complete genome with       X98073.1   HBVCGINCX Hepatitis B virus complete genome with       U95551.1   U95551    Hepatitis B virus subtype ayw, complete genome       D23684.1   HPBC6T588 Hepatitis B virus (C6-TKBS88) complete genome       D23683.1   HPBC5HK02 Hepatitis B virus (C5-HBVK02) complete genome       D23682.1   HPBB5HK01 Hepatitis B virus (BS-HBVK01) complete genome       D23681.1   HPBC4HST2 Hepatitis B virus (C4-HBVST2) complete genome       D23680.1   HPBB4HST1 Hepatitis B virus (B4-HBVST1) complete genome       D00331.1   HPBADW3   Hepatitis B virus genome, complete genome       D00330.1   HPBADW2   Hepatitis B virus genome, complete genome       D50489.1   HPBA11A   Hepatitis B virus DNA, complete genome       D23679.1   HPBA3HMS2 Hepatitis B virus (A3-HBVMS2) complete genome       D23678.1   HPBA2HYS2 Hepatitis B virus (A2-HBVYS2) complete genome       D23677.1   HPBA1HKK2 Hepatitis B virus (A1-HBVKK2) complete genome       D16665.1   HPBADRM   Hepatitis B virus DNA, complete genome       D00329.1   HPHADW1   Hepatitis B virus (HBV) genome, complete genome       X97851.1   HBVP6CSX  Hepatitis B virus (patient 6) complete genome       X97850.1   HBVP4CSX  Hepatitis B virus (patient 4) complete genome       X97849.1   HBVP3CSX  Hepatitis B virus (patient 3) complete genome       X97848.1   HBVP2CSX  Hepatitis B virus (patient 2) complete genome       X51970.1   HVHEPB    Hepatitis B virus (HBV 991) complete genome       M38636.1   HPBCGADR  Hepatitis B virus, subtype adr, complete genome       X59795.1   HBVAYWMCG Hepatitis B virus (ayw subtype mutant)       M38454.1   HPBADR1CG Hepatitis B virus, complete genome       M32138.1   HPBHBVAA  Hepatitis B virus variant HBV-alpha1, complete       J02203.1   HPBAYW    Human hepatitis B virus (subtype ayw), complete       M12906.1   HPBADRA   Hepatitis B virus subtype adr, complete genome       M54923.1   HPBADWZ   Hepatitis B virus (subtype adw), complete genome       L27106.1   HPBMUT    Hepatitis B virus mutant complete genome                    
     [0247]               TABLE IV                          HBV Substrate Sequence                         NT Position*   Substrate   Seq ID                                 82   CUAUCGUCCCCUUCUUCAUC   1       101   CUACCGUUCCGGCC   2       159   CUUCUCAUCU   3       184   CUUCCCUUCACCAC   4       269   GACUCUCAGAAUGUCAACGAC   5       381   CUGUAGGCAUAAAUGGUCUG   6       401   GUUCACCAGCACCAUGCAACUUUUU   7       424   UUUCACGUCUGCCUAAUCAUC   8       524   AUUUGGAGCUUC   9       562   CUGACUUCUUUCCUUCUAUUC   10       649   CUCACCAUACCGCACUCA   11       667   GGCAAGCUAUUCUGUG   12       717   GGAAGUAAUUUGGAAGAC   13       758   CAGCUAUGUCAAUGUUAA   14       783   CUAAAAUCGGCCUAAAAUCAGAC   15       812   CAUUUCCUGUCUCACUUUUGGAAGAG   16       887   UCCUGCUUACAGAC   17       922   CAACACUUCCGGAAACUACUGUUGUUAG   18       989   CUCGCCUCGCAGACGAAGGUCUC   19       1009   CAAUCGCCGCGUCGCAGAAG   20       1031   AUCUCAAUCUCGGGAAUCUCAA   21       1052   AUGUUAGUAUCCCUUGGACUC   22       1072   CAUAAGGUGGGAAACUUUACUG   23       1109   CUGUACCUAUUCUUUAAAUCC   24       1127   CUGAGUGGCAAACUCCC   25       1271   CCAAAUAUCUGCCCUUGGACAA   26       1297   AUUAAACCAUAUUAUCCUGAACA   27       1319   AUGCAGUUAAUCAUUACUUCAAAACUA   28       1340   AAACUAGGCAUUA   29       1370   AGGCCCGCAUUCUAUAUAAGAGAG   30       1393   GAAACUACGCGCAGCGCCUCAUUUUGU   31       1412   CAUUUUGUGGGUCACCAUA   32       1441   CAAGAGCUACAGCAUGGG   33                                                    
     [0248]               TABLE V                          HUMAN HBV HAMMERHEAD ENZYMATIC NUCLEIC ACID AND TARGET SEQUENCE                                 Pos   Substrate   Seq ID   Enzymatic nucleic acid   Rz Seq ID                                         13   CCACCACU U UCCACCAA   34   UUGGUGGA CUGAUGAG  GCCGUUAGGC  CGAA AGUGGUGG   2543       14   CACCACUU U CCACCAAA   35   UUUGGUGG CUGAUGAG  GCCGUUAGGC  CGAA AAGUGGUG   2544       15   ACCACUUU C CACCAAAC   36   GUUUGGUG CUGAUGAG  GCCGUUAGGC  CGAA AAAGUGGU   2545       25   ACCAAACU C UUCAAGAU   37   AUCUUGAA CUGAUGAG  GCCGUUAGGC  CGAA AGUUUGGU   2546       27   CAAACUCU U CAAGAUCC   38   GGAUCUUG CUGAUGAG  GCCGUUAGGC  CGAA AGAGUUUG   2547       28   AAACUCUU C AAGAUCCC   39   GGGAUCUU CUGAUGAG  GCCGUUAGGC  CGAA AAGAGUUU   2548       34   UUCAAGAU C CCAGAGUC   40   GACUCUGG CUGAUGAG  GCCGUUAGGC  CGAA AUCUUGAA   2549       42   CCCAGAGU C AGGGCCCU   41   AGGGCCCU CUGAUGAG  GCCGUUAGGC  CGAA ACUCUGGG   2550       53   GGCCCUGU A CUUUCCUG   42   CAGGAAAG CUGAUGAG  GCCGUUAGGC  CGAA ACAGGGCC   2551       56   CCUGUACU U UCCUGCUG   43   CAGCAGGA CUGAUGAG  GCCGUUAGGC  CGAA AGUACAGG   2552       57   CUGUACUU U CCUGCUGG   44   CCAGCAGG CUGAUGAG  GCCGUUAGGC  CGAA AAGUACAG   2553       58   UGUACUUU C CUGCUGGU   45   ACCAGCAG CUGAUGAG  GCCGUUAGGC  CGAA AAAGUACA   2554       71   UGGUGGCU C CAGUUCAG   46   CUGAACUG CUGAUGAG  GCCGUUAGGC  CGAA AGCCACCA   2555       76   GCUCCAGU U CAGGAACA   47   UGUUCCUG CUGAUGAG  GCCGUUAGGC  CGAA ACUGGAGC   2556       77   CUCCAGUU C AGGAACAG   48   CUGUUCCU CUGAUGAG  GCCGUUAGGC  CGAA AACUGGAG   2557       97   GCCCUGCU C AGAAUACU   49   AGUAUUCU CUGAUGAG  GCCGUUAGGC  CGAA AGCAGGGC   2558       103   CUCAGAAU A CUGUCUCU   50   AGAGACAG CUGAUGAG  GCCGUUAGGC  CGAA AUUCUGAG   2559       108   AAUACUGU C UCUGCCAU   51   AUGGCAGA CUGAUGAG  GCCGUUAGGC  CGAA ACAGUAUU   2560       110   UACUGUCU C UGCCAUAU   52   AUAUGGCA CUGAUGAG  GCCGUUAGGC  CGAA AGACAGUA   2561       117   UCUGCCAU A UCGUCAAU   53   AUUGACGA CUGAUGAG  GCCGUUAGGC  CGAA AUGGCAGA   2562       119   UGCCAUAU C GUCAAUCU   54   AGAUUGAC CUGAUGAG  GCCGUUAGGC  CGAA AUAUGGCA   2563       122   CAUAUCGU C AAUCUUAU   55   AUAAGAUU CUGAUGAG  GCCGUUAGGC  CGAA ACGAUAUG   2564       126   UCGUCAAU C UUAUCGAA   56   UUCGAUAA CUGAUGAG  GCCGUUAGGC  CGAA AUUGACGA   2565       128   GUCAAUCU U AUCGAAGA   57   UCUUCGAU CUGAUGAG  GCCGUUAGGC  CGAA AGAUUGAC   2566       129   UCAAUCUU A UCGAAGAC   58   GUCUUCGA CUGAUGAG  GCCGUUAGGC  CGAA AAGAUUGA   2567       131   AAUCUUAU C GAAGACUG   59   CAGUCUUC CUGAUGAG  GCCGUUAGGC  CGAA AUAAGAUU   2568       150   GACCCUGU A CCGAACAU   60   AUGUUCGG CUGAUGAG  GCCGUUAGGC  CGAA ACAGGGUC   2569       168   GAGAACAU C GCAUCAGG   61   CCUGAUGC CUGAUGAG  GCCGUUAGGC  CGAA AUGUUCUC   2570       173   CAUCGCAU C AGGACUCC   62   GGAGUCCU CUGAUGAG  GCCGUUAGGC  CGAA AUGCGAUG   2571       180   UCAGGACU C CUAGGACC   63   GGUCCUAG CUGAUGAG  GCCGUUAGGC  CGAA AGUCCUGA   2572       183   GGACUCCU A GGACCCCU   64   AGGGGUCC CUGAUGAG  GCCGUUAGGC  CGAA AGGAGUCC   2573       195   CCCCUGCU C GUGUUACA   65   UGUAACAC CUGAUGAG  GCCGUUAGGC  CGAA AGCAGGGG   2574       200   GCUCGUGU U ACAGGCGG   66   CCGCCUGU CUGAUGAG  GCCGUUAGGC  CGAA ACACGAGC   2575       201   CUCGUGUU A CAGGCGGG   67   CCCGCCUG CUGAUGAG  GCCGUUAGGC  CGAA AACACGAG   2576       212   GGCGGGGU U UUUCUUGU   68   ACAAGAAA CUGAUGAG  GCCGUUAGGC  CGAA ACCCCGCC   2577       213   GCGGGGUU U UUCUUGUU   69   AACAAGAA CUGAUGAG  GCCGUUAGGC  CGAA AACCCCGC   2578       214   CGGGGUUU U UCUUGUUG   70   CAACAAGA CUGAUGAG  GCCGUUAGGC  CGAA AAACCCCG   2579       215   GGGGUUUU U CUUGUUGA   71   UCAACAAG CUGAUGAG  GCCGUUAGGC  CGAA AAAACCCC   2580       216   GGGUUUUU C UUGUUGAC   72   GUCAACAA CUGAUGAG  GCCGUUAGGC  CGAA AAAAACCC   2581       218   GUUUUUCU U GUUGACAA   73   UUGUCAAC CUGAUGAG  GCCGUUAGGC  CGAA AGAAAAAC   2582       221   UUUCUUGU U GACAAAAA   74   UUUUUGUC CUGAUGAG  GCCGUUAGGC  CGAA ACAAGAAA   2583       231   ACAAAAAU C CUCACAAU   75   AUUGUGAG CUGAUGAG  GCCGUUAGGC  CGAA AUUUUUGU   2584       234   AAAAUCCU C ACAAUACC   76   GGUAUUGU CUGAUGAG  GCCGUUAGGC  CGAA AGGAUUUU   2585       240   CUCACAAU A CCACAGAG   77   CUCUGUGG CUGAUGAG  GCCGUUAGGC  CGAA AUUGUGAG   2586       250   CACAGAGU C UAGACUCG   78   CGAGUCUA CUGAUGAG  GCCGUUAGGC  CGAA ACUCUGUG   2587       252   CAGAGUCU A GACUCGUG   79   CACGAGUC CUGAUGAG  GCCGUUAGGC  CGAA AGACUCUG   2588       257   UCUAGACU C GUGGUGGA   80   UCCACCAC CUGAUGAG  GCCGUUAGGC  CGAA AGUCUAGA   2589       268   GGUGGACU U CUCUCAAU   81   AUUGAGAG CUGAUGAG  GCCGUUAGGC  CGAA AGUCCACC   2590       269   GUGGACUU C UCUCAAUU   82   AAUUGAGA CUGAUGAG  GCCGUUAGGC  CGAA AAGUCCAC   2591       271   GGACUUCU C UCAAUUUU   83   AAAAUUGA CUGAUGAG  GCCGUUAGGC  CGAA AGAAGUCC   2592       273   ACUUCUCU C AAUUUUCU   84   AGAAAAUU CUGAUGAG  GCCGUUAGGC  CGAA AGAGAAGU   2593       277   CUCUCAAU U UUCUAGGG   85   CCCUAGAA CUGAUGAG  GCCGUUAGGC  CGAA AUUGAGAG   2594       278   UCUCAAUU U UCUAGGGG   86   CCCCUAGA CUGAUGAG  GCCGUUAGGC  CGAA AAUUGAGA   2595       279   CUCAAUUU U CUAGGGGG   87   CCCCCUAG CUGAUGAG  GCCGUUAGGC  CGAA AAAUUGAG   2596       280   UCAAUUUU C UAGGGGGA   88   UCCCCCUA CUGAUGAG  GCCGUUAGGC  CGAA AAAAUUGA   2597       282   AAUUUUCU A GGGGGAAC   89   GUUCCCCC CUGAUGAG  GCCGUUAGGC  CGAA AGAAAAUU   2598       301   CCGUGUGU C UUGGCCAA   90   UUGGCCAA CUGAUGAG  GCCGUUAGGC  CGAA ACACACGG   2599       303   GUGUGUCU U GGCCAAAA   91   UUUUGGCC CUGAUGAG  GCCGUUAGGC  CGAA AGACACAC   2600       313   GCCAAAAU U CGCAGUCC   92   GGACUGCG CUGAUGAG  GCCGUUAGGC  CGAA AUUUUGGC   2601       314   CCAAAAUU C GCAGUCCC   93   GGGACUGC CUGAUGAG  GCCGUUAGGC  CGAA AAUUUUGG   2602       320   UUCGCAGU C CCAAAUCU   94   AGAUUUGG CUGAUGAG  GCCGUUAGGC  CGAA ACUGCGAA   2603       327   UCCCAAAU C UCCAGUCA   95   UGACUGGA CUGAUGAG  GCCGUUAGGC  CGAA AUUUGGGA   2604       329   CCAAAUCU C CAGUCACU   96   AGUGACUG CUGAUGAG  GCCGUUAGGC  CGAA AGAUUUGG   2605       334   UCUCCAGU C ACUCACCA   97   UGGUGAGU CUGAUGAG  GCCGUUAGGC  CGAA ACUGGAGA   2606       338   CAGUCACU C ACCAACCU   98   AGGUUGGU CUGAUGAG  GCCGUUAGGC  CGAA AGUGACUG   2607       349   CAACCUGU U GUCCUCCA   99   UGGAGGAC CUGAUGAG  GCCGUUAGGC  CGAA ACAGGUUG   2608       352   CCUGUUGU C CUCCAAUU   100   AAUUGGAG CUGAUGAG  GCCGUUAGGC  CGAA ACAACAGG   2609       355   GUUGUCCU C CAAUUUGU   101   ACAAAUUG CUGAUGAG  GCCGUUAGGC  CGAA AGGACAAC   2610       360   CCUCCAAU U UGUCCUGG   102   CCAGGACA CUGAUGAG  GCCGUUAGGC  CGAA AUUGGAGG   2611       361   CUCCAAUU U GUCCUGGU   103   ACCAGGAC CUGAUGAG  GCCGUUAGGC  CGAA AAUUGGAG   2612       364   CAAUUUGU C CUGGUUAU   104   AUAACCAG CUGAUGAG  GCCGUUAGGC  CGAA ACAAAUUG   2613       370   GUCCUGGU U AUCGCUGG   105   CCAGCGAU CUGAUGAG  GCCGUUAGGC  CGAA ACCAGGAC   2614       371   UCCUGGUU A UCGCUGGA   106   UCCAGCGA CUGAUGAG  GCCGUUAGGC  CGAA AACCAGGA   2615       373   CUGGUUAU C GCUGGAUG   107   CAUCCAGC CUGAUGAG  GCCGUUAGGC  CGAA AUAACCAG   2616       385   GGAUGUGU C UGCGGCGU   108   ACGCCGCA CUGAUGAG  GCCGUUAGGC  CGAA ACACAUCC   2617       394   UGCGGCGU U UUAUCAUC   109   GAUGAUAA CUGAUGAG  GCCGUUAGGC  CGAA ACGCCGCA   2618       395   GCGGCGUU U UAUCAUCU   110   AGAUGAUA CUGAUGAG  GCCGUUAGGC  CGAA AACGCCGC   2619       396   CGGCGUUU U AUCAUCUU   111   AAGAUGAU CUGAUGAG  GCCGUUAGGC  CGAA AAACGCCG   2620       397   GGCGUUUU A UCAUCUUC   112   GAAGAUGA CUGAUGAG  GCCGUUAGGC  CGAA AAAACGCC   2621       399   CGUUUUAU C AUCUUCCU   113   AGGAAGAU CUGAUGAG  GCCGUUAGGC  CGAA AUAAAACG   2622       402   UUUAUCAU C UUCCUCUG   114   CAGAGGAA CUGAUGAG  GCCGUUAGGC  CGAA AUGAUAAA   2623       404   UAUCAUCU U CCUCUGCA   115   UGCAGAGG CUGAUGAG  GCCGUUAGGC  CGAA AGAUGAUA   2624       405   AUCAUCUU C CUCUGCAU   116   AUGCAGAG CUGAUGAG  GCCGUUAGGC  CGAA AAGAUGAU   2625       408   AUCUUCCU C UGCAUCCU   117   AGGAUGCA CUGAUGAG  GCCGUUAGGC  CGAA AGGAAGAU   2626       414   CUCUGCAU C CUGCUGCU   118   AGCAGCAG CUGAUGAG  GCCGUUAGGC  CGAA AUGCAGAG   2627       423   CUGCUGCU A UGCCUCAU   119   AUGAGGCA CUGAUGAG  GCCGUUAGGC  CGAA AGCAGCAG   2628       429   CUAUGCCU C AUCUUCUU   120   AAGAAGAU CUGAUGAG  GCCGUUAGGC  CGAA AGGCAUAG   2629       432   UGCCUCAU C UUCUUGUU   121   AACAAGAA CUGAUGAG  GCCGUUAGGC  CGAA AUGAGGCA   2630       434   CCUCAUCU U CUUGUUGG   122   CCAACAAG CUGAUGAG  GCCGUUAGGC  CGAA AGAUGAGG   2631       435   CUCAUCUU C UUGUUGGU   123   ACCAACAA CUGAUGAG  GCCGUUAGGC  CGAA AAGAUGAG   2632       437   CAUCUUCU U GUUGGUUC   124   GAACCAAC CUGAUGAG  GCCGUUAGGC  CGAA AGAAGAUG   2633       440   CUUCUUGU U GGUUCUUC   125   GAAGAACC CUGAUGAG  GCCGUUAGGC  CGAA ACAAGAAG   2634       444   UUGUUGGU U CUUCUGGA   126   UCCAGAAG CUGAUGAG  GCCGUUAGGC  CGAA ACCAACAA   2635       445   UGUUGGUU C UUCUGGAC   127   GUCCAGAA CUGAUGAG  GCCGUUAGGC  CGAA AACCAACA   2636       447   UUGGUUCU U CUGGACUA   128   UAGUCCAG CUGAUGAG  GCCGUUAGGC  CGAA AGAACCAA   2637       448   UGGUUCUU C UGGACUAU   129   AUAGUCCA CUGAUGAG  GCCGUUAGGC  CGAA AAGAACCA   2638       455   UCUGGACU A UCAAGGUA   130   UACCUUGA CUGAUGAG  GCCGUUAGGC  CGAA AGUCCAGA   2639       457   UGGACUAU C AAGGUAUG   131   CAUACCUU CUGAUGAG  GCCGUUAGGC  CGAA AUAGUCCA   2640       463   AUCAAGGU A UGUUGCCC   132   GGGCAACA CUGAUGAG  GCCGUUAGGC  CGAA ACCUUGAU   2641       467   AGGUAUGU U GCCCGUUU   133   AAACGGGC CUGAUGAG  GCCGUUAGGC  CGAA ACAUACCU   2642       474   UUGCCCGU U UGUCCUCU   134   AGAGGACA CUGAUGAG  GCCGUUAGGC  CGAA ACGGGCAA   2643       475   UGCCCGUU U GUCCUCUA   135   UAGAGGAC CUGAUGAG  GCCGUUAGGC  CGAA AACGGGCA   2644       478   CCGUUUGU C CUCUAAUU   136   AAUUAGAG CUGAUGAG  GCCGUUAGGC  CGAA ACAAACGG   2645       481   UUUGUCCU C UAAUUCCA   137   UGGAAUUA CUGAUGAG  GCCGUUAGGC  CGAA AGGACAAA   2646       483   UGUCCUCU A AUUCCAGG   138   CCUGGAAU CUGAUGAG  GCCGUUAGGC  CGAA AGAGGACA   2647       486   CCUCUAAU U CCAGGAUC   139   GAUCCUGG CUGAUGAG  GCCGUUAGGC  CGAA AUUAGAGG   2648       487   CUCUAAUU C CAGGAUCA   140   UGAUCCUG CUGAUGAG  GCCGUUAGGC  CGAA AAUUAGAG   2649       494   UCCAGGAU C AUCAACAA   141   UUGUUGAU CUGAUGAG  GCCGUUAGGC  CGAA AUCCUGGA   2650       497   AGGAUCAU C AACAACCA   142   UGGUUGUU CUGAUGAG  GCCGUUAGGC  CGAA AUGAUCCU   2651       535   GCACAACU C CUGCUCAA   143   UUGAGCAG CUGAUGAG  GCCGUUAGGC  CGAA AGUUGUGC   2652       541   CUCCUGCU C AAGGAACC   144   GGUUCCUU CUGAUGAG  GCCGUUAGGC  CGAA AGCAGGAG   2653       551   AGGAACCU C UAUGUUUC   145   GAAACAUA CUGAUGAG  GCCGUUAGGC  CGAA AGGUUCCU   2654       553   GAACCUCU A UGUUUCCC   146   GGGAAACA CUGAUGAG  GCCGUUAGGC  CGAA AGAGGUUC   2655       557   CUCUAUGU U UCCCUCAU   147   AUGAGGGA CUGAUGAG  GCCGUUAGGC  CGAA ACAUAGAG   2656       558   UCUAUGUU U CCCUCAUG   148   CAUGAGGG CUGAUGAG  GCCGUUAGGC  CGAA AACAUAGA   2657       559   CUAUGUUU C CCUCAUGU   149   ACAUGAGG CUGAUGAG  GCCGUUAGGC  CGAA AAACAUAG   2658       563   GUUUCCCU C AUGUUGCU   150   AGCAACAU CUGAUGAG  GCCGUUAGGC  CGAA AGGGAAAC   2659       568   CCUCAUGU U GCUGUACA   151   UGUACAGC CUGAUGAG  GCCGUUAGGC  CGAA ACAUGAGG   2660       574   GUUGCUGU A CAAAACCU   152   AGGUUUUG CUGAUGAG  GCCGUUAGGC  CGAA ACAGCAAC   2661       583   CAAAACCU A CGGACGGA   153   UCCGUCCG CUGAUGAG  GCCGUUAGGC  CGAA AGGUUUUG   2662       604   GCACCUGU A UUCCCAUC   154   GAUGGGAA CUGAUGAG  GCCGUUAGGC  CGAA ACAGGUGC   2663       606   ACCUGUAU U CCCAUCCC   155   GGGAUGGG CUGAUGAG  GCCGUUAGGC  CGAA AUACAGGU   2664       607   CCUGUAUU C CCAUCCCA   156   UGGGAUGG CUGAUGAG  GCCGUUAGGC  CGAA AAUACAGG   2665       612   AUUCCCAU C CCAUCAUC   157   GAUGAUGG CUGAUGAG  GCCGUUAGGC  CGAA AUGGGAAU   2666       617   CAUCCCAU C AUCUUGGG   158   CCCAAGAU CUGAUGAG  GCCGUUAGGC  CGAA AUGGGAUG   2667       620   CCCAUCAU C UUGGGCUU   159   AAGCCCAA CUGAUGAG  GCCGUUAGGC  CGAA AUGAUGGG   2668       622   CAUCAUCU U GGGCUUUC   160   GAAAGCCC CUGAUGAG  GCCGUUAGGC  CGAA AGAUGAUG   2669       628   CUUGGGCU U UCGCAAAA   161   UUUUGCGA CUGAUGAG  GCCGUUAGGC  CGAA AGCCCAAG   2670       629   UUGGGCUU U CGCAAAAU   162   AUUUUGCG CUGAUGAG  GCCGUUAGGC  CGAA AAGCCCAA   2671       630   UGGGCUUU C GCAAAAUA   163   UAUUUUGC CUGAUGAG  GCCGUUAGGC  CGAA AAAGCCCA   2672       638   CGCAAAAU A CCUAUGGG   164   CCCAUAGG CUGAUGAG  GCCGUUAGGC  CGAA AUUUUGCG   2673       642   AAAUACCU A UGGGAGUG   165   CACUCCCA CUGAUGAG  GCCGUUAGGC  CGAA AGGUAUUU   2674       656   GUGGGCCU C AGUCCGUU   166   AACGGACU CUGAUGAG  GCCGUUAGGC  CGAA AGGCCCAC   2675       660   GCCUCAGU C CGUUUCUC   167   GAGAAACG CUGAUGAG  GCCGUUAGGC  CGAA ACUGAGGC   2676       664   CAGUCCGU U UCUCUUGG   168   CCAAGAGA CUGAUGAG  GCCGUUAGGC  CGAA ACGGACUG   2677       665   AGUCCGUU U CUCUUGGC   169   GCCAAGAG CUGAUGAG  GCCGUUAGGC  CGAA AACGGACU   2678       666   GUCCGUUU C UCUUGGCU   170   AGCCAAGA CUGAUGAG  GCCGUUAGGC  CGAA AAACGGAC   2679       668   CCGUUUCU C UUGGCUCA   171   UGAGCCAA CUGAUGAG  GCCGUUAGGC  CGAA AGAAACGG   2680       670   GUUUCUCU U GGCUCAGU   172   ACUGAGCC CUGAUGAG  GCCGUUAGGC  CGAA AGAGAAAC   2681       675   UCUUGGCU C AGUUUACU   173   AGUAAACU CUGAUGAG  GCCGUUAGGC  CGAA AGCCAAGA   2682       679   GGCUCAGU U UACUAGUG   174   CACUAGUA CUGAUGAG  GCCGUUAGGC  CGAA ACUGAGCC   2683       680   GCUCAGUU U ACUAGUGC   175   GCACUAGU CUGAUGAG  GCCGUUAGGC  CGAA AACUGAGC   2684       681   CUCAGUUU A CUAGUGCC   176   GGCACUAG CUGAUGAG  GCCGUUAGGC  CGAA AAACUGAG   2685       684   AGUUUACU A GUGCCAUU   177   AAUGGCAC CUGAUGAG  GCCGUUAGGC  CGAA AGUAAACU   2686       692   AGUGCCAU U UGUUCAGU   178   ACUGAACA CUGAUGAG  GCCGUUAGGC  CGAA AUGGCACU   2687       693   GUGCCAUU U GUUCAGUG   179   CACUGAAC CUGAUGAG  GCCGUUAGGC  CGAA AAUGGCAC   2688       696   CCAUUUGU U CAGUGGUU   180   AACCACUG CUGAUGAG  GCCGUUAGGC  CGAA ACAAAUGG   2689       697   CAUUUGUU C AGUGGUUC   181   GAACCACU CUGAUGAG  GCCGUUAGGC  CGAA AACAAAUG   2690       704   UCAGUGGU U CGUAGGGC   182   GCCCUACG CUGAUGAG  GCCGUUAGGC  CGAA ACCACUGA   2691       705   CAGUGGUU C GUAGGGCU   183   AGCCCUAC CUGAUGAG  GCCGUUAGGC  CGAA AACCACUG   2692       708   UGGUUCGU A GGGCUUUC   184   GAAAGCCC CUGAUGAG  GCCGUUAGGC  CGAA ACGAACCA   2693       714   GUAGGGCU U UCCCCCAC   185   GUGGGGGA CUGAUGAG  GCCGUUAGGC  CGAA AGCCCUAC   2694       715   UAGGGCUU U CCCCCACU   186   AGUGGGGG CUGAUGAG  GCCGUUAGGC  CGAA AAGCCCUA   2695       716   AGGGCUUU C CCCCACUG   187   CAGUGGGG CUGAUGAG  GCCGUUAGGC  CGAA AAAGCCCU   2696       726   CCCACUGU C UGGCUUUC   188   GAAAGCCA CUGAUGAG  GCCGUUAGGC  CGAA ACAGUGGG   2697       732   GUCUGGCU U UCAGUUAU   189   AUAACUGA CUGAUGAG  GCCGUUAGGC  CGAA AGCCAGAC   2698       733   UCUGGCUU U CAGUUAUA   190   UAUAACUG CUGAUGAG  GCCGUUAGGC  CGAA AAGCCAGA   2699       734   CUGGCUUU C AGUUAUAU   191   AUAUAACU CUGAUGAG  GCCGUUAGGC  CGAA AAAGCCAG   2700       738   CUUUCAGU U AUAUGGAU   192   AUCCAUAU CUGAUGAG  GCCGUUAGGC  CGAA ACUGAAAG   2701       739   UUUCAGUU A UAUGGAUG   193   CAUCCAUA CUGAUGAG  GCCGUUAGGC  CGAA AACUGAAA   2702       741   UCAGUUAU A UGGAUGAU   194   AUCAUCCA CUGAUGAG  GCCGUUAGGC  CGAA AUAACUGA   2703       755   GAUGUGGU U UUGGGGGC   195   GCCCCCAA CUGAUGAG  GCCGUUAGGC  CGAA ACCACAUC   2704       756   AUGUGGUU U UGGGGGCC   196   GGCCCCCA CUGAUGAG  GCCGUUAGGC  CGAA AACCACAU   2705       757   UGUGGUUU U GGGGGCCA   197   UGGCCCCC CUGAUGAG  GCCGUUAGGC  CGAA AAACCACA   2706       769   GGCCAAGU C UGUACAAC   198   GUUGUACA CUGAUGAG  GCCGUUAGGC  CGAA ACUUGGCC   2707       773   AAGUCUGU A CAACAUCU   199   AGAUGUUG CUGAUGAG  GCCGUUAGGC  CGAA ACAGACUU   2708       780   UACAACAU C UUGAGUCC   200   GGACUCAA CUGAUGAG  GCCGUUAGGC  CGAA AUGUUGUA   2709       782   CAACAUCU U GAGUCCCU   201   AGGGACUC CUGAUGAG  GCCGUUAGGC  CGAA AGAUGUUG   2710       787   UCUUGAGU C CCUUUAUG   202   CAUAAAGG CUGAUGAG  GCCGUUAGGC  CGAA ACUCAAGA   2711       791   GAGUCCCU U UAUGCCGC   203   GCGGCAUA CUGAUGAG  GCCGUUAGGC  CGAA AGGGACUC   2712       792   AGUCCCUU U AUGCCGCU   204   AGCGGCAU CUGAUGAG  GCCGUUAGGC  CGAA AAGGGACU   2713       793   GUCCCUUU A UGCCGCUG   205   CAGCGGCA CUGAUGAG  GCCGUUAGGC  CGAA AAAGGGAC   2714       803   GCCGCUGU U ACCAAUUU   206   AAAUUGGU CUGAUGAG  GCCGUUAGGC  CGAA ACAGCGGC   2715       804   CCGCUGUU A CCAAUUUU   207   AAAAUUGG CUGAUGAG  GCCGUUAGGC  CGAA AACAGCGG   2716       810   UUACCAAU U UUCUUUUG   208   CAAAAGAA CUGAUGAG  GCCGUUAGGC  CGAA AUUGGUAA   2717       811   UACCAAUU U UCUUUUGU   209   ACAAAAGA CUGAUGAG  GCCGUUAGGC  CGAA AAUUGGUA   2718       812   ACCAAUUU U CUUUUGUC   210   GACAAAAG CUGAUGAG  GCCGUUAGGC  CGAA AAAUUGGU   2719       813   CCAAUUUU C UUUUGUCU   211   AGACAAAA CUGAUGAG  GCCGUUAGGC  CGAA AAAAUUGG   2720       815   AAUUUUCU U UUGUCUUU   212   AAAGACAA CUGAUGAG  GCCGUUAGGC  CGAA AGAAAAUU   2721       816   AUUUUCUU U UGUCUUUG   213   CAAAGACA CUGAUGAG  GCCGUUAGGC  CGAA AAGAAAAU   2722       817   UUUUCUUU U GUCUUUGG   214   CCAAAGAC CUGAUGAG  GCCGUUAGGC  CGAA AAAGAAAA   2723       820   UCUUUUGU C UUUGGGUA   215   UACCCAAA CUGAUGAG  GCCGUUAGGC  CGAA ACAAAAGA   2724       822   UUUUGUCU U UGGGUAUA   216   UAUACCCA CUGAUGAG  GCCGUUAGGC  CGAA AGACAAAA   2725       823   UUUGUCUU U GGGUAUAC   217   GUAUACCC CUGAUGAG  GCCGUUAGGC  CGAA AAGACAAA   2726       828   CUUUGGGU A UACAUUUA   218   UAAAUGUA CUGAUGAG  GCCGUUAGGC  CGAA ACCCAAAG   2727       830   UUGGGUAU A CAUUUAAA   219   UUUAAAUG CUGAUGAG  GCCGUUAGGC  CGAA AUACCCAA   2728       834   GUAUACAU U UAAACCCU   220   AGGGUUUA CUGAUGAG  GCCGUUAGGC  CGAA AUGUAUAC   2729       835   UAUACAUU U AAACCCUC   221   GAGGGUUU CUGAUGAG  GCCGUUAGGC  CGAA AAUGUAUA   2730       836   AUACAUUU A AACCCUCA   222   UGAGGGUU CUGAUGAG  GCCGUUAGGC  CGAA AAAUGUAU   2731       843   UAAACCCU C ACAAAACA   223   UGUUUUGU CUGAUGAG  GCCGUUAGGC  CGAA AGGGUUUA   2732       865   AUGGGGAU A UUCCCUUA   224   UAAGGGAA CUGAUGAG  GCCGUUAGGC  CGAA AUCCCCAU   2733       867   GGGGAUAU U CCCUUAAC   225   GUUAAGGG CUGAUGAG  GCCGUUAGGC  CGAA AUAUCCCC   2734       868   GGGAUAUU C CCUUAACU   226   AGUUAAGG CUGAUGAG  GCCGUUAGGC  CGAA AAUAUCCC   2735       872   UAUUCCCU U AACUUCAU   227   AUGAAGUU CUGAUGAG  GCCGUUAGGC  CGAA AGGGAAUA   2736       873   AUUCCCUU A ACUUCAUG   228   CAUGAAGU CUGAUGAG  GCCGUUAGGC  CGAA AAGGGAAU   2737       877   CCUUAACU U CAUGGGAU   229   AUCCCAUG CUGAUGAG  GCCGUUAGGC  CGAA AGUUAAGG   2738       878   CUUAACUU C AUGGGAUA   230   UAUCCCAU CUGAUGAG  GCCGUUAGGC  CGAA AAGUUAAG   2739       886   CAUGGGAU A UGUAAUUG   231   CAAUUACA CUGAUGAG  GCCGUUAGGC  CGAA AUCCCAUG   2740       890   GGAUAUGU A AUUGGGAG   232   CUCCCAAU CUGAUGAG  GCCGUUAGGC  CGAA ACAUAUCC   2741       893   UAUGUAAU U GGGAGUUG   233   CAACUCCC CUGAUGAG  GCCGUUAGGC  CGAA AUUACAUA   2742       900   UUGGGAGU U UGGGCACA   234   UGUGCCCC CUGAUGAG  GCCGUUAGGC  CGAA ACUCCCAA   2743       910   GGGCACAU U GCCACAGG   235   CCUGUGGC CUGAUGAG  GCCGUUAGGC  CGAA AUGUGCCC   2744       924   AGGAACAU A UUGUACAA   236   UUGUACAA CUGAUGAG  GCCGUUAGGC  CGAA AUGUUCCU   2745       926   GAACAUAU U GUACAAAA   237   UUUUGUAC CUGAUGAG  GCCGUUAGGC  CGAA AUAUGUUC   2746       929   CAUAUUGU A CAAAAAAU   238   AUUUUUUG CUGAUGAG  GCCGUUAGGC  CGAA ACAAUAUG   2747       938   CAAAAAAU C AAAAUGUG   239   CACAUUUU CUGAUGAG  GCCGUUAGGC  CGAA AUUUUUUG   2748       948   AAAUGUGU U UUAGGAAA   240   UUUCCUAA CUGAUGAG  GCCGUUAGGC  CGAA ACACAUUU   2749       949   AAUGUGUU U UAGGAAAC   241   GUUUCCUA CUGAUGAG  GCCGUUAGGC  CGAA AACACAUU   2750       950   AUGUGUUU U AGGAAACU   242   AGUUUCCU CUGAUGAG  GCCGUUAGGC  CGAA AAACACAU   2751       951   UGUGUUUU A GGAAACUU   243   AAGUUUCC CUGAUGAG  GCCGUUAGGC  CGAA AAAACACA   2752       959   AGGAAACU U CCUGUAAA   244   UUUACAGG CUGAUGAG  GCCGUUAGGC  CGAA AGUUUCCU   2753       960   GGAAACUU C CUGUAAAC   245   GUUUACAG CUGAUGAG  GCCGUUAGGC  CGAA AAGUUUCC   2754       965   CUUCCUGU A AACAGGCC   246   GGCCUGUU CUGAUGAG  GCCGUUAGGC  CGAA ACAGGAAG   2755       975   ACAGGCCU A UUGAUUGG   247   CCAAUCAA CUGAUGAG  GCCGUUAGGC  CGAA AGGCCUGU   2756       977   AGGCCUAU U GAUUGGAA   248   UUCCAAUC CUGAUGAG  GCCGUUAGGC  CGAA AUAGGCCU   2757       981   CUAUUGAU U GGAAAGUA   249   UACUUUCC CUGAUGAG  GCCGUUAGGC  CGAA AUCAAUAG   2758       989   UGGAAAGU A UGUCAACG   250   CGUUGACA CUGAUGAG  GCCGUUAGGC  CGAA ACUUUCCA   2759       993   AAGUAUGU C AACGAAUU   251   AAUUCGUU CUGAUGAG  GCCGUUAGGC  CGAA ACAUACUU   2760       1001   CAACGAAU U GUGGGUCU   252   AGACCCAC CUGAUGAG  GCCGUUAGGC  CGAA AUUCGUUG   2761       1008   UUGUGGGU C UUUUGGGG   253   CCCCAAAA CUGAUGAG  GCCGUUAGGC  CGAA ACCCACAA   2762       1010   GUGGGUCU U UUGGGGUU   254   AACCCCAA CUGAUGAG  GCCGUUAGGC  CGAA AGACCCAC   2763       1011   UGGGUCUU U UGGGGUUU   255   AAACCCCA CUGAUGAG  GCCGUUAGGC  CGAA AAGACCCA   2764       1012   GGGUCUUU U GGGGUUUG   256   CAAACCCC CUGAUGAG  GCCGUUAGGC  CGAA AAAGACCC   2765       1018   UUUGGGGU U UGCCGCCC   257   GGGCGGCA CUGAUGAG  GCCGUUAGGC  CGAA ACCCCAAA   2766       1019   UUGGGGUU U GCCGCCCC   258   GGGGCGGC CUGAUGAG  GCCGUUAGGC  CGAA AACCCCAA   2767       1029   CCGCCCCU U UCACGCAA   259   UUGCGUGA CUGAUGAG  GCCGUUAGGC  CGAA AGGGGCGG   2768       1030   CGCCCCUU U CACGCAAU   260   AUUGCGUG CUGAUGAG  GCCGUUAGGC  CGAA AAGGGGCG   2769       1031   GCCCCUUU C ACGCAAUG   261   CAUUGCGU CUGAUGAG  GCCGUUAGGC  CGAA AAAGGGGC   2770       1045   AUGUGGAU A UUCUGCUU   262   AAGCAGAA CUGAUGAG  GCCGUUAGGC  CGAA AUCCACAU   2771       1047   GUGGAUAU U CUGCUUUA   263   UAAAGCAG CUGAUGAG  GCCGUUAGGC  CGAA AUAUCCAC   2772       1048   UGGAUAUU C UGCUUUAA   264   UUAAAGCA CUGAUGAG  GCCGUUAGGC  CGAA AAUAUCCA   2773       1053   AUUCUGCU U UAAUGCCU   265   AGGCAUUA CUGAUGAG  GCCGUUAGGC  CGAA AGCAGAAU   2774       1054   UUCUGCUU U AAUGCCUU   266   AAGGCAUU CUGAUGAG  GCCGUUAGGC  CGAA AAGCAGAA   2775       1055   UCUGCUUU A AUGCCUUU   267   AAAGGCAU CUGAUGAG  GCCGUUAGGC  CGAA AAAGCAGA   2776       1062   UAAUGCCU U UAUAUGCA   268   UGCAUAUA CUGAUGAG  GCCGUUAGGC  CGAA AGGCAUUA   2777       1063   AAUGCCUU U AUAUGCAU   269   AUGCAUAU CUGAUGAG  GCCGUUAGGC  CGAA AAGGCAUU   2778       1064   AUGCCUUU A UAUGCAUG   270   CAUGCAUA CUGAUGAG  GCCGUUAGGC  CGAA AAAGGCAU   2779       1066   GCCUUUAU A UGCAUGCA   271   UGCAUGCA CUGAUGAG  GCCGUUAGGC  CGAA AUAAAGGC   2780       1076   GCAUGCAU A CAAGCAAA   272   UUUGCUUG CUGAUGAG  GCCGUUAGGC  CGAA AUGCAUGC   2781       1092   AACAGGCU U UUACUUUC   273   GAAAGUAA CUGAUGAG  GCCGUUAGGC  CGAA AGCCUGUU   2782       1093   ACAGGCUU U UACUUUCU   274   AGAAAGUA CUGAUGAG  GCCGUUAGGC  CGAA AAGCCUGU   2783       1094   CAGGCUUU U ACUUUCUC   275   GAGAAAGU CUGAUGAG  GCCGUUAGGC  CGAA AAAGCCUG   2784       1095   AGGCUUUU A CUUUCUCG   276   CGAGAAAG CUGAUGAG  GCCGUUAGGC  CGAA AAAAGCCU   2785       1098   CUUUUACU U UCUCGCCA   277   UGGCGAGA CUGAUGAG  GCCGUUAGGC  CGAA AGUAAAAG   2786       1099   UUUUACUU U CUCGCCAA   278   UUGGCGAG CUGAUGAG  GCCGUUAGGC  CGAA AAGUAAAA   2787       1100   UUUACUUU C UCGCCAAC   279   GUUGGCGA CUGAUGAG  GCCGUUAGGC  CGAA AAAGUAAA   2788       1102   UACUUUCU C GCCAACUU   280   AAGUUGGC CUGAUGAG  GCCGUUAGGC  CGAA AGAAAGUA   2789       1110   CGCCAACU U ACAAGGCC   281   GGCCUUGU CUGAUGAG  GCCGUUAGGC  CGAA AGUUGGCG   2790       1111   GCCAACUU A CAAGGCCU   282   AGGCCUUG CUGAUGAG  GCCGUUAGGC  CGAA AAGUUGGC   2791       1120   CAAGGCCU U UCUAAGUA   283   UACUUAGA CUGAUCAG  GCCGUUAGGC  CGAA AGGCCUUG   2792       1121   AAGGCCUU U CUAAGUAA   284   UUACUUAG CUGAUGAG  GCCGUUAGGC  CGAA AAGGCCUU   2793       1122   AGGCCUUU C UAAGUAAA   285   UUUACUUA CUGAUGAG  GCCGUUAGGC  CGAA AAAGGCCU   2794       1124   GCCUUUCU A AGUAAACA   286   UGUUUACU CUGAUGAG  GCCGUUAGGC  CGAA AGAAAGGC   2795       1128   UUCUAAGU A AACAGUAU   287   AUACUGUU CUGAUGAG  GCCGUUAGGC  CGAA ACUUAGAA   2796       1135   UAAACAGU A UGUGAACC   288   GGUUCACA CUGAUGAG  GCCGUUAGGC  CGAA ACUGUUUA   2797       1145   GUGAACCU U UACCCCGU   289   ACGGGGUA CUGAUGAG  GCCGUUAGGC  CGAA AGGUUCAC   2798       1146   UGAACCUU U ACCCCGUU   290   AACGGGGU CUGAUGAG  GCCGUUAGGC  CGAA AAGGUUCA   2799       1147   GAACCUUU A CCCCGUUG   291   CAACGGGG CUGAUGAG  GCCGUUAGGC  CGAA AAAGGUUC   2800       1154   UACCCCGU U GCUCGGCA   292   UGCCGAGC CUGAUGAG  GCCGUUAGGC  CGAA ACGGGGUA   2801       1158   CCGUUGCU C GGCAACGG   293   CCGUUGCC CUGAUGAG  GCCGUUAGGC  CGAA AGCAACGG   2802       1173   GGCCUGGU C UAUGCCAA   294   UUGGCAUA CUGAUGAG  GCCGUUAGGC  CGAA ACCAGGCC   2803       1175   CCUGGUCU A UGCCAAGU   295   ACUUGGCA CUGAUGAG  GCCGUUAGGC  CGAA AGACCAGG   2804       1186   CCAAGUGU U UGCUGACG   296   CGUCAGCA CUGAUGAG  GCCGUUAGGC  CGAA ACACUUGG   2805       1187   CAAGUGUU U GCUGACGC   297   GCGUCAGC CUGAUGAG  GCCGUUAGGC  CGAA AACACUUG   2806       1209   CCACUGGU U GGGGCUUG   298   CAAGCCCC CUGAUGAG  GCCGUUAGGC  CGAA ACCAGUGG   2807       1216   UUGGGGCU U GGCCAUAG   299   CUAUGGCC CUGAUGAG  GCCGUUAGGC  CGAA AGCCCCAA   2808       1223   UUGGCCAU A GGCCAUCA   300   UGAUGGCC CUGAUGAG  GCCGUUAGGC  CGAA AUGGCCAA   2809       1230   UAGGCCAU C AGCGCAUG   301   CAUGCGCU CUGAUGAG  GCCGUUAGGC  CGAA AUGGCCUA   2810       1249   UGGAACCU U UGUGUCUC   302   GAGACACA CUGAUGAG  GCCGUUAGGC  CGAA AGGUUCCA   2811       1250   GGAACCUU U GUGUCUCC   303   GGAGACAC CUGAUGAG  GCCGUUAGGC  CGAA AAGGUUCC   2812       1255   CUUUGUGU C UCCUCUGC   304   GCAGAGGA CUGAUGAG  GCCGUUAGGC  CGAA ACACAAAG   2813       1257   UUGUGUCU C CUCUGCCG   305   CGGCAGAG CUGAUGAG  GCCGUUAGGC  CGAA AGACACAA   2814       1260   UGUCUCCU C UGCCGAUC   306   GAUCGGCA CUGAUGAG  GCCGUUAGGC  CGAA AGGAGACA   2815       1268   CUGCCGAU C CAUACCGC   307   GCGGUAUG CUGAUGAG  GCCGUUAGGC  CGAA AUCGGCAG   2816       1272   CGAUCCAU A CCGCGGAA   308   UUCCGCGG CUGAUGAG  GCCGUUAGGC  CGAA AUGGAUCG   2817       1283   GCGGAACU C CUAGCCGC   309   GCGGCUAG CUGAUGAG  GCCGUUAGGC  CGAA AGUUCCGC   2818       1286   GAACUCCU A GCCGCUUG   310   CAAGCGGC CUGAUGAG  GCCGUUAGGC  CGAA AGGAGUUC   2819       1293   UAGCCGCU U GUUUUGCU   311   AGCAAAAC CUGAUGAG  GCCGUUAGGC  CGAA AGCGGCUA   2820       1296   CCGCUUGU U UUGCUCGC   312   GCGAGCAA CUGAUGAG  GCCGUUAGGC  CGAA ACAAGCGG   2821       1297   CGCUUGUU U UGCUCGCA   313   UGCGAGCA CUGAUGAG  GCCGUUAGGC  CGAA AACAAGCG   2822       1298   GCUUGUUU U GCUCGCAG   314   CUGCGAGC CUGAUGAG  GCCGUUAGGC  CGAA AAACAAGC   2823       1302   GUUUUGCU C GCAGCAGG   315   CCUGCUGC CUGAUGAG  GCCGUUAGGC  CGAA AGCAAAAC   2824       1312   CAGCAGGU C UGGGGCAA   316   UUGCCCCA CUGAUGAG  GCCGUUAGGC  CGAA ACCUGCUG   2825       1325   GCAAAACU C AUCGGGAC   317   GUCCCGAU CUGAUGAG  GCCGUUAGGC  CGAA AGUUUUGC   2826       1328   AAACUCAU C GGGACUGA   318   UCAGUCCC CUGAUGAG  GCCGUUAGGC  CGAA AUGAGUUU   2827       1341   CUGACAAU U CUGUCGUG   319   CACGACAG CUGAUGAG  GCCGUUAGGC  CGAA AUUGUCAG   2828       1342   UGACAAUU C UGUCGUGC   320   GCACGACA CUGAUGAG  GCCGUUAGGC  CGAA AAUUGUCA   2829       1346   AAUUCUGU C GUGCUCUC   321   GAGAGCAC CUGAUGAG  GCCGUUAGGC  CGAA ACAGAAUU   2830       1352   GUCGUGCU C UCCCGCAA   322   UUGCGGGA CUGAUGAG  GCCGUUAGGC  CGAA AGCACGAC   2831       1354   CGUGCUCU C CCGCAAAU   323   AUUUGCGG CUGAUGAG  GCCGUUAGGC  CGAA AGAGCACG   2832       1363   CCGCAAAU A UACAUCAU   324   AUGAUGUA CUGAUGAG  GCCGUUAGGC  CGAA AUUUGCGG   2833       1365   GCAAAUAU A CAUCAUUU   325   AAAUGAUG CUGAUGAG  GCCGUUAGGC  CGAA AUAUUUGC   2834       1369   AUAUACAU C AUUUCCAU   326   AUGGAAAU CUGAUGAG  GCCGUUAGGC  CGAA AUGUAUAU   2835       1372   UACAUCAU U UCCAUGGC   327   GCCAUGGA CUGAUGAG  GCCGUUAGGC  CGAA AUGAUGUA   2836       1373   ACAUCAUU U CCAUGGCU   328   AGCCAUGG CUGAUGAG  GCCGUUAGGC  CGAA AAUGAUGU   2837       1374   CAUCAUUU C CAUGGCUG   329   CAGCCAUG CUGAUGAG  GCCGUUAGGC  CGAA AAAUGAUG   2838       1385   UGGCUGCU A GGCUGUGC   330   GCACAGCC CUGAUGAG  GCCGUUAGGC  CGAA AGCAGCCA   2839       1406   AACUGGAU C CUACGCGG   331   CCGCGUAG CUGAUGAG  GCCGUUAGGC  CGAA AUCCAGUU   2840       1409   UGGAUCCU A CGCGGGAC   332   GUCCCGCG CUGAUGAG  GCCGUUAGGC  CGAA AGGAUCCA   2841       1420   CGGGACGU C CUUUGUUU   333   AAACAAAG CUGAUGAG  GCCGUUAGGC  CGAA ACGUCCCG   2842       1423   GACGUCCU U UGUUUACG   334   CGUAAACA CUGAUGAG  GCCGUUAGGC  CGAA AGGACGUC   2843       1424   ACGUCCUU U GUUUACGU   335   ACGUAAAC CUGAUGAG  GCCGUUAGGC  CGAA AAGGACGU   2844       1427   UCCUUUGU U UACGUCCC   336   GGGACGUA CUGAUGAG  GCCGUUAGGC  CGAA ACAAAGGA   2845       1428   CCUUUGUU U ACGUCCCG   337   CGGGACGU CUGAUGAG  GCCGUUAGGC  CGAA AACAAAGG   2846       1429   CUUUGUUU A CGUCCCGU   338   ACGGGACG CUGAUGAG  GCCGUUAGGC  CGAA AAACAAAG   2847       1433   GUUUACGU C CCGUCGGC   339   GCCGACGG CUGAUGAG  GCCGUUAGGC  CGAA ACGUAAAC   2848       1438   CGUCCCGU C GGCGCUGA   340   UCAGCGCC CUGAUGAG  GCCGUUAGGC  CGAA ACGGGACG   2849       1449   CGCUGAAU C CCGCGGAC   341   GUCCGCGG CUGAUGAG  GCCGUUAGGC  CGAA AUUCAGCG   2850       1465   CGACCCCU C CCGGGGCC   342   GGCCCCGG CUGAUGAG  GCCGUUAGGC  CGAA AGGGGUCG   2851       1477   GGGCCGCU U GGGGCUCU   343   AGAGCCCC CUGAUGAG  GCCGUUAGGC  CGAA AGCGGCCC   2852       1484   UUGGGGCU C UACCGCCC   344   GGGCGGUA CUGAUGAG  GCCGUUAGGC  CGAA AGCCCCAA   2853       1486   GGGGCUCU A CCGCCCGC   345   GCGGGCGG CUGAUGAG  GCCGUUAGGC  CGAA AGAGCCCC   2854       1496   CGCCCGCU U CUCCGCCU   346   AGGCGGAG CUGAUGAG  GCCGUUAGGC  CGAA AGCGGGCG   2855       1497   GCCCGCUU C UCCGCCUA   347   UAGGCGGA CUGAUGAG  GCCGUUAGGC  CGAA AAGCGGGC   2856       1499   CCGCUUCU C CGCCUAUU   348   AAUAGGCG CUGAUGAG  GCCGUUAGGC  CGAA AGAAGCGG   2857       1505   CUCCGCCU A UUGUACCG   349   CGGUACAA CUGAUGAG  GCCGUUAGGC  CGAA AGGCGGAG   2858       1507   CCGCCUAU U GUACCGAC   350   GUCGGUAC CUGAUGAG  GCCGUUAGGC  CGAA AUAGGCGG   2859       1510   CCUAUUGU A CCGACCGU   351   ACGGUCGG CUGAUGAG  GCCGUUAGGC  CGAA ACAAUAGG   2860       1519   CCGACCGU C CACGGGGC   352   GCCCCGUG CUGAUGAG  GCCGUUAGGC  CGAA ACGGUCGG   2861       1534   GCGCACCU C UCUUUACG   353   CGUAAAGA CUGAUGAG  GCCGUUAGGC  CGAA AGGUGCGC   2862       1536   GCACCUCU C UUUACGCG   354   CGCGUAAA CUGAUGAG  GCCGUUAGGC  CGAA AGAGGUGC   2863       1538   ACCUCUCU U UACGCGGA   355   UCCGCGUA CUGAUGAG  GCCGUUAGGC  CGAA AGAGAGGU   2864       1539   CCUCUCUU U ACGCGGAC   356   GUCCGCGU CUGAUGAG  GCCGUUAGGC  CGAA AAGAGAGG   2865       1540   CUCUCUUU A CGCGGACU   357   AGUCCGCG CUGAUGAG  GCCGUUAGGC  CGAA AAAGAGAG   2866       1549   CGCGGACU C CCCGUCUG   358   CAGACGGG CUGAUGAG  GCCGUUAGGC  CGAA AGUCCGCG   2867       1555   CUCCCCGU C UGUGCCUU   359   AAGGCACA CUGAUGAG  GCCGUUAGGC  CGAA ACGGGGAG   2868       1563   CUGUGCCU U CUCAUCUG   360   CAGAUGAG CUGAUGAG  GCCGUUAGGC  CGAA AGGCACAG   2869       1564   UGUGCCUU C UCAUCUGC   361   GCAGAUGA CUGAUGAG  GCCGUUAGGC  CGAA AAGGCACA   2870       1566   UGCCUUCU C AUCUGCCG   362   CGGCAGAU CUGAUGAG  GCCGUUAGGC  CGAA AGAAGGCA   2871       1569   CUUCUCAU C UGCCGGAC   363   GUCCGGCA CUGAUGAG  GCCGUUAGGC  CGAA AUGAGAAG   2872       1588   UGUGCACU U CGCUUCAC   364   GUGAAGCG CUGAUGAG  GCCGUUAGGC  CGAA AGUGCACA   2873       1589   GUGCACUU C GCUUCACC   365   GGUGAAGC CUGAUGAG  GCCGUUAGGC  CGAA AAGUGCAC   2874       1593   ACUUCGCU U CACCUCUG   366   CAGAGGUG CUGAUGAG  GCCGUUAGGC  CGAA AGCGAAGU   2875       1594   CUUCGCUU C ACCUCUGC   367   GCAGAGGU CUGAUGAG  GCCGUUAGGC  CGAA AAGCGAAG   2876       1599   CUUCACCU C UGCACGUC   368   GACGUGCA CUGAUGAG  GCCGUUAGGC  CGAA AGGUGAAG   2877       1607   CUGCACGU C GCAUGGAG   369   CUCCAUGC CUGAUGAG  GCCGUUAGGC  CGAA ACGUGCAG   2878       1651   CCCAAGGU C UUGCAUAA   370   UUAUGCAA CUGAUGAG  GCCGUUAGGC  CGAA ACCUUGGG   2879       1653   CAAGGUCU U GCAUAAGA   371   UCUUAUGC CUGAUGAG  GCCGUUAGGC  CGAA AGACCUUG   2880       1658   UCUUGCAU A AGAGGACU   372   AGUCCUCU CUGAUGAG  GCCGUUAGGC  CGAA AUGCAAGA   2881       1667   AGAGGACU C UUGGACUU   373   AAGUCCAA CUGAUGAG  GCCGUUAGGC  CGAA AGUCCUCU   2882       1669   AGGACUCU U GGACUUUC   374   GAAAGUCC CUGAUGAG  GCCGUUAGGC  CGAA AGAGUCCU   2883       1675   CUUGGACU U UCAGCAAU   375   AUUGCUGA CUGAUGAG  GCCGUUAGGC  CGAA AGUCCAAG   2884       1676   UUGGACUU U CAGCAAUG   376   CAUUGCUG CUGAUGAG  GCCGUUAGGC  CGAA AAGUCCAA   2885       1677   UGGACUUU C AGCAAUGU   377   ACAUUGCU CUGAUGAG  GCCGUUAGGC  CGAA AAAGUCCA   2886       1686   AGCAAUGU C AACGACCG   378   CGGUCGUU CUGAUGAG  GCCGUUAGGC  CGAA ACAUUGCU   2887       1699   ACCGACCU U GAGGCAUA   379   UAUGCCUC CUGAUGAG  GCCGUUAGGC  CGAA AGGUCGGU   2888       1707   UGAGGCAU A CUUCAAAG   380   CUUUGAAG CUGAUGAG  GCCGUUAGGC  CGAA AUGCCUCA   2889       1710   GGCAUACU U CAAAGACU   381   AGUCUUUG CUGAUGAG  GCCGUUAGGC  CGAA AGUAUGCC   2890       1711   GCAUACUU C AAAGACUG   382   CAGUCUUU CUGAUGAG  GCCGUUAGGC  CGAA AAGUAUGC   2891       1725   CUGUGUGU U UAAUGAGU   383   ACUCAUUA CUGAUGAG  GCCGUUAGGC  CGAA ACACACAG   2892       1726   UGUGUGUU U AAUGAGUG   384   CACUCAUU CUGAUGAG  GCCGUUAGGC  CGAA AACACACA   2893       1727   GUGUGUUU A AUGAGUGG   385   CCACUCAU CUGAUGAG  GCCGUUAGGC  CGAA AAACACAC   2894       1743   GGAGGAGU U GGGGGAGG   386   CCUCCCCC CUGAUGAG  GCCGUUAGGC  CGAA ACUCCUCC   2895       1756   GAGGAGGU U AGGUUAAA   387   UUUAACCU CUGAUGAG  GCCGUUAGGC  CGAA ACCUCCUC   2896       1757   AGGAGGUU A GGUUAAAG   388   CUUUAACC CUGAUGAG  GCCGUUAGGC  CGAA AACCUCCU   2897       1761   GGUUAGGU U AAAGGUCU   389   AGACCUUU CUGAUGAG  GCCGUUAGGC  CGAA ACCUAACC   2898       1762   GUUAGGUU A AAGGUCUU   390   AAGACCUU CUGAUGAG  GCCGUUAGGC  CGAA AACCUAAC   2899       1768   UUAAAGGU C UUUGUACU   391   AGUACAAA CUGAUGAG  GCCGUUAGGC  CGAA ACCUUUAA   2900       1770   AAAGGUCU U UGUACUAG   392   CUAGUACA CUGAUGAG  GCCGUUAGGC  CGAA AGACCUUU   2901       1771   AAGGUCUU U GUACUAGG   393   CCUAGUAC CUGAUGAG  GCCGUUAGGC  CGAA AAGACCUU   2902       1774   GUCUUUGU A CUAGGAGG   394   CCUCCUAG CUGAUGAG  GCCGUUAGGC  CGAA ACAAAGAC   2903       1777   UUUGUACU A UGAGGCUG   395   CAGCCUCC CUGAUGAG  GCCGUUAGGC  CGAA AGUACAAA   2904       1787   GAGGCUGU A GGCAUAAA   396   UUUAUGCC CUGAUGAG  GCCGUUAGGC  CGAA ACAGCCUC   2905       1793   GUAGGCAU A AAUUGGUG   397   CACCAAUU CUGAUGAG  GCCGUUAGGC  CGAA AUGCCUAC   2906       1797   GCAUAAAU U GGUGUGUU   398   AACACACC CUGAUGAG  GCCGUUAGGC  CGAA AUUUAUGC   2907       1805   UGGUGUGU U CACCAGCA   399   UGCUGGUG CUGAUGAG  GCCGUUAGGC  CGAA ACACACCA   2908       1806   GGUGUGUU C ACCAGCAC   400   GUGCUGGU CUGAUGAG  GCCGUUAGGC  CGAA AACACACC   2909       1824   AUGCAACU U UUUCACCU   401   AGGUGAAA CUGAUGAG  GCCGUUAGGC  CGAA AGUUGCAU   2910       1825   UGCAACUU U UUCACCUC   402   GAGGUGAA CUGAUGAG  GCCGUUAGGC  CGAA AAGUUGCA   2911       1826   GCAACUUU U UCACCUCU   403   AGAGGUGA CUGAUGAG  GCCGUUAGGC  CGAA AAAGUUGC   2912       1827   CAACUUUU U CACCUCUG   404   CAGAGGUG CUGAUGAG  GCCGUUAGGC  CGAA AAAAGUUG   2913       1828   AACUUUUU C ACCUCUGC   405   GCAGAGGU CUGAUGAG  GCCGUUAGGC  CGAA AAAAAGUU   2914       1833   UUUCACCU C UGCCUAAU   406   AUUAGGCA CUGAUGAG  GCCGUUAGGC  CGAA AGGUGAAA   2915       1839   CUCUGCCU A AUCAUCUC   407   GAGAUGAU CUGAUGAG  GCCGUUAGGC  CGAA AGGCAGAG   2916       1842   UGCCUAAU C AUCUCAUG   408   CAUGAGAU CUGAUGAG  GCCGUUAGGC  CGAA AUUAGGCA   2917       1845   CUAAUCAU C UCAUGUUC   409   GAACAUGA CUGAUGAG  GCCGUUAGGC  CGAA AUGAUUAG   2918       1847   AAUCAUCU C AUGUUCAU   410   AUGAACAU CUGAUGAG  GCCGUUAGGC  CGAA AGAUGAUU   2919       1852   UCUCAUGU U CAUGUCCU   411   AGGACAUG CUGAUGAG  GCCGUUAGGC  CGAA ACAUGAGA   2920       1853   CUCAUGUU C AUGUCCUA   412   UAGGACAU CUGAUGAG  GCCGUUAGGC  CGAA AACAUGAG   2921       1858   GUUCAUGU C CUACUGUU   413   AACAGUAG CUGAUGAG  GCCGUUAGGC  CGAA ACAUGAAC   2922       1861   CAUGUCCU A CUGUUCAA   414   UUGAACAG CUGAUGAG  GCCGUUAGGC  CGAA AGGACAUG   2923       1866   CCUACUGU U CAAGCCUC   415   GAGGCUUG CUGAUGAG  GCCGUUAGGC  CGAA ACAGUAGG   2924       1867   CUACUGUU C AAGCCUCC   416   GGAGGCUU CUGAUGAG  GCCGUUAGGC  CGAA AACAGUAG   2925       1874   UCAAGCCU C CAAGCUGU   417   ACAGCUUG CUGAUGAG  GCCGUUAGGC  CGAA AGGCUUGA   2926       1887   CUGUGCCU U GGGUGGCU   418   AGCCACCC CUGAUGAG  GCCGUUAGGC  CGAA AGGCACAG   2927       1896   GGGUGGCU U UGGGGCAU   419   AUGCCCCA CUGAUGAG  GCCGUUAGGC  CGAA AGCCACCC   2928       1897   GGUGGCUU U GGGGCAUG   420   CAUGCCCC CUGAUGAG  GCCGUUAGGC  CGAA AAGCCACC   2929       1911   AUGGACAU U GACCCGUA   421   UACGGGUC CUGAUGAG  GCCGUUAGGC  CGAA AUGUCCAU   2930       1919   UGACCCGU A UAAAGAAU   422   AUUCUUUA CUGAUGAG  GCCGUUAGGC  CGAA ACGGGUCA   2931       1921   ACCCGUAU A AAGAAUUU   423   AAAUUCUU CUGAUGAG  GCCGUUAGGC  CGAA AUACGGGU   2932       1928   UAAAGAAU U UGGAGCUU   424   AAGCUCCA CUGAUGAG  GCCGUUAGGC  CGAA AUUCUUUA   2933       1929   AAAGAAUU U GGAGCUUC   425   GAAGCUCC CUGAUGAG  GCCGUUAGGC  CGAA AAUUCUUU   2934       1936   UUGGAGCU U CUGUGGAG   426   CUCCACAG CUGAUGAG  GCCGUUAGGC  CGAA AGCUCCAA   2935       1937   UGGAGCUU C UGUGGAGU   427   ACUCCACA CUGAUGAG  GCCGUUAGGC  CGAA AAGCUCCA   2936       1946   UGUGGAGU U ACUCUCUU   428   AAGAGAGU CUGAUGAG  GCCGUUAGGC  CGAA ACUCCACA   2937       1947   GUGGAGUU A CUCUCUUU   429   AAAGAGAG CUGAUGAG  GCCGUUAGGC  CGAA AACUCCAC   2938       1950   GAGUUACU C UCUUUUUU   430   AAAAAAGA CUGAUGAG  GCCGUUAGGC  CGAA AGUAACUC   2939       1952   GUUACUCU C UUUUUUGC   431   GCAAAAAA CUGAUGAG  GCCGUUAGGC  CGAA AGAGUAAC   2940       1954   UACUCUCU U UUUUGCCU   432   AGGCAAAA CUGAUGAG  GCCGUUAGGC  CGAA AGAGAGUA   2941       1955   ACUCUCUU U UUUGCCUU   433   AAGGCAAA CUGAUGAG  GCCGUUAGGC  CGAA AAGAGAGU   2942       1956   CUCUCUUU U UUGCCUUC   434   GAAGGCAA CUGAUGAG  GCCGUUAGGC  CGAA AAAGAGAG   2943       1957   UCUCUUUU U UGCCUUCU   435   AGAAGGCA CUGAUGAG  GCCGUUAGGC  CGAA AAAAGAGA   2944       1958   CUCUUUUU U GCCUUCUG   436   CAGAAGGC CUGAUGAG  GCCGUUAGGC  CGAA AAAAAGAG   2945       1963   UUUUGCCU U CUGACUUC   437   GAAGUCAG CUGAUGAG  GCCGUUAGGC  CGAA AGGCAAAA   2946       1964   UUUGCCUU C UGACUUCU   438   AGAAGUCA CUGAUGAG  GCCGUUAGGC  CGAA AAGGCAAA   2947       1970   UUCUGACU U CUUUCCUU   439   AAGGAAAG CUGAUGAG  GCCGUUAGGC  CGAA AGUCAGAA   2948       1971   UCUGACUU C UUUCCUUC   440   GAAGGAAA CUGAUGAG  GCCGUUAGGC  CGAA AAGUCAGA   2949       1973   UGACUUCU U UCCUUCUA   441   UAGAAGGA CUGAUGAG  GCCGUUAGGC  CGAA AGAAGUCA   2950       1974   GACUUCUU U CCUUCUAU   442   AUAGAAGG CUGAUGAG  GCCGUUAGGC  CGAA AAGAAGUC   2951       1975   ACUUCUUU C CUUCUAUU   443   AAUAGAAG CUGAUGAG  GCCGUUAGGC  CGAA AAAGAAGU   2952       1978   UCUUUCCU U CUAUUCGA   444   UCGAAUAG CUGAUGAG  GCCGUUAGGC  CGAA AGGAAAGA   2953       1979   CUUUCCUU C UAUUCGAG   445   CUCGAAUA CUGAUGAG  GCCGUUAGGC  CGAA AAGGAAAG   2954       1981   UUCCUUCU A UUCGAGAU   446   AUCUCGAA CUGAUGAG  GCCGUUAGGC  CGAA AGAAGGAA   2955       1983   CCUUCUAU U CGAGAUCU   447   AGAUCUCG CUGAUGAG  GCCGUUAGGC  CGAA AUAGAAGG   2956       1984   CUUCUAUU C GAGAUCUC   448   GAGAUCUC CUGAUGAG  GCCGUUAGGC  CGAA AAUAGAAG   2957       1990   UUCGAGAU C UCCUGGAC   449   GUCGAGGA CUGAUGAG  GCCGUUAGGC  CGAA AUCUCGAA   2958       1992   CGAGAUCU C CUCGACAC   450   GUGUCGAG CUGAUGAG  GCCGUUAGGC  CGAA AGAUCUCG   2959       1995   GAUCUCCU C GACACCGC   451   GCGGUGUC CUGAUGAG  GCCGUUAGGC  CGAA AGGAGAUC   2960       2006   CACCGCCU C UGCUCUGU   452   ACAGACCA CUGAUGAG  GCCGUUAGGC  CGAA AGGCGGUG   2961       2011   CCUCUGCU C UGUAUCGG   453   CCGAUACA CUGAUGAG  GCCGUUAGGC  CGAA AGCAGAGG   2962       2015   UGCUCUGU A UCGGGGGG   454   CCCCCCGA CUGAUGAG  GCCGUUAGGC  CGAA ACAGAGCA   2963       2017   CUCUGUAU C GGGGGGCC   45G   GGCCCCCC CUGAUGAG  GCCGUUAGGC  CGAA AUACAGAG   2964       2027   GGGGGCCU U AGAGUCUC   456   GAGACUCU CUGAUGAG  GCCGUUAGGC  CGAA AGGCCCCC   2965       2028   GGGGCCUU A GAGUCUCC   457   GGAGACUC CUGAUGAG  GCCGUUAGGC  CGAA AAGGCCCC   2966       2033   CUUAGAGU C UCCGGAAC   458   GUUCCGGA CUGAUGAG  GCCGUUAGGC  CGAA ACUCUAAG   2967       2035   UAGAGUCU C CGGAACAU   459   AUGUUCCG CUGAUGAG  GCCGUUAGGC  CGAA AGACUCUA   2968       2044   CGGAACAU U GUUCACCU   460   AGGUGAAC CUGAUGAG  GCCGUUAGGC  CGAA AUGUUCCG   2969       2047   AACAUUGU U CACCUCAC   461   GUGAGGUG CUGAUGAG  GCCGUUAGGC  CGAA ACAAUGUU   2970       2048   ACAUUGUU C ACCUCACC   462   GGUGAGGU CUGAUGAG  GCCGUUAGGC  CGAA AACAAUGU   2971       2053   GUUCACCU C ACCAUACG   463   CGUAUGGU CUGAUGAG  GCCGUUAGGC  CGAA AGGUGAAC   2972       2059   CUCACCAU A CGGCACUC   464   GAGUGCCG CUGAUGAG  GCCGUUAGGC  CGAA AUGGUGAG   2973       2067   ACGGCACU C AGGCAAGC   465   GCUUGCCU CUGAUGAG  GCCGUUAGGC  CGAA AGUGCCGU   2974       2077   GGCAAGCU A UUCUGUGU   466   ACACAGAA CUGAUGAG  GCCGUUAGGC  CGAA AGCUUGCC   2975       2079   CAAGCUAU U CUGUGUUG   467   CAACACAG CUGAUGAG  GCCGUUAGGC  CGAA AUAGCUUG   2976       2080   AAGCUAUU C UGUGUUGG   468   CCAACACA CUGAUGAG  GCCGUUAGGC  CGAA AAUAGCUU   2977       2086   UUCUGUGU U GGGGUGAG   469   CUCACCCC CUGAUGAG  GCCGUUAGGC  CGAA ACACAGAA   2978       2096   GGGUGAGU U GAUGAAUC   470   GAUUCAUC CUGAUGAG  GCCGUUAGGC  CGAA ACUCACCC   2979       2104   UGAUGAAU C UAGCCACC   471   GGUGGCUA CUGAUGAG  GCCGUUAGGC  CGAA AGUCAUCA   2980       2106   AUGAAUCU A GCCACCUG   472   CAGGUGGC CUGAUGAG  GCCGUUAGGC  CGAA AGAUUCAU   2981       2125   UGGGAAGU A AUUUGGAA   473   UUCCAAAU CUGAUGAG  GCCGUUAGGC  CGAA ACUUCCCA   2982       2128   GAAGUAAU U UGGAAGAU   474   AUCUUCCA CUGAUGAG  GCCGUUAGGC  CGAA AUUACUUC   2983       2129   AAGUAAUU U GGAAGAUC   475   GAUCUUCC CUGAUGAG  GCCGUUAGGC  CGAA AAUUACUU   2984       2137   UGGAAGAU C CAGCAUCC   476   GGAUGCUG CUGAUGAG  GCCGUUAGGC  CGAA AUCUUCCA   2985       2144   UCCAGCAU C CAGGGAAU   477   AUUCCCUG CUGAUGAG  GCCGUUAGGC  CGAA AUCCUGGA   2986       2153   CAGGGAAU U AGUAGUCA   478   UGACUACU CUGAUGAG  GCCGUUAGGC  CGAA AUUCCCUG   2987       2154   AGGGAAUU A GUAGUCAG   479   CUGACUAC CUGAUGAG  GCCGUUAGGC  CGAA AAUUCCCU   2988       2157   GAAUUAGU A GUCAGCUA   480   UAGCUGAC CUGAUGAG  GCCGUUAGGC  CGAA ACUAAUUC   2989       2160   UUAGUAGU C AGCUAUGU   481   ACAUAGCU CUGAUGAG  GCCGUUAGGC  CGAA ACUACUAA   2990       2165   AGUCAGCU A UGUCAACG   482   CGUGGACA CUGAUGAG  GCCGUUAGGC  CGAA AGCUGACU   2991       2169   AGCUAUGU C AACGUUAA   483   UUAACGUU CUGAUGAG  GCCGUUAGGC  CGAA ACAUAGCU   2992       2175   GUCAACGU U AAUAUGGG   484   CCCAUAUU CUGAUGAG  GCCGUUAGGC  CGAA ACGUUGAC   2993       2176   UCAACGUU A AUAUGGGC   485   GCCCAUAU CUGAUGAG  GCCGUUAGGC  CGAA AACGUUGA   2994       2179   ACGUUAAU A UGGGCCUA   486   UAGGCCCA CUCAUGAG  GCCGUUAGGC  CGAA AUUAACGU   2995       2187   AUGGGCCU A AAAAUCAG   487   CUGAUUUU CUGAUGAG  GCCGUUAGGC  CGAA AGGCCCAU   2996       2193   CUAAAAAU C AGACAACU   488   AGUUGUCU CUGAUGAG  GCCGUUAGGC  CGAA AUUUUUAG   2997       2202   AGACAACU A UUGUGGUU   489   AACCACAA CUGAUGAG  GCCGUUAGGC  CGAA AGUUGUCU   2998       2204   ACAACUAU U GUGGUUUC   490   GAAACCAC CUGAUGAG  GCCGUUAGGC  CGAA AUAGUUGU   2999       2210   AUUGUGGU U UCACAUUU   491   AAAUGUGA CUGAUGAG  GCCGUUAGGC  CGAA ACCACAAU   3000       2211   UUGUGGUU U CACAUUUC   492   GAAAUGUG CUGAUGAG  GCCGUUAGGC  CGAA AACCACAA   3001       2212   UGUGGUUU C ACAUUUCC   493   GGAAAUGU CUGAUGAG  GCCGUUAGGC  CGAA AAACCACA   3002       2217   UUUCACAU U UCCUGUCU   494   AGACAGGA CUGAUGAG  GCCGUUAGGC  CGAA AUGUGAAA   3003       2218   UUCACAUU U CCUGUCUU   495   AAGACAGG CUGAUGAG  GCCGUUAGGC  CGAA AAUGUGAA   3004       2219   UCACAUUU C CUGUCUUA   496   UAAGACAG CUGAUGAG  GCCGUUAGGC  CGAA AAAUGUGA   3005       2224   UUUCCUGU C UUACUUUU   497   AAAAGUAA CUGAUGAG  GCCGUUAGGC  CGAA ACAGGAAA   3006       2226   UCCUGUCU U ACUUUUGG   498   CCAAAAGU CUGAUGAG  GCCGUUAGGC  CGAA AGACAGGA   3007       2227   CCUGUCUU A CUUUUGGG   499   CCCAAAAG CUGAUGAG  GCCGUUAGGC  CGAA AAGACAGG   3008       2230   GUCUUACU U UUGGGCGA   500   UCGCCCAA CUGAUGAG  GCCGUUAGGC  CGAA AGUAAGAC   3009       2231   UCUUACUU U UGGGCGAG   501   CUCGCCCA CUGAUGAG  GCCGUUAGGC  CGAA AAGUAAGA   3010       2232   CUUACUUU U GGGCGAGA   502   UCUCGCCC CUGAUGAG  GCCGUUAGGC  CGAA AAAGUAAG   3011       2247   GAAACUGU U CUUGAAUA   503   UAUUCAAG CUGAUGAG  GCCGUUAGGC  CGAA ACAGUUUC   3012       2248   AAACUGUU C UUGAAUAU   504   AUAUUCAA CUGAUGAG  GCCGUUAGGC  CGAA AACAGUUU   3013       2250   ACUGUUCU U GAAUAUUU   505   AAAUAUUC CUGAUGAG  GCCGUUAGGC  CGAA AGAACAGU   3014       2255   UCUUGAAU A UUUGGUGU   506   ACACCAAA CUGAUGAG  GCCGUUAGGC  CGAA AUUCAAGA   3015       2257   UUGAAUAU U UGGUGUCU   507   AGACACCA CUGAUGAG  GCCGUUAGGC  CGAA AUAUUCAA   3016       2258   UGAAUAUU U GGUGUCUU   508   AAGACACC CUGAUGAG  GCCGUUAGGC  CGAA AAUAUUCA   3017       2264   UUUGGUGU C UUUUGGAG   509   CUCCAAAA CUGAUGAG  GCCGUUAGGC  CGAA ACACCAAA   3018       2266   UGGUGUCU U UUGGAGUG   510   CACUCCAA CUGAUGAG  GCCGUUAGGC  CGAA AGACACCA   3019       2267   GGUGUCUU U UGGAGUGU   511   ACACUCCA CUGAUGAG  GCCGUUAGGC  CGAA AAGACACC   3020       2268   GUGUCUUU U GGAGUGUG   512   CACACUCC CUGAUGAG  GCCGUUAGGC  CGAA AAAGACAC   3021       2280   GUGUGGAU U CGCACUCC   513   GGAGUGCG CUGAUGAG  GCCGUUAGGC  CGAA AUCCACAC   3022       2281   UGUGGAUU C GCACUCCU   514   AGGAGUGC CUGAUGAG  GCCGUUAGGC  CGAA AAUCCACA   3023       2287   UUCGCACU C CUCCUGCA   515   UGCAGGAG CUGAUGAG  GCCGUUAGGC  CGAA AGUGCGAA   3024       2290   GCACUCCU C CUGCAUAU   516   AUAUGCAG CUGAUGAG  GCCGUUAGGC  CGAA AGGAGUGC   3025       2297   UCCUGCAU A UAGACCAC   517   GUGGUCUA CUGAUGAG  GCCGUUAGGC  CGAA AUGCAGGA   3026       2299   CUGCAUAU A GACCACCA   518   UGGUGGUC CUGAUGAG  GCCGUUAGGC  CGAA AUAUGCAG   3027       2317   AUGCCCCU A UCUUAUCA   519   UGAUAAGA CUGAUGAG  GCCGUUAGGC  CGAA AGGGGCAU   3028       2319   GCCCCUAU C UUAUCAAC   520   GUUGAUAA CUGAUGAG  GCCGUUAGGC  CGAA AUAGGGGC   3029       2321   CCCUAUCU U AUCAACAC   521   GUGUUGAU CUGAUGAG  GCCGUUAGGC  CGAA AGAUAGGG   3030       2322   CCUAUCUU A UCAACACU   522   AGUGUUGA CUGAUGAG  GCCGUUAGGC  CGAA AAGAUAGG   3031       2324   UAUCUUAU C AACACUUC   523   GAAGUGUU CUGAUGAG  GCCGUUAGGC  CGAA AUAAGAUA   3032       2331   UCAACACU U CCGGAAAC   524   GUUUCCGG CUGAUGAG  GCCGUUAGGC  CGAA AGUGUUGA   3033       2332   CAACACUU C CGGAAACU   525   AGUUUCCG CUGAUGAG  GCCGUUAGGC  CGAA AAGUGUUG   3034       2341   CGGAAACU A CUGUUGUU   526   AACAACAG CUGAUGAG  GCCGUUAGGC  CGAA AGUUUCCG   3035       2346   ACUACUGU U GUUAGACG   527   CGUCUAAC CUGAUGAG  GCCGUUAGGC  CGAA ACAGUAGU   3036       2349   ACUGUUGU U AGACGAAG   528   CUUCGUCU CUGAUGAG  GCCGUUAGGC  CGAA ACAACAGU   3037       2350   CUGUUGUU A GACGAAGA   529   UCUUCGUC CUGAUGAG  GCCGUUAGGC  CGAA AACAACAG   3038       2366   AGGCAGGU C CCCUAGAA   530   UUCUAGGG CUGAUGAG  GCCGUUAGGC  CGAA ACCUGCCU   3039       2371   GGUCCCCU A GAAGAAGA   531   UCUUCUUC CUGAUGAG  GCCGUUAGGC  CGAA AGGGGACC   3040       2383   GAAGAACU C CCUCGCCU   532   AGGCGAGG CUGAUGAG  GCCGUUAGGC  CGAA AGUUCUUC   3041       2387   AACUCCCU C GCCUCGCA   533   UGCGAGGC CUGAUGAG  GCCGUUAGGC  CGAA AGGGAGUU   3042       2392   CCUCGCCU C GCAGACGA   534   UCGUCUGC CUGAUGAG  GCCGUUAGGC  CGAA AGGCGAGG   3043       2405   ACGAAGGU C UCAAUCGC   535   GCGAUUGA CUGAUGAG  GCCGUUAGGC  CGAA ACCUUCGU   3044       2407   GAAGGUCU C AAUCGCCG   536   CGGCGAUU CUGAUGAG  GCCGUUAGGC  CGAA AGACCUUC   3045       2411   GUCUCAAU C GCCGCGUC   537   GACGCGGC CUGAUGAG  GCCGUUAGGC  CGAA AUUGAGAC   3046       2419   CGCCGCGU C GCAGAAGA   538   UCUUCUGC CUGAUGAG  GCCGUUAGGC  CGAA ACGCGGCG   3047       2429   CAGAAGAU C UCAAUCUC   539   GAGAUUGA CUGAUGAG  GCCGUUAGGC  CGAA AUCUUCUG   3048       2431   GAAGAUCU C AAUCUCGG   540   CCGAGAUU CUGAUGAG  GCCGUUAGGC  CGAA AGAUCUUC   3049       2435   AUCUCAAU C UCGGGAAU   541   AUUCCCGA CUGAUGAG  GCCGUUAGGC  CGAA AUUGAGAU   3050       2437   CUCAAUCU C GGGAAUCU   542   AGAUUCCC CUGAUGAG  GCCGUUAGGC  CGAA AGAUUGAG   3051       2444   UCGGGAAU C UCAAUGUU   543   AACAUUGA CUGAUGAG  GCCGUUAGGC  CGAA AUUCCCGA   3052       2446   GGGAAUCU C AAUGUUAG   544   CUAACAUU CUGAUGAG  GCCGUUAGGC  CGAA AGAUUCCC   3053       2452   CUCAAUGU U AGUAUUCC   545   GGAAUACU CUGAUGAG  GCCGUUAGGC  CGAA ACAUUGAG   3054       2453   UCAAUGUU A GUAUUCCU   546   AGGAAUAC CUGAUGAG  GCCGUUAGGC  CGAA AACAUUGA   3055       2456   AUGUUAGU A UUCCUUGG   547   CCAAGGAA CUGAUGAG  GCCGUUAGGC  CGAA ACUAACAU   3056       2458   GUUAGUAU U CCUUGGAC   548   GUCCAAGG CUGAUGAG  GCCGUUAGGC  CGAA AUACUAAC   3057       2459   UUAGUAUU C CUUGGACA   549   UGUCCAAG CUGAUGAG  GCCGUUAGGC  CGAA AAUACUAA   3058       2462   GUAUUCCU U GGACACAU   550   AUGUGUCC CUGAUGAG  GCCGUUAGGC  CGAA AGGAAUAC   3059       2471   GGACACAU A AGGUGGGA   551   UCCCACCU CUGAUGAG  GCCGUUAGGC  CGAA AUGUGUCC   3060       2484   GGGAAACU U UACGGGGC   552   GCCCCGUA CUGAUGAG  GCCGUUAGGC  CGAA AGUUUCCC   3061       2485   GGAAACUU U ACGGGGCU   553   AGCCCCGU CUGAUGAG  GCCGUUAGGC  CGAA AAGUUUCC   3062       2486   GAAACUUU A CGGGGCUU   554   AAGCCCCG CUGAUGAG  GCCGUUAGGC  CGAA AAAGUUUC   3063       2494   ACGGGGCU U UAUUCUUC   555   GAAGAAUA CUGAUGAG  GCCGUUAGGC  CGAA AGCCCCGU   3064       2495   CGGGGCUU U AUUCUUCU   556   AGAAGAAU CUGAUGAG  GCCGUUAGGC  CGAA AAGCCCCG   3065       2496   GGGGCUUU A UUCUUCUA   557   UAGAAGAA CUGAUGAG  GCCGUUAGGC  CGAA AAAGCCCC   3066       2498   GGCUUUAU U CUUCUACG   558   CGUAGAAG CUGAUGAG  GCCGUUAGGC  CGAA AUAAAGCC   3067       2499   GCUUUAUU C UUCUACGG   559   CCGUAGAA CUGAUGAG  GCCGUUAGGC  CGAA AAUAAAGC   3068       2501   UUUAUUCU U CUACGGUA   560   UACCGUAG CUGAUGAG  GCCGUUAGGC  CGAA AGAAUAAA   3069       2502   UUAUUCUU C UACGGUAC   561   GUACCGUA CUGAUGAG  GCCGUUAGGC  CGAA AAGAAUAA   3070       2504   AUUCUUCU A CGGUACCU   562   AGGUACCG CUGAUGAG  GCCGUUAGGC  CGAA AGAAGAAU   3071       2509   UCUACGGU A CCUUGCUU   563   AAGCAAGG CUGAUGAG  GCCGUUAGGC  CGAA ACCGUAGA   3072       2513   UGGUACCU U GCUUUAAU   564   AUUAAAGC CUGAUGAG  GCCGUUAGGC  CGAA AGGUACCG   3073       2517   ACCUUGCU U UAAUCCUA   565   UAGGAUUA CUGAUGAG  GCCGUUAGGC  CGAA AGCAAGGU   3074       2518   CCUUGCUU U AAUCCUAA   566   UUAGGAUU CUGAUGAG  GCCGUUAGGC  CGAA AAGCAAGG   3075       2519   CUUGCUUU A AUCCUAAA   567   UUUAGGAU CUGAUGAG  GCCGUUAGGC  CGAA AAAGCAAG   3076       2522   GCUUUAAU C CUAAAUGG   568   CCAUUUAG CUGAUGAG  GCCGUUAGGC  CGAA AUUAAAGC   3077       2525   UUAAUCCU A AAUGGCAA   569   UUGCCAUU CUGAUGAG  GCCGUUAGGC  CGAA AGGAUUAA   3078       2537   GGCAAACU C CUUCUUUU   570   AAAAGAAG CUGAUGAG  GCCGUUAGGC  CGAA AGUUUGCC   3079       2540   AAACUCCU U CUUUUCCU   571   AGGAAAAG CUGAUGAG  GCCGUUAGGC  CGAA AGGAGUUU   3080       2541   AACUCCUU C UUUUCCUG   572   CAGGAAAA CUGAUGAG  GCCGUUAGGC  CGAA AAGGAGUU   3081       2543   UUCCUUCU U UUCCUGAC   573   GUCAGGAA CUGAUGAG  GCCGUUAGGC  CGAA AGAAGGAG   3082       2544   UCCUUCUU U UCCUGACA   574   UGUCAGGA CUGAUGAG  GCCGUUAGGC  CGAA AAGAAGGA   3083       2545   CCUUCUUU U CCUGACAU   575   AUGUCAGG CUGAUGAG  GCCGUUAGGC  CGAA AAAGAAGG   3084       2546   CUUCUUUU C CUGACAUU   576   AAUGUCAG CUGAUGAG  GCCGUUAGGC  CGAA AAAAGAAG   3085       2554   CCUGACAU U CAUUUGCA   577   UGCAAAUG CUGAUGAG  GCCGUUAGGC  CGAA AUGUCAGG   3086       2555   CUGACAUU C AUUUGCAG   578   CUGCAAAU CUGAUGAG  GCCGUUAGGC  CGAA AAUGUCAG   3087       2558   ACAUUCAU U UGCAGGAG   579   CUCCUGCA CUGAUGAG  GCCGUUAGGC  CGAA AUGAAUGU   3088       2559   CAUUCAUU U GCAGGAGG   580   CCUCCUGC CUGAUGAG  GCCGUUAGGC  CGAA AAUGAAUG   3089       2572   GAGGACAU U GUUGAUAG   581   CUAUCAAC CUGAUGAG  GCCGUUAGGC  CGAA AUGUCCUC   3090       2575   GACAUUGU U GAUAGAUG   582   CAUCUAUC CUGAUGAG  GCCGUUAGGC  CGAA ACAAUGUC   3091       2579   UUGUUGAU A GAUGUAAG   583   UUUACAUC CUGAUGAG  GCCGUUAGGC  CGAA AUCAACAA   3092       2585   AUAGAUGU A AGCAAUUU   584   AAAUUGCU CUGAUGAG  GCCGUUAGGC  CGAA ACAUCUAU   3093       2592   UAAGCAAU U UGUGGGGC   585   GCCCCACA CUGAUGAG  GCCGUUAGGC  CGAA AUUGCUUA   3094       2593   AAGCAAUU U GUGGGGCC   586   GGCCCCAC CUGAUGAG  GCCGUUAGGC  CGAA AAUUGCUU   3095       2605   GGGCCCCU U ACAGUAAA   587   UUUACUGU CUGAUGAG  GCCGUUAGGC  CGAA AGGGGCCC   3096       2606   GGCCCCUU A CAGUAAAU   588   AUUUACUG CUGAUGAG  GCCGUUAGGC  CGAA AAGGGGCC   3097       2611   CUUACAGU A AAUGAAAA   589   UUUUCAUU CUGAUGAG  GCCGUUAGGC  CGAA ACUGUAAG   3098       2629   AGGAGACU U AAAUUAAC   590   GUUAAUUU CUGAUGAG  GCCGUUAGGC  CGAA AGUCUCCU   3099       2630   GGAGACUU A AAUUAACU   591   AGUUAAUU CUGAUGAG  GCCGUUAGGC  CGAA AAGUCUCC   3100       2634   ACUUAAAU U AACUAUGC   592   GCAUAGUU CUGAUGAG  GCCGUUAGGC  CGAA AUUUAAGU   3101       2635   CUUAAAUU A ACUAUGCC   593   GGCAUAGU CUGAUGAG  GCCGUUAGGC  CGAA AAUUUAAG   3102       2639   AAUUAACU A UGCCUGCU   594   AGCAGGCA CUGAUGAG  GCCGUUAGGC  CGAA AGUUAAUU   3103       2648   UGCCUGCU A GGUUUUAU   595   AUAAAACC CUGAUGAG  GCCGUUAGGC  CGAA AGCAGGCA   3104       2652   UGCUAGGU U UUAUCCCA   596   UGGGAUAA CUGAUGAG  GCCGUUAGGC  CGAA ACCUAGCA   3105       2653   GCUAGGUU U UAUCCCAA   597   UUGGGAUA CUGAUGAG  GCCGUUAGGC  CGAA AACCUAGC   3106       2654   CUAGGUUU U AUCCCAAU   598   AUUGGGAU CUGAUGAG  GCCGUUAGGC  CGAA AAACCUAG   3107       2655   UAGGUUUU A UCCCAAUG   599   CAUUGGGA CUGAUGAG  GCCGUUAGGC  CGAA AAAACCUA   3108       2657   GGUUUUAU C CCAAUGUU   600   AACAUUGG CUGAUGAG  GCCGUUAGGC  CGAA AUAAAACC   3109       2665   CCCAAUGU U ACUAAAUA   601   UAUUUAGU CUGAUGAG  GCCGUUAGGC  CGAA ACAUUGGG   3110       2666   CCAAUGUU A CUAAAUAU   602   AUAUUUAG CUGAUGAG  GCCGUUAGGC  CGAA AACAUUGG   3111       2669   AUGUUACU A AAUAUUUG   603   UAAAUAUU CUGAUGAG  GCCGUUAGGC  CGAA AGUAACAU   3112       2673   UACUAAAU A UUUGCCCU   604   AGGGCAAA CUGAUGAG  GCCGUUAGGC  CGAA AUUUAGUA   3113       2675   CUAAAUAU U UGCCCUUA   605   UAAGGGCA CUGAUGAG  GCCGUUAGGC  CGAA AUAUUUAG   3114       2676   UAAAUAUU U GCCCUUAG   606   CUAAGGGC CUGAUGAG  GCCGUUAGGC  CGAA AAUAUUUA   3115       2682   UUUGCCCU U AGAUAAAG   607   CUUUAUCU CUGAUGAG  GCCGUUAGGC  CGAA AGGGCAAA   3116       2683   UUGCCCUU A GAUAAAGG   608   CCUUUAUC CUGAUGAG  GCCGUUAGGC  CGAA AAGGGCAA   3117       2687   CCUUAGAU A AAGGGAUC   609   GAUCCCUU CUGAUGAG  GCCGUUAGGC  CGAA AUCUAAGG   3118       2695   AAAGGGAU C AAACCGUA   610   UACGGUUU CUGAUGAG  GCCGUUAGGC  CGAA AUCCCUUU   3119       2703   UAAACCGU A UUAUCCAG   611   CUGGAUAA CUGAUGAG  GCCGUUAGGC  CGAA ACGGUUUG   3120       2705   AACCGUAU U AUCCAGAG   612   CUCUGGAU CUGAUGAG  GCCGUUAGGC  CGAA AUACGGUU   3121       2706   ACCGUAUU A UCCAGAGU   613   ACUCUGGA CUGAUGAG  GCCGUUAGGC  CGAA AAUACGGU   3122       2708   CGUAUUAU C CAGAGUAU   614   AUACUCUG CUGAUGAG  GCCGUUAGGC  CGAA AUAAUACG   3123       2715   UCCAGAGU A UGUAGUUA   615   UAACUACA CUGAUGAG  GCCGUUAGGC  CGAA ACUCUGGA   3124       2719   GAGUAUGU A GUUAAUCA   616   UGAUUAAC CUGAUGAG  GCCGUUAGGC  CGAA ACAUACUC   3125       2722   UAUGUAGU U AAUCAUUA   617   UAAUGAUU CUGAUGAG  GCCGUUAGGC  CGAA ACUACAUA   3126       2723   AUGUAGUU A AUCAUUAC   618   GUAAUGAU CUGAUGAG  GCCGUUAGGC  CGAA AACUACAU   3127       2726   UAGUUAAU C AUUACUUC   619   GAAGUAAU CUGAUGAG  GCCGUUAGGC  CGAA AUUAACUA   3128       2729   UUAAUCAU U ACUUCCAG   620   CUGGAAGU CUGAUGAG  GCCGUUAGGC  CGAA AUGAUUAA   3129       2730   UAAUCAUU A CUUCCAGA   621   UCUGGAAG CUGAUGAG  GCCGUUAGGC  CGAA AAUGAUUA   3130       2733   UCAUUACU U CCAGACGC   622   GCGUCUGG CUGAUGAG  GCCGUUAGGC  CGAA AGUAAUGA   3131       2734   CAUUACUU C CAGACGCG   623   UGCGUCUG CUGAUGAG  GCCGUUAGGC  CGAA AAGUAAUG   3132       2747   CGCGACAU U AUUUACAC   624   GUGUAAAU CUGAUGAG  GCCGUUAGGC  CGAA AUGUCGCG   3133       2748   GCGACAUU A UUUACACA   625   UGUGUAAA CUGAUGAG  GCCGUUAGGC  CGAA AAUGUCGC   3134       2750   GACAUUAU U UACACACU   626   AGUGUGUA CUGAUGAG  GCCGUUAGGC  CGAA AUAAUGUC   3135       2751   ACAUUAUU U ACACACUC   627   GAGUGUGU CUGAUGAG  GCCGUUAGGC  CGAA AAUAAUGU   3136       2752   CAUUAUUU A CACACUCU   628   AGAGUGUG CUGAUGAG  GCCGUUAGGC  CGAA AAAUAAUG   3137       2759   UACACACU C UUUGGAAG   629   CUUCCAAA CUGAUGAG  GCCGUUAGGC  CGAA AGUGUGUA   3138       2761   CACACUCU U UGGAAGGC   630   GCCUUCCA CUGAUGAG  GCCGUUAGGC  CGAA AGAGUGUG   3139       2762   ACACUCUU U GGAAGGCG   631   CGCCUUCC CUGAUGAG  GCCGUUAGGC  CGAA AAGAGUGU   3140       2776   GCGGGGAU C UUAUAUAA   632   UUAUAUAA CUGAUGAG  GCCGUUAGGC  CGAA AUCCCCGC   3141       2778   GGGGAUCU U AUAUAAAA   633   UUUUAUAU CUGAUGAG  GCCGUUAGGC  CGAA AGAUCCCC   3142       2779   GGGAUCUU A UAUAAAAG   634   CUUUUAUA CUGAUGAG  GCCGUUAGGC  CGAA AAGAUCCC   3143       2781   GAUCUUAU A UAAAAGAG   635   CUCUUUUA CUGAUGAG  GCCGUUAGGC  CGAA AUAAGAUC   3144       2783   UCUUAUAU A AAAGAGAG   636   CUCUCUUU CUGAUGAG  GCCGUUAGGC  CGAA AUAUAAGA   3145       2793   AAGAGAGU C CACACGUA   637   UACGUGUG CUGAUGAG  GCCGUUAGGC  CGAA ACUCUCUU   3146       2801   CCACACGU A GCGCCUCA   638   UGAGGCGC CUGAUGAG  GCCGUUAGGC  CGAA ACGUGUGG   3147       2808   UAGCGCCU C AUUUUGCG   639   CGCAAAAU CUGAUGAG  GCCGUUAGGC  CGAA AGGCGCUA   3148       2811   CGCCUCAU U UUGCGGGU   640   ACCCGCAA CUGAUGAG  GCCGUUAGGC  CGAA AUGAGGCG   3149       2812   GCCUCAUU U UGCGGGUC   641   GACCCGCA CUGAUGAG  GCCGUUAGGC  CGAA AAUGAGGC   3150       2813   UCUCAUUU U GCGGGUCA   642   UGACCCGC CUGAUGAG  GCCGUUAGGC  CGAA AAAUGAGG   3151       2820   UUGCGGGU C ACCAUAUU   643   AAUAUGGU CUGAUGAG  GCCGUUAGGC  CGAA ACCCGCAA   3152       2826   GUCACCAU A UUCUUGGG   644   CCCAAGAA CUGAUGAG  GCCGUUAGGC  CGAA AUGGUGAC   3153       2828   CACCAUAU U CUUGGGAA   645   UUCCCAAG CUGAUGAG  GCCGUUAGGC  CGAA AUAUGGUG   3154       2829   ACCAUAUU C UUGGGAAC   646   GUUCCCAA CUGAUGAG  GCCGUUAGGC  CGAA AAUAUGGU   3155       2831   CAUAUUCU U GGGAACAA   647   UUGUUCCC CUGAUGAG  GCCGUUAGGC  CGAA AGAAUAUG   3156       2843   AACAAGAU C UACAGCAU   648   AUGCUGUA CUGAUGAG  GCCGUUAGGC  CGAA AUCUUGUU   3157       2845   CAAGAUCU A CAGCAUGG   649   CCAUGCUG CUGAUGAG  GCCGUUAGGC  CGAA AGAUCUUG   3158       2859   UGGGAGGU U GGUCUUCC   650   GGAAGACC CUGAUGAG  GCCGUUAGGC  CGAA ACCUCCCA   3159       2863   AGGUUGGU C UUCCAAAC   651   GUUUGGAA CUGAUGAG  GCCGUUAGGC  CGAA ACCAACCU   3160       2865   GUUGGUCU U CCAAACCU   652   AGGUUUGG CUGAUGAG  GCCGUUAGGC  CGAA AGACCAAC   3161       2866   UUGGUCUU C CAAACCUC   653   GAGGUUUG CUGAUGAG  GCCGUUAGGC  CGAA AAGACCAA   3162       2874   CCAAACCU C GAAAAGGC   654   GCCUUUUC CUGAUGAG  GCCGUUAGGC  CGAA AGGUUUGG   3163       2895   GGACAAAU C UUUCUGUC   655   GACAGAAA CUGAUGAG  GCCGUUAGGC  CGAA AUUUGUCC   3164       2897   ACAAAUCU U UCUGUCCC   656   GGGACAGA CUGAUGAG  GCCGUUAGGC  CGAA AGAUUUGU   3165       2898   CAAAUCUU U CUGUCCCC   657   GGGGACAG CUGAUGAG  GCCGUUAGGC  CGAA AAGAUUUG   3166       2899   AAAUCUUU C UGUCCCCA   658   UGGGGACA CUGAUGAG  GCCGUUAGGC  CGAA AAAGAUUU   3167       2903   UUUUCUGU C CCCAAUCC   659   GGAUUGGG CUGAUGAG  GCCGUUAGGC  CGAA ACAGAAAG   3168       2910   UCCCCAAU C CCCUGGGA   660   UCCCAGGG CUGAUGAG  GCCGUUAGGC  CGAA AUUGGGGA   3169       2920   CCUGGGAU U CUUCCCCG   661   CGGGGAAG CUGAUGAG  GCCGUUAGGC  CGAA AUCCCAGG   3170       2921   CUGGGAUU C UUCCCCGA   662   UCGGGGAA CUGAUGAG  GCCGUUAGGC  CGAA AAUCCCAG   3171       2923   GGGAUUCU U CCCCGAUC   663   GAUCGGGG CUGAUGAG  GCCGUUAGGC  CGAA AGAAUCCC   3172       2924   GGAUUCUU C CCCGAUCA   664   UGAUCGGG CUGAUGAG  GCCGUUAGGC  CGAA AAGAAUCC   3173       2931   UCCCCGAU C AUCAGUUG   665   CAACUGAU CUGAUGAG  GCCGUUAGGC  CGAA AUCGGGGA   3174       2934   CCGAUCAU C AGUUGGAC   666   GUCCAACU CUGAUGAG  GCCGUUAGGC  CGAA AUGAUCGG   3175       2938   UCAUCAGU U GGACCCUG   667   CAGGGUCC CUGAUGAG  GCCGUUAGGC  CGAA ACUGAUGA   3176       2950   CCCUGCAU U CAAAGCCA   668   UGGCUUUG CUGAUGAG  GCCGUUAGGC  CGAA AUGCAGGG   3177       2951   CCUGCAUU C AAAGCCAA   669   UUGGCUUU CUGAUGAG  GCCGUUAGGC  CGAA AAUGCAGG   3178       2962   AGCCAACU C AGUAAAUC   670   GAUUUACU CUGAUGAG  GCCGUUAGGC  CGAA AGUUGGCU   3179       2966   AACUCAGU A AAUCCAGA   671   UCUGGAUU CUGAUGAG  GCCGUUAGGC  CGAA ACUGAGUU   3180       2970   CAGUAAAU C CAGAUUGG   672   CCAAUCUG CUGAUGAG  GCCGUUAGGC  CGAA AUUUACUG   3181       2976   AUCCAGAU U GGGACCUC   673   GAGGUCCC CUGAUGAG  GCCGUUAGGC  CGAA AUCUGGAU   3182       2984   UGGGACCU C AACCCGCA   674   UGCGGGUU CUGAUGAG  GCCGUUAGGC  CGAA AGGUCCCA   3183       3037   GGGAGCAU U CGGGCCAG   675   CUGGCCCG CUGAUGAG  GCCGUUAGGC  CGAA AUGCUCCC   3184       3038   GGAGCAUU C GGGCCAGG   676   CCUGGCCC CUGAUGAG  GCCGUUAGGC  CGAA AAUGCUCC   3185       3049   GCCAGGGU U CACCCCUC   677   GAGGGGUG CUGAUGAG  GCCGUUAGGC  CGAA ACCCUGGC   3186       3050   CCAGGGUU C ACCCCUCC   678   GGAGGGGU CUGAUGAG  GCCGUUAGGC  CGAA AACCCUGG   3187       3057   UCACCCCU C CCCAUGGG   679   CCCAUGGG CUGAUGAG  GCCGUUAGGC  CGAA AGGGGUGA   3188       3073   GGGACUGU U GGGGUGGA   680   UCCACCCC CUGAUGAG  GCCGUUAGGC  CGAA ACAGUCCC   3189       3087   GGAGCCCU C ACGCUCAG   681   CUGAGCGU CUGAUGAG  GCCGUUAGGC  CGAA AGGGCUCC   3190       3093   UUCACGCU C AGGGCCUA   682   UAGGCCCU CUGAUGAG  GCCGUUAGGC  CGAA AGCGUGAG   3191       3101   CAGGGCCU A CUCACAAC   683   GUUGUGAG CUGAUGAG  GCCGUUAGGC  CGAA AGGCCCUG   3192       3104   GGCCUACU C ACAACUGU   684   ACAGUUGU CUGAUGAG  GCCGUUAGGC  CGAA AGUAGGCC   3193       3123   UAGCAGCU C CUCCUCCU   685   AGGAGGAG CUGAUGAG  GCCGUUAGGC  CGAA AGCUGCUG   3194       3126   CAGCUCCU C CUCCUGCC   686   GGCAGGAG CUGAUGAG  GCCGUUAGGC  CGAA AGGAGCUG   3195       3129   CUCCUCCU C CUGCCUCC   687   GGAGGCAG CUGAUGAG  GCCGUUAGGC  CGAA AGGAGGAG   3196       3136   UCCUGCCU C CACCAAUC   688   GAUUGGUG CUGAUGAG  GCCGUUAGGC  CGAA AGGCAGGA   3197       3144   CCACCAAU C GGCAGUCA   689   UGACUGCC CUGAUGAG  GCCGUUAGGC  CGAA AUUGGUGG   3198       3151   UCGGCAGU C AGGAAGGC   690   GCCUUCCU CUGAUGAG  GCCGUUAGGC  CGAA ACUGCCGA   3199       3165   GGCAGCCU A CUCCCUUA   691   UAAGGGAG CUGAUGAG  GCCGUUAGGC  CGAA AGGCUGCC   3200       3168   AGCCUACU C CCUUAUCU   692   AGAUAAGG CUGAUGAG  GCCGUUAGGC  CGAA AGUAGGCU   3201       3172   UACUCCCU U AUCUCCAC   693   GUGGAGAU CUGAUGAG  GCCGUUAGGC  CGAA AGGGAGUA   3202       3173   ACUCCCUU A UCUCCACC   694   GGUGGAGA CUGAUGAG  GCCGUUAGGC  CGAA AAGGGAGU   3203       3175   UCCCUUAU C UCCACCUC   695   GAGGUGGA CUGAUGAG  GCCGUUAGGC  CGAA AUAAGGGA   3204       3177   CCUUAUCU C CACCUCUA   696   UAGAGGUG CUGAUGAG  GCCGUUAGGC  CGAA AGAUAAGG   3205       3183   UUCCACCU C UAAGGGAC   697   GUCCCUUA CUGAUGAG  GCCGUUAGGC  CGAA AGGUGGAG   3206       3185   CCACCUCU A AUGGACAC   698   GUGUCCCU CUGAUGAG  GCCGUUAGGC  CGAA AGAGGUGG   3207       3195   GGGACACU C AUCCUCAG   699   CUGAGGAU CUGAUGAG  GCCGUUAGGC  CGAA AGUGUCCC   3208       3198   ACACUCAG C CUCAGGCC   700   GGCCUGAG CUGAUGAG  GCCGUUAGGC  CGAA AUGAGUGU   3209       3201   CUCAUCCU C AGGCCAUG   701   CAUGGCCU CUGAUGAG  GCCGUUAGGC  CGAA AGGAUGAG   3210                                                                    
     [0249]               TABLE VI                          HUMAN HBV INOZYME AND SUBSTRATE SEQUENCE                                 Pos   Substrate   Seq ID   Inozyme   Seq ID                                         9   AACUCCAC C ACUUUCCA   702   UGGAAAGU CUGAUGAG  GCCGUUAGCC  CGAA IUGGAGUU   3211       10   ACUCCACC A CUUUCCAC   703   GUGGAAAG CUGAUGAG  GCCGUUAGGC  CGAA IGUGGAGU   3212       12   UCCACCAC U UUCCACCA   704   UGGUGGAA CUGAUGAG  GCCGUUAGGC  CGAA IUGGUGGA   3213       16   CCACUUUC C ACCAAACU   705   AGUUUGGU CUGAUGAG  GCCGUUAGGC  CGAA IAAAGUGG   3214       17   CACUUUCC A CCAAACUC   706   GAGUUUGG CUGAUGAG  GCCGUUAGGC  CGAA IGAAAGUG   3215       19   CUUUCCAC C AAACUCUU   707   AAGAGUUU CUGAUGAC  GCCGUUAGGC  CGAA IUGGAAAG   3216       20   UUUCCACC A AACUCUUC   708   GAAGAGUU CUGAUGAG  GCCGUUAGGC  CGAA IGUGGAAA   3217       24   CACCAAAC U CUUCAAGA   709   UCUUGAAG CUGAUGAG  GCCGUUAGGC  CGAA IUUUGGUG   3218       26   CCAAACUC U UCAAGAUC   710   GAUCUUGA CUGAUGAG  GCCGUUAGGC  CGAA IAGUUUGG   3219       29   AACUCUUC A AGAUCCCA   711   UGGGAUCU CUGAUGAG  GCCGUUAGGC  CGAA IAAGAGUU   3220       35   UCAAGAUC C CAGAGUCA   712   UGACUCUG CUGAUGAG  GCCGUUAGGC  CGAA IAUCUUGA   3221       36   CAAGAUCC C AGAGUCAG   713   UUGACUCU CUGAUGAG  GCCGUUAGGC  CGAA IGAUCUUG   3222       37   AAGAUCCC A GAGUCAGG   714   CCUGACUC CUGAUGAG  GCCGUUAGGC  CGAA IGGAUCUU   3223       43   UCAGAGUC A GGGCCCUG   715   CAGGGCCC CUGAUGAG  GCCGUUAGGC  CGAA IACUCUGG   3224       48   GUCAGGGC C CUGUACUU   716   AAGUACAG CUGAUGAG  GCCGUUAGGC  CGAA ICCCUGAC   3225       49   UCAGGGCC C UGUACUUU   717   AAAGUACA CUGAUGAG  GCCGUUAGGC  CGAA IGCCCUGA   3226       50   CAGGGCCC U GUACUGUC   718   GAAAGUAC CUGAUGAG  GCCGUUAGGC  CGAA IGGCCCUG   3227       55   CCCUGUAC U UUCCUGCU   719   AGCAGGAA CUGAUGAG  GCCGUUAGGC  CGAA IUACAGGG   3228       59   GUACUUUC C UGCUGGUG   720   CACCAGCA CUGAUGAG  GCCGUUAGGC  CGAA IAAAGUAC   3229       60   UACUUUCC U GCUGGUGG   721   CCACCAGC CUGAUGAG  GCCGUUAGGC  CGAA IGAAAGUA   3230       63   UUUCCUGC U GGUGGCUC   722   GAGCCACC CUGAUGAG  GCCGUUAGGC  CGAA ICAGGAAA   3231       70   CUGGUGGC U CCAGUUCA   723   UGAACUGG CUGAUGAG  GCCGUUAGGC  CGAA ICCACCAG   3232       72   GGUGGCUC C AGUUCAGG   724   CCUGAACU CUGAUGAG  GCCGUUAGGC  CGAA IAGCCACC   3233       73   GUGGCUCC A GUUCAGGA   725   UCCUGAAC CUGAUGAG  GCCGUUAGGC  CGAA IGAGCCAC   3234       78   UCCAGUUC A GGAACAGU   726   ACUGUUCC CUGAUGAG  GCCGUUAGGC  CGAA IAACUGGA   3235       84   UCAGGAAC A GUGAGCCC   727   GGGCUCAC CUGAUGAG  GCCGUUAGGC  CGAA IUUCCUGA   3236       91   CAGUGAUC C CUGCUCAG   728   CUGAGCAG CUGAUGAG  GCCGUUAGGC  CGAA ICUCACUG   3237       92   AGUGAGCC C UGCUCAGA   729   UCUGAGCA CUGAUGAG  GCCGUUAGGC  CGAA IGCUCACU   3238       93   GUGAGCCC U GCUCAGAA   730   UUCUGAGC CUGAUGAG  GCCGUUAGGC  CGAA IGGCUCAC   3239       96   AGCCCUGC U CAGAAUAC   731   GUAUUCUG CUGAUGAG  GCCGUUAGGC  CGAA ICAGGGCU   3240       98   CCCUGCUC A GAAUACUG   732   CAGUAUUC CUGAUGAG  GCCGUUAGGC  CGAA IAGCAGGG   3241       105   CAGAAUAC U GUCUCUGC   733   GCAGAGAC CUGAUGAG  GCCGUUAGGC  CGAA IUAUUCUG   3242       109   AUACUGUC U CUGCCAUA   734   UAUGGCAG CUGAUGAG  GCCGUUAGGC  CGAA IACAGUAU   3243       111   ACUGUCUC U GCCAUAUC   735   GAUAUGGC CUGAUGAG  GCCGUUAGGC  CGAA IAGACAGU   3244       114   GUCUCUGC C AUAUCGUC   736   GACGAUAU CUGAUGAG  GCCGUUAGGC  CGAA ICAGAGAC   3245       115   UCUCUGCC A UAUCGUCA   737   UGACGAUA CUGAUGAG  GCCGUUAGGC  CGAA ICCAGAGA   3246       123   AUAUCGUC A AUCUUAUC   738   GAUAAGAU CUGAUGAG  GCCGUUAGGC  CGAA IACGAUAU   3247       127   CGUCAAUC U UAUCGAAG   739   CUUCGAUA CUGAUGAG  GCCGUUAGGC  CGAA IAUUGACG   3248       138   UCGAAGAC U GGGGACCC   740   GGGUCCCC CUGAUGAG  GCCGUUAGGC  CGAA TUCUUCGA   3249       145   CUGGGGAC C CUGUACCG   741   CGGUACAG CUGAUGAG  GCCGUUAGGC  CGAA IUCCCCAG   3250       146   UGGGGACC C UGUACCGA   742   UCGGUACA CUGAUGAG  GCCGUUAGGC  CGAA IGUCCCCA   3251       147   GGGGACCC U GUACCGAA   743   UUCGGUAC CUGAUGAG  GCCGUUAGGC  CGAA IGGUCCCC   3252       152   CCCUGUAC C GAACAUGG   744   CCAUGUUC CUGAUGAG  GCCGUUAGGC  CGAA IUACAGGG   3253       157   UACCGAAC A UGGAGAAC   745   GUUCUCCA CUGAUGAG  GCCGUUAGGC  CGAA IUUCGGUA   3254       166   UGGAGAAC A UCOCAUCA   746   UGAUGCGA CUGAUGAG  GCCGUUAGGC  CGAA IUUCUCCA   3255       171   AACAUCGC A UCAGGACU   747   AGUCCUGA CUGAUGAG  GCCGUUAGGC  CGAA ICGAUGUU   3256       174   AUCGCAUC A GGACUCCU   748   AGGAGUCC CUGAUGAG  GCCGUUAGGC  CGAA IAUGCGAU   3257       179   AUCAGGAC U CCUAGGAC   749   GUCCUAGG CUGAUGAG  GCCGUUAGGC  CGAA IUCCUGAU   3258       181   CAGGACUC C UAGGACCC   750   GGGUCCUA CUGAUGAG  GCCGUUAGGC  CGAA IAGUCCUG   3259       182   AGGACUCC U AGGACCCC   751   GGGGUCCU CUGAUGAG  GCCGUUAGGC  CGAA IGAGUCCU   3260       188   CCUAGGAC C CCUGCUCG   752   CGAGCAGG CUGAUGAG  GCCGUUAGGC  CGAA IUCCUAGG   3261       189   CUAGGACC C CUGCUCGU   753   ACGAGCAG CUGAUGAG  GCCGUUAGGC  CGAA IGUCCUAG   3262       190   UAGGACCC C UGCUCGUG   754   CACGAGCA CUGAUGAG  GCCGUUAGGC  CGAA IGGUCCUA   3263       191   AGGACCCC U GCUCGUGU   755   ACACGAGC CUGAUGAG  GCCGUUAGGC  CGAA IGGGUCCU   3264       194   ACCCCUGC U CGUGUUAC   756   GUAACACG CUGAUGAG  GCCGUUAGGC  CGAA ICAGGGGU   3265       203   CGUGUUAC A GGCGGGGU   757   ACCCCGCC CUGAUGAG  GCCGUUAGGC  CGAA IUAACACG   3266       217   GGUUUUUC U UGUUGACA   758   UGUCAACA CUGAUGAG  GCCGUUAGGC  CGAA IAAAAACC   3267       225   UUGUUGAC A AAAAUCCU   759   AGGAUUUU CUGAUGAG  GCCGUUAGGC  CGAA IUCAACAA   3268       232   CAAAAAUC C UCACAAUA   760   UAUUGUGA CUGAUGAG  GCCGUUAGGC  CGAA IAUUUUUG   3269       233   AAAAAUCC U CACAAUAC   761   GUAUUGUG CUGAUGAG  GCCGUUAGGC  CGAA IGAUUUUU   3270       235   AAAUCCUC A CAAUACCA   762   UGGUAUUG CUGAUGAG  GCCGUUAGGC  CGAA IAGGAUUU   3271       237   AUCCUCAC A AUACCACA   763   UGUGGUAU CUGAUGAG  GCCGUUAGGC  CGAA IUGAGGAU   3272       242   CACAAUAC C ACAGAGUC   764   GACUCUGU CUGAUGAG  GCCGUUAGGC  CGAA IUAUUGUG   3273       243   ACAAUACC A CAGAGUCU   765   AGACUCUG CUGAUGAG  GCCGUUAGGC  CGAA IGUAUUGU   3274       245   AAUACCAC A GAGUCUAG   766   CUAGACUC CUGAUGAG  GCCGUUAGGC  CGAA IUGGUAUU   3275       251   ACAGAGUC U AGACUCGU   767   ACGAGUCU CUGAUGAG  GCCGUUAGGC  CGAA IACUCUGU   3276       256   GUCUAGAC U CGUGGUGG   768   CCACCACG CUGAUGAG  GCCGUUAGGC  CGAA IUCUAGAC   3277       267   UGGUGGAC U UCUCUCAA   769   UUGAGAGA CUGAUGAG  GCCGUUAGGC  CGAA IUCCACCA   3278       270   UGGACUUC U CUCAAUUU   770   AAAUUGAG CUGAUGAG  GCCGUUAGGC  CGAA IAAGUCCA   3279       272   GACUUCUC U CAAUUUUC   771   GAAAAUUG CUGAUGAG  GCCGUUAGGC  CGAA IAGAAGUC   3280       274   CUUCUCUC A AUUUUCUA   772   UAGAAAAU CUGAUGAG  GCCGUUAGGC  CGAA IAGAGAAG   3281       281   CAAUUUUC U AGGGGGAA   773   UUCCCCCU CUGAUGAG  GCCGUUAGGC  CGAA IAAAAUUG   3282       291   GGGGGAAC A CCCGUGUG   774   CACACGGG CUGAUGAG  GCCGUUAGGC  CGAA IUUCCCCC   3283       293   GGGAACAC C CGUGUGUC   775   GACACACG CUGAUGAG  GCCGUUAGGC  CGAA IUGUUCCC   3284       294   GGAACACC C GUGUGUCU   776   AGACACAC CUGAUGAG  GCCGUUAGGC  CGAA IGUGUUCC   3285       302   CGUGUGUC U UGGCCAAA   777   UUUGGCCA CUGAUGAG  GCCGUUAGGC  CGAA IACACACG   3286       307   GUCUUGGC C AAAAUUCG   778   CGAAUUUU CUGAUGAG  GCCGUUAGGC  CGAA ICCAAGAC   3287       308   UCUUGGCC A AAAUUCGC   779   GCGAAUUU CUGAUGAG  GCCGUUAGGC  CGAA IGCCAAGA   3288       317   AAAUUCGC A GUCCCAAA   780   UUUGGGAC CUGAUGAG  GCCGUUAGGC  CGAA ICGAAUUU   3289       321   UCGCAGUC C CAAAUCUC   781   GAGAUUUG CUGAUGAG  GCCGUUAGGC  CGAA IACUGCGA   3290       322   CGCAGUCC C AAAUCUCC   782   GGAGAUUU CUGAUGAG  GCCGUUAGGC  CGAA IGACUGCG   3291       323   GCAGUCCC A AAUCUCCA   783   UGGAGAUU CUGAUGAG  GCCGUUAGGC  CGAA IGGACUGC   3292       328   CCCAAAUC U CCAGUCAC   784   GUGACUGG CUGAUGAG  GCCGUUAGGC  CGAA IAUUUGGG   3293       330   CAAAUCUC C AGUCACUC   785   GAGUGACU CUGAUGAG  GCCGUUAGGC  CGAA IAGAUUUG   3294       331   AAAUCUCC A GUCACUCA   786   UGAGUGAC CUGAUGAG  GCCGUUAGGC  CGAA IGAGAUUU   3295       335   CUCCAGUC A CUCACCAA   787   UUGGUGAG CUGAUGAG  GCCGUUAGGC  CGAA IACUGGAG   3296       337   CCAGUCAC U CACCAACC   788   GGUUGGUG CUGAUGAG  GCCGUUAGGC  CGAA IUGACUGG   3297       339   AGUCACUC A CCAACCUG   789   CAGGUUGG CUGAUGAG  GCCGUUAGGC  CGAA IAGUGACU   3298       341   UCACUCAC C AACCUGUU   790   AACAGGUU CUGAUGAG  GCCGUUAGGC  CGAA IUGAGUGA   3299       342   CACUCACC A ACCUGUUG   791   CAACAGGU CUGAUGAG  GCCGUUAGGC  CGAA IGUGAGUG   3300       345   UCACCAAC C UGUUGUCC   792   GGACAACA CUGAUGAG  GCCGUUAGGC  CGAA IUUGGUGA   3301       346   CACCAACC U GUUGUCCU   793   AGGACAAC CUGAUGAG  GCCGUUAGGC  CGAA IGUUGGUG   3302       353   CUGUUGUC C UCCAAUUU   794   AAAUUGGA CUGAUGAG  GCCGUUAGGC  CGAA IACAACAG   3303       354   UGUUGUCC U CCAAUUUG   795   CAAAUUGG CUGAUGAG  GCCGUUAGGC  CGAA IGACAACA   3304       356   UUGUCCUC C AAUUUGUC   796   GACAAAUU CUGAUGAG  GCCGUUAGGC  CGAA IAGGACAA   3305       357   UGUCCUCC A AUUUGUCC   797   GGACAAAU CUGAUGAG  GCCGUUAGGC  CGAA IGAGGACA   3306       365   AAUUUGUC C UGGUUAUC   798   GAUAACCA CUGAUGAG  GCCGUUAGGC  CGAA IACAAAUU   3307       366   AUUUGUCC U GGUUAUCG   799   CGAUAACC CUGAUGAG  GCCGUUAGGC  CGAA IGACAAAU   3308       376   GUUAUCGC U GGAUGUGU   800   ACACAUCC CUGAUGAG  GCCGUUAGGC  CGAA ICGAUAAC   3309       386   GAUGUGUC U GCGGCGUU   801   AACGCCGC CUGAUGAG  GCCGUUAGGC  CGAA IACACAUC   3310       400   GUUUUAUC A UCUUCCUC   802   GAGGAAGA CUGAUGAG  GCCGUUAGGC  CGAA IAUAAAAC   3311       403   UUAUCAUC U UCCUCUGC   803   GCAGAGGA CUGAUGAG  GCCGUUAGGC  CGAA IAUGAUAA   3312       406   UCAUCUUC C UCUGCAUC   804   GAUGCAGA CUGAUGAG  GCCGUUAGGC  CGAA IAAGAUGA   3313       407   CAUCUUCC U CUGCAUCC   805   GGAUGCAG CUGAUGAG  GCCGUUAGGC  CGAA IGAAGAUG   3314       409   UCUUCCUC U GCAUCCUG   806   CAGGAUGC CUGAUGAG  GCCGUUAGGC  CGAA IAGGAAGA   3315       412   UCCUCUGC A UCCUGCUG   807   CACCAGGA CUGAUGAG  GCCGUUAGGC  CGAA ICAGAGGA   3316       415   UCUCCAUC C UGCUGCUA   808   UAGCAGCA CUGAUGAG  GCCGUUAGGC  CGAA IAUGCAGA   3317       416   CUGCAUCC U GCUGCUAU   809   AUAGCAGC CUGAUGAG  GCCGUUAGGC  CGAA IGAUGCAG   3318       419   CAUCCUGC U GCUAUGCC   810   GGCAUAGC CUGAUGAG  GCCGUUAGGC  CGAA ICAGGAUG   3319       422   CCUGCUGC U AUGCCUCA   811   UGAGCCAU CUGAUGAG  GCCGUUAGGC  CGAA ICAGCAGG   3320       427   UGCUAUGC C UCAUCUUC   812   GAAGAUGA CUGAUGAG  GCCGUUAGGC  CGAA ICAUAGCA   3321       428   GCUAUGCC U CAUCUUCU   813   AGAAGAUG CUGAUGAG  GCCGUUAGGC  CGAA IGCAUAGC   3322       430   UAUGCCUC A UCUUCUUG   814   CAAGAAGA CUGAUGAG  GCCGUUAGGC  CGAA IACGCAUA   3323       433   GCCUCAUC U UCUUGUUG   815   CAACAAGA CUGAUGAG  GCCGUUAGGC  CGAA IAUGAGGC   3324       436   UCAUCUUC U UGUUGGUU   816   AACCAACA CUGAUGAG  GCCGUUAGGC  CGAA IAAGAUGA   3325       446   GUUGGUUC U UCUGGACU   817   AGUCCAGA CUGAUGAG  GCCGUUAGGC  CGAA IAACCAAC   3326       449   GGUUCUUC U GGACUAUC   818   GAUAGUCC CUGAUGAG  GCCGUUAGGC  CGAA IAAGAACC   3327       454   UUCUGGAC U AUCAAGGU   819   ACCUUGAU CUGAUGAG  GCCGUUAGGC  CGAA IUCCAGAA   3328       458   GGACUAUC A AGGUAUGU   820   ACAUACCU CUGAUGAG  GCCGUUAGGC  CGAA IAUAGUCC   3329       470   UAUGUUGC C CGUUUGUC   821   GACAAACG CUGAUGAG  GCCGUUAGGC  CGAA ICAACAUA   3330       471   AUGUUGCC C GUUUGUCC   822   GGACAAAC CUGAUGAG  GCCGUUAGGC  CGAA IGCAACAU   3331       479   CGUUUGUC C UCUAAUUC   823   GAAUUAGA CUGAUGAG  GCCGUUAGGC  CGAA IACAAACG   3332       480   GUUUGUCC U CUAAUUCC   824   GGAAUUAG CUGAUGAG  GCCGUUAGGC  CGAA IGACAAAC   3333       482   UUGUCCUC U AAUUCCAG   825   CUGGAAUU CUGAUGAG  GCCGUUAGGC  CGAA IAGGACAA   3334       488   UCUAAUUC C AGGAUCAU   826   AUGAUCCU CUGAUGAG  GCCGUUAGGC  CGAA IAAUUAGA   3335       489   CUAAUUCC A GGAUCAUC   827   GAUGAUCC CUGAUGAG  GCCGUUAGGC  CGAA IGAAUUAG   3336       495   CCAGGAUC A UCAACAAC   828   GUUGUUGA CUGAUGAG  GCCGUUAGGC  CGAA IAUCCUGG   3337       498   GGAUCAUC A ACAACCAG   829   CUGGUUGU CUGAUGAG  GCCGUUAGGC  CGAA IAUGAUCC   3338       501   UCAUCAAC A ACCAGCAC   830   GUGCUGGU CUGAUGAG  GCCGUUAGGC  CGAA IUUGAUGA   3339       504   UCAACAAC C AGCACCGG   831   CCGGUGCU CUGAUGAG  GCCGUUAGGC  CGAA IUUGUUGA   3340       505   CAACAACC A GCACCGGA   832   UCCGGUGC CUGAUGAG  GCCGUUAGGC  CGAA IGUUGUUG   3341       508   CAACCAGC A CCGGACCA   833   UGGUCCGG CUGAUGAG  GCCGUUAGGC  CGAA ICUGGUUG   3342       510   ACCAGCAC C GGACCAUG   834   CAUGGUCC CUGAUGAG  GCCGUUAGGC  CGAA IUGCUGGU   3343       515   CACCGGAC C AUGCAAAA   835   UUUUGCAU CUGAUGAG  GCCGUUAGGC  CGAA IUCCGGUG   3344       516   ACCGGACC A UGCAAAAC   836   GUUUUGCA CUGAUGAG  GCCGUUAGGC  CGAA IGUCCGGU   3345       520   GACCAUGC A AAACCUGC   837   GCAGGUUU CUGAUGAG  GCCGUUAGGC  CGAA ICAUGGUC   3346       525   UGCAAAAC C UGCACAAC   838   GUUGUGCA CUGAUGAG  GCCGUUAGGC  CGAA IUUUUGCA   3347       526   GCAAAACC U GCACAACU   839   AGUUGUGC CUGAUGAG  GCCGUUAGGC  CGAA IGUUUUGC   3348       529   AAACCUGC A CAACUCCU   840   AGGAGUUG CUGAUGAG  GCCGUUAGGC  CGAA ICAGGUUU   3349       531   ACCUGCAC A ACUCCUGC   841   GCAGGAGU CUGAUGAG  GCCGUUAGGC  CGAA IUGCAGGU   3350       534   UGCACAAC U CCUGCUCA   842   UGAGCAGG CUGAUGAG  GCCGUUAGGC  CGAA IUUGUGCA   3351       536   CACAACUC C UGCUCAAG   843   UUUGAGCA CUGAUGAG  GCCGUUAGGC  CGAA IAGUUGUG   3352       537   ACAACUCC U GCUCAAGG   844   CCUUGAGC CUGAUGAG  GCCGUUAGGC  CGAA IGAGUUGU   3353       540   ACUCCUGC U CAAGGAAC   845   GUUCCUUG CUGAUGAG  GCCGUUAGGC  CGAA ICAGGAGU   3354       542   UCCUGCUC A AGGAACCU   846   AGGUUCCU CUGAUGAG  GCCGUUAGGC  CGAA IAGCAGGA   3355       549   CAAGGAAC C UCUAUGUU   847   AACAUAGA CUGAUGAG  GCCGUUAGGC  CGAA IUUCCUUG   3356       550   AAGGAACC U CUAUGUUU   848   AAACAUAG CUGAUGAG  GCCGUUAGGC  CGAA IGUUCCUU   3357       552   GGAACCUC U AUGUUUCC   849   GGAAACAU CUGAUGAG  GCCGUUAGGC  CGAA IAGGUUCC   3358       560   UAUGUUUC C CUCAUGUU   850   AACAUGAG CUGAUGAG  GCCGUUAGGC  CGAA IAAACAUA   3359       561   AUGUUUCC C UCAUGUUG   851   CAACAUGA CUGAUGAG  GCCGUUAGGC  CGAA IGAAACAU   3360       562   UGUUUCCC U CAUGUUGC   852   GCAACAUG CUGAUGAG  GCCGUUAGGC  CGAA IGGAAACA   3361       564   UUUCCCUC A UGUUGCUG   853   UAGCAACA CUGAUGAG  GCCGUUAGGC  CGAA IAGGGAAA   3362       571   CAUGUUGC U GUACAAAA   854   UUUUGUAC CUGAUGAG  GCCGUUAGGC  CGAA ICAACAUG   3363       576   UGCUGUAC A AAACCUAC   855   GUAGGUUU CUGAUGAG  GCCGUUAGGC  CGAA IUACAGCA   3364       581   UACAAAAC C UACGGACG   856   CGUCCGUA CUGAUGAG  GCCGUUAGGC  CGAA IUUUUGUA   3365       582   ACAAAACC U ACGGACGG   857   CCGUCCGU CUGAUGAG  GCCGUUAGGC  CGAA IGUUUUGU   3366       595   ACGGAAAC U GCACCUGU   858   ACAGGUGC CUGAUGAG  GCCGUUAGGC  CGAA IUUUCCGU   3367       598   GAAACUGC A CCUGUAUU   859   AAUACAGG CUGAUGAG  GCCGUUAGGC  CGAA ICAGUUUC   3368       600   AACUGCAC C UGUAUUCC   860   GGAAUACA CUGAUGAG  GCCGUUAGGC  CGAA IUGCAGUU   3369       601   ACUGCACC U GUAUUCCC   861   GGGAAUAC CUGAUGAG  GCCGUUAGGC  CGAA IGUGCAGU   3370       608   CUGUAUUC C CAUCCCAU   862   AUGGGAUG CUGAUGAG  GCCGUUAGGC  CGAA IAAUACAG   3371       609   UGUAUUCC C AUCCCAUC   863   GAUGGGAU CUGAUGAG  GCCGUUAGGC  CGAA IGAAUACA   3372       610   GUAUUCCC A UCCCAUCA   864   UGAUGGGA CUGAUGAG  GCCGUUAGGC  CGAA IGGAAUAC   3373       613   UUCCCAUC C CAUCAUCU   865   AGAUGAUG CUGAUGAG  GCCGUUAGGC  CGAA IAUGGGAA   3374       614   UCCCAUCC C AUCAUCUU   866   AAGAUGAU CUGAUGAG  GCCGUUAGGC  CGAA IGAUGUGA   3375       615   CCCAUCCC A UCAUCUUG   867   CAAGAUGA CUGAUGAG  GCCGUUAGGC  CGAA IGGAUGGG   3376       618   AUCCCAUC A UCUUGGGC   868   GCCCAAGA CUGAUGAG  GCCGUUAGGC  CGAA IAUGGGAU   3377       621   CCAUCAUC U UGGGCUUU   869   AAAGCCCA CUGAUGAG  GCCGUUAGGC  CGAA IAUGAUGG   3378       627   UCUUGGGC U UUCGCAAA   870   UUUGCGAA CUGAUGAG  GCCGUUAGGC  CGAA ICCCAAGA   3379       633   GCUUUCGC A AAAUACCU   871   AGGUAUUU CUGAUGAG  GCCGUUAGGC  CGAA ICGAAAGC   3380       640   CAAAAUAC C UAUGGGAG   872   CUCCCAUA CUGAUGAG  GCCGUUAGGC  CGAA IUAUUUUG   3381       641   AAAAUACC U AUGGGAGU   873   ACUCCCAU CUGAUGAG  GCCGUUAGGC  CGAA IGUAUUUU   3382       654   GAGUGGGC C UCAGUCCG   874   CGGACUGA CUGAUGAG  GCCGUUAGGC  CGAA ICCCACUC   3383       655   AGUGGGCC U CAGUCCGU   875   ACGGACUG CUGAUGAG  GCCGUUAGGC  CGAA IGCCCACU   3384       657   UGGGCCUC A GUCCGUUU   876   AAACGGAC CUGAUGAG  GCCGUUAGGC  CGAA IAGGCCCA   3385       661   CCUCAGUC C GUUUCUCU   877   AGAGAAAC CUGAUGAG  GCCGUUAGGC  CGAA IACUGAGG   3386       667   UCCGUUUC U CUUGGCUC   878   GAGCCAAG CUGAUGAG  GCCGUUAGGC  CGAA IAAACGGA   3387       669   CGUUUCUC U UGGCUCAG   879   CUGAGCCA CUGAUGAG  GCCGUUAGGC  CGAA IAGAAACG   3388       674   CUCUUGGC U CAGUUUAC   880   GUAAACUG CUGAUGAG  GCCGUUAGGC  CGAA ICCAAGAG   3389       676   CUUGGCUC A GUUUACUA   881   UAGUAAAC CUGAUGAG  GCCGUUAGGC  CGAA IAGCCAAG   3390       683   UAGUUUAC U AGUGCCAU   882   AUGGCACU CUGAUGAG  GCCGUUAGGC  CGAA IUAAACUG   3391       689   ACUAGUGC C AUUUGUUC   883   GAACAAAU CUGAUGAG  GCCGUUAGGC  CGAA ICACUAGU   3392       690   CUAGUGCC A UUUGUUCA   884   UGAACAAA CUGAUGAG  GCCGUUAGGC  CGAA IGCACUAG   3393       698   AUUUGUUC A GUGGUUCG   885   CGAACCAC CUGAUGAG  GCCGUUAGGC  CGAA IAACAAAU   3394       713   UGUAGGGC U UUCCCCCA   886   UGGGGGAA CUGAUGAG  GCCGUUAGGC  CGAA ICCCUACG   3395       717   GGGCUUUC C CCCACUGU   887   ACAGUGGG CUGAUGAG  GCCGUUAGGC  CGAA IAAAGCCC   3396       718   GGCUUUCC C CCACUGUC   888   GACAGUGG CUGAUGAG  GCCGUUAGGC  CGAA IGAAAGCC   3397       719   GCUUUCCC C CACUGUCU   889   AGACAGUG CUGAUGAG  GCCGUUAGGC  CGAA IGGAAAGC   3398       720   CUUUCCCC C ACUGUCUG   890   CAGACAGU CUGAUGAG  GCCGUUAGGC  CGAA IGGGAAAG   3399       721   UUUCCCCC A CUGUCUGG   891   CCAGACAG CUGAUGAG  GCCGUUAGGC  CGAA IGGGGAAA   3400       723   UCCCCCAC U GUCUGGCU   892   AGCCAGAC CUGAUGAG  GCCGUUAGGC  CGAA IUGGGGGA   3401       727   CCACUGUC U GGCUUUCA   893   UGAAAGCC CUGAUGAG  GCCGUUAGGC  CGAA IACAGUGG   3402       731   UGUCUGGC U UUCAGUUA   894   UAACUGAA CUGAUGAG  GCCGUUAGGC  CGAA ICCAGACA   3403       735   UGGCUUUC A GUUAUAUG   895   CAUAUAAC CUGAUGAG  GCCGUUAGGC  CGAA IAAAGCCA   3404       764   UUGGGGGC C AAGUCUGU   896   ACAGACUU CUGAUGAG  GCCGUUAGGC  CGAA ICCCCCAA   3405       765   UGGGGGCC A AGUCUGUA   897   UACAGACU CUGAUGAG  GCCGUUAGGC  CGAA IGCCCCCA   3406       770   GCCAAGUC U GUACAACA   898   UGUUGUAC CUGAUGAG  GCCGUUAGGC  CGAA IACUUGGC   3407       775   GUCUGUAC A ACAUCUUG   899   CAAGAUGU CUGAUGAG  GCCGUUAGGC  CGAA IUACAGAC   3408       778   UGUACAAC A UCUUGAGU   900   ACUCAAGA CUGAUGAG  GCCGUUAGGC  CGAA IUUGUACA   3409       781   ACAACAUC U UGAGUCCC   901   GGGACUCA CUGAUGAG  GCCGUUAGGC  CGAA IAUGUUGU   3410       788   CUUGAGUC C CUUUAUGC   902   GCAUAAAG CUGAUGAG  GCCGUUAGGC  CGAA IACUCAAG   3411       789   UUGAGUCC C UUUAUGCC   903   GGCAUAAA CUGAUGAG  GCCGUUAGGC  CGAA IGACUCAA   3412       790   UGAGUCCC U UUAUGCCG   904   CGGCAUAA CUGAUGAG  GCCGUUAGGC  CGAA IGGACUCA   3413       797   CUUUAUGC C GCUGUUAC   905   GUAACAGC CUGAUGAG  GCCGUUAGGC  CGAA ICAUAAAG   3414       800   UAUGCCGC U GUUACCAA   906   UUGGUAAC CUGAUGAG  GCCGUUAGGC  CGAA ICGGCAUA   3415       806   GCUGUUAC C AAUUUUCU   907   AGAAAAUU CUGAUGAG  GCCGUUAGGC  CGAA IUAACAGC   3416       807   CUGUUACC A AUUUUCUU   908   AAGAAAAU CUGAUGAG  GCCGUUAGGC  CGAA IGUAACAG   3417       814   CAAUUUUC U UUUGUCUU   909   AAGACAAA CUGAUGAG  GCCGUUAGGC  CGAA IAAAAUUG   3418       821   CUUUUGUC U UUGGGUAU   910   AUACCCAA CUGAUGAG  GCCGUUAGGC  CGAA IACAAAAG   3419       832   GGGUAUAC A UUUAAACC   911   GGUUUAAA CUGAUGAG  GCCGUUAGGC  CGAA IUAUACCC   3420       840   AUUUAAAC C CUCACAAA   912   GUGGUGAG CUGAUGAG  GCCGUUAGGC  CGAA IUUUAAAU   3421       841   UUUAAACC C UCACAAAA   913   UUUUGUGA CUGAUGAG  GCCGUUAGGC  CGAA IGUUUAAA   3422       842   UUAAACCC U CACAAAAC   914   GUUUUGUG CUGAUGAG  GCCGUUAGGC  CGAA IGGUUUAA   3423       844   AAACCCUC A CAAAACAA   915   UUGUUUUG CUGAUGAG  GCCGUUAGGC  CGAA IAGGGUUU   3424       846   ACCCUCAC A AAACAAAA   916   UUUUGUUU CUGAUGAG  GCCGUUAGGC  CGAA IUGAGGGU   3425       851   CACAAAAC A AAAAGAUG   917   CAUCUUUU CUGAUGAG  GCCGUUAGGC  CGAA IUUUUGUG   3426       869   GGAUAUUC C CUUAACUU   918   AAGUUAAG CUGAUGAG  GCCGUUAGGC  CGAA IAAUAUCC   3427       870   GAUAUUCC C UUAACUUC   919   GAAGUUAA CUGAUGAG  GCCGUUAGGC  CGAA IGAAUAUC   3428       871   AUAUUCCC U UAACUUCA   920   UGAAGUUA CUGAUGAG  GCCGUUAGGC  CGAA IGGAAUAU   3429       876   CCCUUAAC U UCAUGGGA   921   UCCCAUGA CUGAUGAG  GCCGUUAGGC  CGAA IUUAAGGG   3430       879   UUAACUUC A UGGGAUAU   922   AUAUCCCA CUGAUGAG  GCCGUUAGGC  CGAA IAAGUUAA   3431       906   GUUGGGGC A CAUUGCCA   923   UGGCAAUG CUGAUGAG  GCCGUUAGGC  CGAA ICCCCAAC   3432       908   UGGGGCAC A UUGCCACA   924   UGUGGCAA CUGAUGAG  GCCGUUAGGC  CGAA IUGCCCCA   3433       913   UACAUUGC C ACAGGAAC   925   GUUCCUGU CUGAUGAG  GCCGUUAGGC  CGAA ICAAUGUG   3434       914   ACAUUGCC A CAGGAACA   926   UGUUCCUG CUGAUGAG  GCCGUUAGGC  CGAA IGCAAUGU   3435       916   AUUGCCAC A GGAACAUA   927   UAUGUUCC CUGAUGAG  GCCGUUAGGC  CGAA IUGGCAAU   3436       922   ACAGGAAC A UAUUGUAC   928   GUACAAUA CUGAUGAG  GCCGUUAGGC  CGAA IUUCCUGU   3437       931   UAUUGUAC A AAAAAUCA   929   UGAUUUUU CUGAUGAG  GCCGUUAGGC  CGAA IUACAAUA   3438       939   AAAAAAUC A AAAUGUGU   930   ACACAUUU CUGAUGAG  GCCGUUAGGC  CGAA IAUUUUUU   3439       958   UAGGAAAC U UCCUGUAA   931   UUACAGGA CUGAUGAG  GCCGUUAGGC  CGAA IUUUCCUA   3440       961   GAAACUUC C UGUAAACA   932   UGUUUACA CUGAUGAG  GCCGUUAGGC  CGAA IAAGUUUC   3441       962   AAACUUCC U GUAAACAG   933   UUGUUUAC CUGAUGAG  GCCGUUAGGC  CGAA IGAAGUUU   3442       969   CUGUAAAC A GGCCUAUU   934   AAUAGGCC CUGAUGAG  GCCGUUAGGC  CGAA IUUUACAG   3443       973   AAACAGGC C UAUUGAUU   935   AAUCAAUA CUGAUGAG  GCCGUUAGGC  CGAA ICCUGUUU   3444       974   AACAGGCC U AUUGAUUG   936   CAAUCAAU CUGAUGAG  GCCGUUAGGC  CGAA IGCCUGUU   3445       994   AGUAUGUC A ACGAAUUG   937   CAAUUCGU CUGAUGAG  GCCGUUAGGC  CGAA IACAUACU   3446       1009   UGUGGGUC U UUUGGGGU   938   ACCCCAAA CUGAUGAG  GCCGUUAGGC  CGAA IACCCACA   3447       1022   GGGUUUGC C GCCCCUUU   939   AAAGGGGC CUGAUGAG  GCCGUUAGGC  CGAA ICAAACCC   3448       1025   UUUGCCGC C CCUUUCAC   940   GUGAAAGG CUGAUGAG  GCCGUUAGGC  CGAA ICGGCAAA   3449       1026   UUGCCGCC C CUUUCACG   941   CGUGAAAG CUGAUGAG  GCCGUUAGGC  CGAA IGCGGCAA   3450       1027   UGCCGCCC C UUUCACGC   942   GCGUGAAA CUGAUGAG  GCCGUUAGGC  CGAA IGGCGGCA   3451       1028   GCCGCCCC U UUCACGCA   943   UGCGUGAA CUGAUGAG  GCCGUUAGGC  CGAA IGGGCGGC   3452       1032   CCCCUUUC A CGCAAUGU   944   ACAUUGCG CUGAUGAG  GCCGUUAGGC  CGAA IAAAGGGG   3453       1036   UUUCACGC A AUGUGGAU   945   AUCCACAU CUGAUGAG  GCCGUUAGGC  CGAA ICGUGAAA   3454       1049   GGAUAUUC U GCUUUAAU   946   AUUAAAGC CUGAUGAG  GCCGUUAGGC  CGAA IAAUAUCC   3455       1052   UAUUCUGC U UUAAUGCC   947   GGCAUUAA CUGAUGAG  GCCGUUAGGC  CGAA ICAGAAUA   3456       1060   UUUAAUGC C UUUAUAUG   948   CAUAUAAA CUGAUGAG  GCCGUUAGGC  CGAA ICAUUAAA   3457       1061   UUAAUGCC U UUAUAUGC   949   GCAUAUAA CUGAUGAG  GCCGUUAGGC  CGAA IGCAUUAA   3458       1070   UUAUAUGC A UGCAUACA   950   UGUAUGCA CUGAUGAG  GCCGUUAGGC  CGAA ICAUAUAA   3459       1074   AUGCAUGC A UACAAGCA   951   UGCUUGUA CUGAUGAG  GCCGUUAGGC  CGAA ICAUGCAU   3460       1078   AUGCAUAC A AGCAAAAC   952   GUUUUGCU CUGAUGAG  GCCGUUAGGC  CGAA IUAUGCAU   3461       1082   AUACAAGC A AAACAGGC   953   GCCUGUUU CUGAUGAG  GCCGUUAGGC  CGAA ICUUGUAU   3462       1087   AGCAAAAC A GGCUUUUA   954   UAAAAGCC CUGAUGAG  GCCGUUAGGC  CGAA IUUUUGCU   3463       1091   AAACAGGC U UUUACUUU   955   AAAGUAAA CUGAUGAG  GCCGUUAGGC  CGAA ICCUGUUU   3464       1097   GCUUUUAC U UUCUCGCC   956   GGCGAGAA CUGAUGAG  GCCGUUAGGC  CGAA IUAAAAGC   3465       1101   UUACUUUC U CGCCAACU   957   AGUUGGCG CUGAUGAG  GCCGUUAGGC  CGAA IAAAGUAA   3466       1105   UUUCUCGC C AACUUACA   958   UGUAAGUU CUGAUGAG  GCCGUUAGGC  CGAA ICGAGAAA   3467       1106   UUCUCGCC A ACUUACAA   959   UUGUAAGU CUGAUGAG  GCCGUUAGGC  CGAA IGCGAGAA   3468       1109   UCGCCAAC U UACAAGGC   960   GCCUUGUA CUGAUGAG  GCCGUUAGGC  CGAA IUUGGCGA   3469       1113   UAACUUAC A AGGCCUUU   961   AAAGGCCU CUGAUGAG  GCCGUUAGGC  CGAA IUAAGUUG   3470       1118   UACAAGGC C UUUCUAAG   962   CUUAGAAA CUGAUGAG  GCCGUUAGGC  CGAA ICCUUGUA   3471       1119   ACAAGGCC U UUCUAAGU   963   ACUUAGAA CUGAUGAG  GCCGUUAGGC  CGAA IGCCUUGU   3472       1123   GGCCUUUC U AAGUAAAC   964   GUUUACUU CUGAUGAG  GCCGUUAGGC  CGAA IAAAGGCC   3473       1132   AAGUAAAC A GUAUGUGA   965   UCACAUAC CUGAUGAG  GCCGUUAGGC  CGAA IUUUACUU   3474       1143   AUGUGAAC C UUUACCCC   966   GGGGUAAA CUGAUGAG  GCCGUUAGGC  CGAA IUUCACAU   3475       1144   UGUGAACC U UUACCCCG   967   CGGGGUAA CUGAUGAG  GCCGUUAGGC  CGAA IGUUCACA   3476       1149   ACCUUUAC C CCGUUGCU   968   AGCAACGG CUGAUGAG  GCCGUUAGGC  CGAA IUAAAGGU   3477       1150   CCUUUACC C CGUUGCUC   969   GAGCAACG CUGAUGAG  GCCGUUAGGC  CGAA IGUAAAGG   3478       1151   CUUUACCC C GUUGCUCG   970   CGAGCAAC CUGAUGAG  GCCGUUAGGC  CGAA IGGUAAAG   3479       1157   CCCGUUGC U CGGCAACG   971   CGUUGCCG CUGAUGAG  GCCGUUAGGC  CGAA ICAACGGG   3480       1162   UGCUCGGC A ACGGCCUG   972   CAGGCCGU CUGAUGAG  GCCGUUAGGC  CGAA ICCGAGCA   3481       1168   GCAACGGC C UGGUCUAU   973   AUAGACCA CUGAUGAG  GCCGUUAGGC  CGAA ICCGUUGC   3482       1169   CAACGGCC U GGUCUAUG   974   CAUAGACC CUGAUGAG  GCCGUUAGGC  CGAA IGCCGUUG   3483       1174   GCCUGGUC U AUGCCAAG   975   CUUGGCAU CUGAUGAG  GCCGUUAGGC  CGAA IACCAGGC   3484       1179   GUCUAUGC C AAGUGUUU   976   AAACACUU CUGAUGAG  GCCGUUAGGC  CGAA ICAUAGAC   3485       1180   UCUAUGCC A AGUGUUUG   977   CAAACACU CUGAUGAG  GCCGUUAGGC  CGAA IGCAUAGA   3486       1190   GUGUUUGC U GACGCAAC   978   GUUGCGUC CUGAUGAG  GCCGUUAGGC  CGAA ICAAACAC   3487       1196   GCUGACGC A ACCCCCAC   979   GUGGGGGU CUGAUGAG  GCCGUUAGGC  CGAA ICGUCAGC   3488       1199   GACGCAAC C CCCACUGG   980   CCAGUGGG CUGAUGAG  GCCGUUAGGC  CGAA IUUGCGUC   3489       1200   ACGCAACC C CCACUGGU   981   ACCAGUGG CUGAUGAG  GCCGUUAGGC  CGAA IGUUGCGU   3490       1201   CGCAACCC C CACUGGUU   982   AACCAGUG CUGAUGAG  GCCGUUAGGC  CGAA IGGUUGCG   3491       1202   GCAACCCC C ACUGGUUG   983   UAACCAGU CUGAUGAG  GCCGUUAGGC  CGAA IGGGUUGC   3492       1203   CAACCCCC A CUGGUUGG   984   CCAACCAG CUGAUGAG  GCCGUUAGGC  CGAA IGGGGUUG   3493       1205   ACCCCCAC U GGUUGGGG   985   CCCCAACC CUGAUGAG  GCCGUUAGGC  CGAA IUGGGGGU   3494       1215   GUUGGGGC U UGGCCAUA   986   UAUGGCCA CUGAUGAG  GCCGUUAGGC  CGAA ICCCCAAC   3495       1220   GGCUUGGC C AUAGGCCA   987   UGGCCUAU CUGAUGAG  GCCGUUAGGC  CGAA ICCAAGCC   3496       1221   GCUUGGCC A UAGGCCAU   988   AUGGCCUA CUGAUGAG  GCCGUUAGGC  CGAA IGCCAAGC   3497       1227   CCAUAGGC C AUCAGCGC   989   GCGCUGAU CUGAUGAG  GCCGUUAGGC  CGAA ICCUAUGG   3498       1228   CAUAGGCC A UCAGCGCA   990   UGCGCUGA CUGAUGAG  GCCGUUAGGC  CGAA IGCCUAUG   3499       1231   AGGCCAUC A GCGCAUGC   991   GCAUGCGC CUGAUGAG  GCCGUUAGGC  CGAA IAUGGCCU   3500       1236   AUCAGCGC A UGCGUGGA   992   UCCACGCA CUGAUGAG  GCCGUUAGGC  CGAA ICGCUGAU   3501       1247   CGUGGAAC C UUUGUGUC   993   GACACAAA CUGAUGAG  GCCGUUAGGC  CGAA IUUCCACG   3502       1248   GUGGAACC U UUGUGUCU   994   AGACACAA CUGAUGAG  GCCGUUAGGC  CGAA IGUUCCAC   3503       1256   UUUGUGUC U CCUCUGCC   995   GGCAGAGG CUGAUGAG  GCCGUUAGGC  CGAA IACACAAA   3504       1258   UGUGUCUC C UCUGCCGA   996   UCGGCAGA CUGAUGAG  GCCGUUAGGC  CGAA IAGACACA   3505       1259   GUGUCUCC U CUGCCGAU   997   AUCGGCAG CUGAUGAG  GCCGUUAGGC  CGAA IGAGACAC   3506       1261   GUCUCCUC U GCCGAUCC   998   GGAUCGGC CUGAUGAG  GCCGUUAGGC  CGAA IAGGAGAC   3507       1264   UCCUCUGC C GAUCCAUA   999   UAUGGAUC CUGAUGAG  GCCGUUAGGC  CGAA ICAGAGGA   3508       1269   UGCCGAUC C AUACCGCG   1000   CGCGGUAU CUGAUGAG  GCCGUUAGGC  CGAA IAUCGGCA   3509       1270   GCCGAUCC A UACCGCGG   1001   CCGCGGUA CUGAUGAG  GCCGUUAGGC  CGAA IGAUCGGC   3510       1274   AUCCAUAC C GCGGAACU   1002   AGUUCCGC CUGAUGAG  GCCGUUAGGC  CGAA IUAUGGAU   3511       1282   CGCGGAAC U CCUAGCCG   1003   CGGCUAGC CUGAUGAG  GCCGUUAGGC  CGAA IUUCCGCG   3512       1284   CGGAACUC C UAGCCGCU   1004   AGCGGCUA CUGAUGAG  GCCGUUAGGC  CGAA IAGUUCCG   3513       1285   GGAACUCC U AGCCGCUU   1005   AAGCGGCU CUGAUGAG  GCCGUUAGGC  CGAA IGAGUUCC   3514       1289   CUCCUAGC C GCUUGUUU   1006   AAACAAGC CUGAUGAG  GCCGUUAGGC  CGAA ICUAGGAG   3515       1292   CUAGCCGC U UGUUUUGC   1007   GCAAAACA CUGAUGAG  GCCGUUAGGC  CGAA ICGGCUAG   3516       1301   UGUUUUGC U CGCAGCAG   1008   CUGCUGCG CUGAUGAG  GCCGUUAGGC  CGAA ICAAAACA   3517       1305   UUGCUCGC A GCAGGUCU   1009   AGACCUGC CUGAUGAG  GCCGUUAGGC  CGAA ICGAGCAA   3518       1308   CUCGCAGC A GGUCUGUG   1010   CCCAGACC CUGAUGAG  GCCGUUAGGC  CGAA ICUGCGAG   3519       1313   ACCAGGUC U GGGGCAAA   1011   UUUGCCCC CUGAUGAG  GCCGUUAGGC  CGAA IACCUGCU   3520       1319   UCUGGGGC A AAACUCAU   1012   AUGAGGUG CUGAUGAG  GCCGUUAGGC  CGAA ICCCCAGA   3521       1324   GGCAAAAC U CAUCGGGA   1013   UCCCGAUG CUGAUGAG  GCCGUUAGGC  CGAA IUUUUGCC   3522       1326   CAAAACUC A UCGGGACU   1014   AGUCCCGA CUGAUGAG  GCCGUUAGGC  CGAA IAGUUUUG   3523       1334   AUCGGGAC U GACAAUUC   1015   GAAUUGUC CUGAUGAG  GCCGUUAGGC  CGAA IUCCCGAU   3524       1338   GGACUGAC A AGUCUGUC   1016   GACAGAAU CUGAUGAG  GCCGUUAGGC  CGAA IUCAGUCC   3525       1343   GACAAUUC U GUCGUGCU   1017   AGCACGAC CUGAUGAG  GCCGUUAGGC  CGAA IAAUUGUC   3526       1351   UGUCGUGC U CUCCCGCA   1018   UGCGGGAG CUGAUGAG  GCCGUUAGGC  CGAA ICACGACA   3527       1353   UCGUGCUC U CCCGCAAA   1019   UUUGCGGG CUGAUGAG  GCCGUUAGGC  CGAA IAGCACGA   3528       1355   GUGCUCUC C CGCAAAUA   1020   UAUUUGCG CUGAUGAG  GCCGUUAGGC  CGAA IAGAGCAC   3529       1356   UGCUCUCC C GCAAAUAU   1021   AUAUUUGC CUGAUGAG  GCCGUUAGGC  CGAA IGAGAGCA   3530       1359   UCUCCCGC A AAUAUACA   1022   UGUAUAUU CUGAUGAG  GCCGUUAGGC  CGAA ICGGGAGA   3531       1367   AAAUAUAC A UCAUUUCC   1023   GGAAAUGA CUGAUGAG  GCCGUUAGGC  CGAA IUAUAUUU   3532       1370   UAUACAUC A UUUCCAUG   1024   CAUGGAAA CUGAUGAG  GCCGUUAGGC  CGAA IAUGUAUA   3533       1375   AUCAUUUC C AUGGCUGC   1025   GCAGCCAU CUGAUGAG  GCCGUUAGGC  CGAA IAAAUGAU   3534       1376   UCAUUUCC A UGGCUGCU   1026   AGCAGCCA CUGAUGAG  GCCGUUAGGC  CGAA IGAAAUGA   3535       1381   UCCAUGGC U GCUAGGCU   1027   AGCCUAGC CUGAUGAG  GCCGUUAGGC  CGAA ICCAUGGA   3536       1384   AUGGCUGC U AGGCUGUG   1028   CACAGCCU CUGAUGAG  GCCGUUAGGC  CGAA ICAGCCAU   3537       1389   UGCUAGGC U GUGCUGCC   1029   GGCAGCAC CUGAUGAG  GCCGUUAGGC  CGAA ICCUAGCA   3538       1394   GGCUGUGC U GCCAACUG   1030   CAGUUGGC CUGAUGAG  GCCGUUAGGC  CGAA ICACAGCC   3539       1397   UGUGCUGC C AACUGGAU   1031   AUCCAGUU CUGAUGAG  GCCGUUAGGC  CGAA ICAGCACA   3540       1398   GUGCUGCC A ACUGGAUC   1032   GAUCCAGU CUGAUGAG  GCCGUUAGGC  CGAA IGCAGCAC   3541       1401   CUGCCAAC U GGAUCCUA   1033   UAGGAUCC CUGAUGAG  GCCGUUAGGC  CGAA IUUGGCAG   3542       1407   ACUGGAUC C UACGCGGG   1034   CCCGCGUA CUGAUGAG  GCCGUUAGGC  CGAA IAUCCAGU   3543       1408   CUGGAUCC U ACGCGGGA   1035   UCCCGCGU CUGAUGAG  GCCGUUAGGC  CGAA IGAUCCAG   3544       1421   GGGACGUC C UUUGUUUA   1036   UAAACAAA CUGAUGAG  GCCGUUAGGC  CGAA IACGUCCC   3545       1422   GGACGUCC U GUGUUUAC   1037   GUAAACAA CUGAUGAG  GCCGUUAGGC  CGAA IGACGUCC   3546       1434   UUUACGUC C CGUCGGCG   1038   CGCCGACG CUGAUGAG  GCCGUUAGGC  CGAA IACGUAAA   3547       1435   UUACGUCC C GUCGGCGC   1039   GCGCCGAC CUGAUGAG  GCCGUUAGGC  CGAA IGACGUAA   3548       1444   GUCGGCGC U GAAUCCCG   1040   CGGGAUUC CUGAUGAG  GCCGUUAGGC  CGAA ICGCCGAC   3549       1450   GCUGAAUC C CGCGGACG   1041   CGUCCGCG CUGAUGAG  GCCGUUAGGC  CGAA IAUUCAGC   3550       1451   CUGAAUCC C GCGGACGA   1042   UCGUCCGC CUGAUGAG  GCCGUUAGGC  CGAA IGAGUCAG   3551       1461   CGGACGAC C CCUCCCGG   1043   UCGGGAGG CUGAUGAG  GCCGUUAGGC  CGAA IUCGUCCG   3552       1462   GGACGACC C CUCCCGGG   1044   CCCGGGAG CUGAUGAG  GCCGUUAGGC  CGAA IGUCGUCC   3553       1463   GACGACCC C UCCCGGGG   1045   CCCCGGGA CUGAUGAG  GCCGUUAGGC  CGAA IGGUCGUC   3554       1464   ACGACCCC U CCCGGGGC   1046   GCCCCGGG CUGAUGAG  GCCGUUAGGC  CGAA IGGGUCGU   3555       1466   GACCCCUC C CGGGGCCG   1047   CGGCCCCG CUGAUGAG  GCCGUUAGGC  CGAA IAGGGGUC   3556       1467   ACCCCUCC C GGGGCCGC   1048   GCGGCCCC CUGAUGAG  GCCGUUAGGC  CGAA IGAGGGGU   3557       1473   UCCGGGGC C GCUUGGGG   1049   CCCCAAGC CUGAUGAG  GCCGUUAGGC  CGAA ICCCCGGG   3558       1476   GGGGCCGC U UGGGGCUC   1050   GAGCCCCA CUGAUGAG  GCCGUUAGGC  CGAA ICGGCCCC   3559       1483   UUUGGGGC U CUACCGCC   1051   GGCGGUAG CUGAUGAG  GCCGUUAGGC  CGAA ICCCCAAG   3560       1485   UGGGGCUC U ACCGCCCG   1052   CGGGCGGU CUGAUGAG  GCCGUUAGGC  CGAA IAGCCCCA   3561       1488   GGCUCUAC C GCCCGCUU   1053   AAGCGGGC CUGAUGAG  GCCGUUAGGC  CGAA IUAGAGCC   3562       1491   UCUACCGC C CGCUUCUC   1054   GAGAAGCG CUGAUGAG  GCCGUUAGGC  CGAA ICGGUAGA   3563       1492   CUACCGCC C GCUUCUCC   1055   GGAGAAGC CUGAUGAG  GCCGUUAGGC  CGAA IGCGGUAG   3564       1495   CCGCCCGC U UCUCCGCC   1056   GGCGGAGA CUGAUGAG  GCCGUUAGGC  CGAA ICGGGCGG   3565       1498   CCCGCUUC U CCGCCUAU   1057   AUAGGCGG CUGAUGAG  GCCGUUAGGC  CGAA IAAGCGGG   3566       1500   CGCUUCUC C GCCUAUUG   1058   CAAUAGGC CUGAUGAG  GCCGUUAGGC  CGAA IAGAAGCG   3567       1503   UUCUCCGC C UAUUGUAC   1059   GUACAAUA CUGAUGAG  GCCGUUAGGC  CGAA ICGGAGAA   3568       1504   UCUCCGCC U AUUGUACC   1060   GGUACAAU CUGAUGAG  GCCGUUAGGC  CGAA IGCGGAGA   3569       1512   UAUUGUAC C GACCGUCC   1061   GGACGGUC CUGAUGAG  GCCGUUAGGC  CGAA IUACAAUA   3570       1516   GUACCGAC C GUCCACGG   1062   CCGUGGAC CUGAUGAG  GCCGUUAGGC  CGAA IUCGGUAC   3571       1520   CGACCGUC C ACGGGGCG   1063   UGCCCCGU CUGAUGAG  GCCGUUAGGC  CGAA IACGGUCG   3572       1521   GACCGUCC A CGGGGCGC   1064   GCGCCCCG CUGAUGAG  GCCGUUAGGC  CGAA IGACGGUC   3573       1530   CGGGGCGC A CCUCUCUU   1065   AAGAGAGG CUGAUGAG  GCCGUUAGGC  CGAA ICGCCCCG   3574       1532   GGGCGCAC C UCUCUUUA   1066   UAAAGAGA CUGAUGAG  GCCGUUAGGC  CGAA IUGCGCCC   3575       1533   GGCGCACC U CUCUUUAC   1067   GUAAAGAG CUGAUGAG  GCCGUUAGGC  CGAA IGUGCGCC   3576       1535   CGCACCUC U CUUUACGC   1068   GCGUAAAG CUGAUGAG  GCCGUUAGGC  CGAA IAGGUGCG   3577       1537   CACCUCUC U UUACGCGG   1069   CCGCGUAA CUGAUGAG  GCCGUUAGGC  CGAA IAGAGGUG   3578       1548   ACGCGGAC U CCCCGUCU   1070   AGACGGGG CUGAUGAG  GCCGUUAGGC  CGAA IUCCGCGU   3579       1550   UCGGACUC C CCGUCUGU   1071   ACAGACGG CUGAUGAG  GCCGUUAGGC  CGAA IAGUCCGC   3580       1551   CGGACUCC C CGUCUGUG   1072   CACAGACG CUGAUGAG  GCCGUUAGGC  CGAA IGAGUCCG   3581       1552   GGACUCCC C GUCUGUGC   1073   GCACAGAC CUGAUGAG  GCCGUUAGGC  CGAA IGGAGUCC   3582       1556   UCCCCGUC U GUGCCUUC   1074   GAAGGCAC CUGAUGAG  GCCGUUAGGC  CGAA IACGGGGA   3583       1561   GUCUGUGC C UUCUCAUC   1075   GAUGAGAA CUGAUGAG  GCCGUUAGGC  CGAA ICACAGAC   3584       1562   UCUGUGCC U UCUCAUCU   1076   AGAUGAGA CUGAUGAG  GCCGUUAGGC  CGAA IGCACAGA   3585       1565   GUGCCUUC U CAUCUGCC   1077   GGCAGAUG CUGAUGAG  GCCGUUAGGC  CGAA IAAGGCAC   3586       1567   GCCUUCUC A UCUGCCGG   1078   CCGGCAGA CUGAUGAG  GCCGUUAGGC  CGAA IAGAAGGC   3587       1570   UUCUCAUC U GCCGGACC   1079   GGUCCGGC CUGAUGAG  GCCGUUAGGC  CGAA IAUGAGAA   3588       1573   UCAUCUGC C GGACCGUG   1080   CACGGUCC CUGAUGAG  GCCGUUAGGC  CGAA ICAGAUGA   3589       1578   UGCCGGAC C GUGUGCAC   1081   GUGCACAC CUGAUGAG  GCCGUUAGGC  CGAA IUCCGGCA   3590       1585   CCGUGUGC A CUUCGCUU   1082   AAGCGAAG CUGAUGAG  GCCGUUAGGC  CGAA ICACACGG   3591       1587   GUGUGCAC U UCGCUUCA   1083   UGAAGCGA CUGAUGAG  GCCGUUAGGC  CGAA IUGCACAC   3592       1592   CACUUCGC U UCACCUCU   1084   AGAGGUGA CUGAUGAG  GCCGUUAGGC  CGAA ICGAAGUG   3593       1595   UUCGCUUC A CCUCUGCA   1085   UGCAGAGG CUGAUGAG  GCCGUUAGGC  CGAA IAAGCGAA   3594       1597   CGCUUCAC C UCUGCACG   1086   CGUGCAGA CUGAUGAG  GCCGUUAGGC  CGAA IUGAAGCG   3595       1598   GCUUCACC U CUGCACGU   1087   ACGUGCAG CUGAUGAG  GCCGUUAGGC  CGAA IGUGAAGC   3596       1600   UUCACCUC U GCACGUCG   1088   CGACGUGC CUGAUGAG  GCCGUUAGGC  CGAA IAGGUGAA   3597       1603   ACCUCUGC A CGUCGCAU   1089   AUGCGACG CUGAUGAG  GCCGUUAGGC  CGAA ICAGAGGU   3598       1610   CACGUCGC A UGGAGACC   1090   GGUCUCCA CUGAUGAG  GCCGUUAGGC  CGAA ICGACGUG   3599       1618   AUGGAGAC C ACCGUGAA   1091   UUCACGGU CUGAUGAG  GCCGUUAGGC  CGAA IUCUCCAU   3600       1619   UGGAGACC A CCGUGAAC   1092   GUUCACGG CUGAUGAG  GCCGUUAGGC  CGAA IGUCUCCA   3601       1621   GAGACCAC C GUGAACGC   1093   GCGUUCAC CUGAUGAG  GCCGUUAGGC  CGAA IUGGUCUC   3602       1630   GUGAACGC C CACAGGAA   1094   UUCCUGUG CUGAUGAG  GCCGUUAGGC  CGAA ICGUUCAC   3603       1631   UGAACGCC C ACAGGAAC   1095   GUUCCUGU CUGAUGAG  GCCGUUAGGC  CGAA IGCGUUCA   3604       1632   GAACGCCC A CAGGAACC   1096   GGUUCCUG CUGAUGAG  GCCGUUAGGC  CGAA IGGCGUUC   3605       1634   ACGCCCAC A GGAACCUG   1097   CAGGUUCC CUGAUGAG  GCCGUUAGGC  CGAA IUGGGCGU   3606       1640   ACAGGAAC C UGCCCAAG   1098   CUUGGGCA CUGAUGAG  GCCGUUAGGC  CGAA IUUCCUGU   3607       1641   CAGGAACC U GCCCAAGG   1099   CCUUGGGC CUGAUGAG  GCCGUUAGGC  CGAA IGUUCCUG   3608       1644   GAACCUGC C CAAGGUCU   1100   AGACCUUG CUGAUGAG  GCCGUUAGGC  CGAA ICAGGUUC   3609       1645   AACCUGCC C AAGGUCUU   1101   AAGACCUU CUGAUGAG  GCCGUUAGGC  CGAA IGCAGGUU   3610       1646   ACCUGCCC A AGGUCUUG   1102   CAAGACCU CUGAUGAG  GCCGUUAGGC  CGAA IGGCAGGU   3611       1652   CCAAGGUC U UGCAUAAG   1103   UUUAUGCA CUGAUGAG  GCCGUUAGGC  CGAA IACCUUGG   3612       1656   GGUCUUGC A UAAGAGGA   1104   UCCUCUUA CUGAUGAG  GCCGUUAGGC  CGAA ICAAGACC   3613       1666   AAGAGGAC U CUUGGACU   1105   AGUCCAAG CUGAUGAG  GCCGUUAGGC  CGAA IUCCUCUU   3614       1668   GAGGACUC U UGGACUUU   1106   AAAGUCCA CUGAUGAG  GCCGUUAGGC  CGAA IAGUCCUC   3615       1674   UCUUGGAC U UUCAGCAA   1107   UUGCUGAA CUGAUGAG  GCCGUUAGGC  CGAA IUCCAAGA   3616       1678   GGACUUUC A GCAAUGUC   1108   GACAUUGC CUGAUGAG  GCCGUUAGGC  CGAA IAAAGUCC   3617       1681   CUUUCAGC A AUGUCAAC   1109   GUUGACAU CUGAUGAG  GCCGUUAGGC  CGAA ICUGAAAG   3618       1687   GCAAUGUC A ACGACCGA   1110   UCGGUCGU CUGAUGAG  GCCGUUAGGC  CGAA IACAUUGC   3619       1693   UCAACGAC C GACCUUGA   1111   UCAAGGUC CUGAUGAG  GCCGUUAGGC  CGAA IUCGUUGA   3620       1697   CGACCGAC C UUGAGGCA   1112   UGCCUCAA CUGAUGAG  GCCGUUAGGC  CGAA IUCGGUCG   3621       1698   GACCGACC U UGAGGCAU   1113   AUGCCUCA CUGAUGAG  GCCGUUAGGC  CGAA IGUCGGUC   3622       1705   CUUGAGGC A UACUUCAA   1114   UUGAAGUA CUGAUGAG  GCCGUUAGGC  CGAA ICCUCAAG   3623       1709   AGGCAUAC U UCAAAGAC   1115   GUCUUUGA CUGAUGAG  GCCGUUAGGC  CGAA IUAUGCCU   3624       1712   CAUACUUC A AAGACUGU   1116   ACAGUCUU CUGAUGAG  GCCGUUAGGC  CGAA IAAGUAUG   3625       1718   UCAAAGAC U GUGUGUUU   1117   AAACACAC CUGAUGAG  GCCGUUAGGC  CGAA IUCUUUGA   3626       1769   UAAAGGUC U UUGUACUA   1118   UAGUACAA CUGAUGAG  GCCGUUAGGC  CGAA IACCUUUA   3627       1776   CUUUGUAC U AGGAGGCU   1119   AGCCUCCU CUGAUGAG  GCCGUUAGGC  CGAA IUACAAAG   3628       1784   UAGGAGGC U GUAGGCAU   1120   AUGCCUAC CUGAUGAG  GCCGUUAGGC  CGAA ICCUCCUA   3629       1791   CUGUAGGC A UAAAUUGG   1121   CCAAUUUA CUGAUGAG  GCCGUUAGGC  CGAA ICCUACAG   3630       1807   GUGUGUUC A CCAGCACC   1122   GGUGCUGG CUGAUGAG  GCCGUUAGGC  CGAA IAACACAC   3631       1809   GUGUUCAC C AGCACCAU   1123   AUGGUGCU CUGAUGAG  GCCGUUAGGC  CGAA IUGAACAC   3632       1810   UGUUCACC A GCACCAUG   1124   CAUGGUGC CUGAUGAG  GCCGUUAGGC  CGAA IGUGAACA   3633       1813   UCACCAGC A CCAUGCAA   1125   UUGCAUGG CUGAUGAG  GCCGUUAGGC  CGAA ICUGGUGA   3634       1815   ACCAGCAC C AUGCAACU   1126   AGUUGCAU CUGAUGAG  GCCGUUAGGC  CGAA IUGCUGGU   3635       1816   CCAGCACC A UGCAACUU   1127   AAGUUGCA CUGAUGAG  GCCGUUAGGC  CGAA IGUGCUGG   3636       1820   CACCAUGC A ACUUUUUC   1128   GAAAAAGU CUGAUGAG  GCCGUUAGGC  CGAA ICAUGGUG   3637       1823   CAUGCAAC U UUUUCACC   1129   GGUGAAAA CUGAUGAG  GCCGUUAGGC  CGAA IUUGCAUG   3638       1829   ACUUUUUC A CCUCUGCC   1130   GGCAGAGG CUGAUGAG  GCCGUUAGGC  CGAA IAAAAAGU   3639       1831   UUUUUCAC C UCUGCCUA   1131   UAGGCAGA CUGAUGAG  GCCGUUAGGC  CGAA IUGAAAAA   3640       1832   UUUUCACC U CUGCCUAA   1132   UUAGGCAG CUGAUGAG  GCCGUUAGGC  CGAA IGUGAAAA   3641       1834   UUCACCUC U GCCUAAUC   1133   GAUUAGGC CUGAUGAG  GCCGUUAGGC  CGAA IAGGUGAA   3642       1837   ACCUCUGC C UAAUCAUC   1134   GAUGAUUA CUGAUGAG  GCCGUUAGGC  CGAA ICAGAGGU   3643       1838   CCUCUGCC U AAUCAUCU   1135   AGAUGAUU CUGAUGAG  GCCGUUAGGC  CGAA IGCAGAGG   3644       1843   GCCUAAUC A UCUCAUGU   1136   ACAUGAGA CUGAUGAG  GCCGUUAGGC  CGAA IAUUAGGC   3645       1846   UAAUCAUC U CAUGUUCA   1137   UGAACAUG CUGAUGAG  GCCGUUAGGC  CGAA IAUGAUUA   3646       1848   AUCAUCUC A UGUUCAUG   1138   CAUGAACA CUGAUGAG  GCCGUUAGGC  CGAA IAGAUGAU   3647       1854   UCAUGUUC A UGUCCUAC   1139   GUAGGACA CUGAUGAG  GCCGUUAGGC  CGAA IAACAUGA   3648       1859   UUCAUGUC C UACUGUUC   1140   GAACAGUA CUGAUGAG  GCCGUUAGGC  CGAA IACAUGAA   3649       1860   UCAUGUCC U ACUGUUCA   1141   UGAACAGU CUGAUGAG  GCCGUUAGGC  CGAA IGACAUGA   3650       1863   UGUCCUAC U GUUCAAGC   1142   GCUUGAAC CUGAUGAG  GCCGUUAGGC  CGAA IUAGGACA   3651       1868   UACUGUUC A AGCCUCCA   1143   UGGAGGCU CUGAUGAG  GCCGUUAGGC  CGAA IAACAGUA   3652       1872   GUUCAAGC C UCCAAGCU   1144   AGCUUGGA CUGAUGAG  GCCGUUAGGC  CGAA ICUUGAAC   3653       1873   UUCAAGCC U CCAAGCUG   1145   CAGCUUGG CUGAUGAG  GCCGUUAGGC  CGAA IGCUUGAA   3654       1875   CAAGCCUC C AAGCUGUG   1146   CACAGCUU CUGAUGAG  GCCGUUAGGC  CGAA IAGGCUUG   3655       1876   AAGCCUCC A AGCUGUGC   1147   GCACAGCU CUGAUGAG  GCCGUUAGGC  CGAA IGAGGCUU   3656       1880   CUCCAAGC U GUGCCUUG   1148   CAAGGCAC CUGAUGAG  GCCGUUAGGC  CGAA ICUUGGAG   3657       1885   AGCUGUGC C UUGGGUGG   1149   CCACCCAA CUGAUGAG  GCCGUUAGGC  CGAA ICACAGCU   3658       1886   GCUGUGCC U UGGGUGGC   1150   GCCACCCA CUGAUGAG  GCCGUUAGGC  CGAA IGCACAGC   3659       1895   UGGGUGGC U UUGGGGCA   1151   UGCCCCAA CUGAUGAG  GCCGUUAGGC  CGAA ICCACCCA   3660       1903   UUUGGGGC A UGGACAUU   1152   AAUGUCCA CUGAUGAG  GCCGUUAGGC  CGAA ICCCCAAA   3661       1909   GCAUGGAC A UUGACCCG   1153   UGGGUCAA CUGAUGAG  GCCGUUAGGC  CGAA IUCCAUGC   3662       1915   ACAUUGAC C CGUAUAAA   1154   UUUAUACG CUGAUGAG  GCCGUUAGGC  CGAA IUCAAUGU   3663       1916   CAUUGACC C GUAUAAAG   1155   CUUUAUAC CUGAUGAG  GCCGUUAGGC  CGAA IGUCAAUG   3664       1935   UUUGGAGC U UCUGUGGA   1156   UCCACAGA CUGAUGAG  GCCGUUAGGC  CGAA ICUCCAAA   3665       1938   GGAGCUUC U GUGGAGUU   1157   AACUCCAC CUGAUGAG  GCCGUUAGGC  CGAA IAAGCUCC   3666       1949   GGAGUUAC U CUCUUUUU   1158   AAAAAGAG CUGAUGAG  GCCGUUAGGC  CGAA IUAACUCC   3667       1951   AGUUACUC U CUUUUUUG   1159   CAAAAAAG CUGAUGAG  GCCGUUAGGC  CGAA IAGUAACU   3668       1953   UUACUCUC U UUUUUGCC   1160   GGCAAAAA CUGAUGAG  GCCGUUAGGC  CGAA IAGAGUAA   3669       1961   UUUUUUGC C UUCUGACU   1161   AGUCAGAA CUGAUGAG  GCCGUUAGGC  CGAA ICAAAAAA   3670       1962   UUUUUGCC U UCUGACUU   1162   AAGUCAGA CUGAUGAG  GCCGUUAGGC  CGAA IGCAAAAA   3671       1965   UUGCCUUC U GACUUCUU   1163   AAGAAGUC CUGAUGAG  GCCGUUAGGC  CGAA IAAGGCAA   3672       1969   CUUCUGAC U UCUUUCCU   1164   AGGAAAGA CUGAUGAG  GCCGUUAGGC  CGAA IUCAGAAG   3673       1972   CUGACUUC U UUCCUUCU   1165   AGAAGGAA CUGAUGAG  GCCGUUAGGC  CGAA IAAGUCAG   3674       1976   CUUCUUUC C UUCUAUUC   1166   GAAUAGAA CUGAUGAG  GCCGUUAGGC  CGAA IAAAGAAG   3675       1977   UUCUUUCC U UCUAUUCG   1167   CGAAUAGA CUGAUGAG  GCCGUUAGGC  CGAA IGAAAGAA   3676       1980   UUUCCUUC U AUUCGAGA   1168   UCUCGAAU CUGAUGAG  GCCGUUAGGC  CGAA IAAGGAAA   3677       1991   UCGAGAUC U CCUCGACA   1169   UGUCGAGG CUGAUGAG  GCCGUUAGGC  CGAA IAUCUCGA   3678       1993   GAGAUCUC C UCGACACC   1170   GGUGUCGA CUGAUGAG  GCCGUUAGGC  CGAA IAGAUCUC   3679       1994   AGAUCUCC U CGACACCG   1171   CGGUGUCG CUGAUGAG  GCCGUUAGGC  CGAA IGAGAUCU   3680       1999   UCCUCGAC A CCGCCUCU   1172   AGAGGCGG CUGAUGAG  GCCGUUAGGC  CGAA IUCGAGGA   3681       2001   CUCGACAC C GCCUCUGC   1173   GCAGAGGC CUGAUGAG  GCCGUUAGGC  CGAA IUGUCGAG   3682       2004   GACACCGC C UCUGCUCU   1174   AGAGCAGA CUGAUGAG  GCCGUUAGGC  CGAA ICGGUGUC   3683       2005   ACACCGCC U CUGCUCUG   1175   CAGAGCAG CUGAUGAG  GCCGUUAGGC  CGAA IGCGGUGU   3684       2007   ACCGCCUC U GCUCUGUA   1176   UACAGAGC CUGAUGAG  GCCGUUAGGC  CGAA IAGGCGGU   3685       2010   GCCUCUGC U CUGUAUCG   1177   CGAUACAG CUGAUGAG  GCCGUUAGGC  CGAA ICAGAGGC   3686       2012   CUCUCCUC U GUAUCGGG   1178   CCCGAUAC CUGAUGAG  GCCGUUAGGC  CGAA IAGCAGAG   3687       2025   CGGGGGGC C UUAGAGUC   1179   GACUCUAA CUGAUGAG  GCCGUUAGGC  CGAA ICCCCCCG   3688       2026   GGGGGGCC U UAGAGUCU   1180   AGACUCUA CUGAUGAG  GCCGUUAGGC  CGAA IGCCCCCC   3689       2034   UUAGAGUC U CCGGAACA   1181   UGUUCCGG CUGAUGAG  GCCGUUAGGC  CGAA IACUCUAA   3690       2036   AGAGUCUC C GGAACAUU   1182   AAUGUUCC CUGAUGAG  GCCGUUAGGC  CGAA IAGACUCU   3691       2042   UCCGGAAC A UUGUUCAC   1183   GUGAACAA CUGAUGAG  GCCGUUAGGC  CGAA IUUCCGGA   3692       2049   CAUUGUUC A CCUCACCA   1184   UGGUGAGG CUGAUGAG  GCCGUUAGGC  CGAA IAACAAUG   3693       2051   UUGUUCAC C UCACCAUA   1185   UAUGGUGA CUGAUGAG  GCCGUUAGGC  CGAA IUGAACAA   3694       2052   UGUUCACC U CACCAUAC   1186   GUAUGGUG CUGAUGAG  GCCGUUAGGC  CGAA IGUGAACA   3695       2054   UUCACCUC A CCAUACGG   1187   CCGUAUGG CUGAUGAG  GCCGUUAGGC  CGAA IAGGUGAA   3696       2056   CACCUCAC C AUACGGCA   1188   UGCCGUAU CUGAUGAG  GCCGUUAGGC  CGAA IUGAGGUG   3697       2057   ACCUCACC A UACGGCAC   1189   GUGCCGUA CUGAUGAG  GCCGUUAGGC  CGAA IGUGAGGU   3698       2064   CAUACGGC A CUCAGGCA   1190   UGCCUGAG CUGAUGAG  GCCGUUAGGC  CGAA ICCGUAUG   3699       2066   UACGGCAC U CAGGCAAG   1191   CUUUCCUG CUGAUGAG  GCCGUUAGGC  CGAA IUGCCGUA   3700       2068   CGGCACUC A GGCAAGCU   1192   AGCUUGCC CUGAUGAG  GCCGUUAGGC  CGAA IAGUGCCG   3701       2072   ACUCAGGC A AGCUAUUC   1193   GAAUAGCU CUGAUGAG  GCCGUUAGGC  CGAA ICCUGAGU   3702       2076   AGGCAAGC U AUUCUGUG   1194   CACAGAAU CUGAUGAG  GCCGUUAGGC  CGAA ICUUGCCU   3703       2081   AGCUAUUC U GUGUUGGG   1195   CCCAACAC CUGAUGAG  GCCGUUAGGC  CGAA IAAUAGCU   3704       2105   GAUGAAUC U AGCCACCU   1196   AGGUGGCU CUGAUGAG  GCCGUUAGGC  CGAA IAUUCAUC   3705       2109   AAUCUAGC C ACCUGGGU   1197   ACCCAGGU CUGAUGAG  GCCGUUAGGC  CGAA ICUAGAUU   3706       2110   AUCUAGCC A CCUGGGUG   1198   CACCCAGG CUGAUGAG  GCCGUUAGGC  CGAA IGCUAGAU   3707       2112   CUAGCCAC C UGGGUGGG   1199   CCCACCCA CUGAUGAG  GCCGUUAGGC  CGAA IUGGCUAG   3708       2113   UAGCCACC U GGGUGGGA   1200   UCCCACCC CUGAUGAG  GCCGUUAGGC  CGAA IGUGGCUA   3709       2138   GGAAGAUC C AGCAUCCA   1201   UGGAUGCU CUGAUGAG  GCCGUUAGGC  CGAA IAUCUUCC   3710       2139   GAAGAUCC A GCAUCCAG   1202   CUGGAUGC CUGAUGAG  GCCGUUAGGC  CGAA IGAUCUUC   3711       2142   GAUCCAGC A UCCAGGGA   1203   UCCCUGGA CUGAUGAG  GCCGUUAGGC  CGAA ICUGGAUC   3712       2145   CCAGCAUC C AGGGAAUU   1204   AAUUCCCU CUGAUGAG  GCCGUUAGGC  CGAA IAUGCUGG   3713       2146   CAGCAUCC A GGGAAUUA   1205   UAAUUCCC CUGAUGAG  GCCGUUAGGC  CGAA IGAUGCUG   3714       2161   UAGUAGUC A GCUAUGUC   1206   GACAUAGC CUGAUGAG  GCCGUUAGGC  CGAA IACUACUA   3715       2164   UAGUCAGC U AUGUCAAC   1207   GUUGACAU CUGAUGAG  GCCGUUAGGC  CGAA ICUGACUA   3716       2170   GCUAUGUC A ACGUUAAU   1208   AUUAACGU CUGAUGAG  GCCGUUAGGC  CGAA IACAUAGC   3717       2185   AUAUGGGC C UAAAAAUC   1209   GAUUUUUA CUGAUGAG  GCCGUUAGGC  CGAA ICCCAUAU   3718       2186   UAUGGGCC U AAAAAUCA   1210   UGAUUUUU CUGAUGAG  GCCGUUAGGC  CGAA IGCCCAUA   3719       2194   UAAAAAUC A GACAACUA   1211   UAGUUGUC CUGAUGAG  GCCGUUAGGC  CGAA IAUUUUUA   3720       2198   AAUCAGAC A ACUAUUGU   1212   ACAAUAGU CUGAUGAG  GCCGUUAGGC  CGAA IUCUGAUU   3721       2201   CAGACAAC U AUUGUGGU   1213   ACCACAAU CUGAUGAG  GCCGUUAGGC  CGAA IUUGUCUG   3722       2213   GUGGUUUC A CAUUUCCU   1214   AGGAAAUG CUGAUGAG  GCCGUUAGGC  CGAA IAAACCAC   3723       2215   GGUUUCAC A UUUCCUGU   1215   ACAGGAAA CUGAUGAG  GCCGUUAGGC  CGAA IUGAAACC   3724       2220   CACAUUUC C UGUCUUAC   1216   GUAAGACA CUGAUGAG  GCCGUUAGGC  CGAA IAAAUGUG   3725       2221   ACAUUUCC U GUCUUACU   1217   AGUAAGAC CUGAUGAG  GCCGUUAGGC  CGAA IGAAAUGU   3726       2225   UUCCUGUC U UACUUUUG   1218   CAAAAGUA CUGAUGAG  GCCGUUAGGC  CGAA IACAGGAA   3727       2229   UGUCUUAC U UUUGGGCG   1219   CGCCCAAA CUGAUGAG  GCCGUUAGGC  CGAA IUAAGACA   3728       2244   CGAGAAAC U GUUCUUGA   1220   UCAAGAAC CUGAUGAG  GCCGUUAGGC  CGAA IUUUCUCG   3729       2249   AACUGUUC U UGAAUAUU   1221   AAUAUUCA CUGAUGAG  GCCGUUAGGC  CGAA IAACAGUU   3730       2265   UUGGUGUC U UUUGGAGU   1222   ACUCCAAA CUGAUGAG  GCCGUUAGGC  CGAA IACACCAA   3731       2284   GGAUUCGC A CUCCUCCU   1223   AGGAGGAG CUGAUGAG  GCCGUUAGGC  CGAA ICGAAUCC   3732       2286   AUUCGCAC U CCUCCUGC   1224   GCAGGAGG CUGAUGAG  GCCGUUAGGC  CGAA IUGCGAAU   3733       2288   UCGCACUC C UCCUGCAU   1225   AUGCAGGA CUGAUGAG  GCCGUUAGGC  CGAA IAGUGCGA   3734       2289   CGCACUCC U CCUGCAUA   1226   UAUGCAGG CUGAUGAG  GCCGUUAGGC  CGAA IGAGUGCG   3735       2291   CACUCCUC C UGCAUAUA   1227   UAUAUGCA CUGAUGAG  GCCGUUAGGC  CGAA IAGGAGUG   3736       2292   ACUCCUCC U GCAUAUAG   1228   CUAUAUGC CUGAUGAG  GCCGUUAGGC  CGAA IGAGGAGU   3737       2295   CCUCCUGC A UAUAGACC   1229   GGUCUAUA CUGAUGAG  GCCGUUAGGC  CGAA ICAGGAGG   3738       2303   AUAUAGAC C ACCAAAUG   1230   CAUUUGGU CUGAUGAG  GCCGUUAGGC  CGAA IUCUAUAU   3739       2304   UAUAGACC A CCAAAUGC   1231   GCAUUUGG CUGAUGAG  GCCGUUAGGC  CGAA IGUCUAUA   3740       2306   UAGACCAC C AAAUGCCC   1232   GGGCAUUU CUGAUGAG  GCCGUUAGGC  CGAA IUGGUCUA   3741       2307   AGACCACC A AAUGCCCC   1233   GGGGCAUU CUGAUGAG  GCCGUUAGGC  CGAA IGUGGUCU   3742       2313   CCAAAUGC C CCUAUCUU   1234   AAGAUAGG CUGAUGAG  GCCGUUAGGC  CGAA ICAUUUGG   3743       2314   CAAAUGCC C CUAUCUUA   1235   UAAGAUAG CUGAUGAG  GCCGUUAGGC  CGAA IGCAUUUG   3744       2315   AAAUGCCC C UAUCUUAU   1236   AUAAGAUA CUGAUGAG  GCCGUUAGGC  CGAA IGGCAUUU   3745       2316   AAUGCCCC U AUCUUAUC   1237   GAUAAGAU CUGAUGAG  GCCGUUAGGC  CGAA IGGGCAUU   3746       2320   CCCCUAUC U UAUCAACA   1238   UGUUGAUA CUGAUGAG  GCCGUUAGGC  CGAA IAUAGGGG   3747       2325   AUCUUAUC A ACACUUCC   1239   GGAAGUGU CUGAUGAG  GCCGUUAGGC  CGAA IAUAAGAU   3748       2328   UUAUCAAC A CUUCCGGA   1240   UCCGGAAG CUGAUGAG  GCCGUUAGGC  CGAA IUUGAUAA   3749       2330   AUCAACAC U UCCGGAAA   1241   UUUCCGGA CUGAUGAG  GCCGUUAGGC  CGAA IUGUUGAU   3750       2333   AACACUUC C GGAAACUA   1242   UAGUUUCC CUGAUGAG  GCCGUUAGGC  CGAA IAAGUGUU   3751       2340   CCGGAAAC U ACUGUUGU   1243   ACAACAGU CUGAUGAG  GCCGUUAGGC  CGAA IUUUCCGG   3752       2343   GAAACUAC U GUUGUUAG   1244   CUAACAAC CUGAUGAG  GCCGUUAGGC  CGAA IUAGUUUC   3753       2362   GAAGAGGC A GGUCCCCU   1245   AGGGGACC CUGAUGAG  GCCGUUAGGC  CGAA ICCUCUUC   3754       2367   GGCAGGUC C CCUAGAAG   1246   CUUCUAGG CUGAUGAG  GCCGUUAGGC  CGAA IACCUGCC   3755       2368   GCAGGUCC C CUAGAAGA   1247   UCUUCUAG CUGAUGAG  GCCGUUAGGC  CGAA IGACCUGC   3756       2369   CAGGUCCC C UAGAAGAA   1248   UUCUUCUA CUGAUGAG  GCCGUUAGGC  CGAA IGGACCUG   3757       2370   AGGUCCCC U AGAAGAAG   1249   CUUCUUCU CUGAUGAG  GCCGUUAGGC  CGAA IGGGACCU   3758       2382   AGAAGAAC U CCCUCGCC   1250   GGCGAGGG CUGAUGAG  GCCGUUAGGC  CGAA IUUCUUCU   3759       2384   AAGAACUC C CUCGCCUC   1251   GAGGCGAG CUGAUGAG  GCCGUUAGGC  CGAA IAGUUCUU   3760       2385   AGAACUCC C UCGCCUCG   1252   CGAGGCGA CUGAUGAG  GCCGUUAGGC  CGAA IGAGUUCU   3761       2386   GAACUCCC U CGCCUCGC   1253   GCGAGGCG CUGAUGAG  GCCGUUAGGC  CGAA IGGAGUUC   3762       2390   UCCCUCGC C UCGCAGAC   1254   GUCUGCGA CUGAUGAG  GCCGUUAGGC  CGAA ICGAGGGA   3763       2391   CCCUCGCC U CGCAGACG   1255   CGUCUGCG CUGAUGAG  GCCGUUAGGC  CGAA IGCGAGGG   3764       2395   CGCCUCGC A GACGAAGG   1256   CCUUCGUC CUGAUGAG  GCCGUUAGGC  CGAA ICGAGGCG   3765       2406   CGAAGGUC U CAAUCGCC   1257   GGCGAUUG CUGAUGAG  GCCGUUAGGC  CGAA IACCUUCG   3766       2408   AAGGUCUC A AUCGCCGC   1258   GCGGCGAU CUGAUGAG  GCCGUUAGGC  CGAA IAGACCUU   3767       2414   UCAAUCGC C GCGUCGCA   1259   UGCGACGC CUGAUGAG  GCCGUUAGGC  CGAA ICGAUUGA   3768       2422   CGCGUCGC A GAAGAUCU   1260   AGAUCUUC CUGAUGAG  GCCGUUAGGC  CGAA ICGACGCG   3769       2430   AGAAGAUC U CAAUCUCG   1261   CGAGAUUG CUGAUGAG  GCCGUUAGGC  CGAA IAUCUUCU   3770       2432   AAGAUCUC A AUCUCGGG   1262   CCCGAGAU CUGAUGAG  GCCGUUAGGC  CGAA IAGAUCUU   3771       2436   UCUCAAUC U CGGGAAUC   1263   GAUUCCCG CUGAUGAG  GCCGUUAGGC  CGAA IAUUGAGA   3772       2445   CGGGAAUC U CAAUGUUA   1264   UAACAUUG CUGAUGAG  GCCGUUAGGC  CGAA IAUUCCCG   3773       2447   GGAAUCUC A AUGUUAGU   1265   ACUAACAU CUGAUGAG  GCCGUUAGGC  CGAA IAGAUUCC   3774       2460   UAGUAUUC C UUGGACAC   1266   GUGUCCAA CUGAUGAG  GCCGUUAGGC  CGAA IAAUACUA   3775       2461   AGUAUUCC U UGGACACA   1267   UGUGUCCA CUGAUGAG  GCCGUUAGGC  CGAA IGAAUACU   3776       2467   CCUUGGAC A CAUAAGGU   1268   ACCUUAUG CUGAUGAG  GCCGUUAGGC  CGAA IUCCAAGG   3777       2469   UUGGACAC A UAAGGUGG   1269   CCACCUUA CUGAUGAG  GCCGUUAGGC  CGAA IUGUCCAA   3778       2483   UGGGAAAC U UUACGGGG   1270   CCCCGUAA CUGAUGAG  GCCGUUAGGC  CGAA IUUUCCCA   3779       2493   UACGGGGC U UUAUUCUU   1271   AAGAAUAA CUGAUGAG  GCCGUUAGGC  CGAA ICCCCGUA   3780       2500   CUUUAUUC U UCUACGGU   1272   ACCGUAGA CUGAUGAG  GCCGUUAGGC  CGAA IAAUAAAG   3781       2503   UAUUCUUC U ACGGUACC   1273   GGUACCGU CUGAUGAG  GCCGUUAGGC  CGAA IAAGAAUA   3782       2511   UACGGUAC C UUGCUUUA   1274   UAAAGCAA CUGAUGAG  GCCGUUAGGC  CGAA IUACCGUA   3783       2512   ACGGUACC U UGCUUUAA   1275   UUAAAGCA CUGAUGAG  GCCGUUAGGC  CGAA IGUACCGU   3784       2516   UACCUUGC U UUAAUCCU   1276   AGGAUUAA CUGAUGAG  GCCGUUAGGC  CGAA ICAAGGUA   3785       2523   UUUUAAUC C UAAAUGGC   1277   GCCAUUUA CUGAUGAG  GCCGUUAGGC  CGAA IAUUAAAG   3786       2524   UUUAAUCC U AAAUGGCA   1278   UGCCAUUU CUGAUGAG  GCCGUUAGGC  CGAA IGAUUAAA   3787       2532   UAAAUGGC A AACUCCUU   1279   AAGGAGUU CUGAUGAG  GCCGUUAGGC  CGAA ICCAUUUA   3788       2536   UGGCAAAC U CCUUCUUU   1280   AAAGAAGG CUGAUGAG  GCCGUUAGGC  CGAA IUUUGCCA   3789       2538   GCAAACUC C UUCUUUUC   1281   GAAAAGAA CUGAUGAG  GCCGUUAGGC  CGAA IAGUUUGC   3790       2539   CAAACUCC U UCUUUUCC   1282   GGAAAAGA CUGAUGAG  GCCGUUAGGC  CGAA IGAGUUUG   3791       2542   ACUCCUUC U UUUCCUGA   1283   UCAGGAAA CUGAUGAG  GCCGUUAGGC  CGAA IAAGGAGU   3792       2547   UUCUUUUC C UGACAUUC   1284   GAAUGUCA CUGAUGAG  GCCGUUAGGC  CGAA IAAAAGAA   3793       2548   UCUUUUCC U GACAUUCA   1285   UGAAUGUC CUGAUGAG  GCCGUUAGGC  CGAA IGAAAAGA   3794       2552   UUCCUGAC A UUCAUUUG   1286   CAAAUGAA CUGAUGAG  GCCGUUAGGC  CGAA IUCAGGAA   3795       2556   UGACAUUC A UUUGCAGG   1287   CCUGCAAA CUGAUGAG  GCCGUUAGGC  CGAA IAAUGUCA   3796       2562   UCAUUUGC A GGAGGACA   1288   UGUCCUCC CUGAUGAG  GCCGUUAGGC  CGAA ICAAAUGA   3797       2570   AGGAGGAC A UUGUUGAU   1289   AUCAACAA CUGAUGAG  GCCGUUAGGC  CGAA IUCCUCCU   3798       2589   AUGUAAGC A AUUUGUGG   1290   CCACAAAU CUGAUGAG  GCCGUUAGGC  CGAA ICUUACAU   3799       2601   UGUGGGGC C CCUUACAG   1291   CUGUAAGG CUGAUGAG  GCCGUUAGGC  CGAA ICCCCACA   3800       2602   GUGGGGCC C CUUACAGU   1292   ACUGUAAG CUGAUGAG  GCCGUUAGGC  CGAA IGCCCCAC   3801       2603   UGGGGCCC C UUACAGUA   1293   UACUGUAA CUGAUGAG  GCCGUUAGGC  CGAA IGGCCCCA   3802       2604   GGGGCCCC U UACAGUAA   1294   UUACUGUA CUGAUGAG  GCCGUUAGGC  CGAA IGGGCCCC   3803       2608   CCCCUUAC A GUAAAUGA   1295   UCAUUUAC CUGAUGAG  GCCGUUAGGC  CGAA IUAAGGGG   3804       2621   AUGAAAAC A GGAGACUU   1296   AAGUCUCC CUGAUGAG  GCCGUUAGGC  CGAA IUUUUCAU   3805       2628   CAGGAGAC U UAAAUUAA   1297   UUAAUUUA CUGAUGAG  GCCGUUAGGC  CGAA IUCUCCUG   3806       2638   AAAUUAAC U AUGCCUGC   1298   GCAGGCAU CUGAUGAG  GCCGUUAGGC  CGAA IUUAAUUU   3807       2643   AACUAUGC C UGCUAGGU   1299   ACCUAGCA CUGAUGAG  GCCGUUAGGC  CGAA ICAUAGUU   3808       2644   ACUAUGCC U GCUAGGUU   1300   AACCUAGC CUGAUGAG  GCCGUUAGGC  CGAA IGCAUAGU   3809       2647   AUGCCUGC U AGGUUUUA   1301   UAAAACCU CUGAUGAG  GCCGUUAGGC  CGAA ICAGGCAU   3810       2658   GUUUUAUC C CAAUGUUA   1302   UAACAUUG CUGAUGAG  GCCGUUAGGC  CGAA IAUAAAAC   3811       2659   UUUUAUCC C AAUGUUAC   1303   GUAACAUU CUGAUGAG  GCCGUUAGGC  CGAA IGAUAAAA   3812       2660   UUUAUCCC A AUGUUACU   1304   AGUAACAU CUGAUGAG  GCCGUUAGGC  CGAA IGGAUAAA   3813       2668   AAUGUUAC U AAAUAUUU   1305   AAAUAUUU CUGAUGAG  GCCGUUAGGC  CGAA IUAACAUU   3814       2679   AUAUUUGC C CUUAGAUA   1306   UAUCUAAG CUGAUGAG  GCCGUUAGGC  CGAA ICAAAUAU   3815       2680   UAUUUGCC C UUAGAUAA   1307   UUAUCUAA CUGAUGAG  GCCGUUAGGC  CGAA IGCAAAUA   3816       2681   AUUUGCCC U UAGAUAAA   1308   UUUAUCUA CUGAUGAG  GCCGUUAGGC  CGAA IGGCAAAU   3817       2696   AAGGGAUC A AACCGUAU   1309   AUACCGUU CUGAUGAG  GCCGUUAGGC  CGAA IAUCCCUU   3818       2700   GAUCAAAC C GUAUUAUC   1310   GAUAAUAC CUGAUGAG  GCCGUUAGGC  CGAA IUUUGAUC   3819       2709   GUAUUAUC C AGAGUAUG   1311   CAUACUCU CUGAUGAG  GCCGUUAGGC  CGAA IAUAAUAC   3820       2710   UAUUAUCC A GAGUAUGU   1312   ACAUACUC CUGAUGAG  GCCGUUAGGC  CGAA IGAUAAUA   3821       2727   AGUUAAUC A UUACUUCC   1313   GGAAGUAA CUGAUGAG  GCCGUUAGGC  CGAA IAUUAACU   3822       2732   AUCAUUAC U UCCAGACG   1314   CGUCUGGA CUGAUGAG  GCCGUUAGGC  CGAA IUAAUGAU   3823       2735   AUUACUUC C AGACGCGA   1315   UCGCGUCU CUGAUGAG  GCCGUUAGGC  CGAA IAAGUAAU   3824       2736   UUACUUCC A GACGCGAC   1316   GUCGCGUC CUGAUGAG  GCCGUUAGGC  CGAA IGAAGUAA   3825       2745   GACGCGAC A UUAUUUAC   1317   GUAAAUAA CUGAUGAG  GCCGUUAGGC  CGAA IUCGCGUC   3826       2754   UUAUUUAC A CACUCUUU   1318   AAAGAGUG CUGAUGAG  GCCGUUAGGC  CGAA IUAAAUAA   3827       2756   AUUUACAC A CUCUUUGG   1319   CCAAAGAG CUGAUGAG  GCCGUUAGGC  CGAA IUGUAAAU   3828       2758   UUACACAC U CUUUGGAA   1320   UUCCAAAG CUGAUGAG  GCCGUUAGGC  CGAA IUGUGUAA   3829       2760   ACACACUC U UUGGAAGG   1321   CCUUCCAA CUGAUGAG  GCCGUUAGGC  CGAA IAGUGUGU   3830       2777   CGGGGAUC U UAUAUAAA   1322   UUUAUAUA CUGAUGAG  GCCGUUAGGC  CGAA IAUCCCCG   3831       2794   AGAGAGUC C ACACGUAG   1323   UUACGUGU CUGAUGAG  GCCGUUAGGC  CGAA IACUCUCU   3832       2795   GAGAGUCC A CACGUAGC   1324   GCUACGUG CUGAUGAG  GCCGUUAGGC  CGAA IGACUCUC   3833       2797   GAGUCCAC A CGUAGCGC   1325   GCGCUACG CUGAUGAG  GCCGUUAGGC  CGAA IUGGACUC   3834       2806   CGUAGCGC C UCAUUUUG   1326   CAAAAUGA CUGAUGAG  GCCGUUAGGC  CGAA ICGCUACG   3835       2807   GUAGCGCC U CAUUUUGC   1327   GCAAAAUG CUGAUGAG  GCCGUUAGGC  CGAA IGCGCUAC   3836       2809   AGCGCCUC A UUUUGCGG   1328   CCGCAAAA CUGAUGAG  GCCGUUAGGC  CGAA IAGGCGCU   3837       2821   UGCGGGUC A CCAUAUUC   1329   GAAUAUGG CUGAUGAG  GCCGUUAGGC  CGAA IACCCGCA   3838       2823   UGGGUCAC C AUAUUCUU   1330   AAGAAUAU CUGAUGAG  GCCGUUAGGC  CGAA IUGACCCG   3839       2824   GGGUCACC A UAUUCUUG   1331   CAAGAAUA CUGAUGAG  GCCGUUAGGC  CGAA IGUGACCC   3840       2830   CCAUAUUC U UGGGAACA   1332   UGUUCCCA CUGAUGAG  GCCGUUAGGC  CGAA IAAUAUGG   3841       2838   UUGGGAAC A AGAUCUAC   1333   GUAGAUCU CUGAUGAG  GCCGUUAGGC  CGAA IUUCCCAA   3842       2844   ACAAGAUC U ACAGCAUG   1334   CAUGCUGU CUGAUGAG  GCCGUUAGGC  CGAA IAUCUUGU   3843       2847   AGAUCUAC A GCAUGGGA   1335   UCCCAUGC CUGAUGAG  GCCGUUAGGC  CGAA IUAGAUCU   3844       2850   UCUACAGC A UGGGAGGU   1336   ACCUCCCA CUGAUGAG  GCCGUUAGGC  CGAA ICUGUAGA   3845       2864   GGUUGGUC U UCCAAACC   1337   GGUUUGGA CUGAUGAG  GCCGUUAGGC  CGAA IACCAACC   3846       2867   UGGUCUUC C AAACCUCG   1338   CGAGGUUU CUGAUGAG  GCCGUUAGGC  CGAA IAAGACCA   3847       2868   GGUCUUCC A AACCUCGA   1339   UCGAGGUU CUGAUGAG  GCCGUUAGGC  CGAA IGAAGACC   3848       2872   UUCCAAAC C UCGAAAAG   1340   CUUUUCGA CUGAUGAG  GCCGUUAGGC  CGAA IUUUGGAA   3849       2873   UCCAAACC U CGAAAAGG   1341   CCUUUUCG CUGAUGAG  GCCGUUAGGC  CGAA IGUUUGGA   3850       2883   GAAAAGGC A UGGGGACA   1342   UGUCCCCA CUGAUGAG  GCCGUUAGGC  CGAA ICCUUUUC   3851       2891   AUGGGGAC A AAUCUUUC   1343   GAAAGAUU CUGAUGAG  GCCGUUAGGC  CGAA IUCCCCAU   3852       2896   GACAAAUC U UUCUGUCC   1344   GGACAGAA CUGAUGAG  GCCGUUAGGC  CGAA IAUUUGUC   3853       2900   AAUCUUUC U GUCCCCAA   1345   UUGGGGAC CUGAUGAG  GCCGUUAGGC  CGAA IAAAGAUU   3854       2904   UUUCUGUC C CCAAUCCC   1346   GGGAUUGG CUGAUGAG  GCCGUUAGGC  CGAA IACAGAAA   3855       2905   UUCUGUCC C CAAUCCCC   1347   GGGGAUUG CUGAUGAG  GCCGUUAGGC  CGAA IGACAGAA   3856       2906   UCUGUCCC C AAUCCCCU   1348   AGGGGAUU CUGAUGAG  GCCGUUAGGC  CGAA IGGACAGA   3857       2907   CUGUCCCC A AUCCCCUG   1349   CAGGGGAU CUGAUGAG  GCCGUUAGGC  CGAA IGGGACAG   3858       2911   CCCCAAUC C CCUGGGAU   1350   AUCCCAGG CUGAUGAG  GCCGUUAGGC  CGAA IAUUGGGG   3859       2912   CCCAAUCC C CUGGGAUU   1351   AAUCCCAG CUGAUGAG  GCCGUUAGGC  CGAA IGAUUGGG   3860       2913   UCAAUCCC C UGGGAUUC   1352   GAAUCCCA CUGAUGAG  GCCGUUAGGC  CGAA IGGAUUGG   3861       2914   CAAUCCCC U GGGAUUCU   1353   AGAAUCCC CUGAUGAG  GCCGUUAGGC  CGAA IGGGAUUG   3862       2922   UGGGAUUC U UCCCCGAU   1354   AUCGGGGA CUGAUGAG  GCCGUUAGGC  CGAA IAAUCCCA   3863       2925   GAUUCUUC C CCGAUCAU   1355   AUGAUCGG CUGAUGAG  GCCGUUAGGC  CGAA IAAGAAUC   3864       2926   AUUCUUCC C CGAUCAUC   1356   GAUGAUCG CUGAUGAG  GCCGUUAGGC  CGAA IGAAGAAU   3865       2927   UUCUUCCC C GAUCAUCA   1357   UGAUGAUC CUGAUGAG  GCCGUUAGGC  CGAA IGGAAGAA   3866       2932   CCCCGAUC A UCAGUUGG   1358   CCAACUGA CUGAUGAG  GCCGUUAGGC  CGAA IAUCGGGG   3867       2935   CGAUCAUC A GUUGGACC   1359   GGUCCAAC CUGAUGAG  GCCGUUAGGC  CGAA IAUGAUCG   3868       2943   AGUUGGAC C CUGCAUUC   1360   GAAUGCAG CUGAUGAG  GCCGUUAGGC  CGAA IUCCAACU   3869       2944   GUUGGACC C UGCAUUCA   1361   UGAAUGCA CUGAUGAG  GCCGUUAGGC  CGAA IGUCCAAC   3870       2945   UUGGACCC U GCAUUCAA   1362   UUGAAUGC CUGAUGAG  GCCGUUAGGC  CGAA IGGUCCAA   3871       2948   GACCCUGC A UUCAAAGC   1363   GCUUUGAA CUGAUGAG  GCCGUUAGGC  CGAA ICAUGGUC   3872       2952   CUGCAUUC A AAGCCAAC   1364   GUUGGCUU CUGAUGAG  GCCGUUAGGC  CGAA IAAUGCAG   3873       2957   UUCAAAGC C AACUCAGU   1365   ACUGAGUU CUGAUGAG  GCCGUUAGGC  CGAA ICUUUGAA   3874       2958   UCAAAGCC A ACUCAGUA   1366   UACUGAGU CUGAUGAG  GCCGUUAGGC  CGAA IGCUUUGA   3875       2961   AAGCCAAC U CAGUAAAU   1367   AUUUACUG CUGAUGAG  GCCGUUAGGC  CGAA IUUGGCUU   3876       2963   GCCAACUC A GUAAAUCC   1368   GGAUUUAC CUGAUGAG  GCCGUUAGGC  CGAA IAGUUGGC   3877       2971   AGUAAAUC C AGAUUGGG   1369   CCCAAUCU CUGAUGAG  GCCGUUAGGC  CGAA IAUUUACU   3878       2972   GUAAAUCC A GAUUGGGA   1370   UCCCAAUC CUGAUGAG  GCCGUUAGGC  CGAA IGAUUUAC   3879       2982   AUUGGGAC C UCAACCCG   1371   CGGGUUGA CUGAUGAG  GCCGUUAGGC  CGAA IUCCCAAU   3880       2983   UUGGGACC U CAACCCGC   1372   GCGGGUUG CUGAUGAG  GCCGUUAGGC  CGAA IGUCCCAA   3881       2985   GGGACCUC A ACCCGCAC   1373   GUGCGGGU CUGAUGAG  GCCGUUAGGC  CGAA IAGGUCCC   3882       2988   ACCUCAAC C CGCACAAG   1374   CUUGUGCG CUGAUGAG  GCCGUUAGGC  CGAA IUUGAGGU   3883       2989   CCUCAACC C GCACAAGG   1375   CCUUGUGC CUGAUGAG  GCCGUUAGGC  CGAA IGUUGAGG   3884       2992   CAACCCGC A CAAGGACA   1376   UGUCCUUG CUGAUGAG  GCCGUUAGGC  CGAA ICGGGUUG   3885       2994   ACCCGCAC A AGGACAAC   1377   GUUGUCCU CUGAUGAG  GCCGUUAGGC  CGAA IUGCGGGU   3886       3000   ACAAGGAC A ACUGGCCG   1378   CGGCCAGU CUGAUGAG  GCCGUUAGGC  CGAA IUCCUUGU   3887       3003   AGGACAAC U GGCCGGAC   1379   GUCCGGCC CUGAUGAG  GCCGUUAGGC  CGAA IUUGUCCU   3888       3007   CAACUGGC C GGACGCCA   1380   UGGCGUCC CUGAUGAG  GCCGUUAGGC  CGAA ICCAGUUG   3889       3014   CCGGACGC C AACAAGGU   1381   ACCUUGUU CUGAUGAG  GCCGUUAGGC  CGAA ICGUCCGG   3890       3015   CGGACGCC A ACAAGGUG   1382   CACCUUGU CUGAUGAG  GCCGUUAGGC  CGAA IGCGUCCG   3891       3018   ACGCCAAC A AGGUGGGA   1383   UCCCACCU CUGAUGAG  GCCGUUAGGC  CGAA IUUGGCGU   3892       3035   GUGGGAGC A UUCGGGCC   1384   GGCCCGAA CUGAUGAG  GCCGUUAGGC  CGAA ICUCCCAC   3893       3043   AUUCGGGC C AGGGUUCA   1385   UGAACCCU CUGAUGAG  GCCGUUAGGC  CGAA ICCCGAAU   3894       3044   UUCGGGCC A GGGUUCAC   1386   GUGAACCC CUGAUGAG  GCCGUUAGGC  CGAA IGCCCGAA   3895       3051   CAGGGUUC A CCCCUCCC   1387   GGGAGGGG CUGAUGAG  GCCGUUAGGC  CGAA IAACCCUG   3896       3053   GGGUUCAC C CCUCCCCA   1388   UGGGGAGG CUGAUGAG  GCCGUUAGGC  CGAA IUGAACCC   3897       3054   GGUUCACC C CUCCCCAU   1389   AUGGGGAG CUGAUGAG  GCCGUUAGGC  CGAA IGUGAACC   3898       3055   GUUCACCC C UCCCCAUG   1390   CAUGGGGA CUGAUGAG  GCCGUUAGGC  CGAA IGGUGAAC   3899       3056   UUCACCCC U CCCCAUGG   1391   CCAUGGGG CUGAUGAG  GCCGUUAGGC  CGAA IGGGUGAA   3900       3058   CACCCCUC C CCAUGGGG   1392   CCCCAUGG CUGAUGAG  GCCGUUAGGC  CGAA IAGGGGUG   3901       3059   ACCCCUCC C CAUGGGGG   1393   UCCCCAUG CUGAUGAG  GCCGUUAGGC  CGAA IGAGGGGU   3902       3060   CCCCUCCC C AUGGGGGA   1394   UCCCCCAU CUGAUGAG  GCCGUUAGGC  CGAA IGGAGGGG   3903       3061   CCCUCCCC A UGGGGGAC   1395   GUCCCCCA CUGAUGAG  GCCGUUAGGC  CGAA IGGGAGGG   3904       3070   UGGGGGAC U GUUGGGGU   1396   ACCCCAAC CUGAUGAG  GCCGUUAGGC  CGAA IUCCCCCA   3905       3084   GGUGGAGC C CUCACGCU   1397   AGCGUGAG CUGAUGAG  GCCGUUAGGC  CGAA ICUCCACC   3906       3085   GUGGAGCC C UCACGCUC   1398   GAGCGUGA CUGAUGAG  GCCGUUAGGC  CGAA IGCUCCAC   3907       3086   UGGAGCCC U CACGCUCA   1399   UGAGCGUG CUGAUGAG  GCCGUUAGGC  CGAA IGGCUCCA   3908       3088   GAGCCCUC A CGCUCAGG   1400   CCUGAGCG CUGAUGAG  GCCGUUAGGC  CGAA IAGGGCUC   3909       3092   CCUCACGC U CAGGGCCU   1401   AGGCCCUG CUGAUGAG  GCCGUUAGGC  CGAA ICGUGAGG   3910       3094   UCACGCUC A GGGCCUAC   1402   GUAGGCCC CUGAUGAG  GCCGUUAGGC  CGAA IAGCGUGA   3911       3099   CUCAGGGC C UACUCACA   1403   UGUGAGUA CUGAUGAG  GCCGUUAGGC  CGAA ICCCUGAG   3912       3100   UCAGGGCC U ACUCACAA   1404   UUGUGAGU CUGAUGAG  GCCGUUAGGC  CGAA IGCCCUGA   3913       3103   GGGCCUAC U CACAACUG   1405   CAGUUGUG CUGAUGAG  GCCGUUAGGC  CGAA IUAGGCCC   3914       3105   GCCUACUC A CAACUGUG   1406   CACAGUUG CUGAUGAG  GCCGUUAGGC  CGAA IAGUAGGC   3915       3107   CUACUCAC A ACUGUGCC   1407   GGCACAGU CUGAUGAG  GCCGUUAGGC  CGAA IUGAGUAG   3916       3110   CUCACAAC U GUGCCAGC   1408   GCUGGCAC CUGAUGAG  GCCGUUAGGC  CGAA IUUGUGAG   3917       3115   AACUGUGC C AGCAGCUC   1409   GAGCUGCU CUGAUGAG  GCCGUUAGGC  CGAA ICACAGUU   3918       3116   ACUGUGCC A GCAGCUCC   1410   GGAGCUGC CUGAUGAG  GCCGUUAGGC  CGAA IGCACAGU   3919       3119   GUGCCAGC A GCUCCUCC   1411   GGAGGAGC CUGAUGAG  GCCGUUAGGC  CGAA ICUGGCAC   3920       3122   CCAGCAGC U CCUCCUCC   1412   GGAGGAGG CUGAUGAG  GCCGUUAGGC  CGAA ICUGCUGG   3921       3124   AGCAGCUC C UCCUCCUG   1413   CAGGAGGA CUGAUGAG  GCCGUUAGGC  CGAA IAGCUGCU   3922       3125   GCAGCUCC U CCUCCUGC   1414   GCAGGAGG CUGAUGAG  GCCGUUAGGC  CGAA IGAGCUGC   3923       3127   AGCUCCUC C UCCUGCCU   1415   AGGCAGGA CUGAUGAG  GCCGUUAGGC  CGAA IAGGAGCU   3924       3128   GCUCCUCC U CCUGCCUC   1416   GAGGCAGG CUGAUGAG  GCCGUUAGGC  CGAA IGAGGAGC   3925       3130   UCCUCCUC C UGCCUCCA   1417   UGGAGGCA CUGAUGAG  GCCGUUAGGC  CGAA IAGGAGGA   3926       3131   CCUCCUCC U GCCUCCAC   1418   GUGGAGGC CUGAUGAG  GCCGUUAGGC  CGAA IGAGGAGG   3927       3134   CCUCCUGC C UCCACCAA   1419   UUGGUGGA CUGAUGAG  GCCGUUAGGC  CGAA ICAGGAGG   3928       3135   CUCCUGCC U CCACCAAU   1420   AUUGGUGG CUGAUGAG  GCCGUUAGGC  CGAA IGCAGGAG   3929       3137   CCUGCCUC C ACCAAUCG   1421   CGAUUGGU CUGAUGAG  GCCGUUAGGC  CGAA IAGGCAGG   3930       3138   CUGCCUCC A CCAAUCGG   1422   CCGAUUGG CUGAUGAG  GCCGUUAGGC  CGAA IGAGGCAG   3931       3140   GCCUCCAC C AAUCGGCA   1423   UGCCGAUU CUGAUGAG  GCCGUUAGGC  CGAA IUGGAGGC   3932       3141   CCUCCACC A AUCGGCAG   1424   CUGCCGAU CUGAUGAG  GCCGUUAGGC  CGAA IGUGGAGG   3933       3148   CAAUCGGC A GUCAGGAA   1425   UUCCUGAC CUGAUGAG  GCCGUUAGGC  CGAA ICCGAUUG   3934       3152   CGGCAGUC A GGAAGGCA   1426   UGCCUUCC CUGAUGAG  GCCGUUAGGC  CGAA IACUGCCG   3935       3160   AGGAAGGC A GCCUACUC   1427   GAGUAGGC CUGAUGAG  GCCGUUAGGC  CGAA ICCUUCCU   3936       3163   AAGGCAGC C UACUCCCU   1428   AGGGAGUA CUGAUGAG  GCCGUUAGGC  CGAA ICUGCCUU   3937       3164   AGGCAGCC U ACUCCCUU   1429   AAGGGAGU CUGAUGAG  GCCGUUAGGC  CGAA IGCUGCCU   3938       3167   CAGCCUAC U CCCUUAUC   1430   GAUAAGGG CUGAUGAG  GCCGUUAGGC  CGAA IUAGGCUG   3939       3169   GCCUACUC C CUUAUCUC   1431   GAGAUAAG CUGAUGAG  GCCGUUAGGC  CGAA IAGUAGGC   3940       3170   CCUACUCC C UUAUCUCC   1432   GGAGAUAA CUGAUGAG  GCCGUUAGGC  CGAA IGAGUAGG   3941       3171   CUACUCCC U UAUCUCCA   1433   UGGAGAUA CUGAUGAG  GCCGUUAGGC  CGAA IGGAGUAG   3942       3176   CCCUUAUC U CCACCUCU   1434   AGAGGUGG CUGAUGAG  GCCGUUAGGC  CGAA IAUAAGGG   3943       3178   CUUAUCUC C ACCUCUAA   1435   UUAGAGGU CUGAUGAG  GCCGUUAGGC  CGAA IAGAUAAG   3944       3179   UUAUCUCC A CCUCUAAG   1436   CUUAGAGG CUGAUGAG  GCCGUUAGGC  CGAA IGAGAUAA   3945       3181   AUCUCCAC C UCUAAGGG   1437   CCCUUAGA CUGAUGAG  GCCGUUAGGC  CGAA IUGGAGAU   3946       3182   UCUCCACC U CUAAGGGA   1438   UCCCUUAG CUGAUGAG  GCCGUUAGGC  CGAA IGUGGAGA   3947       3184   UCCACCUC U AAGGGACA   1439   UGUCCCUU CUGAUGAG  GCCGUUAGGC  CGAA IAGGUGGA   3948       3192   UAAGGGAC A CUCAUCCU   1440   AGGAUGAG CUGAUGAG  GCCGUUAGGC  CGAA IUCCCUUA   3949       3194   AGGGACAC U CAUCCUCA   1441   UGAGGAUG CUGAUGAG  GCCGUUAGGC  CGAA IUGUCCCU   3950       3196   GGACACUC A UCCUCAGG   1442   CCUGAGGA CUGAUGAG  GCCGUUAGGC  CGAA IAGUGUCC   3951       3199   CACUCAUC C UCAGGCCA   1443   UGGCCUGA CUGAUGAG  GCCGUUAGGC  CGAA IAUGAGUG   3952       3200   ACUCAUCC U CAGGCCAU   1444   AUGGCCUG CUGAUGAG  GCCGUUAGGC  CGAA IGAUGAGU   3953       3202   UCAUCCUC A GGCCAUGC   1445   GCAUGGCC CUGAUGAG  GCCGUUAGGC  CGAA IAGGAUGA   3954       3206   CCUCAGGC C AUGCAGUG   1446   CACUGCAU CUGAUGAG  GCCGUUAGGC  CGAA ICCUGAGG   3955       3207   CUCAGGCC A UGCAGUGG   1447   CCACUGCA CUGAUGAG  GCCGUUAGGC  CGAA IGCCUGAG   3956                                                                            
     [0250]               TABLE VII                          HUMAN HBV G-CLEAVER AND SUBSTRATE SEQUENCE                                 Pos   Substrate   Seq ID   G-cleaver   Seq ID                                         61   ACUUUCCU G CUGGUGGC   1448   GCCACCAG UGAUG GCAUGCACUAUGC GCG AGGAAAGU   3957       87   GGAACAGU G AGCCCUGC   1449   GCAGGGCU UGAUG GCAUGCACUAUGC GCG ACUGUUCC   3958       94   UGAGCCCU G CUCAGAAU   1450   ACUCUGAG UGAUG GCAUGCACUAUGC GCG AGGGCUCA   3959       112   CUGUCUCU G CCAUAUCG   1451   CGAUAUGG UGAUG GCAUGCACUAUGC GCG AGAGACAG   3960       132   AUCUUAUC G AAGACUGG   1452   CCAGUCUU UGAUG GCAUGCACUAUGC GCG GAUAAGAU   3961       153   CCUGUACC G AACAUGGA   1453   UCCAUGUU UGAUG GCAUGCACUAUGC GCG GGUACAGG   3962       169   AGAACAUC G CAUCAGGA   1454   UCCUGAUG UGAUG GCAUGCACUAUGC GCG GAUGUUCU   3963       192   GGACCCCU G CUCGUGUU   1455   AACACGAG UGAUG GCAUGCACUAUGC GCG AGGGGUCC   3964       222   UUCUUGUU G ACAAAAAU   1456   AUUUUUGU UGAUG GCAUGCACUAUGC GCG AACAAGAA   3965       315   CAAAAUUC G CAGUCCCA   1457   UGGGACUG UGAUG GCAUGCACUAUGC GCG GAAUUUUG   3966       374   UGGUUAUC G CUGGAUCU   1458   ACAUCCAG UGAUG GCAUGCACUAUGC GCG GAUAACCA   3967       387   AUGUGUCU G CGGCGUUU   1459   AAACGCCG UGAUG GCAUGCACUAUGC GCG AGACACAU   3968       410   CUUCCUCU G CAUCCUGC   1460   GCAGGAUG UGAUG GCAUGCACUAUGC GCG AGAGGAAG   3969       417   UGCAUCCU G CUGCUAUG   1461   CAUAGCAG UGAUG GCAUGCACUAUGC GCG AGGAUGCA   3970       420   AUCCUGCU G CUAUGCCU   1462   AGGCAUAG UGAUG GCAUGCACUAUGC GCG AGCAGGAU   3971       425   GCUGCUAU G CCUCAUCU   1463   AGAUGAGG UGAUG GCAUGCACUAUGC GCG AUAGCAGC   3972       468   GGUAUGUU G CCCGUUUG   1464   CAAACGGG UGAUG GCAUGCACUAUGC GCG AACAUACC   3973       518   CGGACCAU G CAAAACCU   1465   AGGUUUUG UGAUG GCAUGCACUAUGC GCG AUGGUCCG   3974       527   CAAAACCU G CACAACUC   1466   GAGUUGUG UGAUG GCAUGCACUAUGC GCG AGGUUUUG   3975       538   CAACUCCU G CUCAAGGA   1467   UCCUUGAG UGAUG GCAUGCACUAUGC GCG AGGAGUUG   3976       569   CUCAUGUU G CUGUACAA   1468   UUGUACAG UGAUG GCAUGCACUAUGC GCG AACAUGAG   3977       596   CGGAAACU G CACCUGUA   1469   UACAGGUG UGAUG GCAUGCACUAUGC GCG AGUUUCCG   3978       631   GGGCUUUC G CAAAAUAC   1470   GUAUUUUG UGAUG GCAUGCACUAUGC GCG GAAAGCCC   3979       687   UUACUAGU G CCAUUUGU   1471   ACAAAUGG UGAUG GCAUGCACUAUGC GCG ACUAGUAA   3980       747   AUAUGGAU G AUGUGGUU   1472   AACCACAU UGAUG GCAUGCACUAUGC GCG AUCCAUAU   3981       783   AACAUCUU G AGUCCCUU   1473   AAGGGACU UGAUG GCAUGCACUAUGC GCG AAGAUGUU   3982       795   CCCUUUAU G CCGCUGUU   1474   AACAGCGG UGAUG GCAUGCACUAUGC GCG AUAAAGGG   3983       798   UUUAUGCC G CUGUUACC   1475   GGUAACAG UGAUG GCAUGCACUAUGC GCG GGCAUAAA   3984       911   GGCACAUU G CCACAGGA   1476   UCCUGUGG UGAUG GCAUGCACUAUGC GCG AAUGUGCC   3985       978   GGCCUAUU G AUUGGAAA   1477   UUUCCAAU UGAUG GCAUGCACUAUGC GCG AAUAGGCC   3986       997   AUGUCAAC G AAUUGUGG   1478   CCACAAUU UGAUG GCAUGCACUAUGC GCG GUUGACAU   3987       1020   UGGGGUUU G CCGCCCCU   1479   AGGGGCGG UGAUG GCAUGCACUAUGC GCG AAACCCCA   3988       1023   GGUUUGCC G CCCCUUUC   1480   GAAAGGGG UGAUG GCAUGCACUAUGC GCG GGCAAACC   3989       1034   CCUUUCAC G CAAUGUGG   1481   CCACAUUG UGAUG GCAUGCACUAUGC GCG GUGAAAGG   3990       1050   GAUAUUCU G CUUUAAUG   1482   CAUUAAAG UGAUG GCAUGCACUAUGC GCG AGAAUAUC   3991       1058   GCUUUAAU G CCUUUAUA   1483   UAUAAAGG UGAUG GCAUGCACUAUGC GCG AUUAAAGC   3992       1068   CUUUAUAU G CAUGCAUA   1484   UAUGCAUG UGAUG GCAUGCACUAUGC GCG AUAUAAAG   3993       1072   AUAUGCAU G CAUACAAG   1485   CUUGUAUG UGAUG GCAUGCACUAUGC GCG AUGCAUAU   3994       1103   ACUUUCUC G CCAACUUA   1486   UAAGUUGG UGAUG GCAUGCACUAUGC GCG GAGAAAGU   3995       1139   CAGUAUGU G AACCUUUA   1487   UAAAGGUU UGAUG GCAUGCACUAUGC GCG ACAUACUG   3996       1155   ACCCCGUU G CUCGGCAA   1488   UUGCCGAG UGAUG GCAUGCACUAUGC GCG AACGGGGU   3997       1177   UGGUCUAU G CCAAGUGU   1489   ACACUUGG UGAUG GCAUGCACUAUGC GCG AUAGACCA   3998       1188   AAGUGUUU G CUGACGCA   1490   UGCGUCAG UGAUG GCAUGCACUAUGC GCG AAACACUU   3999       1191   UGUUUGCU G ACGCAACC   1491   GGUUGCGU UGAUG GCAUGCACUAUGC GCG AGCAAACA   4000       1194   UUGCUGAC G CAACCCCC   1492   GGGGGUUG UGAUG GCAUGCACUAUGC GCG GUCAGCAA   4001       1234   CCAUCAGC G CAUGCGUG   1493   CACGCAUG UGAUG GCAUGCACUAUGC GCG GCUGAUGG   4002       1238   CAGCGCAU G CGUGGAAC   1494   GUUCCACG UGAUG GCAUGCACUAUGC GCG AUGCGCUG   4003       1262   UCUCCUCU G CCGAUCCA   1495   UGGAUCGG UGAUG GCAUGCACUAUGC GCG AGAGGAGA   4004       1265   CCUCUGCC G AUCCAUAC   1496   GUAUGGAU UGAUG GCAUGCACUAUGC GCG GGCAGAGG   4005       1275   UCCAUACC G CGGAACUC   1497   GAGUUCCG UGAUG GCAUGCACUAUGC GCG GGUAUGGA   4006       1290   UCCUAGCC G CUUGUUUU   1498   AAAACAAG UGAUG GCAUGCACUAUGC GCG GGCUAGGA   4007       1299   CUUGUUUU G CUCGCAGC   1499   GCUGCGAG UGAUG GCAUGCACUAUGC GCG AAAACAAG   4008       1303   UUUUGCUC G CAGCAGGU   1500   ACCUGCUG UGAUG GCAUGCACUAUGC GCG GAGCAAAA   4009       1335   UCGGGACU G ACAAUUCU   1501   AGAAUUGU UGAUG GCAUGCACUAUGC GCG AGUCCCGA   4010       1349   UCUGUCGU G CUCUCCCG   1502   CGGGAGAG UGAUG GCAUGCACUAUGC GCG ACGACAGA   4011       1357   GCUCUCCC G CAAAUAUA   1503   UAUAUUUG UGAUG GCAUGCACUAUGC GCG GGGAGAGC   4012       1382   CCAUGGCU G CUAGGCUG   1504   CAGCCUAG UGAUG GCAUGCACUAUGC GCG AGCCAUGG   4013       1392   UAGGCUGU G CUGCCAAC   1505   GUUGGCAG UGAUG GCAUGCACUAUGC GCG ACAGCCUA   4014       1395   GCUGUGCU G CCAACUGG   1506   CCAGUUGG UGAUG GCAUGCACUAUGC GCG AGCACAGC   4015       1411   GAUCCUAC G CGGGACGU   1507   ACGUCCCG UGAUG GCAUGCACUAUGC GCG GUAGGAUC   4016       1442   CCGUCGGC G CUGAAUCC   1508   GGAUUCAG UGAUG GCAUGCACUAUGC GCG GCCGACGC   4017       1445   UCGGCGCU G AAUCCCGC   1509   GCGGGAUU UGAUG GCAUGCACUAUGC GCG AGCGCCGA   4018       1452   UGAAUCCC G CGGACGAC   1510   GUCGUCCG UGAUG GCAUGCACUAUGC GCG GGGAUUCA   4019       1458   CCGCGGAC G ACCCCUCC   1511   GGAGGGGU UGAUG GCAUGCACUAUGC GCG GUCCGCGG   4020       1474   CCGGGGCC G CUUGGGGC   1512   GCCCCAAG UGAUG GCAUGCACUAUGC GCG GGCCCCGG   4021       1489   GCUCUACC G CCCGCUUC   1513   GAAGCGGG UGAUG GCAUGCACUAUGC GCG GGUAGAGC   4022       1493   UACCGCCC G CUUCUCCG   1514   CGGAGAAG UGAUG GCAUGCACUAUGC GCG GGGCGGUA   4023       1501   GCUUCUCC G CCUAUUGU   1515   ACAAUAGG UGAUG GCAUGCACUAUGC GCG GGAGAAGC   4024       1513   AUUGUACC G ACCGUCCA   1516   UGGACGGU UGAUG GCAUGCACUAUGC GCG GGUACAAU   4025       1528   CACGGGGC G CACCUCUC   1517   GAGAGGUG UGAUG GCAUGCACUAUGC GCG GCCCCGUG   4026       1542   CUCUUUAC G CGGACUCC   1518   GGAGUCCG UGAUG GCAUGCACUAUGC GCG GUAAAGAG   4027       1559   CCGUCUGU G CCUUCUCA   1519   UGAGAAGG UGAUG GCAUGCACUAUGC GCG ACAGACGG   4028       1571   UCUCAUCU G CCGGACCG   1520   CGGUCCGG UGAUG GCAUGCACUAUGC GCG AGAUGAGA   4029       1583   GACCGUGU G CACUUCGC   1521   GCGAAGUG UGAUG GCAUGCACUAUGC GCG ACACCGUC   4030       1590   UGCACUUC G CUUCACCU   1522   AGGUGAAG UGAUG GCAUGCACUAUGC GCG GAAGUGCA   4031       1601   UCACCUCU G CACGUCGC   1523   GCGACGUG UGAUG GCAUGCACUAUGC GCG AGAGGUGA   4032       1608   UGCACGUC G CAUGGAGA   1524   UCUCCAUG UGAUG GCAUGCACUAUGC GCG GACGUGCA   4033       1624   ACCACCGU G AACGCCCA   1525   UGGGCGUU UGAUG GCAUGCACUAUGC GCG ACGGUGGU   4034       1628   CCGUGAAC G CCCACAGG   1526   CCUGUGGG UGAUG GCAUGCACUAUGC GCG GUUCACGG   4035       1642   AGGAACCU G CCCAAGGU   1527   ACCUUGGG UGAUG GCAUGCACUAUGC GCG AGGUUCCU   4036       1654   AAGGUCUU G CAUAAGAG   1528   CUCUUAUG UGAUG GCAUGCACUAUGC GCG AAGACCUU   4037       1690   AUGUCAAC G ACCGACCU   1529   AGGUCGGU UGAUG GCAUGCACUAUGC GCG GUUGACAU   4038       1694   CAACGACC G ACCUUGAG   1530   CUCAAGGU UGAUG GCAUGCACUAUGC GCG GGUCGUUG   4039       1700   CCGACCUU G AGGCAUAC   1531   GUAUGCCU UGAUG GCAUGCACUAUGC GCG AAGGUCGG   4040       1730   UGUUUAAU G AGUGGGAG   1532   CUCCCACU UGAUG GCAUGCACUAUGC GCG AUUAAACA   4041       1818   AGCACCAU G CAACUUUU   1533   AAAAGUUG UGAUG GCAUGCACUAUGC GCG AUGGUGCU   4042       1835   UCACCUCU G CCUAAUCA   1534   UGAUUAGG UGAUG GCAUGCACUAUGC GCG AGAGGUGA   4043       1883   CAAGCUGU G CCUUGGGU   1535   ACCCAAGG UGAUG GCAUGCACUAUGC GCG ACAGCUUG   4044       1912   UGGACAUU G ACCCGUAU   1536   AUACGGGU UGAUG GCAUGCACUAUGC GCG AAUGUCCA   4045       1959   UCUUUUUU G CCUUCUGA   1537   UCAGAAGG UGAUG GCAUGCACUAUGC GCG AAAAAAGA   4046       1966   UGCCUUCU G ACUUCUUU   1538   AAAGAACU UGAUG GCAUGCACUAUGC GCG AGAAGGCA   4047       1985   UUCUAUUC G AGAUCUCC   1539   GGAGAUCU UGAUG GCAUGCACUAUGC GCG GAAUAGAA   4048       1996   AUCUCCUC G ACACCGCC   1540   GGCGGUGU UGAUG GCAUGCACUAUGC GCG GAGGAGAU   4049       2002   UCGACACC G CCUCUGCU   1541   AGCAGAGG UGAUG GCAUGCACUAUGC GCG GGUGUCGA   4050       2008   CCGCCUCU G CUCUGUAU   1542   AUACAGAG UGAUG GCAUGCACUAUGC GCG AGAGGCGG   4051       2092   GUUGGGGU G AGUUGAUG   1543   CAUCAACU UGAUG GCAUGCACUAUGC GCG ACCCCAAC   4052       2097   GGUGAGUU G AUGAAUCU   1544   AGAUUCAU UGAUG GCAUGCACUAUGC GCG AACUCACC   4053       2100   GAGUUGAU G AAUCUAGC   1545   GCUAGAUU UGAUG GCAUGCACUAUGC GCG AUCAACUC   4054       2237   UUUUGGGC G AGAAACUG   1546   CAGUUUCU UGAUG GCAUGCACUAUGC GCG GCCCAAAA   4055       2251   CUGUUCUU G AAUAUUUG   1547   CAAAUAUU UGAUG GCAUGCACUAUGC GCG AAGAACAG   4056       2282   GUGGAUUC G CACUCCUC   1548   GAGGAGUG UGAUG GCAUGCACUAUGC GCG GAAUCCAC   4057       2293   CUCCUCCU G CAUAUAGA   1549   UCUAUAUG UGAUG GCAUGCACUAUGC GCG AGGAGGAG   4058       2311   CACCAAAU G CCCCUAUC   1550   GAUAGGGG UGAUG GCAUGCACUAUGC GCG AUUUGGUG   4059       2354   UGUUAGAC G AAGAGGCA   1551   UGCCUCUU UGAUG GCAUGCACUAUGC GCG GUCUAACA   4060       2388   ACUCCCUC G CCUCGCAG   1552   CUGCGAGG UGAUG GCAUGCACUAUGC GCG GAGGGAGU   4061       2393   CUCGCCUC G CAGACGAA   1553   UUCGUCUG UGAUG GCAUGCACUAUGC GCG GACGCGAG   4062       2399   UCGCAGAC G AAGGUCUC   1554   GAGACCUU UGAUG GCAUGCACUAUGC GCG GUCUGCGA   4063       2412   UCUCAAUC G CCGCGUCG   1555   CGACGCGG UGAUG GCAUGCACUAUGC GCG GAUUGAGA   4064       2415   CAAUCGCC G CGUCGCAG   1556   CUGCGACG UGAUG GCAUGCACUAUGC GCG GGCGAUUG   4065       2420   GCCGCGUC G CAGAAGAU   1557   AUCUUCUG UGAUG GCAUGCACUAUGC GCG GACGCGGC   4066       2514   GGUACCUU G CUUUAAUC   1558   GAUUAAAG UGAUG GCAUGCACUAUGC GCG AAGGUACC   4067       2549   CUUUUCCU G ACAUUCAU   1559   AUGAAUGU UGAUG GCAUGCACUAUGC GCG AGGAAAAG   4068       2560   AUUCAUUU G CAGGAGGA   1560   UCCUCCUG UGAUG GCAUGCACUAUGC GCG AAAUGAAU   4069       2576   ACAUUGUU G AUAGAUGU   1561   ACAUCUAU UGAUG GCAUGCACUAUGC GCG AACAAUGU   4070       2615   CAGUAAAU G AAAACAGG   1562   CCUGUUUU UGAUG GCAUGCACUAUGC GCG AUUUACUG   4071       2641   UUAACUAU G CCUGCUAG   1563   CUAGCAGG UGAUG GCAUGCACUAUGC GCG AUAGUUAA   4072       2645   CUAUGCCU G CUAGGUUU   1564   AAACCUAG UGAUG GCAUGCACUAUGC GCG AGGCAUAG   4073       2677   AAAUAUUU G CCCUUAGA   1565   UCUAAGGG UGAUG GCAUGCACUAUGC GCG AAAUAUUU   4074       2740   UUCCAGAC G CGACAUUA   1566   UAAUGUCG UGAUG GCAUGCACUAUGC GCG GUCUGGAA   4075       2742   CCAGACGC G ACAUUAUU   1567   AAUAAUGU UGAUG GCAUGCACUAUGC GCG GCGUCUGG   4076       2804   CACGUAGC G CCUCAUUU   1568   AAAUGAGG UGAUG GCAUGCACUAUGC GCG GCUACGUG   4077       2814   CUCAUUUU G CGGGUCAC   1569   GUGACCCG UGAUG GCAUGCACUAUGC GCG AAAAUGAG   4078       2875   CAAACCUC G AAAAGGCA   1570   UGCCUUUU UGAUG GCAUGCACUAUGC GCG GAGGUUUG   4079       2928   UCUUCCCC G AUCAUCAG   1571   CUGAUGAU UGAUG GCAUGCACUAUGC GCG GGGGAAGA   4080       2946   UGGACCCU G CAUUCAAA   1572   UUUGAAUG UGAUG GCAUGCACUAUGC GCG AGGGUCCA   4081       2990   CUCAACCC G CACAAGGA   1573   UCCUUGUG UGAUG GCAUGCACUAUGC GCG GGGUUGAG   4082       3012   GGCCGGAC G CCAACAAG   1574   CUUGUUGG UGAUG GCAUGCACUAUGC GCG GUCCGGCC   4083       3090   GCCCUCAC G CUCAGGGC   1575   GCCCUGAG UGAUG GCAUGCACUAUGC GCG GUGAGGGC   4084       3113   ACAACUGU G CCAGCAGC   1576   GCUGCUGG UGAUG GCAUGCACUAUGC GCG ACAGUUGU   4085       3132   CUCCUCCU G CCUCCACC   1577   GGUGGAGG UGAUG GCAUGCACUAUGC GCG AGGAGGAG   4086       51   AGGGCCCU G UACUUUCC   1578   GGAAAGUA UGAUG GCAUGCACUAUGC GCG AGGGCCCU   4087       106   AGAAUACU G UCUCUGCC   1579   GGCAGAGA UGAUG GCAUGCACUAUGC GCG AGUAUUCU   4088       148   GGGACCCU G UACCGAAC   1580   GUUCGGUA UGAUG GCAUGCACUAUGC GCG AGGGUCCC   4089       198   CUGCUCGU G UUACAGGC   1581   GCCUGUAA UGAUG GCAUGCACUAUGC GCG ACGAGCAG   4090       219   UUUUUCUU G UUGACAAA   1582   UUUGUCAA UGAUG GCAUGCACUAUGC GCG AAGAAAAA   4091       297   ACACCCGU G UGUCUUGG   1583   CCAAGACA UGAUG GCAUGCACUAUGC GCG ACGGGUGU   4092       299   ACCCGUGU G UCUUGGCC   1584   GGCCAAGA UGAUG GCAUGCACUAUGC GCG ACACGGGU   4093       347   ACCAACCU G UUGUCCUC   1585   GAGGACAA UGAUG GCAUGCACUAUGC GCG AGGUUGGU   4094       350   AACCUGUU G UCCUCCAA   1586   UUGGAGGA UGAUG GCAUGCACUAUGC GCG AACAGGUU   4095       362   UCCAAUUU G UCCUGGUU   1587   AACCAGGA UGAUG GCAUGCACUAUGC GCG AAAUUGGA   4096       381   CGCUGGAU G UGUCUGCG   1588   CGCAGACA UGAUG GCAUGCACUAUGC GCG AUCCAGCG   4097       383   CUGGAUGU G UCUGCGGC   1589   GCCGCAGA UGAUG GCAUGCACUAUGC GCG ACAUCCAG   4098       438   AUCUUCUU G UUGGUUCU   1590   AGAACCAA UGAUG GCAUGCACUAUGC GCG AAGAAGAU   4099       465   CAAGGUAU G UUGCCCGU   1591   ACGGGCAA UGAUG GCAUGCACUAUGC GCG AUACCUUG   4100       476   GCCCGUUU G UCCUCUAA   1592   UUAGAGGA UGAUG GCAUGCACUAUGC GCG AAACGGGC   4101       555   ACCUCUAU G UUUCCCUC   1593   GAGGGAAA UGAUG GCAUGCACUAUGC GCG AUAGAGGU   4102       566   UCCCUCAU G UUGCUGUA   1594   UACAGCAA UGAUG GCAUGCACUAUGC GCG AUGAGGGA   4103       572   AUGUUGCU G UACAAAAC   1595   GUUUUGUA UGAUG GCAUGCACUAUGC GCG AGCAACAU   4104       602   CGCCACCU G UAUUCCCA   1596   UGGGAAUA UGAUG GCAUGCACUAUGC GCG AGGUGCAG   4105       694   UGCCAUUU G UUCAGUGG   1597   CCACUGAA UGAUG GCAUGCACUAUGC GCG AAAUGGCA   4106       724   CCCCCACU G UCUGGCUU   1598   AAGCCAGA UGAUG GCAUGCACUAUGC GCG AGUGGGGG   4107       750   UGGAUGAU G UGGUUUUG   1599   CAAAACCA UGAUG GCAUGCACUAUGC GCG AUCAUCCA   4108       771   CCAAGUCU G UACAACAU   1600   AUGUUGUA UGAUG GCAUGCACUAUGC GCG AGACUUGG   4109       801   AUGCCGCU G UUACCAAU   1601   AUUGGUAA UGAUG GCAUGCACUAUGC GCG AGCGGCAU   4110       818   UUUCUUUU G UCUUUGGG   1602   CCCAAAGA UGAUG GCAUGCACUAUGC GCG AAAAGAAA   4111       888   UGGGAUAU G UAAUUGGG   1603   CCCAAUUA UGAUG GCAUGCACUAUGC GCG AUAUCCCA   4112       927   AACAUAUU G UACAAAAA   1604   UUUUUGUA UGAUG GCAUGCACUAUGC GCG AAUAUGUU   4113       944   AUCAAAAU G UGUUUUAG   1605   CUAAAACA UGAUG GCAUGCACUAUGC GCG AUUUUGAU   4114       946   CAAAAUGU G UUUUAGGA   1606   UCCUAAAA UGAUG GCAUGCACUAUGC GCG ACAUUUUG   4115       963   AACUUCCU G UAAACAGG   1607   CCUGUUUA UGAUG GCAUGCACUAUGC GCG AGGAAGUU   4116       991   GAAAGUAU G UCAACGAA   1608   UUCGUUGA UGAUG GCAUGCACUAUGC GCG AUACUUUC   4117       1002   AACGAAUU G UGGGUCUU   1609   AAGACCCA UGAUG GCAUGCACUAUGC GCG AAUUCGUU   4118       1039   CACGCAAU G UGGAUAUU   1610   AAUAUCCA UGAUG GCAUGCACUAUGC GCG AUUGCGUG   4119       1137   AACAGUAU G UGAACCUU   1611   AAGGUUCA UGAUG GCAUGCACUAUGC GCG AUACUGUU   4120       1184   UGCCAAGU G UUUGCUGA   1612   UCAGCAAA UGAUG GCAUGCACUAUGC GCG ACUUGGCA   4121       1251   GAACCUUU G UGUCUCCU   1613   AGGAGACA UGAUG GCAUGCACUAUGC GCG AAAGGUUC   4122       1253   ACCUUUGU G UCUCCUCU   1614   AGAGGAGA UGAUG GCAUGCACUAUGC GCG ACAAAGGU   4123       1294   AGCCGCUU G UUUUGCUC   1615   GAGCAAAA UGAUG GCAUGCACUAUGC GCG AAGCGGCU   4124       1344   ACAAUUCU G UCGUGCUC   1616   GAGCACGA UGAUG GCAUGCACUAUGC GCG AGAAUUGU   4125       1390   GCUAGGCU G UGCUGCCA   1617   UGGCAGCA UGAUG GCAUGCACUAUGC GCG AGCCUAGC   4126       1425   CGUCCUUU G UUUACGUC   1618   GACGUAAA UGAUG GCAUGCACUAUGC GCG AAAGGACG   4127       1508   CGCCUAUU G UACCGACC   1619   GGUCGGUA UGAUG GCAUGCACUAUGC GCG AAUAGGCG   4128       1557   CCCCGUCU G UGCCUUCU   1620   AGAAGGCA UGAUG GCAUGCACUAUGC GCG AGACGGGG   4129       1581   CGGACCGU G UGCACUUC   1621   GAAGUGCA UGAUG GCAUGCACUAUGC GCG ACGGUCCG   4130       1684   UCAGCAAU G UCAACGAC   1622   GUCGUUGA UGAUG GCAUGCACUAUGC GCG AUUGCUGA   4131       1719   CAAAGACU G UGUGUUUA   1623   UAAACACA UGAUG GCAUGCACUAUGC GCG AGUCUUUG   4132       1721   AAGACUGU G UGUUUAAU   1624   AUUAAACA UGAUG GCAUGCACUAUGC GCG ACAGUCUU   4133       1723   GACUGUGU G UUUAAUGA   1625   UCAUUAAA UGAUG GCAUGCACUAUGC GCG ACACAGUC   4134       1772   AGGUCUUU G UACUAGGA   1626   UCCUAGUA UGAUG GCAUGCACUAUGC GCG AAAGACCU   4135       1785   AGGAGGCU G UAGGCAUA   1627   UAUGCCUA UGAUG GCAUGCACUAUGC GCG AGCCUCCU   4136       1801   AAAUUGGU G UGUUCACC   1628   GGUGAACA UGAUG GCAUGCACUAUGC GCG ACCAAUUU   4137       1803   AUGGGUGU G UUCACCAG   1629   CUGGUGAA UGAUG GCAUGCACUAUGC GCG ACACCAAU   4138       1850   CAUCUCAU G UUCAUGUC   1630   GACAUGAA UGAUG GCAUGCACUAUGC GCG AUGAGAUG   4139       1856   AUGUUCAU G UCCUACUG   1631   CAGUAGGA UGAUG GCAUGCACUAUGC GCG AUGAACAU   4140       1864   GUCCUACU G UUCAAGCC   1632   GGCUUGAA UGAUG GCAUGCACUAUGC GCG AGUAGGAC   4141       1881   UCCAAGCU G UGCCUUGG   1633   CCAAGGCA UGAUG GCAUGCACUAUGC GCG AGCUUGGA   4142       1939   GAGCUUCU G UGGAGUUA   1634   UAACUCCA UGAUG GCAUGCACUAUGC GCG AGAAGCUC   4143       2013   UCUGCUCU G UAUCGGGG   1635   CCCCGAUA UGAUG GCAUGCACUAUGC GCG AGAGCAGA   4144       2045   GGAACAUU G UUCACCUC   1636   GAGGUGAA UGAUG GCAUGCACUAUGC GCG AAUGUUCC   4145       2082   GCUAUUCU G UGUUGGGG   1637   CCCCAACA UGAUG GCAUGCACUAUGC GCG AGAAUAGC   4146       2084   UAUUCUGU G UUGGGGUG   1638   CACCCCAA UGAUG GCAUGCACUAUGC GCG ACAGAAUA   4147       2167   UCAGCUAU G UCAACGUU   1639   AACGUUGA UGAUG GCAUGCACUAUGC GCG AUAGCUGA   4148       2205   CAACUAUU G UGGUUUCA   1640   UGAAACCA UGAUG GCAUGCACUAUGC GCG AAUAGUUG   4149       2222   CAUUUCCU G UCUUACUU   1641   AAGUAAGA UGAUG GCAUGCACUAUGC GCG AGGAAAUG   4150       2245   GAGAAACU G UUCUUGAA   1642   UUCAAGAA UGAUG GCAUGCACUAUGC GCG AGUUUCUC   4151       2262   UAUUUGGU G UCUUUUGG   1643   CCAAAAGA UGAUG GCAUGCACUAUGC GCG ACCAAAUA   4152       2274   UUUGGAGU G UGGAUUCG   1644   CGAAUCCA UGAUG GCAUGCACUAUGC GCG ACUCCAAA   4153       2344   AAACUACU G UUGUUAGA   1645   UCUAACAA UGAUG GCAUGCACUAUGC GCG AGUAGUUU   4154       2347   CUACUGUU G UUAGACGA   1646   UCGUCUAA UGAUG GCAUGCACUAUGC GCG AACAGUAG   4155       2450   AUCUCAAU G UUAGUAUU   1647   AAUACUAA UGAUG GCAUGCACUAUGC GCG AUUGAGAU   4156       2573   AGGACAUU G UUGAUAGA   1648   UCUAUCAA UGAUG GCAUGCACUAUGC GCG AAUGUCCU   4157       2583   UGAUAGAU G UAAGCAAU   1649   AUUGCUUA UGAUG GCAUGCACUAUGC GCG AUCUAUCA   4158       2594   AGCAAUUU G UGGGGCCC   1650   GGGCCCCA UGAUG GCAUGCACUAUGC GCG AAAUUGCU   4159       2663   AUCCCAAU G UUACUAAA   1651   UUUAGUAA UGAUG GCAUGCACUAUGC GCG AUUGGGAU   4160       2717   CAGAGUAC G UAGUUAAU   1652   AUUAACUA UGAUG GCAUGCACUAUGC GCG AUACUCUG   4161       2901   AUCUUUCU G UCCCCAAU   1653   AUUGGGGA UGAUG GCAUGCACUAUGC GCG AGAAAGAU   4162       3071   GGGGGACU G UUGGGGUG   1654   CACCCCAA UGAUG GCAUGCACUAUGC GCG AGUCCCCC   4163       3111   UCACAACU G UGCCAGCA   1655   UGCUGGCA UGAUG GCAUGCACUAUGC GCG AGUUGUGA   4164                                                            
     [0251]               TABLE VIII                          HUMAN HBV ZINZYME AND SUBSTRATE SEQUENCE                                 Pos   Substrate   Seq ID   Zinzyme   Seq ID                                         61   ACUUUCCU G GUGGUGGC   1448   GCCACCAG GCcgaaagGCGaGuCaaGGuCu AGGAAAGU   4165       94   UGAGCCCU G CUCAGAAU   1450   AUUCUGAG GCcgaaagGCGaGuCaaGGuCu AGGGCUCA   4166       112   CUGUCUCU G CCAUAUCG   1451   CGAUAUGG GCcgaaagGCGaGuCaaGGuCu AGAGACAG   4167       169   AGAACAUC G CAUCAGGA   1454   UCCUGAUG GCcgaaagGCGaGuCaaGGuCu GAUGUUCU   4168       192   GGACCCCU G CUCGUGUU   1455   AACACGAG GCcgaaagGCGaGuCaaGGuCu AGGGGUCC   4169       315   CAAAAUUC G CAGUCCCA   1457   UGGGACUG GCcgaaagGCGaGuCaaGGuCu GAAUUUUG   4170       374   UGGUUAUC G CUGGAUGU   1458   ACAUCCAG GCcgaaagGCGaGuCaaGGuCu GAUAACCA   4171       387   AUGUGUCU G CGGCGUUU   1459   AAACGCCG GCcgaaagGCGaGuCaaGGuCu AGACACAU   4172       410   CUUCCUCU G CAUCCUGC   1460   GCAGGAUG GCcgaaagGCGaGuCaaGGuCu AGAGGAAG   4173       417   UGCAUCCU G CUGCUAUG   1461   CAUAGCAG GCcgaaagGCGaGuCaaGGuCu AGGAUGCA   4174       420   AUCCUGCU G CUAUGCCU   1462   AGGCAUAG GCcgaaagGCGaGuCaaGGuCu AGCAGGAU   4175       425   GCUGCUAU G CCUCAUCU   1463   AGAUGAGG GCcgaaagGCGaGuCaaGGuCu AUAGCAGC   4176       468   GGUAUGUU G CCCGUUUG   1464   CAAACGGG GCcgaaagGCGaGuCaaGGuCu AACAUACC   4177       518   CGGACCAU G CAAAACCU   1465   AGGUUUUG GCcgaaagGCGaGuCaaGGuCu AUGGUCCG   4178       527   CAAAACCU G CACAACUC   1466   GAGUUGUG GCcgaaagGCGaGuCaaGGuCu AGGUUUUG   4179       538   CAACUCCU G CUCAAGGA   1467   UCCUUGAG GCcgaaagGCGaGuCaaGGuCu AGGAGUUG   4180       569   CUCAUGUU G CUGUACAA   1468   UUGUACAG GCcgaaagGCGaGuCaaGGuCu AACAUGAG   4181       596   CGGAAACU G CACCUGUA   1469   UACAGGUG GCcgaaagGCGaGuCaaGGuCu AGUUUCCG   4182       631   GGGCUUUC G CAAAAUAC   1470   GUAUUUUG GCcgaaagGCGaGuCaaGGuCu GAAAGCCC   4183       687   UUACUAGU G CCAUUUGU   1471   ACAAAUGG GCcgaaagGCGaGuCaaGGuCu ACUAGUAA   4184       795   CCCUUUAU G CCGCUGUU   1474   AACAGCGG GCcgaaagGCGaGuCaaGGuCu AUAAAGGG   4185       798   UUUAUGCC G CUGUUACC   1475   GGUAACAG GCcgaaagGCGaGuCaaGGuCu GGCAUAAA   4186       911   GGCACAUU G CCACAGGA   1476   UCCUGUGG GCcgaaagGCGaGuCaaGGuCu AAUGUGCC   4187       1020   UGGGGUUU G CCGCCCCU   1479   AGGGGCGG GCcgaaagGCGaGuCaaGGuCu AAACCCCA   4188       1023   GGUUUGCC G CCCCUUUC   1480   GAAAGGGG GCcgaaagGCGaGuCaaGGuCu GGCAAACC   4189       1034   CCUUUCAC G CAAUGUGG   1481   CCACAUUG GCcgaaagGCGaGuCaaGGuCu GUGAAAGG   4190       1050   GAUAUUCU G CUUUAAUG   1482   CAUUAAAG GCcgaaagGCGaGuCaaGGuCu AGAAUAUC   4191       1058   GCUUUAAU G CCUUUAUA   1483   UAUAAAGG GCcgaaagGCGaGuCaaGGuCu AUUAAAGC   4192       1068   CUUUAUAU G CAUGCAUA   1484   UAUGCAUG GCcgaaagGCGaGuCaaGGuCu AUAUAAAG   4193       1072   AUAUGCAU G CAUACAAG   1485   CUUGUAUG GCcgaaagGCGaGuCaaGGuCu AUGCAUAU   4194       1103   ACUUUCUC G CCAACUUA   1486   UAAGUUGG GCcgaaagGCGaGuCaaGGuCu GAGAAAGU   4195       1155   ACCCCGUU G CUCGGCAA   1488   UUGCCGAG GCcgaaagGCGaGuCaaGGuCu AACGGGGU   4196       1177   UGGUCUAU G CCAAGUGU   1489   ACACUUGG GCcgaaagGCGaGuCaaGGuCu AUAGACCA   4197       1188   AAGUGUUU G CUGACGCA   1490   UGCGUCAG GCcgaaagGCGaGuCaaGGuCu AAACACUU   4198       1194   UUGCUGAC G CAACCCCC   1492   GGGGGUUG GCcgaaagGCGaGuCaaGGuCu GUCAGCAA   4199       1234   CCAUCAGC G CAUGCGUG   1493   CACGCAUG GCcgaaagGCGaGuCaaGGuCu GCUGAUGG   4200       1238   CAGCGCAU G CGUGGAAC   1494   GUUCCACG GCcgaaagGCGaGuCaaGGuCu AUGCGCUG   4201       1262   UCUCCUCU G CCGAUCCA   1495   UGGAUCGG GCcgaaagGCGaGuCaaGGuCu AGAGGAGA   4202       1275   UCCAUACC G CGGAACUC   1497   GAGUUCCG GCcgaaagGCGaGuCaaGGuCu GGUAUGGA   4203       1290   UCCUAGCC G CUUGUUUU   1498   AAAACAAG GCcgaaagGCGaGuCaaGGuCu GGCUAGGA   4204       1299   CUUGUUUU G CUCGCAGC   1499   GCUGCGAG GCcgaaagGCGaGuCaaGGuCu AAAACAAG   4205       1303   UUUUGCUC G CAGCAGGU   1500   ACCUGCUG GCcgaaagGCGaGuCaaGGuCu GAGCAAAA   4206       1349   UCUGUCGU G CUCUCCCG   1502   CGGGAGAG GCcgaaagGCGaGuCaaGGuCu ACGACAGA   4207       1357   GCUCUCCC G CAAAUAUA   1503   UAUAUUUG GCcgaaagGCGaGuCaaGGuCu GGGAGAGC   4208       1382   CCAUGGCU G CUAGGCUG   1504   CAGCCUAG GCcgaaagGCGaGuCaaGGuCu AGCCAUGG   4209       1392   UAGGCUGU G CUGCCAAC   1505   GUUGGCAG GCcgaaagGCGaGuCaaGGuCu ACAGCCUA   4210       1395   GCUGUGCU G CCAACUGG   1506   CCAGUUGG GCcgaaagGCGaGuCaaGGuCu AGCACAGC   4211       1411   GAUCCUAC G CGGGACGU   1507   ACGUCCCG GCcgaaagGCGaGuCaaGGuCu GUAGGAUC   4212       1442   CCGUCGGC G CUGAAUCC   1508   GGAUUCAG GCcgaaagGCGaGuCaaGGuCu GCCGACGG   4213       1452   UGAAUCCC G CGGACGAC   1510   GUCGUCCG GCcgaaagGCGaGuCaaGGuCu GGGAUUCA   4214       1474   CCGGGGCC G CUUGGGGC   1512   GCCCCAAG GCcgaaagGCGaGuCaaGGuCu GGCCCCGG   4215       1489   GCUCUACC G CCCGCUUC   1513   GAAGCGGG GCcgaaagGCGaGuCaaGGuCu GGUAGAGC   4216       1493   UACCGCCC G CUUCUCCG   1514   CGGAGAAG GCcgaaagGCGaGuCaaGGuCu GGGCGGUA   4217       1501   GCUUCUCC G CCUAUUGU   1515   ACAAUAGG GCcgaaagGCGaGuCaaGGuCu GGAGAAGC   4218       1528   CACGGGGC G CACCUCUC   1517   GAGAGGUG GCcgaaagGCGaGuCaaGGuCu GCCCCGUG   4219       1542   CUCUUUAC G CGGACUCC   1518   GGAGUCCG GCcgaaagGCGaGuCaaGGuCu GUAAAGAG   4220       1559   CCGUCUGU G CCUUCUCA   1519   UGAGAAGG GCcgaaagGCGaGuCaaGGuCu ACAGACGG   4221       1571   UCUCAUCU G CCGGACCG   1520   CGGUCCGG GCcgaaagGCGaGuCaaGGuCu AGAUGAGA   4222       1583   GACCGUGU G CACUUCGC   1521   GCGAAGUG GCcgaaagGCGaGuCaaGGuCu ACACGGUC   4223       1590   UGCACUUC G CUUCACCU   1522   AGGUGAAG GCcgaaagGCGaGuCaaGGuCu GAAGUGCA   4224       1601   UCACCUCU G CACGUCGC   1523   GCGACGUG GCcgaaagGCGaGuCaaGGuCu AGAGGUGA   4225       1608   UGCACGUC G CAUGGAGA   1524   UCUCCAUG GCcgaaagGCGaGuCaaGGuCu GACGUGCA   4226       1628   CCGUGAAC G CCCACAGG   1526   CCUGUGGG GCcgaaagGCGaGuCaaGGuCu GUUCACGG   4227       1642   AGGAACCU G CCCAAGGU   1527   ACCUUGGG GCcgaaagGCGaGuCaaGGuCu AGGUUCCU   4228       1654   AAGGUCUU G CAUAAGAG   1528   CUCUUAUG GCcgaaagGCGaGuCaaGGuCu AAGACCUU   4229       1818   AGCACCAU G CAACUUUU   1533   AAAAGUUG GCcgaaagGCGaGuCaaGGuCu AUGGUGCU   4230       1835   UCACCUCU G CCUAAUCA   1534   UGAUUAGG GCcgaaagGCGaGuCaaGGuCu AGAGGUGA   4231       1883   CAAGCUGU G CCUUGGGU   1535   ACCCAAGG GCcgaaagGCGaGuCaaGGuCu ACACGUUG   4232       1959   UCUUUUUU G CCUUCUGA   1537   UCAGAAGG GCcgaaagGCGaGuCaaGGuCu AAAAAAGA   4233       2002   UCGACACC G CCUCUGCU   1541   AGCAGAGG GCcgaaagGCGaGuCaaGGuCu GGUGUCGA   4234       2008   CCGCCUCU G CUCUGUAU   1542   AUACAGAG GCcgaaagGCGaGuCaaGGuCu AGAGGCGG   4235       2282   GUGGAUUC G CACUCCUC   1548   GAGGAGUG GCcgaaagGCGaGuCaaGGuCu GAAUCCAC   4236       2293   CUCCUCCU G CAUAUAGA   1549   UCUAUAUG GCcgaaagGCGaGuCaaGGuCu AGGAGGAG   4237       2311   CACCAAAU G CCCCUAUC   1550   GAUAGGGG GCcgaaagGCGaGuCaaGGuCu AUUUGGUG   4238       2388   ACUCCCUC G CCUCGCAG   1552   CUGCGAGG GCcgaaagGCGaGuCaaGGuCu GAGGGAGU   4239       2393   CUCGCCUC G CAGACGAA   1553   UUCGUCUG GCcgaaagGCGaGuCaaGGuCu GAGGCGAG   4240       2412   UCUCAAUC G CCGCGUCG   1555   CGACGCGG GCcgaaagGCGaGuCaaGGuCu GAUUGAGA   4241       2415   CAAUCGCC G CGUCGCAG   1556   CUGCGACG GCcgaaagGCGaGuCaaGGuCu GGCGAUUG   4242       2420   GCCGCGUC G CAGAAGAU   1557   AUCUUCUG GCcgaaagGCGaGuCaaGGuCu GACGCGGC   4243       2514   GGUACCUU G CUUUAAUC   1558   GAUUAAAG GCcgaaagGCGaGuCaaGGuCu AAGGUACC   4244       2560   AUUCAUUU G CAGGAGGA   1560   UCCUCCUG GCcgaaagGCGaGuCaaGGuCu AAAUGAAU   4245       2641   UUAACUAU G CCUGCUAG   1563   CUAGCAGG GCcgaaagGCGaGuCaaGGuCu AUAGUUAA   4246       2645   CUAUGCCU G CUAGGUUU   1564   AAACCUAG GCcgaaagGCGaGuCaaGGuCu AGGCAUAG   4247       2677   AAAUAUUU G CCCUUAGA   1565   UCUAAGGG GCcgaaagGCGaGuCaaGGuCu AAAUAUUU   4248       2740   UUCCAGAC G CGACAUUA   1566   UAAUGUCG GCcgaaagGCGaGuCaaGGuCu GUCUGGAA   4249       2804   CACGUAGC G CCUCAUUU   1568   AAAUGAGG GCcgaaagGCGaGuCaaGGuCu GCUACGUG   4250       2814   CUCAUUUU G CGGGUCAC   1569   GUGACCCG GCcgaaagGCGaGuCaaGGuCu AAAAUGAG   4251       2946   UGGACCCU G CAUUCAAA   1572   UUUGAAUG GCcgaaagGCGaGuCaaGGuCu AGGGUCCA   4252       2990   CUCAACCC G CACAAGGA   1573   UCCUUGUG GCcgaaagGCGaGuCaaGGuCu GGGUUGAG   4253       3012   GGCCGGAC G CCAACAAG   1574   CUUGUUGG GCcgaaagGCGaGuCaaGGuCu GUCCGGCC   4254       3090   GCCCUCAC G CUCAGGGC   1575   GCCCUGAG GCcgaaagGCGaGuCaaGGuCu GUGAGGGC   4255       3113   ACAACUGU G CCAGCAGC   1576   GCUGCUGG GCcgaaagGCGaGuCaaGGuCu ACAGUUGU   4256       3132   CUCCUCCU G CCUCCACC   1577   GGUGGAGG GCcgaaagGCGaGuCaaGGuCu AGGAGGAG   4257       51   AGGGCCCU G UACUUUCC   1578   GGAAAGUA GCcgaaagGCGaGuCaaGGuCu AGGGCCCU   4258       106   AGAAUACU G UCUCUGCC   1579   GGCAGAGA GCcgaaagGCGaGuCaaGGuCu AGUAUUCU   4259       148   GGGACCCU G UACCGAAC   1580   GUUCGGUA GCcgaaagGCGaGuCaaGGuCu AGGGUCCC   4260       198   CUGCUCGU G UUACAGGC   1581   GCCUGUAA GCcgaaagGCGaGuCaaGGuCu ACGAGCAG   4261       219   UUUUUCUU G UUGACAAA   1582   UUUGUCAA GCcgaaagGCGaGuCaaGGuCu AAGAAAAA   4262       297   ACACCCGU G UGUCUUGG   1583   CCAAGACA GCcgaaagGCGaGuCaaGGuCu ACGGGUGU   4263       299   ACCCGUGU G UCUUGGCC   1584   GGCCAAGA GCcgaaagGCGaGuCaaGGuCu ACACGGGU   4264       347   ACCAACCU G UUCUCCUC   1585   GAGGACAA GCcgaaagGCGaGuCaaGGuCu AGGUUGGU   4265       350   AACCUGUU G UCCUCCAA   1586   UUGGAGGA GCcgaaagGCGaGuCaaGGuCu AACAGGUU   4266       362   UCCAAUUU G UCCUGGUU   1587   AACCAGGA GCcgaaagGCGaGuCaaGGuCu AAAUUGGA   4267       381   CGCUGGAU G UGUCUGCG   1588   CGCAGACA GCcgaaagGCGaGuCaaGGuCu AUCCAGCG   4268       383   CUGGAUGU G UCUGCGGC   1589   GCCGCAGA GCcgaaagGCGaGuCaaGGuCu ACAUCCAG   4269       438   AUCUUCUU G UUGGUUCU   1590   AGAACCAA GCcgaaagGCGaGuCaaGGuCu AAGAAGAU   4270       465   CAAGGUAU G UUGCCCGU   1591   ACGGGCAA GCcgaaagGCGaGuCaaGGuCu AUACCUUG   4271       476   GCCCGUUU G UCCUCUAA   1592   UUAGAGGA GCcgaaagGCGaGuCaaGGuCu AAACGGGC   4272       555   ACCUCUAU G UUUCCCUC   1593   GAGGGAAA GCcgaaagGCGaGuCaaGGuCu AUAGAGGU   4273       566   UCCCUCAU G UUGCUGUA   1594   UACAGCAA GCcgaaagGCGaGuCaaGGuCu AUGAGGGA   4274       572   AUGUUGCU G UACAAAAC   1595   GUUUUGUA GCcgaaagGCGaGuCaaGGuCu AGCAACAU   4275       602   CUGCACCU G UAUUCCCA   1596   UGGGAAUA GCcgaaagGCGaGuCaaGGuCu AGGUGCAG   4276       694   UGCCAUUU G UUCAGUGG   1597   CCACUGAA GCcgaaagGCGaGuCaaGGuCu AAAUGGCA   4277       724   CCCCCACU G UCUGGCUU   1598   AAGCCAGA GCcgaaagGCGaGuCaaGGuCu AGUGGGGG   4278       750   UGGAUGAU G UGGUUUUG   1599   CAAAACCA GCcgaaagGCGaGuCaaGGuCu AUCAUCCA   4279       771   CCAAGUCU G UACAACAU   1600   AUGUUGUA GCcgaaagGCGaGuCaaGGuCu AGACUUGG   4280       801   AUGCCGCU G UUACCAAU   1601   AUUGGUAA GCcgaaagGCGaGuCaaGGuCu AGCGGCAU   4281       818   UUUCUUUU G UCUUUGGG   1602   CCCAAAGA GCcgaaagGCGaGuCaaGGuCu AAAAGAAA   4282       888   UGGGAUAU G UAAUUGGG   1603   CCCAAUUA GCcgaaagGCGaGuCaaGGuCu AUAUCCCA   4283       927   AACAUAUU G UACAAAAA   1604   UUUUUGUA GCcgaaagGCGaGuCaaGGuCu AAUAUGUU   4284       944   AUCAAAAU G UGUUUUAG   1605   CUAAAACA GCcgaaagGCGaGuCaaGGuCu AUUUUGAU   4285       946   CAAAAUGU G UUUUAGGA   1606   UCCUAAAA GCcgaaagGCGaGuCaaGGuCu ACAUUUUG   4286       963   AACUUCCU G UAAACAGG   1607   CCUGUUUA GCcgaaagGCGaGuCaaGGuCu AGGAAGUU   4287       991   GAAAGUAU G UCAACGAA   1608   UUCGUUGA GCcgaaagGCGaGuCaaGGuCu AUACUUUC   4288       1002   AACGAAUU G UGGGUCUU   1609   AAGACCCA GCcgaaagGCGaGuCaaGGuCu AAUUCGUU   4289       1039   CACGCAAU G UGGAUAUU   1610   AAUAUCCA GCcgaaagGCGaGuCaaGGuCu AUUGCGUG   4290       1137   AACAGUAU G UGAACCUU   1611   AAGGUUCA GCcgaaagGCGaGuCaaGGuCu AUACUGUU   4291       1184   UGCCAAGU G UUUGCUGA   1612   UCAGCAAA GCcgaaagGCGaGuCaaGGuCu ACUUGGCA   4292       1251   GAACCUUU G UGUCUCCU   1613   AGGAGACA GCcgaaagGCGaGuCaaGGuCu AAAGGUUC   4293       1253   ACCUUUGU G UCUCCUCU   1614   AGAGGAGA GCcgaaagGCGaGuCaaGGuCu ACAAAGGU   4294       1294   AGCCGCUU G UUUUGCUC   1615   GAGCAAAA GCcgaaagGCGaGuCaaGGuCu AAGCGGCU   4295       1344   ACAAUUCU G UCGUGCUC   1616   GAGCACGA GCcgaaagGCGaGuCaaGGuCu AGAAUUGU   4296       1390   GCUAGGCU G UGCUGCCA   1617   UGGCAGCA GCcgaaagGCGaGuCaaGGuCu ACCCUAGC   4297       1425   CGUCCUUU G UUUACGUC   1618   GACGUAAA GCcgaaagGCGaGuCaaGGuCu AAAGGACG   4298       1508   CGCCUAUU G UACCGACC   1619   GGUCGGUA GCcgaaagGCGaGuCaaGGuCu AAUAGGCG   4299       1557   CCCCGUCU G UGCCUUCU   1620   AGAAGGCA GCcgaaagGCGaGuCaaGGuCu AGACGGGG   4300       1581   CGGACCGU G UGCACUUC   1621   GAAGUGCA GCcgaaagGCGaGuCaaGGuCu ACGGUCCG   4301       1684   UCAGCAAU G UCAACGAC   1622   GUCGUUGA GCcgaaagGCGaGuCaaGGuCu AUUGCUGA   4302       1719   CAAAGACU G UGUGUUUA   1623   UAAACACA GCcgaaagGCGaGuCaaGGuCu AGUCUUUG   4303       1721   AAGACUGU G UGUUUAAU   1624   AUUAAACA GCcgaaagGCGaGuCaaGGuCu ACAGUCUU   4304       1723   GACUGUGU G UUUAAUGA   1625   UCAUUAAA GCcgaaagGCGaGuCaaGGuCu ACACAGUC   4305       1772   AGGUCUUU G UACUAGGA   1626   UCCUAGUA GCcgaaagGCGaGuCaaGGuCu AAAGACCU   4306       1785   AGGAGGCU G UAGGCAUA   1627   UAUGCCUA GCcgaaagGCGaGuCaaGGuCu AGCCUCCU   4307       1801   AAAUUGGU G UGUUCACC   1628   GGUGAACA GCcgaaagGCGaGuCaaGGuCu ACCAAUUU   4308       1803   AUUGGUGU G UUCACCAG   1629   CUGGUGAA GCcgaaagGCGaGuCaaGGuCu ACACCAAU   4309       1850   CAUCUCAU G UUCAUGUC   1630   GACAUGAA GCcgaaagGCGaGuCaaGGuCu AUGAGAUG   4310       1856   AUGUUCAU G UCCUACUG   1631   CAGUAGGA GCcgaaagGCGaGuCaaGGuCu AUGAACAU   4311       1864   GUCCUACH G UUCAAGCC   1632   GGCUUGAA GCcgaaagGCGaGuCaaGGuCu AGUAGGAC   4312       1881   UCCAACCU G UGCCUUGG   1633   CCAAGGCA GCcgaaagGCGaGuCaaGGuCu AGCUUGGA   4313       1939   GAGCUUCU G UGGAGUUA   1634   UAACUCCA GCcgaaagGCGaGuCaaGGuCu AGAAGCUC   4314       2013   UCUGCUCU G UAUCGGGG   1635   CCCCGAUA GCcgaaagGCGaGuCaaGGuCu AGAGCAGA   4315       2045   GGAACAUU G UUCACCUC   1636   CAGGUGAA GCcgaaagGCGaGuCaaGGuCu AAUGUUCC   4316       2082   GCUAUUCU G UGUUGGGG   1637   CCCCAACA GCcgaaagGCGaGuCaaGGuCu AGAAUAGC   4317       2084   UAUUCUGU G UUGGGGUG   1638   CACCCCAA GCcgaaagGCGaGuCaaGGuCu ACAGAAUA   4318       2167   UCAGCUAU G UCAACGUU   1639   AACGUUGA GCcgaaagGCGaGuCaaGGuCu AUAGCUGA   4319       2205   CAACUAUU G UGGUUUCA   1640   UGAAACCA GCcgaaagGCGaGuCaaGGuCu AAUAGUUG   4320       2222   CAUUUCCU G UCUUACUU   1641   AAGUAAGA GCcgaaagGCGaGuCaaGGuCu AGGAAAUG   4321       2245   GAGAAACU G UUCUUGAA   1642   UUCAAGAA GCcgaaagGCGaGuCaaGGuCu AGUUUCUC   4322       2262   UAUUUGGU G UCUUUUGG   1643   CGAAAAGA GCcgaaagGCGaGuCaaGGuCu ACCAAAUA   4323       2274   UUUGGAGU G UGGAUUCG   1644   CGAAUCCA GCcgaaagGCGaGuCaaGGuCu ACUCCAAA   4324       2344   AAACUACU G UUGUUAGA   1645   UCUAACAA GCcgaaagGCGaGuCaaGGuCu AGUAGUUU   4325       2347   CUACUGUU G UUAGACGA   1646   UCGUCUAA GCcgaaagGCGaGuCaaGGuCu AACAGUAG   4326       2450   AUCUCAAU G UUAGUAUU   1647   AAUACUAA GCcgaaagGCGaGuCaaGGuCu AUUGAGAU   4327       2573   AGGACAUU G UUGAUAGA   1648   UCUAUCAA GCcgaaagGCGaGuCaaGGuCu AAUGUCCU   4328       2583   UGAUAGAU G UAAGCAAU   1649   AUUGCUUA GCcgaaagGCGaGuCaaGGuCu AUCUAUCA   4329       2594   AGCAUUUU G UGGGGCCC   1650   GGGCCCCA GCcgaaagGCGaGuCaaGGuCu AAAUUGCU   4330       2663   AUCCCAAU G UUACUAAA   1651   UUUAGUAA GCcgaaagGCGaGuCaaGGuCu AUUGGGAU   4331       2717   CAGAGUAU G UAGUUAAU   1652   AUUAACUA GCcgaaagGCGaGuCaaGGuCu AUACUCUG   4332       2901   AUCUUUCU G UCCCCAAU   1653   AUUGGGGA GCcgaaagGCGaGuCaaGGuCu AGAAAGAU   4333       3071   GGGGGACU G UUGGGGUG   1654   CACCCCAA GCcgaaagGCGaGuCaaGGuCu AGUCCCCC   4334       3111   UCACAACU G UGCCAGCA   1655   UGCUGGCA GCcgaaagGCGaGuCaaGGuCu AGUUGUGA   4335       40   AUCCCACA G UCAGGGCC   1656   GGCCCUGA GCcgaaagGCGaGuCaaGGuCu UCUGGGAU   4336       46   GAGUCAGG G CCCUGUAC   1657   GUACAGGG GCcgaaagGCGaGuCaaGGuCu CCUGACUC   4337       65   UCCUGCUG G UGGCUCCA   1658   UGGAGCCA GCcgaaagGCGaGuCaaGGuCu CAGCAGGA   4338       68   UGCUGGUG G CUCCAGUU   1659   AACUGGAG GCcgaaagGCGaGuCaaGGuCu CACCAGCA   4339       74   UGGCUCCA G UUCAGGAA   1660   UUCCUGAA GCcgaaagGCGaGuCaaGGuCu UGGAGCCA   4340       85   CAGGAACA G UGAGCCCU   1661   AGGGCUCA GCcgaaagGCGaGuCaaGGuCu UGUUCCUG   4341       89   AACAGUGA G CCCUGCUC   1662   GAGCAGGG GCcgaaagGCGaGuCaaGGuCu UCACUGUU   4342       120   GCCAUAUC G UCAAUCUU   1663   AAGAUUGA GCcgaaagGCGaGuCaaGGuCu GAUAUGGC   4343       196   CCCUGCUC G UGUUACAG   1664   CUGUAACA GCcgaaagGCGaGuCaaGGuCu GAGCAGGG   4344       205   UGUUACAG G CGGGGUUU   1665   AAACCCCG GCcgaaagGCGaGuCaaGGuCu CUGUAACA   4345       210   CAGGCGGG G UUUUUCUU   1666   AAGAAAAA GCcgaaagGCGaGuCaaGGuCu CCCGCCUG   4346       248   ACCACAGA G UCUAGACU   1667   AGUCUAGA GCcgaaagGCGaGuCaaGGuCu UCUGUGGU   4347       258   CUAGACUC G UGGUGGAC   1668   GUCCACCA GCcgaaagGCGaGuCaaGGuCu GAGUCUAG   4348       261   GACUCGUG G UGGACUUC   1669   GAAGUCCA GCcgaaagGCGaGuCaaGGuCu CACGAGUC   4349       295   GAACACCC G UGUGUCUU   1670   AAGACACA GCcgaaagGCGaGuCaaGGuCu GGGUGUUC   4350       305   GUGUCUUG G CCAAAAUU   1671   AAUUUUGG GCcgaaagGCGaGuCaaGGuCu CAAGACAC   4351       318   AAUUCGCA G UCCCAAAU   1672   AUUUGGGA GCcgaaagGCGaGuCaaGGuCu UGCGAAUU   4352       332   AAUCUCCA G UCACUCAC   1673   GUGAGUGA GCcgaaagGCGaGuCaaGGuCu UGGAGAUU   4353       368   UUGUCCUG G UUAUCGCU   1674   AGCGAUAA GCcgaaagGCGaGuCaaGGuCu CAGGACAA   4354       390   UGUCUGCG G CGUUUUAU   1675   AUAAAACG GCcgaaagGCGaGuCaaGGuCu CGCAGACA   4355       392   UCUGCGGC G UUUUAUCA   1676   UGAUAAAA GCcgaaagGCGaGuCaaGGuCu GCCGCAGA   4356       442   UCUUGUUG G UUCUUCUG   1677   CAGAAGAA GCcgaaagGCGaGuCaaGGuCu CAACAAGA   4357       461   CUAUCAAG G UAUGUUGC   1678   GCAACAUA GCcgaaagGCGaGuCaaGGuCu CUUGAUAG   4358       472   UGUUGCCC G UUUGUCCU   1679   AGGACAAA GCcgaaagGCGaGuCaaGGuCu CGGCAACA   4359       650   AACAACCA G CACCGGAC   1680   GUCCGGUG GCcgaaagGCGaGuCaaGGuCu UGGUUGUU   4360       625   CAUCUUGG G CUUUCGCA   1681   UGCGAAAG GCcgaaagGCGaGuCaaGGuCu CCAAGAUG   4361       648   CUAUGGGA G UGGGCCUC   1682   GAGGCCCA GCcgaaagGCGaGuCaaGGuCu UCCCAUAG   4362       652   GGGAGUGG G CCUCAGUC   1683   GACUGAGG GCcgaaagGCGaGuCaaGGuCu CCACUCCC   4363       658   GGGCCUCA G UCCGUUUC   1684   GAAACGGA GCcgaaagGCGaGuCaaGGuCu UGAGGCCC   4364       662   CUCAGUCC G UUUCUCUU   1685   AAGAGAAA GCcgaaagGCGaGuCaaGGuCu GGACUGAG   4365       672   UUCUCUUG G CUCAGUUU   1686   AAACUGAG GCcgaaagGCGaGuCaaGGuCu CAAGAGAA   4366       677   UUGGCUCA G UUUACUAG   1687   CUAGUAAA GCcgaaagGCGaGuCaaGGuCu UGAGCCAA   4367       685   GUUUACUA G UGCCAUUU   1688   AAAUGGCA GCcgaaagGCGaGuCaaGGuCu UAGUAAAC   4368       699   UUUGUUCA G UGGUUCGU   1689   ACGAACCA GCcgaaagGCGaGuCaaGGuCu UGAACAAA   4369       702   GUUCAGUG G UUCGUAGG   1690   CCUACGAA GCcgaaagGCGaGuCaaGGuCu CACUGAAC   4370       706   AGUGGUUC G UAGGGCUU   1691   AAGCCCUA GCcgaaagGCGaGuCaaGGuCu GAACCACU   4371       711   UUCGUAGG G CUUUCCCC   1692   GGGGAAAG GCcgaaagGCGaGuCaaGGuCu CCUACGAA   4372       729   ACUGUCUG G CUUUCAGU   1693   ACUGAAAG GCcgaaagGCGaGuCaaGGuCu CAGACAGU   4373       736   GGCUUUCA G UUAUAUGG   1694   CCAUAUAA GCcgaaagGCGaGuCaaGGuCu UGAAAGCC   4374       753   AUGAUGUG G UUUUGGGG   1695   CCCCAAAA GCcgaaagGCGaGuCaaGGuCu CACAUCAU   4375       762   UUUUGGGG G CCAAGUCU   1696   AGACUUGG GCcgaaagGCGaGuCaaGGuCu CCCCAAAA   4376       767   GGGGCCAA G UCUGUACA   1697   UGUACAGA GCcgaaagGCGaGuCaaGGuCu UUGGCCCC   4377       785   CAUCUUGA G UCCCUUUA   1698   UAAAGGGA GCcgaaagGCGaGuCaaGGuCu UCAAGAUG   4378       826   GUCUUUGG G UAUACAUU   1699   AAUGUAUA GCcgaaagGCGaGuCaaGGuCu CCAAAGAC   4379       898   AAUUGGGA G UUGGGGCA   1700   UGCCCCAA GCcgaaagGCGaGuCaaGGuCu UCCCAAUU   4380       904   GAGUUGGG G CACAUUGC   1701   GCAAUGUG GCcgaaagGCGaGuCaaGGuCu CCCAACUC   4381       971   GUAAACAG G CCUAUUGA   1702   UCAAUAGG GCcgaaagGCGaGuCaaGGuCu CUGUUUAC   4382       987   AUUGGAAA G UAUGUCAA   1703   UUGACAUA GCcgaaagGCGaGuCaaGGuCu UUUCCAAU   4383       1006   AAUUGUGG G UCUUUUGG   1704   CCAAAAGA GCcgaaagGCGaGuCaaGGuCu CCACAAUU   4384       1016   CUUUUGGG G UUUGCCGC   1705   GCGGCAAA GCcgaaagGCGaGuCaaGGuCu CCCAAAAG   4385       1080   GCAUACAA G CAAAACAG   1706   CUGUUUUG GCcgaaagGCGaGuCaaGGuCu UUGUAUGC   4386       1089   CAAAACAG G CUUUUACU   1707   AGUAAAAG GCcgaaagGCGaGuCaaGGuCu CUGUUUUG   4387       1116   CUUACAAG G CCUUUCUA   1708   UAGAAAGG GCcgaaagGCGaGuCaaGGuCu CUUGUAAG   4388       1126   CUUUCUAA G UAAACAGU   1709   ACUGUUUA GCcgaaagGCGaGuCaaGGuCu UUAGAAAG   4389       1133   AGUAAACA G UAUGUGAA   1710   UUCACAUA GCcgaaagGCGaGuCaaGGuCu UGUUUACU   4390       1152   UUUACCCC G UUGCUCGG   1711   CCGAGCAA GCcgaaagGCGaGuCaaGGuCu GGGGUAAA   4391       1160   GUUGCUCG G CAACGGCC   1712   GGCCGUUG GCcgaaagGCGaGuCaaGGuCu CGAGCAAC   4392       1166   CGGCAACG G CCUGGUCU   1713   AGACCAGG GCcgaaagGCGaGuCaaGGuCu CGUUGCCG   4393       1171   ACGGCCUG G UCUAUGCC   1714   GGCAUAGA GCcgaaagGCGaGuCaaGGuCu CAGGCCGU   4394       1182   UAUGCCAA G UGUUUGCU   1715   AGCAAACA GCcgaaagGCGaGuCaaGGuCu UUGGCAUA   4395       1207   CCCCACUG G UUGGGGCU   1716   AGCCCCAA GCcgaaagGCGaGuCaaGGuCu CACUGGGG   4396       1213   UGGUUGGG G CUUGGCCA   1717   UGGCCAAG GCcgaaagGCGaGuCaaGGuCu CCCAACCA   4397       1218   GGGGCUUG G CCAUAGGC   1718   GCCUAUGG GCcgaaagGCGaGuCaaGGuCu CAAGCCCC   4398       1225   GGCCAUAG G CCAUCAGC   1719   GCUGAUGG GCcgaaagGCGaGuCaaGGuCu CUAUGGCC   4399       1232   GGCCAUCA G CGCAUGCG   1720   CGCAUGCG GCcgaaagGCGaGuCaaGGuCu UGAUGGCC   4400       1240   GCGCAUGC G UGGAACCU   1721   AGGUUCCA GCcgaaagGCGaGuCaaGGuCu GCAUGCGC   4401       1287   AACUCCUA G CCGCUUGU   1722   ACAAGCGG GCcgaaagGCGaGuCaaGGuCu UAGGAGUU   4402       1306   UGCUCGCA G CAGGUCUG   1723   CAGACCUG GCcgaaagGCGaGuCaaGGuCu UGCGAGCA   4403       1310   CGCAGCAG G UCUGGGGC   1724   GCCCCAGA GCcgaaagGCGaGuCaaGGuCu CUGCUGCG   4404       1317   GGUCUGGG G CAAAACUC   1725   GAGUUUUG GCcgaaagGCGaGuCaaGGuCu CCCAGACC   4405       1347   AUUCUGUC G UGCUCUCC   1726   GGAGAGCA GCcgaaagGCGaGuCaaGGuCu GACAGAAU   4406       1379   UUUCCAUG G CUGCUAGG   1727   CCUAGCAG GCcgaaagGCGaGuCaaGGuCu CAUGGAAA   4407       1387   GCUGCUAG G CUGUGCUG   1728   CAGCACAG GCcgaaagGCGaGuCaaGGuCu CUAGCAGC   4408       1418   CGCGGGAC G UCCUUUGU   1729   ACAAAGGA GCcgaaagGCGaGuCaaGGuCu GUCCCGCG   4409       1431   UUGUUUAC G UCCCGUCG   1730   CGACGGGA GCcgaaagGCGaGuCaaGGuCu GUAAACAA   4410       1436   UACGUCCC G UCGGCGCU   1731   AGCGCCGA GCcgaaagGCGaGuCaaGGuCu GGGACGUA   4411       1440   UCCCGUCG G CGCUGAAU   1732   AUUCAGCG GCcgaaagGCGaGuCaaGGuCu CGACGGGA   4412       1471   CUCCCGGG G CCGCUUGG   1733   CCAAGCGG GCcgaaagGCGaGuCaaGGuCu CCCGGGAG   4413       1481   CGCUUGGG G CUCUACCG   1734   CGGUAGAG GCcgaaagGCGaGuCaaGGuCu CCCAAGCG   4414       1517   UACCGACC G UCCACGGG   1735   CCCGUGGA GCcgaaagGCGaGuCaaGGuCu GGUCGGUA   4415       1526   UCCACGGG G CGCACCUC   1736   GAGGUGCG GCcgaaagGCGaGuCaaGGuCu CCCGUGGA   4416       1553   GACUCCCC G UCUGUGCC   1737   GGCACAGA GCcgaaagGCGaGuCaaGGuCu GGGGAGUC   4417       1579   GCCGGACC G UGUGCACU   1738   AGUGCACA GCcgaaagGCGaGuCaaGGuCu GGUCCGGC   4418       1605   CUCUGCAC G UCGCAUGG   1739   CCAUGCGA GCcgaaagGCGaGuCaaGGuCu GUGCAGAG   4419       1622   AGACCACC G UGAACGCC   1740   GGCGUUCA GCcgaaagGCGaGuCaaGGuCu GGUGGUCU   4420       1649   UGCCCAAG G UCUUGCAU   1741   AUGCAAGA GCcgaaagGCGaGuCaaGGuCu CUUGGGCA   4421       1679   GACUUUCA G CAAUGUCA   1742   UGACAUUG GCcgaaagGCGaGuCaaGGuCu UGAAAGUC   4422       1703   ACCUUGAG G CAUACUUC   1743   GAAGUAUG GCcgaaagGCGaGuCaaGGuCu CUCAAGGU   4423       1732   UUUAAUGA G UGGGAGGA   1744   UCCUCCCA GCcgaaagGCGaGuCaaGGuCu UCAUUAAA   4424       1741   UGGGAGGA G UUGGGGGA   1745   UCCCCCAA GCcgaaagGCGaGuCaaGGuCu UCCUCCCA   4425       1754   GGGAGGAG G UUAGGUUA   1746   UAACCUAA GCcgaaagGCGaGuCaaGGuCu CUCCUCCC   4426       1759   GAGGUUAG G UUAAAGGU   1747   ACCUUUAA GCcgaaagGCGaGuCaaGGuCu CUAACCUC   4427       1766   GGUUAAAG G UCUUUGUA   1748   UACAAAGA GCcgaaagGCGaGuCaaGGuCu CUUUAACC   4428       1782   ACUAGGAG G CUGUAGGC   1749   GCCUACAG GCcgaaagGCGaGuCaaGGuCu CUCCUAGU   4429       1789   GGCUGUAG G CAUAAAUU   1750   AAUUUAUG GCcgaaagGCGaGuCaaGGuCu CUACAGCC   4430       1799   AUAAAUUG G UGUGUUCA   1751   UGAACACA GCcgaaagGCGaGuCaaGGuCu CAAUUUAU   4431       1811   GUUCACCA G CACCAUGC   1752   GCAUGGUG GCcgaaagGCGaGuCaaGGuCu UGGUGAAC   4432       1870   CUGUUCAA G CCUCCAAG   1753   CUUGGAGG GCcgaaagGCGaGuCaaGGuCu UUGAACAG   4433       1878   GCCUCCAA G CUGUGCCU   1754   AGGCACAG GCcgaaagGCGaGuCaaGGuCu UUGGAGGC   4434       1890   UGCCUUGG G UGGCUUUG   1755   CAAAGCCA GCcgaaagGCGaGuCaaGGuCu CCAAGGCA   4435       1893   CUUGGGUG G CUUUGGGG   1756   CCCCAAAG GCcgaaagGCGaGuCaaGGuCu CACCCAAG   4436       1901   GCUUUGGG G CAUGGACA   1757   UGUCCAUG GCcgaaagGCGaGuCaaGGuCu CCCAAAGC   4437       1917   AUUGACCC G UAUAAAGA   1758   UCUUUAUA GCcgaaagGCGaGuCaaGGuCu GGGUCAAU   4438       1933   AAUUUGGA G CUUCUGUG   1759   CACAGAAG GCcgaaagGCGaGuCaaGGuCu UCCAAAUU   4439       1944   UCUGUGGA G UCACUCUC   1760   GAGAGUAA GCcgaaagGCGaGuCaaGGuCu UCCACAGA   4440       2023   AUCGGGGG G CCUUAGAG   1761   CUCUAAGG GCcgaaagGCGaGuCaaGGuCu CCCCCGAU   4441       2031   GCCUUAGA G UCUCCGGA   1762   UCCGGAGA GCcgaaagGCGaGuCaaGGuCu UCUAAGGC   4442       2062   ACCAUACG G CACUCAGG   1763   CCUGAGUG GCcgaaagGCGaGuCaaGGuCu CGUAUGGU   4443       2070   GCACUCAG G CAAGCUAU   1764   AUACGUUG GCcgaaagGCGaGuCaaGGuCu CUGAGUGC   4444       2074   UCAGGCAA G CUAUUCUG   1765   CAGAAUAG GCcgaaagGCGaGuCaaGGuCu UUGCCUGA   4445       2090   GUGUUGGG G UGAGUUGA   1766   UCAACUCA GCcgaaagGCGaGuCaaGGuCu CCCAACAC   4446       2094   UGGGGUGA G UUGAUGAA   1767   UUCAUCAA GCcgaaagGCGaGuCaaGGuCu UCACCCCA   4447       2107   UGAAUCUA G CCACCUGG   1768   CCAGGUGG GCcgaaagGCGaGuCaaGGuCu UAGAUUCA   4448       2116   CCACCUGG G UGGGAAGU   1769   ACUUCCCA GCcgaaagGCGaGuCaaGGuCu CCAGGUGG   4449       2123   GGUGGGAA G UAAUUUGG   1770   CCAAAUUA GCcgaaagGCGaGuCaaGGuCu UUCCCACC   4450       2140   AAGAUCCA G CAUCCAGG   1771   CCUGGAUG GCcgaaagGCGaGuCaaGGuCu UGGAUCUU   4451       2155   GGGAAUUA G UAGUCAGC   1772   GCUGACUA GCcgaaagGCGaGuCaaGGuCu UAAUUCCC   4452       2158   AAUUAGUA G UCAUGUAU   1773   AUAGCUGA GCcgaaagGCGaGuCaaGGuCu UACUAAUU   4453       2162   AGUAGUCA G CUAUGUCA   1774   UGACAUAG GCcgaaagGCGaGuCaaGGuCu UGACUACU   4454       2173   AUGUCAAC G UUAAUAUG   1775   CAUAUUAA GCcgaaagGCGaGuCaaGGuCu GUUGACAU   4455       2183   UAAUAUGG G CCUAAAAA   1776   UUUUUAGG GCcgaaagGCGaGuCaaGGuCu CCAUAUUA   4456       2208   CUAUUGUG G UUUCACAU   1777   AUGUGAAA GCcgaaagGCGaGuCaaGGuCu CACAAUAG   4457       2235   ACUUUUGG G CGAGAAAC   1778   GUUUCUCG GCcgaaagGCGaGuCaaGGuCu CCAAAAGU   4458       2260   AAUAUUUG G UGUCUUUU   1779   AAAAGACA GCcgaaagGCGaGuCaaGGuCu CAAAUAUU   4459       2272   CUUUUGGA G UGUGGAUU   1780   AAUCCACA GCcgaaagGCGaGuCaaGGuCu UCCAAAAG   4460       2360   ACGAAGAG G CAGGUCCC   1781   GGGACCUG GCcgaaagGCGaGuCaaGGuCu CUCUUCGU   4461       2364   AGAGGCAG G UCCCCUAG   1782   CUAGGGGA GCcgaaagGCGaGuCaaGGuCu CUGCCUCU   4462       2403   AGACGAAG G UCUCAAUC   1783   GAUUGAGA GCcgaaagGCGaGuCaaGGuCu CUUCGUCU   4463       2417   AUCGCCGC G UCGCAGAA   1784   UUCUGCGA GCcgaaagGCGaGuCaaGGuCu GCGGCGAU   4464       2454   CAAUGUUA G UAUUCCUU   1785   AAGGAAUA GCcgaaagGCGaGuCaaGGuCu UAACAUUG   4465       2474   CACAUAAG G UGGGAAAC   1786   GUUUCCCA GCcgaaagGCGaGuCaaGGuCu CUUAUGUG   4466       2491   UUUACGGG G CUUUAUUC   1787   GAAUAAAG GCcgaaagGCGaGuCaaGGuCu CCCGUAAA   4467       2507   CUUCUACG G UACCUUGC   1788   GCAAGGUA GCcgaaagGCGaGuCaaGGuCu CGUAGAAG   4468       2530   CCUAAAUG G CAAACUCC   1789   GGAGUUUG GCcgaaagGCGaGuCaaGGuCu CAUUUAGG   4469       2587   AGAUGUAA G CAAUUUGU   1790   ACAAAUUG GCcgaaagGCGaGuCaaGGuCu UUACAUCU   4470       2599   UUUGUGGG G CCCCUUAC   1791   GUAAGGGG GCcgaaagGCGaGuCaaGGuCu CCCACAAA   4471       2609   CCCUUACA G UAAAUGAA   1792   UUCAUUUA GCcgaaagGCGaGuCaaGGuCu UGUAAGGG   4472       2650   CCUGCUAG G UUUUAUCC   1793   GGAUAAAA GCcgaaagGCGaGuCaaGGuCu CUAGCAGG   4473       2701   AUCAAACC G UAUUAUCC   1794   GGAUAAUA GCcgaaagGCGaGuCaaGGuCu GGUUUGAU   4474       2713   UAUCCAGA G UAUGUAGU   1795   ACUACAUA GCcgaaagGCGaGuCaaGGuCu UCUGGAUA   4475       2720   AGUAUGUA G UUAAUCAU   1796   AUGAUUAA GCcgaaagGCGaGuCaaGGuCu UACAUACU   4476       2768   UUUGGAAG G CGGGGAUC   1797   GAUCCCCG GCcgaaagGCGaGuCaaGGuCu CUUCCAAA   4477       2791   AAAAGAGA G UCCACACG   1798   CGUGUGGA GCcgaaagGCGaGuCaaGGuCu UCUCUUUU   4478       2799   GUCCACAC G UAGCGCCU   1799   AGGCGCUA GCcgaaagGCGaGuCaaGGuCu GUCUGGAC   4479       2802   CACACGUA G CGCCUCAU   1800   AUGAGGCG GCcgaaagGCGaGuCaaGGuCu UACGUGUG   4480       2818   UUUUGCGG G UCACCAUA   1801   UAUGGUGA GCcgaaagGCGaGuCaaGGuCu CCGCAAAA   4481       2848   GAUCUACA G CAUGGGAG   1802   CUCCCAUG GCcgaaagGCGaGuCaaGGuCu UGUAGAUC   4482       2857   CAUGGGAG G UUGGUCUU   1803   AAGACCAA GCcgaaagGCGaGuCaaGGuCu CUCCCAUG   4483       2861   GGAGGUUG G UCUUCCAA   1804   UUGGAAGA GCcgaaagGCGaGuCaaGGuCu CAACCUCC   4484       2881   UCGAAAAG G CAUGGGGA   1805   UCCCCAUG GCcgaaagGCGaGuCaaGGuCu CUUUUCGA   4485       2936   GAUCAUCA G UUGGACCC   1806   GGGUCCAA GCcgaaagGCGaGuCaaGGuCu UGAUGAUC   4486       2955   CAUUCAAA G CCAACUCA   1807   UGAGUUGG GCcgaaagGCGaGuCaaGGuCu UUUGAAUG   4487       2964   CCAACUCA G UAAAUCCA   1808   UGGAUUUA GCcgaaagGCGaGuCaaGGuCu UGAGUUGG   4488       3005   GACAACUG G CCGGACGC   1809   GCGUCCGG GCcgaaagGCGaGuCaaGGuCu CAGUUGUC   4489       3021   CCAACAAG G UGGGAGUG   1810   CACUCCCA GCcgaaagGCGaGuCaaGGuCu CUUGUUGG   4490       3027   AGGUGGGA G UGGGAGCA   1811   UGCUCCCA GCcgaaagGCGaGuCaaGGuCu UCCCACCU   4491       3033   GAGUGGGA G CAUUCGGG   1812   CCCGAAUG GCcgaaagGCGaGuCaaGGuCu UCCCACUC   4492       3041   GCAUUCGG G CCAGGGUU   1813   AACCCUGG GCcgaaagGCGaGuCaaGGuCu CCGAAUGC   4493       3047   GGGCCAGG G UUCACCCC   1814   GGGGUGAA GCcgaaagGCGaGuCaaGGuCu CCUGGCCC   4494       3077   CUGUUGGG G UGGAGCCC   1815   GGGCUCCA GCcgaaagGCGaGuCaaGGuCu CCCAACAG   4495       3082   GGGGUGGA G CCCUCACG   1816   CGUGAGGG GCcgaaagGCGaGuCaaGGuCu UCCACCCC   4496       3097   CGCUCACG G CCUACUCA   1817   UGAGUAGG GCcgaaagGCGaGuCaaGGuCu CCUGAGCG   4497       3117   CUGUGCCA G CAGCUCCU   1818   AGGAGCUG GCcgaaagGCGaGuCaaGGuCu UGGCACAG   4498       3120   UGCCAGCA G CUCCUCCU   1819   AGGAGGAG GCcgaaagGCGaGuCaaGGuCu UGCUGGCA   4499       3146   ACCAAUCG G CAGUCAGG   1820   CCUGACUG GCcgaaagGCGaGuCaaGGuCu CGAUUGGU   4500       3149   AAUCGGCA G UCAGGAAG   1821   CUUCCUGA GCcgaaagGCGaGuCaaGGuCu UGCCGAUU   4501       3158   UCAGGAAG G CAGCCUAC   1822   GUAGGCUG GCcgaaagGCGaGuCaaGGuCu CUUCCUGA   4502       3161   GGAAGGCA G CCUACUCC   1823   GGAGUAGG GCcgaaagGCGaGuCaaGGuCu UGCCUUCC   4503       3204   AUCCUCAG G CCAUGCAG   1824   CUGCAUGG GCcgaaagGCGaGuCaaGGuCu CUGAGGAU   4504                                                            
     [0252]               TABLE IX                          HUMAN HBV DNAZYME AND SUBSTRATE SEQUENCE                                 Pos   Substrate   Seq ID   DNAzyme   Seq ID                                         508   CAACCAGC A CCGGACCA   833   TGGTCCGG GGCTAGCTACAACGA GCTGGTTG   4505       1632   GAACGCCC A CAGGAACC   1096   GGTTCCTG GGCTAGCTACAACGA GGGCGTTC   4506       2992   CAACCCGC A CAAGGACA   1376   TGTCCTTG GGCTAGCTACAACGA GCGGGTTG   4507       61   ACUUUCCU G CUGGUGGC   1448   GCCACCAG GGCTAGCTACAACGA AGCAAAGT   4508       94   UGAGCCCU G CUCAGAAU   1450   ATTCTGAG GGCTAGCTACAACGA AGGGCTCA   4509       112   CUGUCUCU G CCAUAUCG   1451   CGATATGG GGCTAGCTACAACGA AGAGACAG   4510       169   AGAACAUC G CAUCAGGA   1454   TCCTGATG GGCTAGCTACAACGA GATGTTCT   4511       192   GGACCCCU G CUCGUGUU   1455   AACACGAG GGCTAGCTACAACGA AGGGGTCC   4512       315   CAAAAUUC G CAGUCCCA   1457   TGGGACTG GGCTAGCTACAACGA GAATTTTG   4513       374   UGGUUAUC G CUGGAUGU   1458   ACATCCAG GGCTAGCTACAACGA GATAACCA   4514       387   AUGUGUCU G CGGCGUUU   1459   AAACGCCG GGCTAGCTACAACGA AGACACAT   4515       410   CUUCCUCU G CAUCCUGC   1460   GCAGGATG GGCTAGCTACAACGA AGAGGAAG   4516       417   UGCAUCCU G CUGCUAUG   1461   CATAGCAG GGCTAGCTACAACGA AGGATGCA   4517       420   AUCCUGCU G CUAUGCCU   1462   AGGCATAG GGCTAGCTACAACGA AGCAGGAT   4518       425   GCUGCUAU G CCUCAUCU   1463   AGATGAGG GGCTAGCTACAACGA ATAGCAGC   4519       468   GGUAUGUU G CCCGUUUG   1464   CAAACGGG GGCTAGCTACAACGA AACATACC   4520       518   CGGACCAU G CAAAACCU   1465   AGGTTTTG GGCTAGCTACAACGA ATGGTCCG   4521       527   CAAAACCU G CACAACUC   1466   GAUTTGTG GGCTAGCTACAACGA AGGTTTTG   4522       538   CAACUCCU G CUCAAGGA   1467   TCCTTGAG GGCTAGCTACAACGA AGGAGTTG   4523       569   CUCAUGUU G CUGUACAA   1468   TTGTACAG GGCTAGCTACAACGA AACATGAG   4524       596   CGGAAACU G CACCUGUA   1469   TACAGGTG GGCTAGCTACAACGA AGTTTCCG   4525       631   GGGCUUUC G CAAAAUAC   1470   GTATTTTG GGCTAGCTACAACGA GAAAGCCC   4526       687   UUACUAGU G CCAUUUGU   1471   ACAAATGG GGCTAGCTACAACGA ACTAGTAA   4527       795   CCCUUUAU G CCGCUGUU   1474   AACAGCGG GGCTAGCTACAACGA ATAAAGGG   4528       798   UUUAUGCC G CUGUUACC   1475   GGTAACAG GGCTAGCTACAACGA GGCATAAA   4529       911   GGCACAUU G CCACAGGA   1476   TCCTGTGG GGCTAGCTACAACGA AATGTGCC   4530       1020   UUGGGUUU G CCGCCCCU   1479   AGGGGCGG GGCTAGCTACAACGA AAACCCCA   4531       1023   GGUUUGCC G CCCCUUUC   1480   GAAAGGGG GGCTAGCTACAACGA GGCAAACC   4532       1034   CCUUUCAC G CAAUGUGG   1481   CCACATTG GGCTAGCTACAACGA GTGAAAGG   4533       1050   GAUAUUCU G CUUUAAUG   1482   CATTAAAG GGCTAGCTACAACGA AGAATATC   4534       1058   GCUUUAAU G CCUUUAUA   1483   TATAAAGG GGCTAGCTACAACGA ATTAAAGC   4535       1068   CUUUAUAU G CAUGCAUA   1484   TATGCATG GGCTAGCTACAACGA ATATAAAG   4536       1072   AUAUGCAU G CAUACAAG   1485   CTTGTATG GGCTAGCTACAACGA ATGCATAT   4537       1103   ACUUUCUC G CCAACUUA   1486   TAAGTTGG GGCTAGCTACAACGA GAGAAAGT   4538       1155   ACCCCGUU G CUCGGCAA   1488   TTGCCGAG GGCTAGCTACAACGA AACGGGGT   4539       1177   UGGUCUAU G CCAAGUGU   1489   ACACTTGG GGCTAGCTACAACGA ATAGACCA   4540       1188   AAGUGUUU G CUGACGCA   1490   TGCGTCAG GGCTAGCTACAACGA AAACACTT   4541       1194   UUGCUGAC G CAACCCCC   1492   GGGGGTTG GGCTAGCTACAACGA GTCAGCAA   4542       1234   CCAUCAGC G CAUGCGUG   1493   CACGCATG GGCTAGCTACAACGA GCTGATGG   4543       1238   CAGCGCAU G CGUGGAAC   1494   GTTCCACG GGCTAGCTACAACGA ATGCGCTG   4544       1262   UCUCCUCU G CCGAUCCA   1495   TGGATCGG GGCTAGCTACAACGA AGAGGAGA   4545       1275   UCCAUACC G CGGAACUC   1497   GAGTTCCG GGCTAGCTACAACGA GGTATGGA   4546       1290   UCCUAGCC G CUUGUUUU   1498   AAAACAAG GGCTAGCTACAACGA GGCTAGGA   4547       1299   CUUGUUUU G CUCGCAGC   1499   GCTGCGAG GGCTAGCTACAACGA AAAACAAG   4548       1303   UUUUGCUC G CAGCAGGU   1500   ACCTGCTG GGCTAGCTACAACGA GAGCAAAA   4549       1349   UCUGUCGU G CUCUCCCG   1502   CGGGAGAG GGCTAGCTACAACGA ACGACAGA   4550       1357   GCUCUCCC G CAAAUAUA   1503   TATATTTG GGCTAGCTACAACGA GGGAGAGC   4551       1382   CCAUGGCU G CUAGGCUG   1504   CAGCCTAG GGCTAGCTACAACGA AGCCATGG   4552       1392   UAGGCUGU G CUGCCAAC   1505   GTTGGCAG GGCTAGCTACAACGA ACAGCCTA   4553       1395   GCUGUGCU G CCAACUGG   1506   CCAGTTGC GGCTAGCTACAACGA AGCACAGC   4554       1411   GAUCCUAC G CGGGACGU   1507   ACGTCCCG GGCTAGCTACAACGA GTACCATC   4555       1442   CCGUCGGC G CUGAAUCC   1508   GGATTCAG GGCTAGCTACAACGA GCCGACGG   4556       1452   UGAAUCCC G CGGACGAC   1510   GTCGTCCG GGCTAGCTACAACGA GGGATTCA   4557       1474   CCGGGGCC G CUUGGGGC   1512   GCCCCAAG GGCTAGCTACAACGA GGCCCCGG   4558       1489   GCUCUACC G CCCGCUUC   1513   GAAGCGGG GGCTAGCTACAACGA CGTACAGC   4559       1493   UACCGCCC G CUUCUCCG   1514   CGGAGAAG GGCTAGCTACAACGA GGGCGGTA   4560       1501   GCUUCUCC G CCUAUUGU   1515   ACAATAGG GGCTAGCTACAACGA GGACAAGC   4561       1528   CACGGGGC G CACCUCUC   1517   GAGAGGTG GGCTAGCTACAACGA GCCCCGTG   4562       1542   CUCUUUAC G CGGACUCC   1518   GGAGTCCG GGCTAGCTACAACGA GTAAAGAG   4563       1559   CCGUCUGU G CCUUCUCA   1519   TGAGAAGG GGCTAGCTACAACGA ACAGACGG   4564       1571   UCUCAUCU G CCGGACCG   1520   CGGTCCGG GGCTAGCTACAACGA AGATGAGA   4565       1583   GACCGUGU G CACUUCGC   1521   GCGAAGTG GGCTAGCTACAACGA ACACGGTC   4566       1590   UGCACUUC G CUUCACCU   1522   AGGTGAAG GGCTAGCTACAACGA GAAGTGCA   4567       1601   UCACCUCU G CACGUCGC   1523   GCGACGTG GGCTAGCTACAACGA AGAGGTGA   4568       1608   UGCACGUC G CAUGGAGA   1524   TCTCCATG GGCTAGCTACAACGA GACGTGCA   4569       1628   CCGUGAAC G CCCACAGG   1526   CCTGTGGG GGCTAGCTACAACGA GTTCACGG   4570       1642   AGGAACCU G CCCAAGGU   1527   ACCTTGGG GGCTAGCTACAACGA AGGTTCCT   4571       1654   AAGGUCUU G CAUAAGAG   1528   CTCTTATG GGCTAGCTACAACGA AAGACCTT   4572       1818   AGCACCAU G CAACUUUU   1533   AAAAGTTG GGCTAGCTACAACGA ATGGTGCT   4573       1835   UCACCUCU G CCUAAUCA   1534   TGATTAGG GGCTAGCTACAACGA AGAGGTGA   4574       1883   CAAGCUGU G CCUUGGGU   1535   ACCCAAGG GGCTAGCTACAACGA ACAGCTTG   4575       1959   UCUUUUUU G CCUUCUGA   1537   TCAGAAGG GGCTAGCTACAACGA AAAAAAGA   4576       2002   UCGACACC G CCUCUGCU   1541   AGCAGAGG GGCTAGCTACAACGA GGTGTCGA   4577       2008   CCGCCUCU G CUCUGUAU   1542   ATACAGAG GGCTAGCTACAACGA AGAGGCGG   4578       2282   GUGGAUUC G CACUCCUC   1548   GAGGAGTG GGCTAGCTACAACGA GAATCCAC   4579       2293   CUCCUCCU G CAUAUAGA   1549   TCTATATG GGCTAGCTACAACGA AGGAGGAG   4580       2311   CACCAAAU G CCCCUAUC   1550   GATAGGGG GGCTAGCTACAACGA ATTTGGTG   4581       2388   ACUCCCUC G CCUCGCAG   1552   CTGCGAGG GGCTAGCTACAACGA GAGGGAGT   4582       2393   CUCGCCUC G CAGACGAA   1553   TTCGTCTG GGCTAGCTACAACGA GAGGCGAG   4583       2412   UCUCAAUC G CCGCGUCG   1555   CGACGCGG GGCTAGCTACAACGA GATTGAGA   4584       2415   CAAUCGCC G CGUCGCAG   1556   CTGCGACG GGCTAGCTACAACGA GGCGATTG   4585       2420   GCCGCGUC G CAGAAGAU   1557   ATCTTCTG GGCTAGCTACAACGA GACGCGGC   4586       2514   GGUACCUU G CUUUAAUC   1558   GATTAAAG GGCTAGCTACAACGA AAGGTACC   4587       2560   AUUCAUUU G CAGGAGGA   1560   TCCTCCTG GGCTAGCTACAACGA AAATGAAT   4588       2641   UUAACUAU G CCUGCUAG   1563   CTAGCAGG GGCTAGCTACAACGA ATAGTTAA   4589       2645   CUAUGCCU G CUAGGUUU   1564   AAACCTAG GGCTAGCTACAACGA AGGCATAG   4590       2677   AAAUAUUU G CCCUUAGA   1565   TCTAAGGG GGCTAGCTACAACGA AAATATTT   4591       2740   UUCCAGAC G CGACAUUA   1566   TAATGTCG GGCTAGCTACAACGA GTCTGGAA   4592       2804   CACGUAGC G CCUCAUUU   1568   AAATGAGG GGCTAGCTACAACGA GCTACGTG   4593       2814   CUCAUUUU G CGGGUCAC   1569   GTGACCCG GGCTAGCTACAACGA AAAATGAG   4594       2946   UGGACCCU G CAUUCAAA   1572   TTTGAATG GGCTAGCTACAACGA AGGGTCCA   4595       2990   CUCAACCC G CACAAGGA   1573   TCCTTGTG GGCTAGCTACAACGA GGGTTGAG   4596       3012   GGCCGGAC G CCAACAAG   1574   CTTGTTGG GGCTAGCTACAACGA GTCCGGCC   4597       3090   GCCCUCAC G CUCAGGGC   1575   GCCCTGAG GGCTAGCTACAACGA GTGAGGGC   4598       3113   ACAACUGU G CCAGCAGC   1576   GCTGCTGG GGCTAGCTACAACGA ACAGTTGT   4599       3132   CUCCUCCU G CCUCCACC   1577   GGTGGAGG GGCTAGCTACAACGA AGGAGGAG   4600       51   AGGGCCCU G UACUUUCC   1578   GGAAAGTA GGCTAGCTACAACGA AGGGCCCT   4601       106   AGAAUACU G UCUCUGCC   1579   GGCAGAGA GGCTAGCTACAACGA AGTATTCT   4602       148   GGGACCCU G UACCGAAC   1580   GTTCGGTA GGCTAGCTACAACGA AGGGTCCC   4603       198   CUGCUCGU G UUACAGGC   1581   GCCTGTAA GGCTAGCTACAACGA ACGAGCAG   4604       219   UUUUUCUU G UUGACAAA   1582   TTTGTCAA GGCTAGCTACAACGA AAGAAAAA   4605       297   ACACCCGU G UGUCUUCG   1583   CCAAGACA GGCTAGCTACAACGA ACGGGTGT   4606       299   ACCCGUGU G UCUUGGCC   1584   GGCCAAGA GGCTAGCTACAACGA ACACGGGT   4607       347   ACCAACCU G UUGUCCUC   1585   GAGGACAA GGCTAGCTACAACGA AGGTTGGT   4608       350   AACCUGUU G UCCUCCAA   1586   TTGGAGGA GGCTAGCTACAACGA AACAGGTT   4609       362   UCCAAUUU G UCCUGGUU   1587   AACCAGGA GGCTAGCTACAACGA AAATTGGA   4610       381   CGCUGGAU G UGUCUGCG   1588   CGCAGACA GGCTAGCTACAACGA ATCCAGCG   4611       383   CUGGAUGU G UCUGCGGC   1589   GCCGCAGA GGCTAGCTACAACGA ACATCCAG   4612       438   AUCUUCUU G UUGGUUCU   1590   AGAACCAA GGCTAGCTACAACGA AAGAAGAT   4613       465   CAAGGUAU G UUGCCCGU   1591   ACGGGCAA GGCTAGCTACAACGA ATACCTTG   4614       476   GCCCGUUU G UCCUCUAA   1592   TTAGAGGA GGCTAGCTACAACGA AAACGGGC   4615       555   ACCUCUAU G UUUCCCUC   1593   GAGGGAAA GGCTAGCTACAACGA ATAGAGGT   4616       566   UCCCUCAU G UUGCUGUA   1594   TACAGCAA GGCTAGCTACAACGA ATGAGGGA   4617       572   AUGUUGCU G UACAAAAC   1595   GTTTTGTA GGCTAGCTACAACGA AGCAACAT   4618       602   CUGCACCU G UAUUCCCA   1596   TGGGAATA GGCTAGCTACAACGA AGGTGCAG   4619       694   UGCCAUUU G UUCAGUGG   1597   CCACTGAA GGCTAGCTACAACGA AAATGGCA   4620       724   CCCCCACU G UCUGGCUU   1598   AAGCCAGA GGCTAGCTACAACGA AGTGGGGG   4621       750   UGGAUGAU G UGGUUUUG   1599   CAAAACCA GGCTAGCTACAACGA ATCATCCA   4622       771   CCAAGUCU G UACAACAU   1600   ATGTTGTA GGCTAGCTACAACGA AGACTTGG   4623       801   AUGCCGCU G UUACCAAU   1601   ATTGGTAA GGCTAGCTACAACGA AGCGGCAT   4624       818   UUUCUUUU G UCUUUGGG   1602   CCCAAAGA GGCTAGCTACAACGA AAAAGAAA   4625       888   UGGGAUAU G UAAUUGGG   1603   CCCAATTA GGCTAGCTACAACGA ATATCCCA   4626       927   AACAUAUU G UACAAAAA   1604   TTTTTGTA GGCTAGCTACAACGA AATATGTT   4627       944   AUCAAAAU G UGUUUUAG   1605   CTAAAACA GGCTAGCTACAACGA ATTTTGAT   4628       946   CAAAAUGU G UUUUAGGA   1606   TCCTAAAA GGCTAGCTACAACGA ACATTTTG   4629       963   AACUUCCU G UAAACAGG   1607   CCTGTTTA GGCTAGCTACAACGA AGGAAGTT   4630       991   GAAAGUAU G UCAACGAA   1608   TTCGTTGA GGCTAGCTACAACGA ATACTTTC   4631       1002   AACGAAUU G UGGGUCUU   1609   AAGACCCA GGCTAGCTACAACGA AATTCGTT   4632       1039   CACGCAAU G UGGAUAUU   1610   AATATCCA GGCTAGCTACAACGA ATTGCGTG   4633       1137   AACAGUAU G UGAACCUU   1611   AAGGTTCA GGCTAGCTACAACGA ATACTGTT   4634       1184   UGCCAAGU G UUUGCUGA   1612   TCAGCAAA GGCTAGCTACAACGA ACTTGGCA   4635       1251   GAACCUUU G UGUCUCCU   1613   AGGAGACA GGCTAGCTACAACGA TAAGGTTC   4636       1253   ACCUUUGU G UCUCCUCU   1614   AGAGGAGA GGCTAGCTACAACGA ACAAAGGT   4637       1294   AGCCGCUU G UUUUGCUC   1615   GAGCAAAA GGCTAGCTACAACGA AAGCGGCT   4638       1344   ACAAUUCU G UCGUGCUC   1616   GAGCACGA GGCTAGCTACAACGA AGAATTGT   4639       1390   GCUAGGCU G UGCUGCCA   1617   TGGCAGCA GGCTAGCTACAACGA AGCCTAGC   4640       1425   CGUCCUUU G UUUACGUC   1618   GACGTAAA GGCTAGCTACAACGA AAAGGACG   4641       1508   CGCCUAUU G UACCGACC   1619   GGTCGGTA GGCTAGCTACAACGA AATAGGCG   4642       1557   CCCCGUCU G UGCCUUCU   1620   AGAAGGCA GGCTAGCTACAACGA AGACGGGG   4643       1581   CGGACCGU G UGCACUUC   1621   GAAGTGCA GGCTAGCTACAACGA ACCGTCCG   4644       1684   UCAGCAAU G UCAACGAC   1622   GTCGTTGA GGCTAGCTACAACGA ATTGCTGA   4645       1719   CAAAGACU G UGUGUUUA   1623   TAAACACA GGCTAGCTACAACGA AGTCTTTG   4646       1721   AAGACUGU G UGUUUAAU   1624   ATTAAACA GGCTAGCTACAACGA ACAGTCTT   4647       1723   GACUGUGU G UUUAAUGA   1625   TCATTAAA GGCTAGCTACAACGA ACACAGTC   4648       1772   AGGUCUUU G UACUAGGA   1626   TCCTAGTA GGCTAGCTACAACGA AAACACCT   4649       1785   AGGAGGCU G UAGGCAUA   1627   TATCCCTA GGCTAGCTACAACGA ACCCTCCT   4650       1801   AAAUUGGU G UGUUCACC   1628   GGTGAACA GGCTAGCTACAACGA ACCAATTT   4651       1803   AUUGGUGU G UUCACCAG   1629   CTGGTGAA GGCTAGCTACAACGA ACACCAAT   4652       1850   CAUCUCAU G UUCAUGUC   1630   GACATGAA GGCTAGCTACAACGA ATGAGATG   4653       1856   AUGUUCAU G UCCUACUG   1631   CAGTAGGA GGCTAGCTACAACGA ATGAACAT   4654       1864   GUCCUACU G UUCAAGCC   1632   GGCTTGAA GGCTAGCTACAACGA AGTAGGAC   4655       1881   UCCAAGCU G UGCCUUGG   1633   CCAAGGCA GGCTAGCTACAACGA AGCTTGGA   4656       1939   GAGCUUCU G UGGAGUUA   1634   TAACTCCA GGCTAGCTACAACGA AGAAGCTC   4657       2013   UCUGCUCU G UAUCGGGG   1635   CCCCGATA GGCTAGCTACAACGA AGAGCAGA   4658       2045   GGAACAUU G UUCACCUC   1636   GAGGTGAA GGCTAGCTACAACGA AATGTTCC   4659       2082   GCUAUUCU G UGUUGGGG   1637   CCCCAACA GGCTAGCTACAACGA AGAATAGC   4660       2084   UAUUCUGU G UUGGGGUG   1638   CACCCCAA GGCTAGCTACAACGA ACAGAATA   4661       2167   UCAGCUAU G UCAACGUU   1639   AACGTTGA GGCTAGCTACAACGA ATAGCTGA   4662       2205   CAACUAUU G UGGUCUCA   1640   TGAAACCA GGCTAGCTACAACGA AATAGTTG   4663       2222   CAUUUCCU G UCUUACUU   1641   AAGTAAGA GGCTAGCTACAACGA AGGAAATG   4664       2245   GAGAAACU G UUCUUGAA   1642   TTCAAGAA GGCTAGCTACAACGA AGTTTCTC   4665       2262   UAUUUGGU G UCUUUUGG   1643   CCAAAAGA GGCTAGCTACAACGA ACCAAATA   4666       2274   UUUGGAGU G UGGAUUCG   1644   CGAATCCA GGCTAGCTACAACGA ACTCCAAA   4667       2344   AAACUACU G UUGUUAGA   1645   TCTAACAA GGCTAGCTACAACGA AGTAGTTT   4668       2347   CUACUGUU G UUAGACGA   1646   TCGTCTAA GGCTAGCTACAACGA AACAGTAG   4669       2450   AUCUCAAU G UUAGUAUU   1647   AATACTAA GGCTAGCTACAACGA ATTGAGAT   4670       2573   AGGACAUC G UUGAUAGA   1648   TCTATCAA GGCTAGCTACAACGA AATGTCCT   4671       2583   UGAUAGAU G UAAGCAAU   1649   ATTGCTTA GGCTAGCTACAACGA ATCTATCA   4672       2594   AGCAAUUU G UGGGGCCC   1650   GGGCCCCA GGCTAGCTACAACGA AAATTGCT   4673       2663   AUCCCAAU G UUACUAAA   1651   TTATGTAA GGCTAGCTACAACGA ATTGGGAT   4674       2717   CAGAGUAU G UAGUUAAU   1652   ATTAACTA GGCTAGCTACAACGA ATACTCTG   4675       2901   AUCUUUCU G UCCCCAAU   1653   ATTGGGGA GGCTAGCTACAACGA AGAAAGAT   4676       3071   GGGGGACU G UUGFGGUG   1654   CACCCCAA GGCTAGCTACAACGA AGTCCCCC   4677       3111   UCACAACU G UGCCAGCA   1655   TGCTGGCA GGCTAGCTACAACGA AGTTGTGA   4678       40   AUCCCAGA G UCAGGGCC   1656   GGCCCTGA GGCTAGCTACAACGA TCTGGGAT   4679       46   GAGUCAGG G CCCUGUAC   1657   GTACAGGG GGCTAGCTACAACGA CCTGACTC   4680       65   UCCUGCUG G UGGCUCCA   1658   TGGAGCCA GGCTAGCTACAACGA CAGCAGGA   4681       68   UGCUGGUG G CUCCAGUU   1659   AACTGGAG GGCTAGCTACAACGA CACCAGCA   4682       74   UGGCUCCA G UUCAGGAA   1660   TTCCTGAA GGCTAGCTACAACGA TGGAGCCA   4683       85   CAGGAACA G UGAGCCCU   1661   AGGGCTCA GGCTAGCTACAACGA TGTTCCTG   4684       89   AACAGUGA G CCCUGCUC   1662   GAGCAGGG GGCTAGCTACAACGA TCACTGTT   4685       120   GCCAUAUC G UCAAUCUU   1663   AAGATTGA GGCTAGCTACAACGA GATATGGC   4686       196   CCCUGCUC G UGUUACAG   1664   CTGTAACA GGCTAGCTACAACGA GAGCAGGG   4687       205   UGUUACAG G CGGGGUUU   1665   AAACCCCG GGCTAGCTACAACGA CTGTAACA   4688       210   CAGGCGGG G UUUUUCUU   1666   AAGAAAAA GGCTAGCTACAACGA CCCGCCTG   4689       248   ACCACAGA G UCUAGACU   1667   AGTCTAGA GGCTAGCTACAACGA TCTGTGGT   4690       258   CUAGACUC G UGGUGGAC   1668   GTCCACCA GGCTAGCTACAACGA GAGTCTAG   4691       261   GACUCGUG G UGGACUUC   1669   GAAGTCCA GGCTAGCTACAACGA CACGAGTC   4692       295   GAACACCC G UGUGUCUU   1670   AAGACACA GGCTAGCTACAACGA GGGTGTTC   4693       305   GUGUCUUG G CCAAAAUU   1671   AATTTTGG GGCTAGCTACAACGA CAAGACAC   4694       318   AAUUCGCA G UCCCAAAU   1672   ATTTGGGA GGCTAGCTACAACGA TGCGAATT   4695       332   AAUCUCCA G UCACUCAC   1673   GTGAGTGA GGCTAGCTACAACGA TGGAGATT   4696       368   UUGUCCUG G UUAUCGCU   1674   AGCGATAA GGCTAGCTACAACGA CAGGACAA   4697       390   UGUCUGCG G CGUUUUAU   1675   ATAAAACG GGCTAGCTACAACGA CGCAGACA   4698       392   UCUGCGGC G UUUUAUCA   1676   TGATAAAA GGCTAGCTACAACGA GCCGCAGA   4699       442   UCUUGUUG G UUCUUCUG   1677   CAGAAGAA GGCTAGCTACAACGA CAACAAGA   4700       461   CUAUCAAG G UAUGUUGC   1678   GCAACATA GGCTAGCTACAACGA CTTGATAG   4701       472   UGUUGCCC G UUUGUCCU   1679   AGGACAAA GGCTAGCTACAACGA GGGCAACA   4702       506   AACAACCA G CACCGGAC   1680   GTCCGGTG GGCTAGCTACAACGA TGGTTGTT   4703       625   CAUCUUGG G CUUUCGCA   1681   TGCGAAAG GGCTAGCTACAACGA CCAAGATG   4704       648   CUAUGGGA G UGGGCCUC   1682   GAGGCCCA GGCTAGCTACAACGA TCCCATAG   4705       652   GGGAGUGG G CCUCAGUC   1683   GACTGAGG GGCTAGCTACAACGA CCACTCCC   4706       658   GGGCCUCA G UCCGUUUC   1684   GAAACGGA GGCTAGCTACAACGA TGAGGCCC   4707       662   CUCAGUCC G UUUCUCUU   1685   AAGAGAAA GGCTAGCTACAACGA GGACTGAG   4708       672   UUCUCUUG G CUCAGUUU   1686   AAACTGAG GGCTAGCTACAACGA CAAGAGAA   4709       677   UUGGCUCA G UUUACUAG   1687   CTAGTAAA GGCTAGCTACAACGA TGAGCCAA   4710       685   GUUUACUA G UGCCAUUU   1688   AAATGGCA GGCTAGCTACAACGA TAGTAAAC   4711       699   UUUGUUCA G UGGUUCGU   1689   ACGAACCA GGCTAGCTACAACGA TGAACAAA   4712       702   GUUCAGUG G UUCGUAGG   1690   CCTACGAA GGCTAGCTACAACGA CACTGAAC   4713       706   AGUGGUUC G UAGGGCUU   1691   AAGCCCTA GGCTAGCTACAACGA GAACCACT   4714       711   UUCGUAGG G CUUUCCCC   1692   GGGGAAAG GGCTAGCTACAACGA CCTACGAA   4715       729   ACUGUCUG G CUUUCAGU   1693   ACTGAAAG GGCTAGCTACAACGA CAGACAGT   4716       736   GGCUUUCA G UUAUAUGG   1694   CCATATAA GGCTAGCTACAACGA TGAAAGCC   4717       753   AUGAUGUG G UUUUGGGG   1695   CCCCAAAA GGCTAGCTACAACGA CACATCAT   4718       762   UUUUGGGG G CCAAGUCU   1696   AGACTTGG GGCTAGCTACAACGA CCCCAAAA   4719       767   GGGGCCAA G UCUGUACA   1697   TGTACAGA GGCTAGCTACAACGA TTGGCCCC   4720       785   CAUCUUGA G UCCCUUUA   1698   TAAAGGGA GGCTAGCTACAACGA TCAAGATG   4721       826   GUCUUUGG G UAUACAUU   1699   AATGTATA GGCTAGCTACAACGA CCAAAGAC   4722       898   AAUUGGGA G UUGGGGCA   1700   TGCCCCAA GGCTAGCTACAACGA TCCCAATT   4723       904   GAGUUGGG G CACAUUGC   1701   GCAATGTC GGCTAGCTACAACGA CCCAACTC   4724       971   GUAAACAG G CCUAUUGA   1702   TCAATAGG GGCTAGCTACAACGA CTGTTTAC   4725       987   AUUGGAAA G UAUGUCAA   1703   TTGACATA GGCTAGCTACAACGA TTTCCAAT   4726       1006   AAUUGUGG G UCUUUUGG   1704   CCAAAAGA GGCTAGCTACAACGA CCACAATT   4727       1016   CUUUUGGG G UUUGCCGC   1705   GCGGCAAA GGCTAGCTACAACGA CCCAAAAG   4728       1080   GCAUACAA G CAAAACAG   1706   CTGTTTTG GGCTAGCTACAACGA TTGTATGC   4729       1089   CAAAACAG G CUUUUACU   1707   AGTAAAAG GGCTAGCTACAACGA CTGTTTTG   4730       1116   CUUACAAG G CCUUUCUA   1708   TAGAAAGG GGCTAGCTACAACGA CTTGTAAG   4731       1126   CUUUCUAA G UAAACAGU   1709   ACTGTTTA GGCTAGCTACAACGA TTAGAAAG   4732       1133   AGUAAACA G UAUGUGAA   1710   TTCACATA GGCTAGCTACAACGA TGTTTACT   4733       1152   UUUACCCC G UUGCUCGG   1711   CCGAGCAA GGCTAGCTACAACGA GGGGTAAA   4734       1160   GUUGCUCG G CAACGGCC   1712   GGCCGTTG GGCTAGCTACAACGA CGAGCAAC   4735       1166   CGGCAACG G CCUGGUCU   1713   AGACCAGG GGCTAGCTACAACGA CGTTGCCG   4736       1171   ACGGCCUG G UCUAUGCC   1714   GGCATAGA GGCTAGCTACAACGA CAGGCCGT   4737       1182   UAUGCCAA G UGUUUGCU   1715   AGCAAACA GGCTAGCTACAACGA TTGGCATA   4738       1207   CCCCACUG G UUGGGGCU   1716   AGCCCCAA GGCTAGCTACAACGA CAGTGGGG   4739       1213   UGGUUGGG G CUUGGCCA   1717   TGGCCAAG GGCTAGCTACAACGA CCCAACCA   4740       1218   GGGGCUUG G CCAUAGGC   1718   GCCTATGG GGCTAGCTACAACGA CAAGCCCC   4741       1225   GGCCAUAG G CCAUCAGC   1719   GCTGATGG GGCTAGCTACAACGA CTATGGCC   4742       1232   GGCCAUCA G CGCAUGCG   1720   CGCATGCG GGCTAGCTACAACGA TGATGGCC   4743       1240   GCGCAUGC G UGGAACCU   1721   AGGTTCCA GGCTAGCTACAACGA GCATGCGC   4744       1287   AACUCCUA G CCGCUUGU   1722   ACAAGCGG GGCTAGCTACAACGA TAGGAGTT   4745       1306   UGCUCGCA G CAGGUCUG   1723   CAGACCTG GGCTAGCTACAACGA TGCGAGCA   4746       1310   CGCAGCAG G UCUGGGGC   1724   GCCCCAGA GGCTAGCTACAACGA CTGCTGCG   4747       1317   CGUCUGGG G CAAAACUC   1725   GAGTTTTG GGCTAGCTACAACGA CCCAGACC   4748       1347   AUUCUGUC G UGCUCUCC   1726   GGAGAGCA GGCTAGCTACAACGA GACAGAAT   4749       1379   UUUCCAUG G CUGCUAGG   1727   CCTAGCAG GGCTAGCTACAACGA CATGGAAA   4750       1387   GCUGCUAG G CUGUGCUG   1728   CAGCACAG GGCTAGCTACAACGA CTAGCAGC   4751       1418   CGCGGGAC G UCCUUUGU   1729   ACAAAGGA GGCTAGCTACAACGA GTCCCGCG   4752       1431   UUGUUUAC G UCCCGUCG   1730   CGACGGGA GGCTAGCTACAACGA GTAAACAA   4753       1436   UACGUCCC G UCGGCGCU   1731   AGCGCCGA GGCTAGCTACAACGA GGGACGTA   4754       1440   UCCCGUCG G CGCUGAAU   1732   ATTCAGCG GGCTAGCTACAACGA CGACGGGA   4755       1471   CUCCCGGG G CCGCUUGG   1733   CCAAGCGG GGCTAGCTACAACGA CCCGGGAG   4756       1481   CGCUUGGG G CUCUACCG   1734   CGGTAGAG GGCTAGCTACAACGA CCCAAGCG   4757       1517   UACCGACC G UCCACGGG   1735   CCCGTGGA GGCTAGCTACAACGA GGTCGGTA   4758       1526   UCCACGGG G CGCACCUC   1736   GACGTGCG GGCTAGCTACAACGA CCCGTGGA   4759       1553   GACUCCCC G UCUGUGCC   1737   GGCACAGA GGCTAGCTACAACGA GGGGAGTC   4760       1579   GCCGGACC G UGUGCACU   1738   AGTGCACA GGCTAGCTACAACGA GGTCCGGC   4761       1605   CUCUGCAC G UCGCAUGG   1739   CCATGCGA GGCTAGCTACAACGA GTGCAGAG   4762       1622   AGACCACC G UGAACGCC   1740   GGCGTTCA GGCTAGCTACAACGA GGTGGTCT   4763       1649   UGCCCAAG G UCUUGCAU   1741   ATGCAAGA GGCTAGCTACAACGA CTTGGGCA   4764       1679   GACUUUCA G CAAUGUCA   1742   TGACATTG GGCTAGCTACAACGA TGAAAGTC   4765       1703   ACCUUGAG G CAUACUUC   1743   GAAGTATG GGCTAGCTACAACGA CTCAAGGT   4766       1732   UUUAAUGA G UGGGAGGA   1744   TCCTCCCA GGCTAGCTACAACGA TCATTAAA   4767       1741   UGGGAGGA G GUGGGGGA   1745   TCCCCCAA GGCTAGCTACAACGA TCCTCCCA   4768       1754   GGGAGGAG G UUAGGUUA   1746   TAACCTAA GGCTAGCTACAACGA CTCCTCCC   4769       1759   GAGGUUAG G UUAAAGGU   1747   ACCTTTAA GGCTAGCTACAACGA CTAACCTC   4770       1766   GGUUAAAG G UCUUUGUA   1748   TACAAAGA GGCTAGCTACAACGA CTTTAACC   4771       1782   ACUAGGAG G CUGUAGGC   1749   GCCTACAG GGCTAGCTACAACGA CTCCTAGT   4772       1789   GCCUCUAG G CAUAAAUU   1750   AATTTATG GGCTAGCTACAACGA CTACAGCC   4773       1799   AUAAAUUG G UGUGUUCA   1751   TGAACACA GGCTAGCTACAACGA CAATTTAT   4774       1811   GUUCACCA G CACCAUGC   1752   GCATGGTG GGCTAGCTACAACGA TGGTGAAC   4775       1870   CUGUUCAA G CCUCCAAG   1753   CTTGGAGG GGCTAGCTACAACGA TTGAACAG   4776       1878   GCCUCCAA G CUGUGCCU   1754   AGGCACAG GGCTAGCTACAACGA TTGGAGGC   4777       1890   UGCCUUGG G UGGCUUUG   1755   CAAAGCCA GGCTAGCTACAACGA CCAAGGCA   4778       1893   CUUGGGUG G CUUUGGGG   1756   CCCCAAAG GGCTAGCTACAACGA CACCCAAG   4779       1901   GCUUUGGG G CAUGGACA   1757   TGTCCATG GGCTAGCTACAACGA CCCAAAGC   4780       1917   AUUGACCC G UAUAAAGA   1758   TCTTTATA GGCTAGCTACAACGA GGGTCAAT   4781       1933   AAUUUGGA G CUUCUGUG   1759   CACAGAAG GGCTAGCTACAACGA TCCAAATT   4782       1944   UCUGUGGA G GUACUCUC   1760   GAGAGTAA GGCTAGCTACAACGA TCCACAGA   4783       2023   AUCGGGGG G CCUUAGAG   1761   CTCTAAGG GGCTAGCTACAACGA CCCCCGAT   4784       2031   GCCUUAGA G UCUCCGGA   1762   TCCGGAGA GGCTAGCTACAACGA TCTAAGGC   4785       2062   ACCAUACG G CACUCAGG   1763   CCTGAGTG GGCTAGCTACAACGA CGTATGGT   4786       2070   GCACUCAG G CAAGCUAU   1764   ATAGCTTG GGCTAGCTACAACGA CTGAGTGC   4787       2074   UCAGGCAA G CUAUUCUG   1765   CAGAATAG GGCTAGCTACAACGA TTGCCTGA   4788       2090   GUGUUGGG G UGAGUUGA   1766   TCAACTCA GGCTAGCTACAACGA CCCAACAC   4789       2094   UGGGGUGA G UUGAUGAA   1767   TTCATCAA GGCTAGCTACAACGA TCACCCCA   4790       2107   UGAAUCUA G CCACCUGG   1768   CCAGGTGG GGCTAGCTACAACGA TAGATTCA   4791       2116   CCACCUGG G UGGGAAGU   1769   ACTTCCCA GGCTAGCTACAACGA CCAGGTGG   4792       2123   GGUGGGAA G UAAUUUGG   1770   CCAAATTA GGCTAGCTACAACGA TTCCCACC   4793       2140   AAGAUCCA G CAUCCAGG   1771   CCTGGATG GGCTAGCTACAACGA TGGATCTT   4794       2155   GGGAAUUA G UAGUCAGC   1772   GCTGACTA GGCTAGCTACAACGA TAATTCCC   4795       2158   AAUUAGUA G UCAGCUAU   1773   ATAGCTGA GGCTAGCTACAACGA TACTAATT   4796       2162   AGUAGUCA G CUAUGUCA   1774   TGACATAG GGCTAGCTACAACGA TGACTACT   4797       2173   AUGUCAAC G UUAAUAUG   1775   CATATTAA GGCTAGCTACAACGA GTTGACAT   4798       2183   UAAUAUGG G CCUAAAAA   1776   TTTTTAGG GGCTAGCTACAACGA CCATATTA   4799       2208   CUAUUGUG G UUUCACAU   1777   ATGTGAAA GGCTAGCTACAACGA CACAATAG   4800       2235   ACUUUUGG G CGAGAAAC   1778   GTTTCTCG GGCTAGCTACAACGA CCAAAAGT   4801       2260   AAUAUUUG G UGUCUUUU   1779   AAAAGACA GGCTAGCTACAACGA CAAATATT   4802       2272   CUUUUGGA G UGUGGAUU   1780   AATCCACA GGCTAGCTACAACGA TCCAAAAG   4803       2360   ACGAAGAG G CAGGUCCC   1781   GGGACCTG GGCTAGCTACAACGA CTCTTCGT   4804       2364   AGAGGCAG G UCCCCUAG   1782   CTAGGGGA GGCTAGCTACAACGA CTGCCTCT   4805       2403   AGACGAAG G UCUCAAUC   1783   GATTGAGA GGCTAGCTACAACGA CTTCGTCT   4806       2417   AUCGCCGC G UCGCAGAA   1784   TTCTGCGA GGCTAGCTACAACGA GCGGCGAT   4807       2454   CAAUGUUA G UAUUCCUU   1785   AAGGAATA GGCTAGCTACAACGA TAACATTG   4808       2474   CACAUAAG G UGGGAAAC   1786   GTTTCCCA GGCTAGCTACAACGA CTTATGTG   4809       2491   UUUACGGG G CUUUAUUC   1787   GAATAAAG GGCTAGCTACAACGA CCCGTAAA   4810       2507   CUUCUACG G UACCUUGC   1788   GCAAGGTA GGCTAGCTACAACGA CGTAGAAG   4811       2530   CCUAAAUG G CAAACUCC   1789   GGAGTTTG GGCTAGCTACAACGA CATTTAGG   4812       2587   AGAUGUAA G CAAUUUGU   1790   ACAAATTG GGCTAGCTACAACGA TTACATCT   4813       2599   UUUGUGGG G CCCCUUAC   1791   GTAAGGGG GGCTAGCTACAACGA CCCACAAA   4814       2609   CCCUUACA G UAAAUGAA   1792   TTCATTTA GGCTAGCTACAACGA TGTAAGGG   4815       2650   CCUGCUAG G UUUUAUCC   1793   GGATAAAA GGCTAGCTACAACGA CTAGCAGG   4816       2701   AUCAAACC G UAUUAUCC   1794   GGATAATA GGCTAGCTACAACGA GGTTTGAT   4817       2713   UAUCCAGA G UAUGUAGU   1795   ACTACATA GGCTAGCTACAACGA TCTGGATA   4818       2720   AGUAUGUA G UUAAUCAU   1796   ATGATTAA GGCTAGCTACAACGA TACATACT   4819       2768   UUUGGAAG G CGGGGAUC   1797   GATCCCCG GGCTAGCTACAACGA CTTCCAAA   4820       2791   AAAAGAGA G UCCACACG   1798   CGTGTGGA GGCTAGCTACAACGA TCTCTTTT   4821       2799   GUCCACAC G UAGCGCCU   1799   AGGCGCTA GGCTAGCTACAACGA GTGTGGAC   4822       2802   CACACGUA G CGCCUCAU   1800   ATGAGGCG GGCTAGCTACAACGA TACGTGTC   4823       2818   UUUUGCGG G UCACCAUA   1801   TATGGTGA GGCTAGCTACAACGA CCGCAAAA   4824       2848   GAUCUACA G CAUGGGAG   1802   CTCCCATG GGCTAGCTACAACGA TGTAGATC   4825       2857   CAUGGGAG G UUGGUCUU   A803   AAGACCAA GGCTAGCTACAACGA CTCCCATG   4826       2861   GGAGGUUG G UCUUCCAA   1804   TTGGAAGA GGCTAGCTACAACGA CAACCTCC   4827       2881   UCGAAAAG G CAUGGGGA   1805   TCCCCATG GGCTAGCTACAACGA CTTTTCGA   4828       2936   GAUCAUCA G UUGGACCC   1806   GGGTCCAA GGCTAGCTACAACGA TGATGATC   4829       2955   CAUUCAAA G CCAACUCA   1807   TGAGTTGG GGCTAGCTACAACGA TTTGAATG   4830       2964   CCAACUCA G UAAAUCCA   1808   TGGATTTA GGCTAGCTACAACGA TGAGTTGG   4831       3005   GACAACUG G CCGGACGC   1809   GCGTCCGG GGCTAGCTACAACGA CAGTTGTC   4832       3021   CCAACAAG G UGGGAGUG   1810   CACTCCCA GGCTAGCTACAACGA CTTGTTGG   4833       3027   AGGUGGGA G UGGGAGCA   1811   TGCTCCCA GGCTAGCTACAACGA TCCCACCT   4834       3033   GAGUGGGA G CAUUCGGG   1812   CCCGAATG GGCTAGCTACAACGA TCCCACTC   4835       3041   GCAUUCGG G CCAGGGUU   1813   AACCCTGG GGCTAGCTACAACGA CCGAATGC   4836       3047   GGGCCAGG G UUCACCCC   1814   GGGGTGAA GGCTAGCTACAACGA CCTGGCCC   4837       3077   CUGUUGGG G UGGAGCCC   1815   GGGCTCCA GGCTAGCTACAACGA CCCAACAG   4838       3082   GGGGUGGA G CCCUCACG   1816   CGTGAGGG GGCTAGCTACAACGA TCCACCCC   4839       3097   CGCUCAGG G CCUACUCA   1817   TGAGTAGG GGCTAGCTACAACGA CCTGAGCG   4840       3117   CUGUGCCA G CAGCUCCU   1818   AGGAGCTG GGCTAGCTACAACGA TGGCACAG   4841       3120   UGCCAGCA G CUCCUCCU   1819   AGGAGGAG GGCTAGCTACAACGA TGCTGGCA   4842       3146   ACCAAUCG G CAGUCAGG   1820   CCTGACTG GGCTAGCTACAACGA CGATTGGT   4843       3149   AAUCGGCA G UCAGGAAG   1821   CTTCCTGA GGCTAGCTACAACGA TGCCGATT   4844       3158   UCAGGAAG G CAGCCUAC   1822   GTAGGCTG GGCTAGCTACAACGA CTTCCTGA   4845       3161   GGAAGGCA G CCUACUCC   1823   GGAGTAGG GGCTAGCTACAACGA TGCCTTCC   4846       3204   AUCCUCAG G CCAUGCAG   1824   CTGCATGG GGCTAGCTACAACGA CTGAGGAT   4847       10   ACUCCACC A CUUUCCAC   1825   GTGGAAAG GGCTAGCTACAACGA GGTGGAGT   4848       17   CACUUUCC A CCAAACUC   1826   GAGTTTGG GGCTAGCTACAACGA GGAAAGTG   4849       22   UCCACCAA A CUCUUCAA   1827   TTGAAGAG GGCTAGCTACAACGA TTGGTGGA   4850       32   UCUUCAAG A UCCCAGAG   1828   CTCTGGGA GGCTAGCTACAACGA CTTGAAGA   4851       53   GGCCCUGU A CUUUCCUG   1829   CAGGAAAG GGCTAGCTACAACGA ACAGGGCC   4852       82   GUUCAGGA A CAGUGAGC   1830   GCTCACTG GGCTAGCTACAACGA TCCTGAAC   4853       101   UGCUCAGA A UACUGUCU   1831   ACACAGTA GGCTAGCTACAACGA TCTGAGCA   4854       103   CUGAGAAU A CUGUCUCU   1832   AGAGACAG GGCTAGCTACAACGA ATTCTGAG   4855       115   UCUCUGCC A UAUCGUCA   1833   TGACGATA GGCTAGCTACAACGA GGCAGAGA   4856       117   UCUGCCAU A UCGUCAAU   1834   ATTGACGA GGCTAGCTACAACGA ATGGCAGA   4857       124   UAUCGUCA A UCUUAUCG   1835   CGATAAGA GGCTAGCTACAACGA TGACGATA   4858       129   UCAAUCUU A UCGAAGAC   1836   GTCTTCGA GGCTAGCTACAACGA AAGATTGA   4859       136   UAUCGAAG A CUGGGGAC   1837   GTCCCCAG GGCTAGCTACAACGA CTTCGATA   4860       143   GACUGGGG A CCCUGUAC   1838   GTACAGGG GGCTAGCTACAACGA CCCCAGTC   4861       150   GACCCUGU A CCGAACAU   1839   ATGTTCGG GGCTAGCTACAACGA ACAGGGTC   4862       155   UGUACCGA A CAUGGAGA   1840   TCTCCATG GGCTAGCTACAACGA TCGGTACA   4863       157   UACCGAAC A UGGAGAAC   1841   GTTCTCCA GGCTAGCTACAACGA GTTCGGTA   4864       164   CAUGGAGA A CAUCGCAU   1842   ATGCGATG GGCTAGCTACAACGA TCTCCATG   4865       166   UGGAGAAC A UCGCAUCA   1843   TGATGCGA GGCTAGCTACAACGA GTTCTCCA   4866       171   AACAUCGC A UCAGGACU   1844   AGTCCTGA GGCTAGCTACAACGA GCGATGTT   4867       177   GCAUCAGG A CUCCUAGG   1845   CCTAGGAG GGCTAGCTACAACGA CCTGATGC   4868       186   CUCCUAGG A CCCCUGCU   1846   AGCAGGGG GGCTAGCTACAACGA CCTAGGAG   4869       201   CUCGUGUU A CAGGCGGG   1847   CCCGCCTG GGCTAGCTACAACGA AACACGAG   4870       223   UCUUGUUG A CAAAAAUC   1848   GATTTTTG GGCTAGCTACAACGA CAACAAGA   4871       229   UGACAAAA A UCCUCACA   1849   TGTGAGGA GGCTAGCTACAACGA TTTTGTCA   4872       235   AAAUCCUC A CAAUACCA   1850   TGGTATTG GGCTAGCTACAACGA GAGGATTT   4873       238   UCCUCACA A UACCACAG   1851   CTGTGGTA GGCTAGCTACAACGA TGTGAGGA   4874       240   CUCACAAU A CCACAGAG   1852   CTCTGTGG GGCTAGCTACAACGA ATTGTGAG   4875       243   ACAAUACC A CAGAGUCU   1853   AGACTCTG GGCTAGCTACAACGA GGTATTGT   4876       254   GAGUCUAG A CUCGUGGU   1854   ACCACGAG GGCTAGCTACAACGA CTAGACTC   4877       265   CGUGGUGG A CUUCUCUC   1855   GAGAGAAG GGCTAGCTACAACGA CCACCACG   4878       275   GUCUCUCA A UUUUCUAG   1856   CTAGAAAA GGCTAGCTACAACGA TGAGAGAA   4879       289   UAGGGGGA A CACCCGUG   1857   CACGGGTG GGCTAGCTACAACGA TCCCCCTA   4880       291   GGGGGAAC A CCCGUGUG   1858   CACACGGG GGCTAGCTACAACGA GTTCCCCC   4881       311   UGGCCAAA A UUCGCAGU   1859   ACTGCGAA GGCTAGCTACAACGA TTTGGCCA   4882       325   AGUCCCAA A UCUCCAGU   1860   ACTGGAGA GGCTAGCTACAACGA TTGGGACT   4883       335   CUCCAGUC A CUCACCAA   1861   TTGGTGAG GGCTAGCTACAACGA GACTGGAG   4884       339   AGUCACUC A CCAACCUG   1862   CAGGTTGG GGCTAGCTACAACGA GAGTGACT   4885       343   ACUCACCA A CCUGUUGU   1863   ACAACAGG GGCTAGCTACAACGA TGGTGAGT   4886       358   GUCCUCCA A UUUGUCCU   1864   AGGACAAA GGCTAGCTACAACGA TGGAGGAC   4887       371   UCCUGGUU A UCGCUGGA   1865   TCCAGCGA GGCTAGCTACAACGA AACCAGGA   4888       379   AUCGCUGG A UGUGUCUG   1866   CAGACACA GGCTAGCTACAACGA CCAGCGAT   4889       397   GGCGUUUU A UCAUCUUC   1867   GAAGATGA GGCTAGCTACAACGA AAAACGCC   4890       400   GUUUUAUC A UCUUCCUC   1868   GAGGAAGA GGCTAGCTACAACGA GATAAAAC   4891       412   UCCUCUGC A UCCUGCUG   1869   CAGCAGGA GGCTAGCTACAACGA GCAGAGGA   4892       423   CUGCUGCU A UGCCUCAU   1870   ATGAGGCA GGCTAGCTACAACGA AGCAGCAG   4893       430   UAUGCCUC A UCUUCUUG   1871   CAAGAAGA GGCTAGCTACAACGA GAGGCATA   4894       452   UCUUCUGG A CUAUCAAG   1872   CTTGATAG GGCTAGCTACAACGA CCAGAAGA   4895       455   UCUGGACU A UCAAGGUA   1873   TACCTTGA GGCTAGCTACAACGA AGTCCAGA   4896       463   AUCAAGGU A UGUUGCCC   1874   GGGCAACA GGCTAGCTACAACGA ACCTTGAT   4897       484   GUCCUCUA A UUCCAGGA   1875   TCCTGGAA GGCTAGCTACAACGA TAGAGGAC   4898       492   AUUCCAGG A UCAUCAAC   1876   GTTGATGA GGCTAGCTACAACGA CCTGGAAT   4899       495   CCAGGAUC A UCAACAAC   1877   GTTGTTGA GGCTAGCTACAACGA GATCCTGG   4900       499   GAUCAUCA A CAACCAGC   1878   GCTGGTTG GGCTAGCTACAACGA TGATGATC   4901       502   CAUCAACA A CCAGCACC   1879   GGTGCTGG GGCTAGCTACAACGA TGTTGATG   4902       513   AGCACCGG A CCAUGCAA   1880   TTGCATGG GGCTAGCTACAACGA CCGGTGCT   4903       516   ACCGGACC A UGCAAAAC   1881   GTTTTGCA GGCTAGCTACAACGA GGTCCGGT   4904       523   CAUGCAAA A CCUGCACA   1882   TGTGCAGG GGCTAGCTACAACGA TTTGCATG   4905       529   AAACCUGC A CAACUCCU   1883   AGGAGTTG GGCTAGCTACAACGA GCAGGTTT   4906       532   CCUGCACA A CUCCUGCU   1884   AGCAGGAG GGCTAGCTACAACGA TGTGCAGG   4907       547   CUCAAGGA A CCUCUAUG   1885   CATAGAGG GGCTAGCTACAACGA TCCTTGAG   4908       553   GAACCUCU A UGUUUCCC   1886   GGGAAACA GGCTAGCTACAACGA AGAGGTTC   4909       564   UUUCCCUC A UGUUGCUG   1887   CAGCAACA GGCTAGCTACAACGA GAGGGAAA   4910       574   GUUGCUGU A CAAAACCU   1888   AGGTTTTG GGCTAGCTACAACGA ACAGCAAC   4911       579   UGUACAAA A CCUACGGA   1889   TCCGTAGG GGCTAGCTACAACGA TTTGTACA   4912       583   CAAAACCU A CGGACGGA   1890   TCCGTCCG GGCTAGCTACAACGA AGGTTTTG   4913       587   ACCUACGG A CGGAAACU   1891   AGTTTCCG GGCTAGCTACAACGA CCGTAGGT   4914       593   GGACGGAA A CUGCACCU   1892   ACGTGCAG GGCTAGCTACAACGA TTCCGTCC   4915       598   GAAACUGC A CCUGUAUU   1893   AATACAGG GGCTAGCTACAACGA GCAGTTTC   4916       604   GCACCUGU A UUCCCAUC   1894   GATGGGAA GGCTAGCTACAACGA ACAGGTGC   4917       610   GUAUUCCC A UCCCAUCA   1895   TGATGGGA GGCTAGCTACAACGA GGGAATAC   4918       615   CCCAUCCC A UCAUCUUG   1896   CAAGATGA GGCTAGCTACAACGA GGGATGGG   4919       618   AUCCCAUC A UCUUGGGC   1897   GCCCAAGA GGCTAGCTACAACGA GATGGGAT   4920       636   UUCGCAAA A UACCUAUG   1898   CATAGGTA GGCTAGCTACAACGA TTTGCGAA   4921       638   CGCAAAAU A CCUAUGGG   1899   CCCATAGG GGCTAGCTACAACGA ATTTTGCG   4922       642   AAAUACCU A UGGGAGUG   1900   CACTCCCA GGCTAGCTACAACGA AGGTATTT   4923       681   CUCAGUUU A CUAGUGCC   1901   GGCACTAG GGCTAGCTACAACGA AAACTTAG   4924       690   CUAGUGCC A UUUGUUCA   1902   TGAACAAA GGCTAGCTACAACGA GGCACTAG   4925       721   UUUCCCCC A CUGUCUGG   1903   CCAGACAG GGCTAGCTACAACGA GGGGGAAA   4926       739   UUUCAGUU A UAUGGAUG   1904   CATCCATA GGCTAGCTACAACGA AACTGAAA   4927       741   UCAGUUAU A UGGAUGAU   1905   ATCATCCA GGCTAGCTACAACGA ATAACTGA   4928       745   UUAUAUGG A UGAUGUGG   1906   CCACATCA GGCTAGCTACAACGA CCATATAA   4929       748   UAUGGAUG A UGUGGUUU   1907   AAACCACA GGCTAGCTACAACGA CATCCATA   4930       773   AAGUCUGU A CAACAUCU   1908   AGATGTTG GGCTAGCTACAACGA ACAGACTT   4931       776   UCUGUACA A CAUCUUGA   1909   TCAAGATG GGCTAGCTACAACGA TGTACAGA   4932       778   UGUACAAC A UCUUGAGU   1910   ACTCAAGA GGCTAGCTACAACGA GTTGTACA   4933       793   GUCCCUUU A UGCCGCUG   1911   CAGCGGCA GGCTAGCTACAACGA AAAGGGAC   4934       804   CCGCUGUU A CCAAUUUU   1912   AAAATTGG GGCTAGCTACAACGA AACAGCGG   4935       808   UGUUACCA A UUUUCUUU   1913   AAAGAAAA GGCTAGCTACAACGA TGGTAACA   4936       828   CUUUGGGU A UACAUUUA   1914   TAAATGTA GGCTAGCTACAACGA ACCCAAAG   4937       830   UUGGGUAU A CAUUUAAA   1915   TTTAAATG GGCTAGCTACAACGA ATACCCAA   4938       832   GGGUAUAC A UUUAAACC   1916   GGTTTAAA GGCTAGCTACAACGA GTATACCC   4939       838   ACAUUUAA A CCCUCACA   1917   TGTGAGGG GGCTAGCTACAACGA TTAAATGT   4940       844   AAACCCUC A CAAAACAA   1918   TTGTTTTG GGCTAGCTACAACGA GAGGGTTT   4941       849   CUCACAAA A CAAAAAGA   1919   TCTTTTTG GGCTAGCTACAACGA TTTGTGAG   4942       857   ACAAAAAG A UGGGGAUA   1920   TATCCCCA GGCTAGCTACAACGA CTTTTTGT   4943       863   AGAUGGGG A UAUUCCCU   1921   AGGGAATA GGCTAGCTACAACGA CCCCATCT   4944       865   AUGGGGAG A UUCCCUUA   1922   TAAGGGAA GGCTAGCTACAACGA ATCCCCAT   4945       874   UUCCCUUA A CUUCAUGG   1923   CCATGAAG GGCTAGCTACAACGA TAAGGGAA   4946       879   UUAACUUC A UGGGAUAU   1924   ATATCCCA GGCTAGCTACAACGA GAAGTTAA   4947       884   UUCAUGGG A UAUGUAAU   1925   ATTACATA GGCTAGCTACAACGA CCCATGAA   4948       886   CAUGGGAU A UGUAAUUG   1926   CAATTACA GGCTAGCTACAACGA ATCCCATG   4949       891   GAUAUGUA A UUGGGAGU   1927   ACTCCCAA GGCTAGCTACAACGA TACATATC   4950       906   GUUGGGGC A CAUUGCCA   1928   TGGCAATG GGCTAGCTACAACGA GCCCCAAC   4951       908   UGGGGCAC A UUGCCACA   1929   TGTGGCAA GGCTAGCTACAACGA GTGCCCCA   4952       914   ACAUUGCC A CAGGAACA   1930   TGTTCCTG GGCTAGCTACAACGA GGCAATGT   4953       920   CCACAGGA A CAUAUUGU   1931   ACAATATG GGCTAGCTACAACGA TCCTGTGG   4954       922   ACAGGAAC A UAUUGUAC   1932   GTACAATA GGCTAGCTACAACGA GTTCCTGT   4955       924   AGGAACAU A UUGUACAA   1933   TTGTACAA GGCTAGCTACAACGA ATGTTCCT   4956       929   CAUAUUGU A CAAAAAAU   1934   ATTTTTTG GGCTAGCTACAACGA ACAATATG   4957       936   UACAAAAA A UCAAAAUG   1935   CATTTTGA GGCTAGCTACAACGA TTTTTGTA   4958       942   AAAUCAAA A UGUGUUUU   1936   AAAACACA GGCTAGCTACAACGA TTTGATTT   4959       956   UUUAGGAA A CUUCCUGU   1937   ACAGGAAG GGCTAGCTACAACGA TTCCTAAA   4960       967   UCCUGUAA A CAGGCCUA   1938   TAGGCCTG GGCTAGCTACAACGA TTACAGGA   4961       975   ACAGGCCU A UUGAUUGG   1939   CCAATCAA GGCTAGCTACAACGA AGGCCTGT   4962       979   GCCUAUUG A UUGGAAAG   1940   CTTTCCAA GGCTAGCTACAACGA CAATAGGC   4963       989   UGGAAAGU A UGUCAACG   1941   CGTTGACA GGCTAGCTACAACGA ACTTTCCA   4964       995   GUAUGUCA A CGAAUUGU   1942   ACAATTCG GGCTAGCTACAACGA TGACATAC   4965       999   GUCAACGA A UUGUGGGU   1943   ACCCACAA GGCTAGCTACAACGA TCGTTGAC   4966       1032   CCCCUUUC A CGCAAUGU   1944   ACATTGCG GGCTAGCTACAACGA GAAAGGGG   4967       1037   UUCACGCA A UGUGGAUA   1945   TATCCACA GGCTAGCTACAACGA TGCGTGAA   4968       1043   CAAUGUGG A UAUUCUGC   1946   GCAGAATA GGCTAGCTACAACGA CCACATTG   4969       1045   AUGUGGAU A UUCUGCUU   1947   AAGCAGAA GGCTAGCTACAACGA ATCCACAT   4970       1056   CUGCUUUA A UGCCUUUA   1948   TAAAGGCA GGCTAGCTACAACGA TAAAGCAG   4971       1064   AUGCCUUU A UAUGCAUG   1949   CATGCATA GGCTAGCTACAACGA AAAGGCAT   4972       1066   GCCUUUAU A UGCAUGCA   1950   TGCATGCA GGCTAGCTACAACGA ATAAAGGC   4973       1070   UUAUAUGC A UGCAUACA   1951   TGTATGCA GGCTAGCTACAACGA GCATATAA   4974       1074   AUGCAUGC A UACAAGCA   1952   TGCTTGTA GGCTAGCTACAACGA GCATGCAT   4975       1076   GCAUGCAU A CAAGCAAA   1953   TTTGCTTG GGCTAGCTACAACGA ATGCATGC   4976       1085   CAAGCAAA A CAGGCUUU   1954   AAAGCCTG GGCTAGCTACAACGA TTTGCTTG   4977       1095   AGGCUUUU A CUUUCUCG   1955   CGAGAAAG GGCTAGCTACAACGA AAAAGCCT   4978       1107   UCUCGCCA A CUUACAAG   1956   CTTGTAAG GGCTAGCTACAACGA TGGCGAGA   4979       1111   GCCAACUU A CAAGGCCU   1957   AGGCCTTG GGCTAGCTACAACGA AAGTTGGC   4980       1130   CUAAGUAA A CAGUAUGU   1958   ACATACTG GGCTAGCTACAACGA TTACTTAG   4981       1135   UAAACAGU A UGUGAACC   1959   GGTTCACA GGCTAGCTACAACGA ACTGTTTA   4982       1141   GUAUGUGA A CCUUUACC   1960   GGTAAAGG GGCTAGCTACAACGA TCACATAC   4983       1147   GAACCUUU A CCCCGUUG   1961   CAACGGGG GGCTAGCTACAACGA AAAGGTTC   4984       1163   GCUCGGCA A CGGCCUGG   1962   CCAGGCCG GGCTAGCTACAACGA TGCCGAGC   4985       1175   CCUGGUCU A UGCCAAGU   1963   ACTTGGCA GGCTAGCTACAACGA AGACCAGG   4986       1192   GUUUGCUG A CGCAACCC   1964   GGGTTGCG GGCTAGCTACAACGA CAGCAAAC   4987       1197   CUGACGCA A CCCCCACU   1965   AGTGGGGG GGCTAGCTACAACGA TGCGTCAG   4988       1203   CAACCCCC A CUGGUUGG   1966   CCAACCAG GGCTAGCTACAACGA GGCGGTTG   4989       1221   GCUUGGCC A UAGGCCAU   1967   ATGGCCTA GGCTAGCTACAACGA GGCCAAGC   4990       1228   CAUAGGCC A UCAGCGCA   1968   TGCGCTGA GGCTAGCTACAACGA GGCCTATG   4991       1236   AUCAGCGC A UGCGUGGA   1969   TCCACGCA GGCTAGCTACAACGA GCGCTGAT   4992       1245   UGCGUGGA A CCUUUGUG   1970   CACAAAGG GGCTAGCTACAACGA TCCACGCA   4993       1266   CUCUGCCG A UCCAUACC   1971   GGTATGGA GGCTAGCTACAACGA CGGCAGAG   4994       1270   GCCGAUCC A UACCGCCG   1972   CCGCGGTA GGCTAGCTACAACGA GGATCGGC   4995       1272   CGAUCCAU A CCGCGGAA   1973   TTCCGCCG GGCTAGCTACAACGA ATGGATCG   4996       1280   ACCGCGGA A CUCCUAGC   1974   GCTAGGAG GGCTAGCTACAACGA TCCGCGGT   4997       1322   GGGGCAAA A CUCAUCGG   1975   CCGATGAG GGCTAGCTACAACGA TTTGCCCC   4998       1326   CAAAACUC A UCGGGACU   1976   AGTCCCGA GGCTAGCTACAACGA GAGTTTTG   4999       1332   UCAUCGGG A CUGACAAU   1977   ATTGTCAG GGCTAGCTACAACGA CCCGATGA   5000       1336   CGGGACUG A CAAUUCUG   1978   CAGAATTG GGCTAGCTACAACGA CAGTCCCG   5001       1339   GACUGACA A UUCUGUCG   1979   CGACAGAA GGCTAGCTACAACGA TGTCAGTC   5002       1361   UCCCGCAA A UAUACAUC   1980   GATGTATA GGCTAGCTACAACGA TTGCGGGA   5003       1363   CCGCAAAU A UACAUCAU   1981   ATGATGTA GGCTAGCTACAACGA ATTTGCGG   5004       1365   GCAAAUAU A CAUCAUUU   1982   AAATGATG GGCTAGCTACAACGA ATATTTGC   5005       1367   AAAUAUAC A UCAUUUCC   1983   GGAAATGA GGCTAGCTACAACGA GTATATTT   5006       1370   UAUACAUC A UUUCCAUG   1984   CATGGAAA GGCTAGCTACAACGA GATGTATA   5007       1376   UCAUUUCC A UGGCUGCU   1985   AGCAGCCA GGCTAGCTACAACGA GGAAATGA   5008       1399   UGCUGCCA A CUGGAUCC   1986   GGATCCAG GGCTAGCTACAACGA TGGCAGCA   5009       1404   CCAACUGG A UCCUACGC   1987   GCGTAGGA GGCTAGCTACAACGA CCAGTTGG   5010       1409   UGGAUCCU A CGCGGGAC   1988   GTCCCGCG GGCTAGCTACAACGA AGGATCCA   5011       1416   UACGCGCG A CGUCCUUU   1989   AAAGGACG GGCTAGCTACAACGA CCCGCGTA   5012       1429   CUUUGUUU A CGUCCCGU   1990   ACGGGACG GGCTAGCTACAACGA AAACAAAG   5013       1447   GGCGCUGA A UCCCGCGG   1991   CCGCGGGA GGCTAGCTACAACGA TCAGCGCC   5014       1456   UCCCGCGG A CGACCCCU   1992   AGGGGTCG GGCTAGCTACAACGA CCGCCGGA   5015       1459   CGCGGACG A CCCCUCCC   1993   GGGAGGGG GGCTAGCTACAACGA CGTCCGCG   5016       1486   GGGGCUCU A CCGCCCGC   1994   GCGGGCGG GGCTAGCTACAACGA AGAGCCCC   5017       1505   CUCCGCCU A UUGUACCG   1995   CGGTACAA GGCTAGCTACAACGA AGGCGGAG   5018       1510   CCUAUUGU A CCGACCGU   1996   ACGGTCGG GGCTAGCTACAACGA ACAATAGG   5019       1514   UUGUACCG A CCGUCCAC   1997   GTGGACGG GGCTAGCTACAACGA CGGTACAA   5020       1521   GACCGUCC A CGGGGCGC   1998   GCGCCCCG GGCTAGCTACAACGA GGACGGTC   5021       1530   CGGGGCGC A CCUCUCUU   1999   AAGAGAGG GGCTAGCTACAACGA GCGCCCCG   5022       1540   CUCUCUUU A CGCGGACU   2000   AGTCCGCG GGCTAGCTACAACGA AAAGAGAG   5023       1546   UUACGCGG A CUCCCCGU   2001   ACGGGGAG GGCTAGCTACAACGA CCGCGTAA   5024       1567   GCCUUCUC A UCUGCCGG   2002   CCGGCAGA GGCTAGCTACAACGA GAGAAGGC   5025       1576   UCUGCCGG A CCGUGUGC   2003   GCACACGG GGCTAGCTACAACGA CCGGCAGA   5026       1585   CCGUGUGC A CUUCGCUU   2004   AAGCGAAG GGCTAGCTACAACGA GCACACGG   5027       1595   UUCGCUUC A CCUCUGCA   2005   TGCAGAGG GGCTAGCTACAACGA GAAGCGAA   5028       1603   ACCUCUGC A CGUCGCAU   2006   ATGCGACG GGCTAGCTACAACGA GCAGAGGT   5029       1610   CACGUCGC A UGGAGACC   2007   GGTCTCCA GGCTAGCTACAACGA GCGACGTG   5030       1616   GCAUGGAG A CCACCGUG   2008   CACGGTGG GGCTAGCTACAACGA CTCCATGC   5031       1619   UGGAGACC A CCGUGAAC   2009   GTTCACGG GGCTAGCTACAACGA GGTCTCCA   5032       1626   CACCGUGA A CGCCCACA   2010   TGTGGGCG GGCTAGCTACAACGA TCACGGTG   5033       1638   CCACAGGA A CCUGCCCA   2011   TGGGCAGG GGCTAGCTACAACGA TCCTGTGG   5034       1656   GGUCUUGC A UAAGAGGA   2012   TCCTCTTA GGCTAGCTACAACGA GCAAGACC   5035       1664   AUAAGAGG A CUCUUGGA   2013   TCCAAGAG GGCTAGCTACAACGA CCTCTTAT   5036       1672   ACUCUUGG A CUUUCAGC   2014   GCTGAAAG GGCTAGCTACAACGA CCAAGAGT   5037       1682   UUUCAGCA A UGUCAACG   2015   CGTTGACA GGCTAGCTACAACGA TGCTGAAA   5038       1688   CAAUGUCA A CGACCGAC   2016   GTCGGTCG GGCTAGCTACAACGA TGACATTG   5039       1691   UGUCAACG A CCGACCUU   2017   AAGGTCGG GGCTAGCTACAACGA CGTTGACA   5040       1695   AACGACCG A CCUUGAGG   2018   CCTCAAGG GGCTAGCTACAACGA CGGTCGTT   5041       1705   CUUGAGGC A UACUUCAA   2019   TTGAAGTA GGCTAGCTACAACGA GCCTCAAG   5042       1707   UGAGGCAU A CUUCAAAG   2020   CTTTGAAG GGCTAGCTACAACGA ATGCCTCA   5043       1716   CUUCAAAG A CUGUGUGU   2021   ACACACAG GGCTAGCTACAACGA CTTTGAAG   5044       1728   UGUGUUUA A UGAGUGGG   2022   CCCACTCA GGCTAGCTACAACGA TAAACACA   5045       1774   GUCUUUGU A CUAGGAGG   2023   CCTCCTAG GGCTAGCTACAACGA ACAAAGAC   5046       1791   CUGUAGGC A UAAAUUGG   2024   CCAATTTA GGCTAGCTACAACGA GCCTACAG   5047       1795   AGGCAUAA A UUGGUGUG   2025   CACACCAA GGCTAGCTACAACGA TTATGCCT   5048       1807   GUGUGUUC A CCAGCACC   2026   GGTGCTGG GGCTAGCTACAACGA GAACACAC   5049       1813   UCACCAGC A CCAUGCAA   2027   TTGCATGG GGCTAGCTACAACGA GCTGGTGA   5050       1816   CCAGCACC A UGCAACUU   2028   AAGTTGCA GGCTAGCTACAACGA GGTGCTGG   5051       1821   ACCAUGCA A CUUUUUCA   2029   TGAAAAAG GGCTAGCTACAACGA TGCATGGT   5052       1829   ACUUUUUC A CCUCUGCC   2030   GGCAGAGG GGCTAGCTACAACGA GAAAAAGT   5053       1840   UCUGCCUA A UCAUCUCA   2031   TGAGATGA GGCTAGCTACAACGA TAGGCAGA   5054       1843   GCCUAAUC A UCUCAUGU   2032   ACATGAGA GGCTAGCTACAACGA GATTAGGC   5055       1848   AUCAUCUC A UGUUCAUG   2033   CATGAACA GGCTAGCTACAACGA GAGATGAT   5056       1854   UCAUGUUC A UGUCCUAC   2034   GTAGGACA GGCTAGCTACAACGA GAACATGA   5057       1861   CAUGUCCU A CUGUUCAA   2035   TTGAACAG GGCTAGCTACAACGA AGGACATG   5058       1903   UUUGGGGC A UGGACAUU   2036   AATGTCCA GGCTAGCTACAACGA GCCCCAAA   5059       1907   GGGCAUGG A CAUUGACC   2037   GGTCAATG GGCTAGCTACAACGA CCATGCCC   5060       1909   GCAUGGAC A UUGACCCG   2038   CGGGTCAA GGCTAGCTACAACGA GTCCATGC   5061       1913   GGACAUUG A CCCGUAUA   2039   TATACGGG GGCTAGCTACAACGA CAATGTCC   5062       1919   UGACCCCU A UAAAGAAU   2040   ATTCTTTA GGCTAGCTACAACGA ACGGGTCA   5063       1926   UAUAAAGA A UUUGGAGC   2041   GCTCCAAA GGCTAGCTACAACGA TCTTTATA   5064       1947   GUGGAGUU A CUCUCUUU   2042   AAAGAGAG GGCTAGCTACAACGA AACTCCAC   5065       1967   GCCUUCUG A CUUCUUUC   2043   GAAAGAAG GGCTAGCTACAACGA CAGAAGGC   5066       1981   UUCCUUCU A UUCGAGAU   2044   ATCTCGAA GGCTAGCTACAACGA AGAAGGAA   5067       1988   UAUUCGAG A UCUCCUCG   2045   CCAGGAGA GGCTAGCTACAACGA CTCGAATA   5068       1997   UCUCCUCG A CACCGCCU   2046   AGGCGGTG GGCTAGCTACAACGA CGAGGAGA   5069       1999   UCCUCGAC A CCGCCUCU   2047   AGAGGCGG GGCTAGCTACAACGA GTCGAGGA   5070       2015   UGCUCUGU A UCGGGGGG   2048   CCCCCCGA GGCTAGCTACAACGA ACAGAGCA   5071       2040   UCUCCGGA A CAUUGUUC   2049   GAACAATG GGCTAGCTACAACGA TCCGGAGA   5072       2042   UCCGGAAC A UUGUUCAC   2050   GTGAACAA GGCTAGCTACAACGA GTTCCGGA   5073       2049   CAUUGUUC A CCUCACCA   2051   TGGTGAGG GGCTAGCTACAACGA GAACAATG   5074       2054   UUCACCUC A CCAUACGG   2052   CCGTATGG GGCTAGCTACAACGA CAGGTGAA   5075       2057   ACCUCACC A UACGGCAC   2053   GTGCCGTA GGCTAGCTACAACGA GGTGAGGT   5076       2059   CUCACCAU A CGGCACUC   2054   GAGTGCCG GGCTAGCTACAACGA ATGGTGAG   5077       2064   CAUACGGC A CUCAGGCA   2055   TCCCTGAG GGCTAGCTACAACGA GCCGTATG   5078       2077   GGCAAGCU A UUCUGUGU   2056   ACACAGAA GGCTAGCTACAACGA AGCTTGCC   5079       2098   GUGAGUUG A UGAAUCUA   2057   TAGATTCA GGCTAGCTACAACGA CAACTCAC   5080       2102   GUUGAUGA A UCUAGCCA   2058   TGGCTAGA GGCTAGCTACAACGA TCATCAAC   5081       2110   AUCUAGCC A CCUGGGUG   2059   CACCCAGG GGCTAGCTACAACGA GGCTAGAT   5082       2126   GGGAAGUA A UUUGGAAG   2060   CTTCCAAA GGCTAGCTACAACGA TACTTCCC   5083       2135   UUUGGAAG A UCCAGCAU   2061   ATGCTGGA GGCTAGCTACAACGA CTTCCAAA   5084       2142   GAUCCAGC A UCCAGGGA   2062   TCCCTGGA GGCTAGCTACAACGA GCTGGATC   5085       2151   UCCAGGGA A UUAGUAGU   2063   ACTACTAA GGCTAGCTACAACGA TCCCTGGA   5086       2165   AGUCAGCU A UGUCAACG   2064   CGTTGACA GGCTAGCTACAACGA AGCTGACT   5087       2171   CUAUGUCA A CGUUAAUA   2065   TATTAACG GGCTAGCTACAACGA TGACATAG   5088       2177   CAACGUUA A UAUGGGCC   2066   GGCCCATA GGCTAGCTACAACGA TAACGTTG   5089       2179   ACGUUAAU A UGGGCCUA   2067   TAGGCCCA GGCTAGCTACAACGA ATTAACGT   5090       2191   GCCUAAAA A UCAGACAA   2068   TTGTCTGA GGCTAGCTACAACGA TTTTAGGC   5091       2196   AAAAUCAG A CAACUAUU   2069   AATAGTTG GGCTAGCTACAACGA CTGATTTT   5092       2199   AUCAGACA A CUAUUGUG   2070   CACAATAG GGCTAGCTACAACGA TGTCTGAT   5093       2202   AGACAACU A UUGUGGUU   2071   AACCACAA GGCTAGCTACAACGA AGTTGTCT   5094       2213   GUGGUUUC A CAUUUCCU   2072   AGGAAATG GGCTAGCTACAACGA GAAACCAC   5095       2215   GGUUUCAC A UUUCCUGU   2073   ACAGGAAA GGCTAGCTACAACGA GTGAAACC   5096       2227   CCUGUCUU A CUUUUGGG   2074   CCCAAAAG GGCTAGCTACAACGA AAGACAGG   5097       2242   GGCGAGAA A CUGUUCUU   2075   AAGAACAG GGCTAGCTACAACGA TTCTCGCC   5098       2253   GUUCUUGA A UAUUUGGU   2076   ACCAAATA GGCTAGCTACAACGA TCAAGAAC   5099       2255   UCUUGAAU A UUUGGUGU   2077   ACACCAAA GGCTAGCTACAACGA ATTCAAGA   5100       2278   GAGUGUGG A UUCGCACU   2078   AGTGCGAA GGCTAGCTACAACGA CCACACTC   5101       2284   GGAUUCGC A CUCCUCCU   2079   AGGAGGAG GGCTAGCTACAACGA GCGAATCC   5102       2295   CCUCCUGC A UAUAGACC   2080   GGTCTATA GGCTAGCTACAACGA GCAGGAGG   5103       2297   UCCUGCAU A UAGACCAC   2081   GTGGTCTA GGCTAGCTACAACGA ATGCAGGA   5104       2301   GCAUAUAG A CCACCAAA   2082   TTTGGTGG GGCTAGCTACAACGA CTATATGC   5105       2304   UAUAGACC A CCAAAUGC   2083   GCATTTGG GGCTAGCTACAACGA GGTCTATA   5106       2309   ACCACCAA A UGCCCCUA   2084   TAGGGGCA GGCTAGCTACAACGA TTGGTGGT   5107       2317   AUGCCCCU A UCUUAUCA   2085   TGATAAGA GGCTAGCTACAACGA AGGGGCAT   5108       2322   CCUAUCUU A UCAACACU   2086   AGTGTTGA GGCTAGCTACAACGA AAGATAGG   5109       2326   UCUUAUCA A CACUUCCG   2087   CGGAAGTG GGCTAGCTACAACGA TGATAAGA   5110       2328   UUAUCAAC A CUUCCGGA   2088   TCCGGAAG GGCTAGCTACAACGA GTTGATAA   5111       2338   UUCCGGAA A CUACUGUU   2089   AACAGTAG GGCTAGCTACAACGA TTCCGGAA   5112       2341   CGGAAACU A CUGUUGUU   2090   AACAACAG GGCTAGCTACAACGA AGTTTCCG   5113       2352   GUUGUUAG A CGAAGAGG   2091   CCTCTTCG GGCTAGCTACAACGA CTAACAAC   5114       2380   GAAGAAGA A CUCCCUCG   2092   CCAGGGAG GGCTAGCTACAACGA TCTTCTTC   5115       2397   CCUCCCAG A CGAAGGUC   2093   GACCTTCG GGCTAGCTACAACGA CTGCGAGG   5116       2409   AGGUCUCA A UCGCCGCG   2094   CGCGGCGA GGCTAGCTACAACGA TGAGACCT   5117       2427   CGCAGAAG A UCUCAAUC   2095   GATTGAGA GGCTAGCTACAACGA CTTCTGCG   5118       2433   AGAUCUCA A UCUCGGGA   2096   TCCCGAGA GGCTAGCTACAACGA TGAGATCT   5119       2442   UCUCGGGA A UCUCAAUG   2097   CATTGAGA GGCTAGCTACAACGA TCCCGAGA   5120       2448   GAAUCUCA A UGUUAGUA   2098   TACTAACA GGCTAGCTACAACGA TGAGATTC   5121       2456   AUGUUAGU A UUCCUUGG   2099   CCAAGGAA GGCTAGCTACAACGA ACTAACAT   5122       2465   UUCCUUGG A CACAUAAG   2100   CTTATGTG GGCTAGCTACAACGA CCAAGGAA   5123       2467   CCUUGGAC A CAUAAGGU   2101   ACCTTATG GGCTAGCTACAACGA GTCCAAGG   5124       2469   UUGGACAC A UAAGGUGG   2102   CCACCTTA GGCTAGCTACAACGA GTGTCCAA   5125       2481   GGUGGGAA A CUUUACGG   2103   CCGTAAAG GGCTAGCTACAACGA TTCCCACC   5126       2486   GAAACUUU A CGGGGCUU   2104   AAGCCCCG GGCTAGCTACAACGA AAAGTTTC   5127       2496   GGGGCUUU A UUCUUCUA   2105   TAGAAGAA GGCTAGCTACAACGA AAAGCCCC   5128       2504   AUUCUUCU A CGGUACCU   2106   AGGTACCG GGCTAGCTACAACGA AGAAGAAT   5129       2509   UCUACGGU A CCUUGCUU   2107   AAGCAAGG GGCTAGCTACAACGA ACCGTAGA   5130       2520   UUGCUUUA A UCCUAAAU   2108   ATTTAGGA GGCTAGCTACAACGA TAAAGCAA   5131       2527   AAUCCUAA A UGGCAAAC   2109   GTTTGCCA GGCTAGCTACAACGA TTAGGATT   5132       2534   AAUGGCAA A CUCCUUCU   2110   AGAAGGAG GGCTAGCTACAACGA TTGCCATT   5133       2550   UUUUCCUG A CAUUCAUU   2111   AATGAATG GGCTAGCTACAACGA CAGGAAAA   5134       2552   UUCCUGAC A UUCAUUUG   2112   CAAATGAA GGCTAGCTACAACGA GTCAGGAA   5135       2556   UGACAUUC A UUUGCAGG   2113   CCTGCAAA GGCTAGCTACAACGA GAATGTCA   5136       2568   GCAGGAGG A CAUUGUUG   2114   CAACAATG GGCTAGCTACAACGA CCTCCTGC   5137       2570   AGGAGGAC A UUGUUGAU   2115   ATCAACAA GGCTAGCTACAACGA GTCCTCCT   5138       2577   CAUUGUUG A UAGAUGUA   2116   TACATCTA GGCTAGCTACAACGA CAACAATG   5139       2581   GUUGAUAG A UGUAAGCA   2117   TGCTTACA GGCTAGCTACAACGA CTATCAAC   5140       2590   UGUAAGCA A UUUGUGGG   2118   CCCACAAA GGCTAGCTACAACGA TGCTTACA   5141       2606   GGCCCCUU A CAGUAAAU   2119   ATTTACTG GGCTAGCTACAACGA AAGGGGCC   5142       2613   UACAGUAA A UGAAAACA   2120   TGTTTTCA GGCTAGCTACAACGA TTACTGTA   5143       2619   AAAUGAAA A CAGGAGAC   2121   GTCTCCTG GGCTAGCTACAACGA TTTCATTT   5144       2626   AACAGGAG A CUUAAAUU   2122   AATTTAAG GGCTAGCTACAACGA CTCCTGTT   5145       2632   AGACUUAA A UUAACUAU   2123   ATAGTTAA GGCTAGCTACAACGA TTAAGTCT   5146       2636   UUAAAUUA A CUAUGCCU   2124   AGGCATAG GGCTAGCTACAACGA TAATTTAA   5147       2639   AAUUAACU A UGCCUGCU   2125   AGCAGGCA GGCTAGCTACAACGA AGTTAATT   5148       2655   UAGGUUUU A UCCCAAUG   2126   CATTGGGA GGCTAGCTACAACGA AAAACCTA   5149       2661   UUAUCCCA A UGUUACUA   2127   TAGTAACA GGCTAGCTACAACGA TGGGATAA   5150       2666   CCAAUGUU A CUAAAUAU   2128   ATATTTAG GGCTAGCTACAACGA AACATTGG   5151       2671   GUUACUAA A UAUUUGCC   2129   GGCAAATA GGCTAGCTACAACGA TTAGTAAC   5152       2673   UACUAAAU A UUUGCCCU   2130   AGGGCAAA GGCTAGCTACAACGA ATTTAGTA   5153       2685   GCCCUUAG A UAAAGGGA   2131   CGGTTTGA GGCTAGCTACAACGA CTAAGGGC   5154       2693   AUAAAGGG A UCAAACCG   2132   CGGTTTGA GGCTAGCTACAACGA CCCTTTAT   5155       2698   GGGAUCAA A CCGUAUUA   2133   TAATACGG GGCTAGCTACAACGA TTGATCCC   5156       2703   CAAACCGU A UUAUCCAG   2134   CTGGATAA GGCTAGCTACAACGA ACGGTTTG   5157       2706   ACCGUAUU A UCCAGAGU   2135   ACTCTGGA GGCTAGCTACAACGA AATACGGT   5158       2715   UCCAGAGU A UGUAGUUA   2136   TAACTACA GGCTAGCTACAACGA ACTCTGGA   5159       2724   UGUAGUUA A UCAUUACU   2137   AGTAATGA GGCTAGCTACAACGA TAACTACA   5160       2727   AGUUAAUC A UUACUUCC   2138   GGAAGTAA GGCTAGCTACAACGA GATTAACT   5161       2730   UAAUCAUU A CUUCCAGA   2139   TCTGGAAG GGCTAGCTACAACGA AATGATTA   5162       2738   ACUUCCAG A CGCGACAU   2140   ATGTCGCG GGCTAGCTACAACGA CTGGAAGT   5163       2743   CAGACGCG A CAUUAUUU   2141   AAATAATG GGCTAGCTACAACGA CGCGTCTG   5164       2745   CACGCGAC A UUAUUUAC   2142   GTAAATAA GGCTAGCTACAACGA GTCGCGTC   5165       2748   GCGACAUU A UUUACACA   2143   TGTGTAAA GGCTAGCTACAACGA AATGTCGC   5166       2752   CAUUAUUU A CACACUCU   2144   AGAGTGTG GGCTAGCTACAACGA AAATAATG   5167       2754   UUAUUUAC A CACUCUUU   2145   AAAGAGTG GGCTAGCTACAACGA GTAAATAA   5168       2756   AUUUACAC A CUCUUUGG   2146   CCAAAGAG GGCTAGCTACAACGA GTGTAAAT   5169       2774   AGGCGGGG A UCUUAUAU   2147   ATATAAGA GGCTAGCTACAACGA CCCCGCCT   5170       2779   GGGAUCUU A UAUAAAAG   2148   CTTTTATA GGCTAGCTACAACGA AAGATCCC   5171       2781   GAUCUUAU A UAAAAGAG   2149   CTCTTTTA GGCTAGCTACAACGA ATAAGATC   5172       2795   CAGAGUCC A CACGUAGC   2150   GCTACGTG GGCTAGCTACAACGA GGACTCTC   5173       2797   CAGUCCAC A CGUAGCGC   2151   GCGCTACG GGCTAGCTACAACGA GTGGACTC   5174       2809   AGCGCCUC A UUUUGCGG   2152   CCGCAAAA GGCTAGCTACAACGA GAGGCGCT   5175       2821   UGCGGGUC A CCAUAUUC   2153   GAATATGG GGCTAGCTACAACGA GACCCGCA   5176       2824   GGGUCACC A UAUUCUUG   2154   CAAGAATA GGCTAGCTACAACGA GGTGACCC   5177       2826   GUCACCAU A UUCUUGGG   2155   CCCAAGAA GGCTAGCTACAACGA ATGGTGAC   5178       2836   UCUUGGGA A CAAGAUCU   2156   AGATCTTG GGCTAGCTACAACGA TCCCAAGA   5179       2841   GGAACAAG A UCUACAGC   2157   GCTGTAGA GGCTAGCTACAACGA CTTGTTCC   5180       2845   CAAGAUCU A CAGCAUGG   2158   CCATGCTG GGCTAGCTACAACGA AGATCTTG   5181       2850   UCUACAGC A UGGGAGGU   2159   ACCTCCCA GGCTAGCTACAACGA GCTGTAGA   5182       2870   UCUUCCAA A CCUCGAAA   2160   TTTCGAGG GGCTAGCTACAACGA TTGGAAGA   5183       2883   GAAAAGGC A UGUGGACA   2161   TGTCCCCA GGCTAGCTACAACGA GCCTTTTC   5184       2889   GCAUGGGG A CAAAUCUU   2162   AAGATTTG GGCTAGCTACAACGA CCCCATGC   5185       2893   GGGGACAA A UCUUUCUG   2163   CAGAAAGA GGCTAGCTACAACGA TTGTCCCC   5186       2908   UGUCCCCA A UCCCCUGG   2164   CCAGGGGA GGCTAGCTACAACGA TGGGGACA   5187       2918   CCCCUGGG A UUCUUCCC   2165   GGGAAGAA GGCTAGCTACAACGA CCCAGGGG   5188       2929   CUUCCCCG A UCAUCAGU   2166   ACTGATGA GGCTAGCTACAACGA CGGGGAAG   5189       2932   CCCCGAUC A UCAGUUGG   2167   CCAACTGA GGCTAGCTACAACGA GATCGGGG   5190       2941   UCAGUUGG A CCCUGCAU   2168   ATGCAGGG GGCTAGCTACAACGA CCAACTGA   5191       2948   GACCCUGC A UUCAAAGC   2169   GCTTTGAA GGCTAGCTACAACGA GCAGGGTC   5192       2959   CAAAGCCA A CUCAGUAA   2170   TTACTGAG GGCTAGCTACAACGA TGGCTTTG   5193       2968   CUCAGUAA A UCCAGAUU   2171   AATCTGGA GGCTAGCTACAACGA TTACTGAG   5194       2974   AAAUCCAG A UUGGGACC   2172   GGTCCCAA GGCTAGCTACAACGA CTGGATTT   5195       2980   AGAUUGGG A CCUCAACC   2173   GGTTGAGG GGCTAGCTACAACGA CCCAATCT   5196       2986   GGACCUCA A CCCGCACA   2174   TGTGCGGG GGCTAGCTACAACGA TGAGGTCC   5197       2998   GCACAAGG A CAACUGGC   2175   GCCAGTTG GGCTAGCTACAACGA CCTTGTGC   5198       3001   CAAGGACA A CUGGCCGG   2176   CCGGCCAG GGCTAGCTACAACGA TGTCCTTG   5199       3010   CUGGCCGG A CGCCAACA   2177   TGTTGGCG GGCTAGCTACAACGA CCGGCCAG   5200       3016   GGACGCCA A CAAGGUGG   2178   CCACCTTG GGCTAGCTACAACGA TGGCGTCC   5201       3035   GUGGGAGC A UUCCGGCC   2179   GGCCCGAA GGCTAGCTACAACGA GCTCCCAC   5202       3051   CAUGGUUC A CCCCUCCC   2180   GGGAGGGG GGCTAGCTACAACGA GAACCCTG   5203       3061   CCCUCCCC A UGGGGGAC   2181   GTCCCCCA GGCTAGCTACAACGA GGGGAGGG   5204       3068   CAUGGGGG A CUGUUGGG   2182   CCCAACAG GGCTAGCTACAACGA CCCCCATG   5205       3088   GAGCCCUC A CGCUCAGG   2183   CCTGAGCG GGCTAGCTACAACGA GAGGGCTC   5206       3101   CAGGGCCU A CUCACAAC   2184   GTTGTGAG GGCTAGCTACAACGA AGGCCCTG   5207       3105   GCCUACUC A CAACUGUG   2185   CACAGTTG GGCTAGCTACAACGA GAGTAGGC   5208       3108   UACUCACA A CUGUGCCA   2186   TGGCACAG GGCTAGCTACAACGA TGTGAGTA   5209       3138   CUGCCUCC A CCAAUCGG   2187   CCGATTGG GGCTAGCTACAACGA GGAGGCAG   5210       3142   CUCCACCA A UCGGCAGU   2188   ACTGCCGA GGCTAGCTACAACGA TGGTGGAG   5211       3165   GGCAGCCU A CUCCCUUA   2189   TAAGGGAG GGCTAGCTACAACGA AGGCTGCC   5212       3173   ACUCCCUU A UCUCCACC   2190   GGTGGAGA GGCTAGCTACAACGA AAGGGAGT   5213       3179   UUAUCUCC A CCUCUAAG   2191   CTTAGAGG GGCTAGCTACAACGA GGAGATAA   5214       3190   UCUAAGGG A CACUCAUC   2192   GATGAGTG GGCTAGCTACAACGA CCCTTAGA   5215       3192   UAAGGGAC A CUCAUCCU   2193   AGGATGAG GGCTAGCTACAACGA GTCCCTTA   5216       3196   GGACACUC A UCCUCAGG   2194   CCTGAGGA GGCTAGCTACAACGA GAGTGTCC   5217       3207   CUCAGGCC A UGCAGUGG   2195   CCACTGCA GGCTAGCTACAACGA GGCCTGAG   5218                                                            
     [0253]                   TABLE X                          HUMAN HBV AMBERZYME AND SUBSTRATE SEQUENCE                                     Pos   Substrate   Seq ID   Amberzyme   Seq ID                                             61   ACUUUCCU G CUGGUGGC   1448   GCCACCAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGAAAGU   5219                   87   GGAACAGU G AGCCCUGC   1449   GCAGGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGUUCC   5220               94   UGAGCCCU G CUCAGAAU   1450   AUUCUGAG GGAGGAAACUCC CU UCAAGGACAUCCUCCGGG AGGGCUCA   5221               112   CUGUCUCU G CCAUAUCG   1451   CGAUAUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCCGG AGAGACAG   5222               132   AUCUUAUC G AACACUCG   1452   CCACUCUU GCACGAAACUCC CU UCAACGACAUCGUCCGGC GAUAAGAU   5223               153   CCUGUACC G AACAUGCA   1453   UCCAUGUU GCAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCUACAGG   5224               159   ACAACAUC G CAUCAGGA   1454   UCCUGAUG GGACGAAACUCC CU UCAAGCACAUCGUCCGGG GAUGUUCU   5225               192   GGACCCCU G CUCCUCUU   1455   AACACCAG GCAGCAAACUCC CU UCAAGGACAUCCUCCCCG AGCCGUCC   5226               222   UUCUUCUU G ACAAAAAU   1456   AUUUUUGU GCACGAAACUCC CU UCAACCACAUCCUCCCCG AACAAGAA   5227               315   CAAAAUUC G CAGUCCCA   1457   UGCGACUC GGAGCAAACUCC CU UCAACGACAUCGUCCGGC CAAUUUUC   5228               374   UCCUUAUC G CUGGAUGU   1458   ACAUCCAG GGAGGAAACUCC CU UCAAGGACAUCCUCCCCG CAUAACCA   5229               387   AUGUGUCU G CGCCCTUU   1459   AAACCCCG GGAGGAAACUCC CU UCAAGGACAUCGUCCCGC AGACACAU   5230               410   CUUCCUCU G CAUCCUCC   1460   GCAGGAUG GGAGGAAACUCC CU UCAACGACAUCGUCCCCG AGACGAAG   5231               417   UGCAUCCU G CUGCUAUG   1461   CAUACCAC GCACCAAACUCC CU UCAAGGACAUCGUCCGGC AGGAUGCA   5232               420   AUCCUGCU G CUAUCCCU   1462   ACCCAUAC GGACCAAACUCC CU UCAAGCACAUCGUCCGCC AGCAGGAU   5233               425   GCUGCUAU G CCUCAUCU   1463   AGAUCAGC GGAGCAAACUCC CU UCAACGACAUCGUCCGGC AUAGCAGC   5234               468   GGUAUGUU G CCCGUUUG   1464   CAAACCCG GGACGAAACUCC CU UCAAGGACAUCGUCCGCG AACAUACC   5235               518   CGGACCAU G CAAAACCU   1465   AGCUUUUC CGAGGAAACUCC CU UCAAGCACAUCGUCCGGC AUGCUCCC   5236               527   CAAAACCU G CACAACUC   1466   CACUUGUC GCAGCAAACUCC CU UCAACGACAUCGUCCCCC AGGUUUUC   5237               538   CAACUCCU G CUCAAGGA   1467   UCCUUCAG GGACGAAACUCC CU UCAAGGACAUCGUCCGCC ACGACUUG   5238               569   CUCAUGUU G CUCUACAA   1468   UUGUACAC GGACGAAACUCC CU UCAACGACAUCCUCCCGG AACAUCAC   5239               596   CCCAAACU G CACCUGUA   1469   UACACCUC GGAGGAAACUCC CU UCAACGACAUCGUCCGCC AGUUUCCG   5240               631   GGCCUUUC G CAAAAUAC   1470   CUAUUUUG GGAGGAAACUCC CU UCAAGCACAUCGUCCGCG GAAACCCC   5241               687   UUACUAGU G CCAUUUCU   1471   ACAAAUCC CGACCAAACUCC CU UCAAGCACAUCCUCCCCG ACUACUAA   5242               747   AUAUGCAU G AUCUCGUU   1472   AACCACAU CGAGCAAACUCC CU UCAACCACAUCCUCCCCC AUCCAUAU   5243               783   AACAUCUU G ACUCCCUU   1473   AACCCACU CCAGCAAACUCC CU UCAACCACAUCCUCCCCC AACAUCUU   5244               795   CCCUUUAU G CCCCUCUU   1474   AACACCCC GCACCAAACUCC CU UCAACCACAUCCUCCCCC AUAAACCC   5245               798   UUUAUGCC G CUCUUACC   1475   GCUAACAC GCACGAAACUCC CU UCAACGACAUCCUCCCCC CCCAUAAA   5246               911   GCCACAUU G CCACACCA   1476   UCCUGUGC CCACGAAACUCC CU UCAACCACAUCCUCCCGC AAUCUCCC   5247               978   GCCCUAUU G AUUCCAAA   1477   UUUCCAAU CCACCAAACUCC CU UCAACCACAUCGUCCCCC AAUACGCC   5248               997   AUCUCAAC G AAUUCUCC   1478   CCACAAUU CCACCAAACUCC CU UCAAGCACAUCCUCCCCC CUUCACAU   5249               1020   UCCCCUUU G CCCCCCCU   1479   ACCCCCCC CCACCAAACUCC CU UCAAGCACAUCCUCCGCG AAACCCCA   5250               1023   CCUUUCCC G CCCCUUUC   1480   CAAACGCC CCACCAAACUCC CU UCAACCACAUCCUCCGCC GCCAAACC   5251               1034   CCUUUCAC G CAAUGUGG   1481   CCACAUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGC CUCAAAGG   5252               1050   GAUAUUCU G CUUUAAUG   1482   CAUUAAAC CGACGAAACUCC CU UCAACCACAUCGUCCGGC AGAAUAUC   5253               1058   GCUUUAAU G CCTUUAUA   1483   UAUAAAGG GGAGGAAACUCC CU UCAAGCACAUCGUCCGGG AUUAAAGC   5254               1068   CUUUAUAU G CAUGCAUA   1484   UAUGCAUC GGAGCAAACUCC CU UCAAGCACAUCCUCCCGG AUAUAAAG   5255               1072   AUAUCCAU G CAUACAAG   1485   CUUGUAUG GGAGCAAACUCC CU UCAAGGACAUCCUCCGGC AUGCAUAU   5256               1103   ACUUUCUC G CCAACUUA   1485   UAAGUUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAGAAAGU   5257               1139   CACUAUGU G AACCUUUA   1487   UAAAGGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAUACUG   5258               1155   ACCCCGUU G CUCGGCAA   1488   UUGCCGAC CCAGGAAACUCC CU UCAAGCACAUCGUCCGGG AACGGGGU   5259               1177   UCGUCUAU G CCAAGUGU   1489   ACACUUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAGACCA   5260               1188   AAGUGUUU G CUCACCCA   1490   UGCGUCAG GGAGGAAACUCC CU UCAACGACAUCGUCCGGG AAACACUU   5261               1191   UCUUUGCU G ACCCAACC   1491   CGUUGCGU GGAGCAAACUCC CU UCAAGCACAUCGUCCCGC AGCAAACA   5262               1194   UUGCUGAC G CAACCCCC   1492   GGCGCUUG GGAGCAAACUCC CU UCAAGCACAUCCUCCGCG CUCAGCAA   5263               1234   CCAUCACC G CAUGCGUG   1493   CACGCAUC CCACCAAACUCC CU UCAACCACAUCGUCCGGC CCUGAUCC   5264               1238   CACCGCAU G CCUCGAAC   1494   GUUCCACC GGAGGAAACUCC CU UCAAGCACAUCGUCCGCG AUCCGCUC   5265               1262   UCUCCUCU G CCCAUCCA   1495   UCCAUCGC CCACGAAACUCC CU UCAACGACAUCCUCCGCG AGAGGACA   5266               1265   CCUCUGCC G AUCCAUAC   1496   GUAUCGAU CCAGGAAACUCC CU UCAAGCACAUCGUCCGGG GCCAGACG   5267               1275   UCCAUACC G CGGAACUC   1497   GACUUCCG GGAGCAAACUCC CU UCAACGACAUCGUCCCGG GGUAUGGA   5268               1290   UCCUACCC G CUUGUUUU   1498   AAAACAAG CGAGCAAACUCC CU UCAAGGACAUCGUCCGGG GGCUAGCA   5269               1299   CUUCUEUU G CUCCCAGC   1499   GCUGCGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGC AAAACAAG   5270               1303   UUUUGCUC G CAGCAGCU   1500   ACCUCCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGC GACCAAAA   5271               1335   UCGGGACU G ACAAUUCU   1501   AGAAUUCU CGAGCAAACUCC CU UCAAGGACAUCGUCCGGG AGUCCCCA   5272               1349   UCUCUCGU G CUCUCCCG   1502   CGGCACAG GCACGAAACUCC CU UCAAGGACAUCGUCCGGG ACGACAGA   5273               1357   GCUCUCCC G CAAAUAUA   1503   UAUAUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCAGAGC   5274               1382   CCAUGCCU G CUAGGCUG   1504   CAGCCUAG GGAGGAAACUCC CU UCAAGGACAUCCUCCGGG ACCCAUCC   5275               1392   UAGCCUCU G CUGCCAAC   1505   GUUGGCAC CCACCAAACUCC CU UCAACCACAUCCUCCCCC ACACCCUA   5276               1395   CCUCUCCU G CCAACUGG   1506   CCAGUUGC CCACCAAACUCC CU UCAACCACAUCGUCCCCG ACCACAGC   5277               1411   CAUCCUAC G CGCGACCU   1507   ACCUCCCC CCACCAAACUCC CU UCAACCACAUCGUCCGGG GUAGGAUC   5278               1442   CCCUCGCC G CUGAAUCC   1508   CGAUUCAC CCACGAAACUCC CU UCAACGACAUCGUCCGGG GCCGACGC   5279               1445   UCCCCCCU G AAUCCCCC   1509   CCCGCAUU CGAGCAAACUCC CU UCAACCACAUCCUCCGCC ACCCCCGA   5280               1452   UGAAUCCC G CCGACGAC   1510   GUCGUCCC CGAGGAAACUCC CU UCAAGCACAUCCUCCCCC CCCAUUCA   5281               1458   CCCCGCAC G ACCCCUCC   1511   CGAGGGCU CCACCAAACUCC CU UCAACCACAUCCUCCCCC CUCCGCCC   5282               1474   CCCCCCCC G CUUCGGCC   1512   GCCCCAAC CGACCAAACUCC CU UCAACCACAUCCUCCCCC CGCCCCGC   5283               1489   CCUCUACC G CCCGCUUC   1513   GAAGCCCC CGAGCAAACUCC CU UCAACCACAUCGUCCCCG GGUACAGC   5284               1493   UACCCCCC G CUUCUCCG   1514   CGGACAAG CGAGCAAACUCC CU UCAAGGACAUCCUCCCGG GGCCGGUA   5285               1501   GCUUCUCC G CCUAUUGU   1515   ACAAUACG GCAGCAAACUCC CU UCAACGACAUCCUCCCGC CGAGAACC   5286               1513   AUUCUACC G ACCCUCCA   1516   UCGACGCU GGACGAAACUCC CU UCAACGACAUCCUCCGGG GGUACAAU   5287               1528   CACCCGCC G CACCUCUC   1517   GACACCUC GCACGAAACUCC CU UCAACGACAUCCUCCCCC CCCCCGUG   5288               1542   CUCUUUAC G CGGACUCC   1518   GGAGUCCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUAAAGAG   5289               1559   CCGUCUGU G CCUUCUCA   1519   UGAGAAGG GGAGGAAACUCC CU UCAAGGACAUCCUCCGGG ACAGACGG   5290               1571   UCUCAUCU G CCGGACCG   1520   CGGUCCGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAUGAGA   5291               1583   GACCGUGU G CACUUCGC   1521   GCGAAGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACACGGUC   5292               1590   UCCACUUC G CUUCACCU   1522   AGGUGAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAAGUGCA   5293               1601   UCACCUCU G CACGUCGC   1523   GCGACGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGGUGA   5294               1608   UGCACGUC G CAUGGAGA   1524   UCUCCAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GACGUGCA   5295               1624   ACCACCGU G AACGCCCA   1525   UGGGCGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACGGUGGU   5296               1628   CCGUGAAC G CCCACAGG   1526   CCUGUGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUUCACGG   5297               1642   AGGAACCU G CCCAAGGU   1527   ACCUUGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUUCCU   5298               1654   AAGGUCUU G CAUAAGAG   1528   CUCUUAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGACCUU   5299               1690   AUGUCAAC G ACCGACCU   1529   AGGUCGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUUGACAU   5300               1694   CAACGACC G ACCUUGAG   1530   CUCAAGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGUCGUUG   5301               1700   CCGACCUU G AGGCAUAC   1531   GUAUGCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGGUCGG   5302               1730   UGUUUAAU G AGUGGGAG   1532   CUCCCACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUAAACA   5303               1818   AGCACCAU G CAACUUUU   1533   AAAAGUUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGGUGCU   5304               1835   UCACCUCU G CCUAAUCA   1534   UGAUUAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGGUGA   5305               1883   CAAGCUGU G CCUUGGGU   1535   ACCCAAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAGCUUG   5306               1912   UGGACAUU G ACCCGUAU   1536   AUACGGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGUCCA   5307               1959   UCUTUUUU G CCUUCUGA   1537   UCAGAAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAAAAGA   5308               1966   UGCCUUCU G ACUUCUUU   1538   AAAGAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAGGCA   5309               1985   UUCUAUUC G AGAUCUCC   1539   GGAGAUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAAUAGAA   5310               1996   AUCUCCUC G ACACCGCC   1540   GGCGGUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAGGAGAU   5311               2002   UCCACACC G CCUCUGCU   1541   AGCAGAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGUGUCCA   5312               2008   CCGCCUCU G CUCUCUAU   1542   AUACAGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGACGCGC   5313               2092   GUUGGGGU G AGUUGAUG   1543   CAUCAACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCCCAAC   5314               2097   GGUGAGUU G AUGAAUCU   1544   AGAUUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACUCACC   5315               2100   CAGUUGAU G AAUCUAGC   1545   GCUAGAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCAACUC   5316               2237   UUUUGGGC G AGAAACUC   1546   CAGUUUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCCCAAAA   5317               2251   CUGUUCUU G AAUAUUUG   1547   CAAAUAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGAACAG   5318               2282   GUGGAUUC G CACUCCUC   1548   CACCACUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAAUCCAC   5319               2293   CUCCUCCU G CAUAUAGA   1549   UCUAUAUC GCAGGAAACUCC CU UCAAGCACAUCGUCCGCG ACCAGGAC   5320               2311   CACCAAAU G CCCCUAUC   1550   CAUAGGGG GGAGGAAACUCC CU UCAAGCACAUCGUCCGGG AUUUGGUG   5321               2354   UGUUAGAC G AAGAGGCA   1551   UGCCUCUU GCAGGAAACUCC CU UCAAGGACAUCCUCCGGG GUCUAACA   5322               2388   ACUCCCUC G CCUCGCAG   1552   CUCCCACC GCACGAAACUCC CU UCAAGGACAUCGUCCCGC CAGCGACU   5323               2393   CUCCCCUC G CAGACGAA   1553   UUCGUCUG GCACGAAACUCC CU UCAAGGACAUCCUCCGGC CACCCGAG   5324               2399   UCGCACAC G AAGCUCUC   1554   GACACCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCCGG CUCUGCGA   5325               2412   UCUCAAUC G CCCCCUCC   1555   CGACGCCC CCACGAAACUCC CU UCAAGGACAUCGUCCGGG CAUUCACA   5326               2415   CAAUCGCC G CGUCGCAG   1556   CUGCGACG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGCGAUUG   5327               2420   GCCGCGUC G CAGAAGAU   1557   AUCUUCUG CGAGGAAACUCC CU UCAAGGACAUCCUCCGGG GACCCCGC   5328               2514   CGUACCUU G CUUUAAUC   1558   GAUUAAAG GGACGAAACUCC CU UCAACCACAUCGUCCGCG AAGCUACC   5329               2549   CUUUUCCU G ACAUUCAU   1559   AUGAAUCU GGAGGAAACUCC CU UCAAGCACAUCGUCCGGG AGGAAAAC   5330               2560   AUUCAUUU G CAGGAGGA   1560   UCCUCCUG GGAGGAAACUCC CU UCAAGCACAUCCUCCGCG AAAUGAAU   5331               2576   ACAUUGUU G AUACAUGU   1561   ACAUCUAU GCAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACAAUGU   5332               2615   CAGUAAAU G AAAACAGC   1562   CCUGUUUU GCAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUACUG   5333               2641   UUAACUAU G CCUCCUAC   1563   CUAGCAGG GCAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUACUUAA   5334               2645   CUAUGCCU G CUAGCUUU   1564   AAACCUAG GCAGCAAACUCC CU UCAAGCACAUCCUCCCGC AGCCAUAC   5335               2677   AAAUAUUU G CCCUUACA   1565   UCUAAGCG GCACGAAACUCC CU UCAAGGACAUCCUCCGGC AAAUAUUU   5336               2740   CUCCAGAC G CGACAUUA   1566   UAAUGUCG GCACCAAACUCC CU UCAAGGACAUCCUCCGCC CUCUCCAA   5337               2742   CCACACGC G ACAUUAUU   1567   AAUAAUCU GGACGAAACUCC CU UCAACGACAUCGUCCCGC GCGUCUGG   5338               2804   CACGUAGC G CCUCAUUU   1568   AAAUGAGG CGACGAAACUCC CU UCAAGGACAUCGUCCCGG GCUACGUG   5339               2814   CUCAUUUU G CCGCUCAC   1569   GUGACCCG CGACGAAACUCC CU UCAAGGACAUCGUCCCGG AAAAUGAG   5340               2875   CAAACCUC G AAAACGCA   1570   UGCCUUUU GCACCAAACUCC CU UCAACGACAUCGUCCGGC CAGCUUUC   5341               2928   UCUUCCCC G AUCAUCAG   1571   CUGAUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGGAAGA   5342               2946   UCGACCCU G CAUUCAAA   1572   UUUCAAUC GGAGGAAACUCC CU UCAACGACAUCGUCCGCG ACCGUCCA   5343               2990   CUCAACCC G CACAACGA   1573   UCCUUCUC CGAGGAAACUCC CU UCAAGCACAUCCUCCCCG GCCUUGAC   5344               3012   GGCCCGAC G CCAACAAC   1574   CUUCUUCC CCACCAAACUCC CU UCAAGCACAUCCUCCGCC CUCCCCCC   5345               3090   CCCCUCAC G CUCAGCGC   1575   CCCCUCAC CCACCAAACUCC CU UCAACCACAUCCUCCCCC CUCACCCC   5346               3113   ACAACUGU G CCACCAGC   1576   CCUCCUCC CCACCAAACUCC CU UCAAGCACAUCCUCCCCC ACACUUGU   5347               3132   CUCCUCCU G CCUCCACC   1577   GGUGGAGG GGACCAAACUCC CU UCAAGGACAUCGUCCGCG ACCACCAC   5348               51   ACGCCCCU G UACUUUCC   1578   CGAAAGUA GCACCAAACUCC CU UCAAGCACAUCCUCCGCG ACCCCCCU   5349               106   AGAAUACU G UCUCUCCC   1579   GGCACACA GCACCAAACUCC CU UCAAGCACAUCCUCCCCC ACUAUUCU   5350               148   CGCACCCU G UACCCAAC   1580   CUUCCCUA GCACGAAACUCC CU UCAACCACAUCCUCCGCG ACGCUCCC   5351               198   CUGCUCCU G UUACAGGC   1581   CCCUCUAA CCACCAAACUCC CU UCAAGCACAUCCUCCCCG ACGAGCAG   5352               219   UUUUUCUU G UUCACAAA   1582   UUUCUCAA CCACCAAACUCC CU UCAAGGACAUCCUCCCCG AACAAAAA   5353               297   ACACCCCU G UCUCUUCG   1583   CCAAGACA GCACGAAACUCC CU UCAACCACAUCCUCCCCC ACGCCUGU   5354               299   ACCCCUCU G UCUUGGCC   1584   GCCCAAGA CCAGGAAACUCC CU UCAACCACAUCCUCCCCC ACACGGGU   5355               347   ACCAACCU G UUGUCCUC   1585   GACCACAA CCACGAAACUCC CU UCAACGACAUCCUCCCGC ACGUUCCU   5356               350   AACCUCUU G UCCUCCAA   1586   UUGCACCA CGACCAAACUCC CU UCAACGACAUCCUCCCGC AACACCUU   5357               362   UCCAAUUU G UCCUGCUU   1587   AACCACGA CGAGGAAACUCC CU UCAACCACAUCCUCCCGG AAAUUCCA   5358               381   CGCUGCAU G UGUCUCCC   1588   CCCACACA GGAGCAAACUCC CU UCAAGGACAUCGUCCCGC AUCCAGCG   5359               383   CUCCAUGU G UCUGCCGC   1589   GCCCCACA CCAGCAAACUCC CU UCAACCACAUCCUCCCCC ACAUCCAG   5360               438   AUCUUCUU G UUCGUUCU   1590   AGAACCAA GGACCAAACUCC CU UCAACGACAUCGUCCCGC AACAAGAU   5361               465   CAACCUAU G UUCCCCCU   1591   ACCGCCAA CGAGGAAACUCC CU UCAAGCACAUCCUCCGGG AUACCUUG   5362               476   GCCCGUUU G UCCUCUAA   1592   UUAGAGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAACGGGC   5363               555   ACCUCUAU G UUUCCCUC   1593   GAGGGAAA GGACGAAACUCC CU UCAAGGACAUCGUCCGGG AUAGAGGU   5364               566   UCCCUCAU G UUGCUGUA   1594   UACAGCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGAGCGA   5365               572   AUGUUGCU G UACAAAAC   1595   GUUUUGUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCAACAU   5366               602   CUGCACCU G UAUUCCCA   1596   UCGCAAUA GCAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGUCCAG   5367               694   UCCCAUUU G UUCAGUGG   1597   CCACUGAA GCAGGAAACUCC CU UCAAGGACAUCGUCCCCG AAAUGCCA   5368               724   CCCCCACU G UCUGGCUU   1598   AAGCCAGA GCACGAAACUCC CU UCAAGGACAUCGUCCGCG ACUGGCGC   5369               750   UGCAUGAU G UGGUUUUG   1599   CAAAACCA GCACGAAACUCC CU UCAAGGACAUCGUCCGGG AUCAUCCA   5370               771   CCAAGUCU G UACAACAU   1600   AUGUUGUA GCAGCAAACUCC CU UCAACGACAUCGUCCCGC ACACUUGG   5371               801   AUGCCGCU G UUACCAAU   1601   AUUCGUAA GCACGAAACUCC CU UCAAGGACAUCGUCCGGG AGCGGCAU   5372               818   UUUCUUUU G UCUUUGGG   1602   CCCAAACA GCACCAAACUCC CU UCAACGACAUCGUCCGCG AAAAGAAA   5373               888   UGCGAUAU G UAAUUCGG   1603   CCCAAUUA CGACGAAACUCC CU UCAAGCACAUCGUCCGGG AUAUCCCA   5374               927   AACAUAUU G UACAAAAA   1604   UUUUUGUA GCAGGAAACUCC CU UCAAGCACAUCGUCCGGG AAUAUGUU   5375               944   AUCAAAAU G UCUUUUAC   1605   CUAAAACA GGAGGAAACUCC CU UCAAGCACAUCGUCCGGG AUUUUGAU   5376               946   CAAAAUGU G UTUUAGGA   1606   UCCUAAAA CCACGAAACUCC CU UCAAGGACAUCGUCCCGG ACAUUUUG   5377               963   AACUUCCU G UAAACAGC   1607   CCUCUUUA CGAGGAAACUCC CU UCAAGCACAUCCUCCCGG AGGAAGUU   5378               991   GAAAGUAU G UCAACGAA   1608   UUCGUUGA CCACCAAACUCC CU UCAAGCACAUCGUCCGGC AUACUUUC   5379               1002   AACCAAUU G UGGGUCUU   1609   AACACCCA GGAGGAAACUCC CU UCAAGCACAUCCUCCCGC AAUUCCUU   5380               1039   CACCCAAU G UGGAUAUU   1610   AAUAUCCA GGAGCAAACUCC CU UCAAGCACAUCCUCCCGC AUUGCCUG   5381               1137   AACAGUAU G UCAACCUU   1611   AACGUUCA CGAGCAAACUCC CU UCAAGCACAUCGUCCGGC AUACUCUU   5382               1184   UCCCAAGU G UUUCCUGA   1612   UCAGCAAA CGAGCAAACUCC CU UCAAGCACAUCCUCCCGC ACUUGCCA   5383               1251   GAACCUUU G UGUCUCCU   1613   ACCACACA CGAGCAAACUCC CU UCAACCACAUCCUCCCGG AAACCUUC   5384               1253   ACCUUUGU G UCUCCUCU   1614   AGACCAGA CCAGCAAACUCC CU UCAACCACAUCCUCCCCC ACAAACGU   5385               1294   AGCCCCUU G UUUUCCUC   1615   CACCAAAA CGAGCAAACUCC CU UCAAGCACAUCCUCCGCC AACCGCCU   5386               1344   ACAAUUCU G UCCUCCUC   1616   GACCACCA CCACCAAACUCC CU UCAACCACAUCCUCCCCC ACAAUUGU   5387               1390   CCUACCCU G UCCUCCCA   1617   UCCCAGCA CGACCAAACUCC CU UCAAGCACAUCCUCCCCC AGCCUAGC   5388               1425   CCUCCUUU G UUUACGUC   1618   GACGUAAA CCACCAAACUCC CU UCAACCACAUCCUCCCGC AAAGCACC   5389               1508   CCCCUAUU G UACCCACC   1619   GCUCCGUA CCAGCAAACUCC CU UCAACCACAUCCUCCCGC AAUACCCC   5390               1557   CCCCCUCU G UCCCUUCU   1620   ACAACGCA CCAGCAAACUCC CU UCAACCACAUCCUCCCGC AGACCCCC   5391               1581   CCCACCCU G UCCACUUC   1621   GAACUGCA GCAGCAAACUCC CU UCAACCACAUCCUCCCGC ACCGUCCC   5392               1684   UCACCAAU G UCAACCAC   1622   GUCCUUCA GCACCAAACUCC CU UCAACCACAUCCUCCCCC AUUGCUCA   5393               1719   CAAAGACU G UCUCUUUA   1623   UAAACACA GCACCAAACUCC CU UCAACGACAUCCUCCCCC ACUCUUUC   5394               1721   AACACUGU G UCUTUAAU   1624   AUUAAACA CCACGAAACUCC CU UCAACGACAUCCUCCCGC ACAGUCUU   5395               1723   GACUCUCU G UUUAAUCA   1625   UCAUUAAA GCACGAAACUCC CU UCAACGACAUCCUCCCCC ACACAGUC   5396               1772   ACCUCUUU G UACUACCA   1626   UCCUACUA GCACGAAACUCC CU UCAACGACAUCCUCCCGC AAAGACCU   5397               1785   ACGACCCU G UACCCAUA   1627   UAUCCCUA GCACGAAACUCC CU UCAACGACAUCGUCCGGC AGCCUCCU   5398               1801   AAAUUCGU G UGUUCACC   1628   GCUCAACA GCACGAAACUCC CU UCAACCACAUCGUCCGCG ACCAAUUU   5399               1803   AUUGGUGU G UUCACCAG   1629   CUGGUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACACCAAU   5400               1850   CAUCUCAU G UUCAUGUC   1630   GACAUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGAGAUG   5401               1856   AUGUUCAU G UCCUACUG   1631   CAGUAGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGAACAU   5402               1864   GUCCUACU G UUCAAGCC   1632   GGCUUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUAGGAC   5403               1881   UCCAAGCU G UGCCUUGG   1633   CCAAGGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCUUGGA   5404               1939   GAGCUUCU G UGGAGUUA   1634   UAACUCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAGCUC   5405               2013   UCUGCUCU G UAUCGGGG   1635   CCCCGAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAGCAGA   5406               2045   GGAACAUU G UUCACCUC   1636   GAGGUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGUUCC   5407               2082   GCUAUUCU G UGUUGGGG   1637   CCCCAACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAUAGC   5408               2084   UAUUCUGU G UUGGGGUG   1638   CACCCCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAGAAUA   5409               2167   UCAGCUAU G UCAACGUU   1639   AACGUUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAGCUGA   5410               2205   CAACUAUU G UGGLUUCA   1640   UGAAACCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUAGUUG   5411               2222   CAUUUCCU G UCUUACUU   1641   AAGUAAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGAAAUG   5412               2245   GAGAAACU G UUCUUGAA   1642   UUCAAGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUUUCUC   5413               2262   UAUUUGGU G UCUUUUGG   1643   CCAAAAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCAAAUA   5414               2274   UUUGGAGU G UGGAUUCG   1644   CGAAUCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUCCAAA   5415               2344   AAACUACU G UUGUUAGA   1645   UCUAACAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUAGUUU   5416               2347   CUACUGUU G UUAGACGA   1646   UCGUCUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACAGUAG   5417               2450   AUCUCAAU G UUAGUAUU   1647   AAUACUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUGAGAU   5418               2573   AGGACAUU G UUGAUAGA   1648   UCUAUCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAUGUCCU   5419               2583   UGAUAGAU G UAAGCAAU   1649   AUUGCUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUCUAUCA   5420               2594   AGCAAUUU G UGGGGCCC   1650   GGGCCCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAUUGCU   5421               2663   AUCCCAAU G UUACUAAA   1651   UUUAGUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUGGGAU   5422               2717   CAGAGUAU G UAGUUAAU   1652   AUUAACUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUACUCUG   5423               2901   AUCUUUCU G UCCCCAAU   1653   AUUGGGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAAGAU   5424               3071   GGGGGACU G UUGGGGUG   1654   CACCCCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUCCCCC   5425               3111   UCACAACU G UGCCAGCA   1655   UGCUGGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUUGUGA   5426               40   AUCCCAGA G UCAGGGCC   1656   GGCCCUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUGGGAU   5427               46   GAGUCAGG G CCCUGUAC   1657   GUACAGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUGACUC   5428               65   UCCUGCUG G UGGCUCCA   1658   UGGAGCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGCAGGA   5429               68   UCCUGGUG G CUCCAGUU   1659   AACUGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACCAGCA   5430               74   UGGCUCCA G UUCAGGAA   1660   UUCCUGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAGCCA   5431               85   CAGGAACA G UGAGCCCU   1661   AGGGCUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUCCUG   5432               89   AACAGUGA G CCCUGCUC   1662   GAGCAGGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCACUGUU   5433               120   GCCAUAUC G UCAAUCUU   1663   AAGAUUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAUAUGGC   5434               196   CCCUGCUC G UGUUACAG   1664   CUGUAACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAGCAGGG   5435               205   UGUUACAG G CGGGGUUU   1665   AAACCCCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGUAACA   5436               210   CAGGCGGG G UUUUUCUU   1666   AAGAAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCGCCUG   5437               248   ACCACAGA G UCUAGACU   1667   AGUCUAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUGUGGU   5438               258   CUAGACUC G UGGUGGAC   1668   GUCCACCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAGUCUAG   5439               261   GACUCGUG G UGGACUUC   1669   GAAGUCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACGAGUC   5440               295   GAACACCC G UGUGUCUU   1670   AAGACACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGUGUUC   5441               305   GUGUCUUG G CCAAAAUU   1671   AAUUUUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGACAC   5442               318   AAUUCGCA G UCCGAAAU   1672   AUUUGGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCGAAUU   5443               332   AAUCUCCA G UCACUCAC   1673   GUGAGUGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAGAUU   5444               368   UUGUCCUG G UUAUCGCU   1674   AGCGAUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGGACAA   5445               390   UGUCUGCG G CGUUUUAU   1675   AUAAAACG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGCAGACA   5446               392   UCUGCGGC G UUUUAUCA   1676   UGAUAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCCGCAGA   5447               442   UCUUGUUG G UUCUUCUG   1677   CAGAAGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAACAAGA   5448               461   CUAUCAAG G UAUGUUGC   1678   GCAACAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUGAUAG   5449               472   UGUUGCCC G UUUGUCCU   1679   AGGACAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGCAACA   5450               506   AACAACCA G CACCGGAC   1680   GUCCGGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGUUGUU   5451               625   CAUCUUGG G CUUUCGCA   1681   UGCGAAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAAGAUG   5452               648   CUAUGGGA G UGGGCCUC   1682   GAGGCCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCCAUAG   5453               652   GGGAGUGG G CCUCAGUC   1683   GACUGAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCACUCCC   5454               658   GGGCCUCA G UCCGUUUC   1684   GAAACGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGGCCC   5455               662   CUCAGUCC G UUUCUCUU   1685   AAGAGAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGACUGAG   5456               672   UUCUCUUG G CUCAGUUU   1686   AAACUGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGAGAA   5457               677   UUGGCUCA G UUUACUAG   1687   CUAGUAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGCCAA   5458               685   GUUUACUA G UGCCAUUU   1688   AAAUGGCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGUAAAC   5459               699   UUUGUUCA G UGGUUCGU   1689   ACGAACCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAACAAA   5460               702   GUUCAGUG G UUCGUAGG   1690   CCUACGAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACUGAAC   5461               706   AGUGGUUC G UAGGGCUU   1691   AAGCCCUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAACCACU   5462               711   UUCGUAGG G CUUUCCCC   1692   GGGGAAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUACGAA   5463               729   ACUGUCUG G CUUUCAGU   1693   ACUGAAAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGACAGU   5464               736   GGCUUUCA G UUAUAUGG   1694   CCAUAUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAAGCC   5465               753   AUGAUGUG G UUUUGGGG   1695   CCCCAAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACAUCAU   5466               762   UUUUGGGG G CCAAGUCU   1696   AGACUUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCCAAAA   5467               767   GGGGCCAA G UCUGUACA   1697   UGUACAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGGCCCC   5468               785   CAUCUUGA G UCCCUUUA   1698   UAAAGGGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAAGAUG   5469               826   GUCUUUGG G UAUACAUU   1699   AAUGUAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAAAGAC   5470               898   AAUUGGGA G UUGGGGCA   1700   UGCCCCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCCAAUU   5471               904   GAGUUGGG G CACAUUGC   1701   GCAAUGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCAACUC   5472               971   GUAAACAG G CCUAUUGA   1702   UCAAUAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGUUUAC   5473               987   AUUGGAAA G UAUGUCAA   1703   UUGACAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UTUCCAAU   5474               1006   AAUUGUGG G UCUUUUCG   1704   CCAAAAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGCG CCACAAUU   5475               1016   CUUUUGGG G UUUGCCCC   1705   GCGGCAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCAAAAC   5476               1080   GCAUACAA G CAAAACAG   1706   CUGUUUUG GGAGGAAACUCC CU UCAACGACAUCGUCCCCC UUGUAUGC   5477               1089   CAAAACAG G CUUUUACU   1707   ACUAAAAG GCAGCAAACUCC CU UCAACGACAUCGUCCCGG CUCUUUUC   5478               1116   CUUACAAC G CCUUUCUA   1708   UACAAAGC GCAGCAAACUCC CU UCAACCACAUCCUCCGGG CUUGUAAG   5479               1126   CUUUCUAA G UAAACACU   1709   ACUGUUUA GGACGAAACUCC CU UCAACGACAUCCUCCCGC UUACAAAC   5480               1133   AGUAAACA G UAUCUCAA   1710   UUCACAUA CCACCAAACUCC CU UCAACCACAUCCUCCCCC UCUUUACU   5481               1152   UUUACCCC G UUGCUCCC   1711   CCCAGCAA CGAGCAAACUCC CU UCAAGGACAUCCUCCGCG CCGCUAAA   5482               1160   GUUGCUCG G CAACCCCC   1712   CCCCCUUG CGACGAAACUCC CU UCAAGGACAUCCUCCGCG CCACCAAC   5483               1166   CCGCAACC G CCUGGUCU   1713   ACACCACG GCAGCAAACUCC CU UCAAGCACAUCGUCCGGC CGUUCCCG   5484               1171   ACCGCCUC G UCUAUCCC   1714   CGCAUAGA GCAGCAAACUCC CU UCAACGACAUCGUCCCGC CACGCCCU   5485               1182   UAUGCCAA G UCUUUGCU   1715   ACCAAACA GCACCAAACUCC CU UCAACGACAUCCUCCCCC UUCCCAUA   5486               1207   CCCCACUG G UUCCCCCU   1716   ACCCCCAA CGAGGAAACUCC CU UCAACGACAUCGUCCGCG CACUGCGG   5487               1213   UGCUUCGC G CUUCCCCA   1717   UGCCCAAG CCACCAAACUCC CU UCAACGACAUCGUCCGGG CCCAACCA   5488               1218   GCCGCUUG G CCAUAGGC   1718   GCCUAUCC CCAGGAAACUCC CU UCAACGACAUCCUCCCCG CAAGCCCC   5489               1225   CGCCAUAC G CCAUCACC   1719   CCUCAUCC CCACCAAACUCC CU UCAACCACAUCCUCCCCC CUAUCCCC   5490               1232   CCCCAUCA G CGCAUCCC   1720   CCCAUCCC CCACCAAACUCC CU UCAACCACAUCCUCCCGC UGAUCGCC   5491               1240   CCCCAUCC G UCCAACCU   1721   ACCUUCCA GCACCAAACUCC CU UCAACCACAUCCUCCCCC CCAUCCCC   5492               1287   AACUCCUA G CCCCUUCU   1722   ACAACCCC CCACCAAACUCC CU UCAACCACAUCCUCCCGC UACCACUU   5493               1306   UCCUCCCA G CACCUCUC   1723   CACACCUC CCACCAAACUCC CU UCAACGACAUCCUCCCGC UGCGAGCA   5494               1310   CCCACCAC G UCUCCCCC   1724   CCCCCACA CCACCAAACUCC CU UCAACCACAUCCUCCCCC CUCCUCCC   5495               1317   CCUCUGCC G CAAAACUC   1725   CACUUUUC CCACCAAACUCC CU UCAACCACAUCCUCCCCC CCCACACC   5496               1347   AUUCUCUC G UCCUCUCC   1726   CCACACCA CCACCAAACUCC CU UCAACCACAUCCUCCCCC CACACAAU   5497               1379   UUUCCAUC G CUCCUACC   1727   CCUACCAC CCACCAAACUCC CU UCAACCACAUCCUCCCCC CAUCCAAA   5498               1387   CCUCCUAC G CUCUCCUC   1728   CACCACAC CCACCAAACUCC CU UCAACCACAUCCUCCCCC CUACCACC   5499               1418   CCCCCCAC G UCCUUUCU   1729   ACAAACCA CGACCAAACUCC CU UCAACCACAUCCUCCCCC CUCCCCCC   5500               1431   UUCUUUAC G UCCCCUCC   1730   CCACCCCA CCACCAAACUCC CU UCAACCACAUCCUCCCCC CUAAACAA   5501               1436   UACCUCCC G UCCCCCCU   1731   ACCCCCCA CGACCAAACUCC CU UCAAGCACAUCCUCCCCC CCCACCUA   5502               1440   UCCCCUCC G CGCUCAAU   1732   AUUCACCC CCACCAAACUCC CU UCAACCACAUCCUCCGCC CCACCCCA   5503               1471   CUCCCCCC G CCCCUUCC   1733   CCAACCCC CCACCAAACUCC CU UCAACCACAUCCUCCCCC CCCCCCAC   5504               1481   CCCUUCCC G CUCUACCC   1734   CCCUACAC CCACCAAACUCC CU UCAAGCACAUCCUCCGCC CCCAACCC   5505               1517   UACCCACC G UCCACCCC   1735   CCCCUCCA CCACCAAACUCC CU UCAAGCACAUCCUCCCCC CCUCCCUA   5506               1526   UCCACCCC G CCCACCUC   1736   CACCUCCC CCACCAAACUCC CU UCAACCACAUCCUCCCCC CCCCUCCA   5507               1553   CACUCCCC G UCUCUCCC   1737   CCCACACA CCACCAAACUCC CU UCAACCACAUCCUCCCCC GCGCACUC   5508               1579   CCCCCACC G UCUCCACU   1738   ACUCCACA CCACCAAACUCC CU UCAACCACAUCCUCCCCC CCUCCCCC   5509               1605   CUCUCCAC G UCGCAUCC   1739   CCAUCCCA CCACCAAACUCC CU UCAACCACAUCCUCCCCC CUCCACAC   5510               1622   AGACCACC G UGAACGCC   1740   GGCGUUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGUGGUCU   5511               1649   UGCCCAAG G UCUUGCAU   1741   AUGCAAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUGGGCA   5512               1679   GACUUUCA G CAAUGUCA   1742   UGACACUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAAAGUC   5513               1703   ACCUUGAG G CAUACUUC   1743   GAAGUAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCAAGGU   5514               1732   UUUAAUGA G UGGGAGGA   1744   UCCUCCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCAUUAAA   5515               1741   UGGUAGGA G UUGGGGGA   1745   UCCCCCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUCCCA   5516               1754   UGGAGGAG G UUAGGUUA   1746   UAACCUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCUCCC   5517               1759   GAGGUUAG G UUAAAGGU   1747   ACCUUUAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUAACCUC   5518               1766   GGUUAAAG G UCUUUGUA   1748   UACAAAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUUAACC   5519               1782   ACUAGGAG G CUGUAGGC   1749   GCCUACAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCUAGU   5520               1789   GGCUGUAG G CAUAAAUU   1750   AAUUUAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUACAGCC   5521               1799   AUAAAUUG G UGUGUUCA   1751   UGAACACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAUUUAU   5522               1811   GUCCACCA G CACCAUGC   1752   UCAUGGUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGUGAAC   5523               1870   CUGUUCAA G CCUCCAAG   1753   CUUGGAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGAACAG   5524               1878   GCCUCCAA G CUGUGCCU   1754   AGGCACAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGGAUGC   5525               1890   UGCCUUGG G UUGCUUUG   1755   CAAAGCCA GGAGUAAACUCC CU UCAAGGACAUCGUCCGGG CCAAGGCA   5526               1893   CUUGGGUG G CUUUGGGG   1756   CCCCAAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACCCAAG   5527               1901   GCUUUGGG G CAUGGACA   1757   UGUCCAUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCAAAGC   5528               1917   AUUGACCC G UAUAAAGA   1758   UCUUUAUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGGUCAAU   5529               1933   AAUUUGGA G CUUCUGUU   1759   CACAGAAG GGAGUAAACUCC CU UCAAGGACAUCGUCCGGG UCCAAAUU   5530               1944   UCUGUGGA G UUACUCUC   1760   GAGAUUAA GUAGUAAACUCC CU UCAAGUACAUCUUCCGGU UCCACAGA   5531               2023   AUCUGGUG G CCUUAGAG   1761   CUCUAAGG GGAGGAAACUCC CU UCAAGGACAUCGUCCUGU CCCCCGAU   5532               2031   GCCUUAGA G UCUCCGGA   1762   UCCUGAGA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUAAGGC   5533               2062   ACCAUACG G CACUCAGG   1763   CCUUAGUG GGAUGAAACUCC CU UCAAGGACAUCUUCCUGU CGUAUGGU   5534               2070   UCACUCAG G CAAGCUAU   1764   AUAGCUUG GGAGGAAACUCC CU UCAAUGACAUCGUCCGGG CUGAGUGC   5535               2074   UCAGGCAA G CUAUUCUG   1765   CAGAAUAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGCCUGA   5536               2090   GUGUUGGG G UGAGUUGA   1766   UCAACUCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCAACAC   5537               2094   UGGUGUGA G UUGAUGAA   1767   UUCAUCAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCACCCCA   5538               2107   UGAAUCUA G CCACCUGG   1768   CCAGGUGG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGAUUCA   5539               2116   CCACCUGG G UGGGAAGU   1769   ACUUCCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAGGUGG   5540               2123   GGUGGGAA G UAAUUUGG   1770   CCAAAUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCCACC   5541               2140   AAGAUCCA G CAUCCAUG   1771   CCUUGAUG GGAGGAAACUCC CU UCAAGUACAUCGUCCGGG UGGAUCUU   5542               2155   GGGAAUUA G UAGUCAUC   1772   GCUGACUA UGAGUAAACUCC CU UCAAGGACAUCGUCCGGG UAAUUCCC   5543               2158   AAUUAGUA G UCAUCUAC   1773   AUAGCUUA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UACUAAUU   5544               2162   AGUAGUCA G CUAUGUCA   1774   UGACAUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUACUACU   5545               2173   AUGUCAAC G UUAAUAUG   1775   CAUAUUAA GGAGGAAACUCC CU UCAAGGACAUCUUCCGGG GUUGACAU   5546               2183   UAAUAUGG G CCUAAAAA   1776   UCCUCAUG GGAGGAAACUCC CU UCAAUGACAUCGUCCGGG CCAUAUUA   5547               2208   CUAUUGUG G UUUCACAU   1777   AUGUGAAA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACAAUAG   5548               2235   ACUUUUGG G CGAGAAAC   1778   GUUUCUCG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAAAAGU   5545               2260   AAUATUUG G UGUCUUUU   1779   AAAAGACA GUAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAAUAUU   5550               2272   CUUUUGCA G UGUGUAUU   1780   AAUCCACA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAAAAG   5551               2360   ACGAAGAG G CAGGUCCC   1781   GGGACCUG GGAGUAAACUCC CU UCAAUUACAUCGUCCGGG CUCUUCGU   5552               2364   AGAGGCAG G UCCCCUAG   1782   CUAGUGGA UGAGUAAACUCC CU UCAAGUACAUCUUCCUUG CUUCCUCU   5553               2403   AGACUAAG G UCUCAAUC   1783   GAUUGAGA UGAUGAAACUCC CU UCAAGUACAUCGUCCGGG CUUCGUCU   5554               2417   AUCUCCUC G UCGCAUAA   1784   UUCUGCGA UGAGUAAACUCC CU UCAAGGACAUCUUCCGGU GCGGCUAU   5555               2454   CAAUGUUA G UAUUCCUU   1785   AAGUAAUA GGAGUAAACUCC CU UCAAGGACAUCUUCCGUU UAACAUUU   5556               2474   CACAUAAU G UUGUAAAC   1786   UUUUCCCA GGAGUAAACUCC CU UCAAGGACAUCGUCCGUG CUUAUGUG   5557               2491   UUUACGUG G CUUUAUUC   1787   UAAUAAAU GGAGUAAACUCC CU UCAAGUACAUCGUCCGUG CCCUUAAA   5558               2507   CUUCUACG G UACCUUGC   1788   UCAAGGUA GGAGUAAACUCC CU UCAAGUACAUCGUCCGGG CGUAGAAG   5559               2530   CCUAAAUG G CAAACUCC   1789   GGAUUUUU GGAGUAAACUCC CU UCAAGUACAUCUUCCGGG CAUUUAGG   5560               2587   AUAUUUAA G CAAUUUUU   1790   ACAAAUUG GGAGUAAACUCC CU UCAAGUACAUCUUCCUUG UUACAUCU   5561               2599   UUUGUGGU G CCCCUUAC   1791   UUAAUUUU UUAUUAAACUCC CU UCAAUUACAUCUUCCUGU CCCACAAA   5562               2609   CCCUUACA G UAAAUUAA   1792   UUCAUUUA UUAUUAAACUCC CU UCAAGUACAUCUUCCUGU UGUAAUGU   5563               2650   CCUUCUAU G UUUUAUCC   1793   UUAUAAAA GUAUUAAACUCC CU UCAAUUACAUCUUCCUUU CUAUCAUU   5564               2701   AUCAAACC G UAUUAUCC   1794   UUAUAAUA GUAUGAAACUCC CU UCAAUGACAUCGUCCGUU UGUUUUAU   5565               2713   UAUCCAUA G UAUGUAUU   1795   ACUACAUA GUAUGAAACUCC CU UCAAUGACAUCGUCCGGG UCUGUAUA   5566               2720   AUUAUUUA G UUAAUCAU   1796   AUUAUUAA UUAUUAAACUCC CU UCAAUGACAUCGUCCGUG UACAUACU   5567               2768   UUUUUAAG G CUGUGAUC   1797   GAUCCCCU UUAUGAAACUCC CU UCAAUGACAUCGUCCGGG CUUCCAAA   5568               2791   AAAAGAUA G UCCACACG   1798   CUUUUGUA GUAUUAAACUCC CU UCAAUUACAUCGUCCGUG UCUCUUUU   5569               2799   GUCCACAC G UAGCGCCU   1799   AUGCGCUA UUAUGAAACUCC CU UCAAUUACAUCUUCCUUU UUUUUUAC   5570               2802   CACACUUA G CUCCUCAU   1800   AUUAGUCU UUAUGAAACUCC CU UCAAUGACAUCUUCCGUG UACGUGUG   5571               2818   UUUUGCGU G UCACCAUA   1801   UAUUGUGA UGAGGAAACUCC CU UCAAUUACAUCUUCCGUG CCUCAAAA   5572               2848   GAUCUACA G CAUUUUAU   1802   CUCCCAUU UUAGUAAACUCC CU UCAAUUACAUCUUCCGUG UGUAGAUC   5573               2857   CAUGUGAG G UUGGUCUU   1803   AAGACCAA UGAUUAAACUCC CU UCAAUUACAUCUUCCUUG CUCCCAUG   5574               2861   UGAGGUUU G UCUUCCAA   1804   UUGUAAUA UUAGUAAACUCC CU UCAAGUACAUCUUCCUUU CAACCUCC   5575               2881   UCUAAAAU G CAUGUGGA   1805   UCCCCAUU UUAUUAAACUCC CU UCAAGUACAUCUUCCUUG CUUUUCUA   5576               2936   GAUCAUCA G UUUUACCC   1806   UGUUCCAA UGAGUAAACUCC CU UCAAUUACAUCUUCCUUG UGAUGAUC   5577               2955   CAUUCAAA G CCAACUCA   1807   UGAGUUUU UUAGUAAACUCC CU UCAAGUACAUCUUCCUUG UUUUAAUU   5578               2964   CCAACUCA G UAAAUCCA   1808   UGUAUUUA GUAUUAAACUCC CU UCAAUUACAUCUUCCUUG UUAUUUUG   5579               3005   GACAACUU G CCGUACUC   1809   UCUUCCUG GUAUUAAACUCC CU UCAAUUACAUCUUCCUGU CAUUUUUC   5580               3021   CCAACAAG G UUGUAUUU   1810   CACUCCCA GUAUUAAACUCC CU UCAAUUACAUCUUCCUGU CUUGUUGG   5581               3027   AGGUGUGA G UGUGAUCA   1811   UGCUCCCA GUAUGAAACUCC CU UCAAUGACAUCUUCCUGU UCCCACCU   5582               3033   GAGUGUGA G CAUUCUGU   1812   CCCUAAUG UUAUGAAACUCC CU UCAAUGACAUCUUCCUGU UCCCACUC   5583               3041   UCAUUCUG G CCAUGUUU   1813   AACCCUUU GUAUGAAACUCC CU UCAAUUACAUCGUCCGGG CCUAAUUC   5584               3047   GGGCCAGG G UUCACCCC   1814   GGGGUCAA GCAGGAAACUCC CU UCAAGCACAUCGUCCGGG CCUGGCCC   5585               3077   CUGUUGGG G UGGAGCCC   1815   GGGCUCCA GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCAACAG   5586               3082   GGGGUGGA G CCCUCACG   1816   CGUGAGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCACCCC   5587               3097   CGCUCAGG G CCUACUCA   1817   UGACUAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUGAGCG   5588               3117   CUGUGCCA G CAGCUCCU   1818   AGGACCUG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGCACAG   5589               3120   UGCCAGCA G CUCCUCCU   1819   AGGAGGAG GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCUGGCA   5590               3146   ACCAAUCG G CACUCAGG   1820   CCUGACUC GGAGGAAACUCC CU UCAAGGACAUCCUCCGCG CGAUUGGU   5591               3149   AAUCCGCA G UCAGGAAG   1821   CUUCCUGA GGAGCAAACUCC CU UCAAGGACAUCGUCCGGG UGCCGAUU   5592               3158   UCAGGAAG G CACCCUAC   1822   GUAGGCUC GGAGCAAACUCC CU UCAAGGACAUCCUCCGGG CUUCCUCA   5593               3161   GGAAGGCA G CCUACUCC   1823   CGACUACG CGAGCAAACUCC CU UCAAGGACAUCCUCCGGC UCCCUUCC   5594               3204   AUCCUCAG G CCAUGCAG   1824   CUGCAUGG GCAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGAGGAU   5595               31   CUCUUCAA G AUCCCACA   2196   UCUGCGAU GGAGGAAACUCC CU UCAAGGACAUCCUCCGGG UUGAACAG   5596               38   ACAUCCCA G AGUCAGGG   2197   CCCUGACU GGAGGAAACUCC CU UCAAGGACAUCGUCCCGG UGGGAUCU   5597               44   CACAGUCA G GCCCCUGU   2198   ACAGCGCC GCACGAAACUCC CU UCAAGGACAUCGUCCGGG UGACUCUG   5598               45   AGAGUCAG G GCCCUGUA   2199   UACAGGCC GGACGAAACUCC CU UCAAGGACAUCGUCCCGG CUGACUCU   5599               64   UUCCUCCU G GUGGCUCC   2200   CCACCCAC CGAGCAAACUCC CU UCAACCACAUCGUCCGGG AGCAGGAA   5800               67   CUGCUGCU G GCUCCAGU   2201   ACUGGAGC CGAGCAAACUCC CU UCAAGGACAUCGUCCGCG ACCAGCAG   5601               79   CCAGUUCA G GAACACUC   2202   CACUGUUC GGAGCAAACUCC CU UCAAGCACAUCCUCCGCC UGAACUGG   5602               80   CAGUUCAC G AACAGUCA   2203   UCACUCUU CGAGCAAACUCC CU UCAAGCACAUCGUCCGGC CUCAACUG   5603               99   CCUGCUCA G AAUACUGU   2204   ACAGUAUU CCAGCAAACUCC CU UCAAGCACAUCGUCCGGG UGACCACC   5604               135   UUAUCGAA G ACUCCCCA   2205   UCCCCACU CCACCAAACUCC CU UCAAGCACAUCCUCCCCG UUCCAUAA   5605               139   CGAAGACU G GCCACCCU   2206   AGCCUCCC CCACCAAACUCC CU UCAACGACAUCGUCCGGC ACUCUUCG   5606               140   GAAGACUG G GGACCCUG   2207   CAGGGUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGUCUUC   5607               141   AACACUCC G CACCCUGU   2208   ACAGCGUC GCACCAAACUCC CU UCAACCACAUCCUCCCCG CCACUCUU   5608               142   AGACUGGG G ACCCUCUA   2209   UACAGCCU CGAGGAAACUCC CU UCAACCACAUCGUCCCCC CCCACUCU   5609               159   CCGAACAU G GAGAACAU   2210   AUCUUCUC GGAGGAAACUCC CU UCAAGGACAUCCUCCCCC AUGUUCGG   5610               160   CGAACAUC G AGAACAUC   2211   CAUCUUCU CCACCAAACUCC CU UCAAGGACAUCCUCCCCC CAUGUUCG   5611               162   AACAUCCA G AACAUCCC   2212   CCCAUCUU GCACGAAACUCC CU UCAACCACAUCGUCCGCC UCCAUCUU   5612               175   UCCCAUCA G GACUCCUA   2213   UACCACUC CCACGAAACUCC CU UCAACCACAUCGUCCCGC UCAUCCCA   5613               176   CCCAUCAG G ACUCCUAG   2214   CUAGGAGU GGAGCAAACUCC CU UCAACCACAUCGUCCCGG CUGAUGCC   5614               184   CACUCCUA G GACCCCUC   2215   CAGGGGUC GCAGGAAACUCC CU UCAACCACAUCGUCCGGG UACCACUC   5615               185   ACUCCUAC G ACCCCUCC   2216   CCAGGGCU CCAGGAAACUCC CU UCAACCACAUCCUCCCCC CUACCACU   5616               204   CUGUUACA G CCCGCGUU   2217   AACCCCCC GCAGCAAACUCC CU UCAAGGACAUCCUCCCGG UGUAACAC   5617               207   UUACAGGC G CCCUUUUU   2218   AAAAACCC CCACCAAACUCC CU UCAAGGACAUCCUCCGCC CCCUGUAA   5618               208   UACACCCC G GGUUUUUC   2219   CAAAAACC GCACGAAACUCC CU UCAAGCACAUCGUCCGGC CCCCUCUA   5619               209   ACAGCCCC G CUUUUUCU   2220   AGAAAAAC GGAGGAAACUCC CU UCAACCACAUCGUCCGGG CCCCCUCU   5620               246   AUACCACA G AGUCUACA   2221   UCUAGACU GCACCAAACUCC CU UCAACCACAUCGUCCCCC UCUCCUAU   5621               253   AGAGUCUA G ACUCGUGG   2222   CCACGAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGACUCU   5622               260   AGACUCGU G CUGCACUU   2223   AAGUCCAC GCAGCAAACUCC CU UCAAGGACAUCGUCCGGG ACGAGUCU   5623               263   CUCGUGGU G GACUUCUC   2224   CAGAAGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCACGAC   5624               264   UCGUGGUG G ACUUCUCU   2225   AGAGAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACCACGA   5625               283   AUUUUCUA G GGGGAACA   2226   UGUUCCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGAAAAU   5626               284   UUUUCUAC G GGGAACAC   2227   GUGUUCCC GGAGGAAACUCC CU UCAAGGACAUCCUCCGGG CUAGAAAA   5627               285   UUUCUAGG G GGAACACC   2228   GGUGUUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUAGAAA   5628               286   UUCUAGGG G GAACACCC   2229   GGGUGUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGCG CCCUACAA   5629               287   UCUAGGGG G AACACCCG   2230   CGGGUGUU GGAGCAAACUCC CU UCAAGGACAUCGUCCGGG CCCCUAGA   5630               304   UGUGUCUU G GCCAAAAU   2231   AUUUUGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGACACA   5631               367   UUUGUCCU G GUUAUCGC   2232   GCGAUAAC GCACCAAACUCC CU UCAAGGACAUCGUCCCGG AGGACAAA   5632               377   UUAUCGCU G GAUGUGUC   2233   GACACAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGCGAUAA   5633               378   UAUCGCUG G AUGUGUCU   2234   AGACACAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGCGAUA   5634               389   GUGUCUGC G GCGUUUUA   2235   UAAAACCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCAGACAC   5635               441   UUCUUGUU G GUUCUUCU   2236   AGAAGAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACAAGAA   5636               450   GUUCUUCU G GACUAUCA   2237   UGAUAGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGAAGAAC   5637               451   UUCUUCUG G ACUAUCAA   2238   UUGAUAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAGAAGAA   5638               460   ACUAUCAA G GUAUGUUG   2239   CAACAUAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGAUAGU   5639               490   UAAUUCCA G GAUCAUCA   2240   UGAUGAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAAUUA   5640               491   AAUUCCAG G AUCAUCAA   2241   UUGAUGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGGAAUU   5641               511   CCAGCACC G GACCAUGC   2242   GCAUGGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGUGCUGG   5642               512   CAGCACCG G ACCAUGCA   2243   UGCAUGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGUGCUG   5643               544   CUGCUCAA G GAACCUCU   2244   AGAGGUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGAGCAG   5644               545   UGCUCAAG G AACCUCUA   2245   UAGAGGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUGAGCA   5645               585   AAACCUAC G GACGGAAA   2246   UUUCCGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUAGGUUU   5646               586   AACCUACG G ACGGAAAC   2247   GUUUCCGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGUAGGUU   5647               589   CUACGGAC G GAAACUGC   2248   GCAGUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUCCGUAG   5648               590   UACGGACG G AAACUGCA   2249   UGCAGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGUCCGUA   5649               623   AUCAUCUU G CCCUUUCG   2250   CGAAACCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGAUGAU   5650               624   UCAUCUUC G GCUUUCGC   2251   CCGAAAGC CGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGAUCA   5651               644   AUACCUAU G GGAGUGGG   2252   CCCACUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAGGUAU   5652               645   UACCUAUG G GAGUGGGC   2253   GCCCACUC GGAGCAAACUCC CU UCAAGGACAUCGUCCGCG CAUAGGUA   5653               646   ACCUAUGG G AGUGCGCC   2254   CGCCCACU GGAGCAAACUCC CU UCAAGCACAUCGUCCGCG CCAUACGU   5654               650   AUGGGAGU G GGCCUCAC   2255   CUGAGGCC CGAGCAAACUCC CU UCAAGCACAUCGUCCGGG ACUCCCAU   5655               651   UGGCAGUG G GCCUCAGU   2256   ACUGAGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACUCCCA   5656               671   UUUCUCUU G GCUCAGUU   2257   AACUCACC GGAGGAAACUCC CU UCAAGGACAUCGUCCGCG AAGAGAAA   5657               701   UGUUCACU G GUUCCUAG   2258   CUACGAAC GCAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACUGAACA   5658               709   GGUUCGUA G GGCUUUCC   2259   GGAAAGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UACGAACC   5659               710   GUUCGUAG G GCUUUCCC   2260   GGGAAAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUACGAAC   5660               728   CACUGUCU G GCUUUCAG   2261   CUGAAAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCCGG AGACAGUG   5661               743   AGUUAUAU G GAUGAUGU   2262   ACAUCAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAUAACU   5662               744   GUUAUAUG G AUGAUGUG   2263   CACAUCAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUAUAAC   5663               752   GAUGAUGU G GUUUUGCG   2264   CCCAAAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCCGC ACAUCAUC   5664               758   GUGGUUUU G GGGGCCAA   2265   UUGGCCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAACCAC   5665               759   UGGUUUUG G GGGCCAAG   2266   CUUGGCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAAACCA   5666               760   GGUUUUGG G GGCCAAGU   2267   ACUUGGCC GGAGGAAACUCC CU UCAAGGACAUCCUCCGGG CCAAAACC   5667               761   GUUUUGGG G GCCAACUC   2268   CACUUGGC CGAGGAAACUCC CU UCAAGCACAUCGUCCGCC CCCAAAAC   5668               824   UUGUCUUU G GGUAUACA   2269   UGUAUACC CGAGCAAACUCC CU UCAAGGACAUCGUCCGGG AAAGACAA   5669               825   UGUCUUUC G CUAUACAU   2270   AUGUAUAC CGAGCAAACUCC CU UCAAGGACAUCGUCCCGG CAAAGACA   5670               856   AACAAAAA G AUGGGGAU   2271   AUCCCCAU GGAGCAAACUCC CU UCAAGGACAUCGUCCGGG UUUUUGUU   5671               859   AAAAAGAU G CGGAUAUU   2272   AAUAUCCC GGAGGAAACUCC CU UCAAGCACAUCCUCCGGC AUCUUUUU   5672               860   AAAAGAUC G GGAUAUUC   2273   GAAUAUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUCUUUU   5673               861   AAACAUGC G GAUAUUCC   2274   GGAAUAUC CGAGGAAACUCC CU UCAACGACAUCGUCCGGG CCAUCUUU   5674               862   AAGAUGGC G AUAUUCCC   2275   GGGAAUAU CGAGCAAACUCC CU UCAAGGACAUCGUCCCCG CCCAUCUU   5675               881   AACUUCAU G GGAUAUGU   2276   ACAUAUCC CGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGAAGUU   5676               882   ACUUCAUC G GAUAUGUA   2277   UACAUAUC CGAGCAAACUCC CU UCAAGGACAUCCUCCGGC CAUGAAGU   5677               883   CUUCAUGC G AUAUGUAA   2278   UUACAUAU GGAGGAAACUCC CU UCAAGGACAUCCUCCGGC CCAUGAAG   5678               894   AUGUAAUU G GGAGUUGG   2279   CCAACUCC GGAGGAAACUCC CU UCAACGACAUCGUCCGGG AAUUACAU   5679               895   UCUAAUUG G GAGUUCGG   2280   CCCAACUC GGACGAAACUCC CU UCAAGGACAUCGUCCGGG CAAUUACA   5680               896   CUAAUUGC G AGUUGGGC   2281   CCCCAACU CCAGCAAACUCC CU UCAAGGACAUCCUCCGCG CCAAUUAC   5681               901   UGGCACUU G CCGCACAU   2282   AUGUGCCC GGAGGAAACUCC CU UCAACCACAUCCUCCGGG AACUCCCA   5682               902   GCGAGUUG G CGCACAUU   2283   AAUGUCCC GCAGGAAACUCC CU UCAACGACAUCCUCCCCG CAACUCCC   5683               903   GGACUUCC G CCACAUUC   2284   CAAUCUCC GGAGGAAACUCC CU UCAACCACAUCCUCCCCC CCAACUCC   5684               917   UUCCCACA G CAACAUAU   2285   AUAUCUUC CCACCAAACUCC CU UCAACCACAUCCUCCCGC UCUCCCAA   5685               918   UCCCACAC G AACAUAUU   2286   AAUAUCUU CCACCAAACUCC CU UCAAGGACAUCCUCCCGG CUGUGGCA   5686               952   CUCUUUUA G GAAACUUC   2287   GAAGUUUC GCACCAAACUCC CU UCAACCACAUCCUCCCGC UAAAACAC   5687               953   UCUUUUAC G AAACUUCC   2288   CGAAGUUU CCACCAAACUCC CU UCAACGACAUCCUCCCCC CUAAAACA   5688               970   UCUAAACA G CCCUAUUC   2289   CAAUAGGC GCACCAAACUCC CU UCAACCACAUCCUCCCCC UCUUUACA   5689               982   UAUUCAUU G CAAAGUAU   2290   AUACUUUC CCACCAAACUCC CU UCAACCACAUCCUCCCCC AAUCAAUA   5690               983   AUUCAUUC G AAACUAUG   2291   CAUACUUU CCACCAAACUCC CU UCAACGACAUCCUCCCCC CAAUCAAU   5691               1004   CGAAUUCU G CCUCUUUU   2292   AAAACACC CCACCAAACUCC CU UCAACCACAUCCUCCCCC ACAAUUCC   5692               1005   CAAUUCUC G GUCUUUUC   2293   CAAAACAC CCAGCAAACUCC CU UCAACGACAUCCUCCCCC CACAAUUC   5693               1013   GGUCUUUU G GCCUUUGC   2294   CCAAACCC CGAGGAAACUCC CU UCAAGGACAUCCUCCGCC AAAAGACC   5694               1014   GUCUUUUC G CCUUUGCC   2295   CCCAAACC GGAGCAAACUCC CU UCAAGCACAUCGUCCCGC CAAAACAC   5695               1015   UCUUUUGG G GUUUGCCG   2296   CGGCAAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAAAAGA   5696               1041   CGCAAUGU G GAUAUUCU   2297   AGAAUAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAUUGCG   5697               1042   GCAAUGUG G AUAUUCUG   2298   CAGAAUAU GCAGCAAACUCC CU UCAAGGACAUCGUCCGGG CACAUUGC   5698               1088   GCAAAACA G GCUUUUAC   2299   GUAAAAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUUUGC   5699               1115   ACUUACAA G GCCUUUCU   2300   AGAAAGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUGUAAGU   5700               1159   CGUUGCUC G GCAACGGC   2301   GCCGUUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAGCAACG   5701               1165   UCGGCAAC G GCCUGGUC   2302   GACCAGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUUGCCGA   5702               1170   AACGGCCU G GUCUAUGC   2303   GCAUAGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGGCCGUU   5703               1206   CCCCCACU G GUUGGGGC   2304   GCCCCAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AGUGGGGG   5704               1210   CACUGGUU G GGGCUUGG   2305   CCAAGCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACCAGUG   5705               1211   ACUGCUUG G GGCUUGGC   2306   GCCAAGCC GGAGGAAACUCC CU UCAAGGACAUCCUCCGGC CAACCAGU   5706               1212   CUGUUUGC G GCUUGGCC   2307   GGCCAAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAACCAG   5707               1217   UGGGGCUU G GCCAUAGG   2308   CCUAUGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGCCCCA   5708               1224   UGGCCAUA G GCCAUCAG   2309   CUGAUGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUGGCCA   5709               1242   GCAUGCGU G GAACCUUU   2310   AAAGGUUC GCAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACGCAUGC   5710               1243   CAUGCGUG G AACCUUUG   2311   CAAACGUU GGACGAAACUCC CU UCAAGCACAUCGUCCCCG CACCCAUG   5711               1277   CAUACCCC G GAACUCCU   2312   AGGAGUUC GCAGGAAACUCC CU UCAACGACAUCGUCCGCG GCGCUAUG   5712               1278   AUACCCCC G AACUCCUA   2313   UACGAGUU GCAGGAAACUCC CU UCAAGGACAUCGUCCCCC CGCCCUAU   5713               1309   UCCCACCA G GUCUCGCG   2314   CCCCACAC CGAGGAAACUCC CU UCAAGGACAUCGUCCGCG UGCUGCGA   5714               1314   GCAGGUCU G CGCCAAAA   2315   UUUUGCCC GGACGAAACUCC CU UCAACGACAUCGUCCCGC AGACCUCC   5715               1315   CAGGUCUC G GGCAAAAC   2316   CUUUUGCC CGAGGAAACUCC CU UCAACGACAUCGUCCCGC CAGACCUG   5716               1316   AGGUCUGG G GCAAAACU   2317   ACUUUUGC GGACCAAACUCC CU UCAAGCACAUCCUCCGGC CCAGACCU   5717               1329   AACUCAUC G GGACUGAC   2318   GUCAGUCC GCACCAAACUCC CU UCAAGCACAUCCUCCGGG GAUCACUU   5718               1330   ACUCAUCC G CACUGACA   2319   UGUCACUC CGACGAAACUCC CU UCAAGCACAUCCUCCGCG CCAUGACU   5719               1331   CUCAUCCC G ACUCACAA   2320   UUGUCAGU GGAGGAAACUCC CU UCAACCACAUCCUCCGCG CCGAUGAG   5720               1378   AUUUCCAU G CCUGCUAG   2321   CUACCAGC CGAGGAAACUCC CU UCAACCACAUCCUCCGGC AUGGAAAU   5721               1386   GGCUGCUA G CCUCUCCU   2322   ACCACACC CGAGCAAACUCC CU UCAAGCACAUCCUCCGCC UACCACCC   5722               1402   UCCCAACU G CAUCCUAC   2323   GUACCAUC CCACCAAACUCC CU UCAAGCACAUCCUCCCCG ACUUCGCA   5723               1403   CCCAACUC G AUCCUACC   2324   CCUACCAU CCACCAAACUCC CU UCAACCACAUCCUCCCCG CACUUCCC   5724               1413   UCCUACCC G CGACCUCC   2325   CGACCUCC CCACCAAACUCC CU UCAACCACAUCCUCCCCC GCGUACCA   5725               1414   CCUACCCC G CACCUCCU   2326   ACCACCUC CCAGCAAACUCC CU UCAACCACAUCCUCCGCC CCCCUACC   5726               1415   CUACCCCG G ACCUCCUU   2327   AACGACCU CCACCAAACUCC CU UCAACCACAUCCUCCCCC CCGCCUAC   5727               1439   CUCCCCUC G GCCCUCAA   2328   UUCACCCC GCACCAAACUCC CU UCAACCACAUCCUCCCCC GACCCCAC   5728               1454   AAUCCCCC G GACCACCC   2329   CGCUCCUC GCACGAAACUCC CU UCAACGACAUCCUCCCCC CCGCCAUU   5729               1455   AUCCCCCC G ACCACCCC   2330   CCCGUCCU CCACGAAACUCC CU UCAACGACAUCCUCCCCC CCCCGCAU   5730               1468   CCCCUCCC G GCCCCCCU   2331   ACCCCCCC CCACCAAACUCC CU UCAACGACAUCGUCCCGC CCCAGCCC   5731               1469   CCCUCCCC G CCCCCCUU   2332   AACCCCCC CCACCAAACUCC CU UCAACCACAUCGUCCCCC CCCCACGC   5732               1470   CCUCCCGG G GCCGCUUG   2333   CAAGCGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCGGGAGG   5733               1478   GGCCCCUU G GGGCUCUA   2334   UAGAGCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGCGGCC   5734               1478   GCCGCUUG G GGCUCUAC   2335   GUAGAGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGCGGC   5735               1480   CCGCUUGG G GCUCUACC   2336   GGUAGAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAAGCGG   5736               1523   CCGUCCAC G GGGCGCAC   2337   GUGCGCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUGGACGG   5737               1524   CGUCCACG G GGCGCACC   2338   GGUGCGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGUGGACG   5738               1525   GUCCACGG G GCGCACCU   2339   AGGUGCGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCGUGGAC   5739               1544   CUUUACGC G UACUCCCC   2340   GGGGAGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCGUAAAG   5740               1545   UUUACGCG G ACUCCCCG   2341   CGGGUAUU GGAGGAAACUCC CU UCAAUGACAUCGUCCGGG CGCGUAAA   5741               1574   CAUCUGCC G GACCUUUU   2342   ACACUGUC GUAGUAAACUCC CU UCAAUGACAUCUUCCGUG UGCAGAUG   5742               1575   AUCUUCCG G ACCGUGUG   2343   CACACGUU GGAUGAAACUCC CU UCAAUGACAUCUUCCGGG CGGCAGAU   5743               1612   CUUCGCAU G GAGACCAC   2344   GUGGUCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCUGG AUUCGACG   5744               1613   UUCGCAUG G AGACCACC   2345   GUUGGUCU GUAGGAAACUCC CU UCAAGGACAUCGUCCUGU CAUGCGAC   5745               1615   CGCAUGUA G ACCACCGU   2346   ACGGUUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCAUGCU   5746               1635   CGCCCACA G GAACCUGC   2347   GCAGGUUC GUAUGAAACUCC CU UCAAGGACAUCGUCCGGG UGUGGGCG   5747               1636   GCCCACAG G AACCUGCC   2348   GUCAGUUU UGAUGAAACUCC CU UCAAUGACAUCGUCCGGG CUGUGGUC   5748               1648   CUGCCCAA G GUCUUGCA   2349   UGCAAGAC GGAGGAAACUCC CU UCAAGUACAUCGUCCGGG UUGGGCAG   5749               1660   UUGCAUAA G AUGACUCU   2350   AUAUUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAUUCAA   5750               1662   GCAUAAGA G GACUCUUG   2351   CAAUAUUC GGAGUAAACUCC CU UCAAGGACAUCGUCCGUG UCUUAUUC   5751               1663   CAUAAGAG G ACUCUUUU   2352   CCAAUAGU GUAGGAAACUCC CU UCAAGGACAUCUUCCGGG CUCUUAUG   5752               1670   UUACUCUU G UACUUUCA   2353   UUAAAGUC GUAUGAAACUCC CU UCAAGUACAUCGUCCGUU AAUAUUCC   5753               1671   UACUCUUG G ACUUUCAU   2354   CUGAAAGU UUAUUAAACUCC CU UCAAUUACAUCUUCCGUG CAAUAUUC   5754               1702   UACCUUUA G UCAUACUU   2355   AAUUAUUC UGAGUAAACUCC CU UCAAUUACAUCGUCCUUU UCAAGUUC   5755               1715   ACUUCAAA G ACUUUUUU   2356   CACACAUU UGAGUAAACUCC CU UCAAGUACAUCUUCCUUU UUUUAAGU   5756               1734   UAAUUAUU G UUAUUAUU   2357   ACUCCUCC UUAGUAAACUCC CU UCAAUUACAUCUUCCGUU ACUCAUUA   5757               1735   AAUGAUUU G UAGGAGUU   2358   AACUCCUC GUAUGAAACUCC CU UCAAUUACAUCUUCCGUG CACUCAUU   5758               1736   AUUAUUUU G AUGAUUUG   2359   CAACUCCU GUAGGAAACUCC CU UCAAUUACAUCUUCCUUU CCACUCAU   5759               1738   UAUUUGUA G GAUUUUUU   2360   CCCAACUC UUAUUAAACUCC CU UCAAUGACAUCUUCCUGG UCCCACUC   5760               1739   AGUGGUAG G AUUUUUUG   2361   CCCCAACU UUAUGAAACUCC CU UCAAUGACAUCUUCCUUU CUCCCACU   5761               1744   UAUGAGUU G GUGUAGGA   2362   UCCUCCCC GUAGGAAACUCC CU UCAAUGACAUCUUCCUUG AACUCCUC   5762               1745   AUUAUUUU G GUGAGUAG   2363   CUCCUCCC GUAUGAAACUCC CU UCAAUUACAUCGUCCUUU CAACUCCU   5763               1746   GGAUUUUU G UGAGGAUG   2364   CCUCCUCC UGAGGAAACUCC CU UCAAGGACAUCUUCCUUU CCAACUCC   5764               1747   GAGUUUGU G UAUGAUGU   2365   ACCUCCUC UUAUUAAACUCC CU UCAAGUACAUCGUCCGGU CCCAACUC   5765               1748   AGUUGGGG G AUUAGUUU   2366   AACCUCCU UGAUUAAACUCC CU UCAAGUACAUCGUCCGGU CCCCAACU   5766               1750   UUUGUGUA G UAUUUUAU   2367   CUAACCUC UGAGUAAACUCC CU UCAAGUACAUCUUCCGGU UCCCCCAA   5767               1751   UGUGUGAG G AUUUUAGU   2368   CCUAACCU UUAUUAAACUCC CU UCAAUUACAUCGUCCGGG CUCCCCCA   5768               1753   GUGGAGGA G UUUAGGUU   2369   AACCUAAC UGAGUAAACUCC CU UCAAUGACAUCUUCCGGG UCCUCCCCU   5769               1758   GGAGGUUA G GUUAAAGC   2370   CCUUUAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGC UAACCUCC   5770               1765   AGGUUAAA G GUCUUUGU   2372   ACAAAGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUUAACCU   5771               1778   UUGUACUA G CAGGCUGU   2372   ACACCCUC GCAGGAAACUCC CU UCAAGGACAUCGUCCGGC UAGUACAA   5772               1779   UGUACUAG G AGGCUGUA   2373   UACAGCCU GCAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUAGUACA   5773               1781   UACUAGCA G GCUGUAGG   2374   CCUACAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCCCG UCCUAGUA   5774               1788   AGGCUGUA G GCAUAAAU   2375   AUUUAUGC GGACGAAACUCC CU UCAACGACAUCGUCCGGG UACAGCCU   5775               1798   CAUAAAUU G GUGUCUUC   2376   GAACACAC GGACGAAACUCC CU UCAACGACAUCGUCCGGG AAUUUAUG   5776               1888   UGUGCCUU G GGUGCCUU   2377   AAGCCACC GGAGGAAACUCC CU UCAAGGACAUCGUCCGCG AAGGCACA   5777               1889   GUGCCUUG G GUGGCUUU   2378   AAACCCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAACGCAC   5778               1892   CCUUCGGU G GCUUUGCG   2379   CCCAAAGC CGAGCAAACUCC CU UCAAGGACAUCGUCCGCG ACCCAAGG   5779               1898   GUGGCUUU G GGGCAUGG   2380   CCAUGCCC GGACCAAACUCC CU UCAAGGACAUCGUCCGCC AAAGCCAC   5780               1899   UCGCUUUC G GCCAUGGA   2381   UCCAUCCC GGAGGAAACUCC CU UCAAGGACAUCCUCCCCC CAAAGCCA   5781               1900   GGCUUUGG G CCAUGGAC   2382   GUCCAUGC GGAGGAAACUCC CU UCAAGGACAUCCUCCGCG CCAAAGCC   5782               1905   UCGGGCAU G CACAUUCA   2383   UCAAUCUC CGAGCAAACUCC CU UCAAGCACAUCCUCCGCG AUGCCCCA   5783               1906   CCCCCAUC G ACAUUCAC   2384   CUCAAUGU CGAGCAAACUCC CU UCAAGCACAUCGUCCGCG CAUCCCCC   5784               1924   CCUAUAAA G AAUUUCCA   2385   UCCAAAUU CGACCAAACUCC CU UCAAGCACAUCCUCCGCC UUUAUACC   5785               1930   AACAAUUU G CAGCUUCU   2386   AGAACCUC CGAGCAAACUCC CU UCAAGCACAUCGUCCGGC AAAUUCUU   5786               1931   AGAAUUUC G ACCUUCUC   2387   CACAAGCU CGACCAAACUCC CU UCAAGCACAUCCUCCCGC CAAAUUCU   5787               1941   GCUUCUGU G CAGUUACU   2388   AGUAACUC CGAGCAAACUCC CU UCAAGGACAUCCUCCCGC ACAGAACC   5788               1942   CUUCUGUG G AGUUACUC   2389   GACUAACU CGAGCAAACUCC CU UCAAGCACAUCCUCCCGC CACACAAC   5789               1987   CUAUUCCA G AUCUCCUC   2390   GACGAGAU CGAGGAAACUCC CU UCAAGCACAUCCUCCCGC UCCAAUAG   5790               2018   UCUGUAUC G CGCGGCCU   2391   AGGCCCCC GCAGGAAACUCC CU UCAACCACAUCCUCCCGC CAUACACA   5791               2019   CUCUAUCG G GGCGCCUU   2392   AAGCCCCC GCAGGAAACUCC CU UCAACCACAUCCUCCCGC CGAUACAG   5792               2020   UCUAUCCG G GGCCCUUA   2393   UAAGGCCC GCACGAAACUCC CU UCAAGGACAUCCUCCCGG CCCAUACA   5793               2021   GUAUCGCG G GGCCUUAG   2394   CUAAGGCC GCACGAAACUCC CU UCAAGGACAUCGUCCCGC CCCGAUAC   5794               2022   UAUCGGGG G CCCUUACA   2395   UCUAACCC GCACGAAACUCC CU UCAACGACAUCCUCCCGC CCCCCAUA   5795               2029   CCCCCUUA G ACUCUCCC   2396   CCGACACU GCACCAAACUCC CU UCAACCACAUCCUCCCGC UAACCCCC   5796               2037   GAGUCUCC G CAACAUUG   2397   CAAUGUUC CCACGAAACUCC CU UCAACCACAUCCUCCGCC GGAGACUC   5797               2038   ACUCUCCC G AACAUUCU   2398   ACAAUCUU GCACGAAACUCC CU UCAACGACAUCCUCCCCG CCGAGACU   5798               2061   CACCAUAC G CCACUCAG   2399   CUCAGUCC CCACCAAACUCC CU UCAAGGACAUCCUCCGGG CUAUCCUG   5799               2069   CCCACUCA G CCAACCUA   2400   UACCUUCC CCACCAAACUCC CU UCAACCACAUCGUCCGCG UCACUCCC   5800               2087   UCUCUCUU G CCCUCACU   2401   ACUCACCC CCAGCAAACUCC CU UCAACCACAUCGUCCCCC AACACACA   5801               2088   CUCUCUUC G CCUGACUU   2402   AACUCACC GCAGGAAACUCC CU UCAAGCACAUCCUCCCCC CAACACAC   5802               2089   UCUCUUGC G GUCACUUC   2403   CAACUCAC CGACCAAACUCC CU UCAACCACAUCCUCCCCC CCAACACA   5803               2114   ACCCACCU G GGUCCCAA   2404   UUCCCACC CCACCAAACUCC CU UCAACGACAUCGUCCGCG AGCUGCCU   5804               2115   GCCACCUG G CUCGCAAC   2405   CUUCCCAC CCACCAAACUCC CU UCAACCACAUCCUCCCGC CACGUCCC   5805               2118   ACCUCCCU G CGAACUAA   2406   UUACUUCC CGACCAAACUCC CU UCAAGCACAUCGUCCCGC ACCCACCU   5806               2119   CCUGGGUG G GAAGUAAU   2407   AUUACUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACCCAGG   5807               2120   CUGGGUGG G AAGUAAUU   2408   AAUUACUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCACCCAG   5808               2130   AGUAAUUU G GAAGAUCC   2409   GGAUCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAUUACU   5809               2131   GUAAUUUG G AACAUCCA   2410   UGGAUCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAAUUAC   5810               2134   AUUUGGAA G AUCCAGCA   2411   UGCUGGAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCAAAU   5811               2147   AGCAUCCA G GGAAUUAG   2412   CUAAUUCC GGAGGAAACUCC CU UCAAGGACAUCCUCCGGG UGGAUGCU   5812               2148   GCAUCCAG G GAAUUAGU   2413   ACUAAUUC GGAGGAAACUCC CU UCAAGGACAUCCUCCGGG CUGGAUGC   5813               2149   CAUCCAGG G AAUUAGUA   2414   UACUAAUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCUGGAUG   5814               2181   GUUAAUAU G GGCCUAAA   2415   UWUAGGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUAUUAAC   5815               2182   UUAAUAUG G GCCUAAAA   2416   UUUUAGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUAUUAA   5816               2195   AAAAAUCA G ACAACUAU   2417   AUAGUUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAUUUUU   5817               2207   ACUAUUGU G GUUUCACA   2418   UGUGAAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAAUAGU   5818               2233   UUACUUUU G GGCGAGAA   2419   UUCUCGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAAGUAA   5819               2234   UACUUUUG G GCGAGAAA   2420   UUUCUCGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAAAGUA   5820               2239   UUGGGCGA G AAACUGUU   2421   AACAGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCGCCCAA   5821               2259   GAAUAUUU G GUGUCUUU   2422   AAAGACAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAAUAUUC   5822               2269   UGUCUUUU G GAGUGUGG   2423   CCACACUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGC AAAAGACA   5823               2270   GUCUUUUG G AGUGUGGA   2424   UCCACACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAAAGAC   5824               2276   UGGAGUGU G GAUUCGCA   2425   UGCGAAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACACUCCA   5825               2277   GGAGUGUG G AUUCGCAC   2426   GUGCGAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACACUCC   5826               2300   UGCAUAUA G ACCACCAA   2427   UUGGUGGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUAUGCA   5827               2334   ACACUUCC G GAAACUAC   2428   GUAGUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GGAAGUGU   5828               2335   CACUUCCG G AAACUACU   2429   AGUAGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGGAAGUG   5829               2351   UGUUGUUA G ACGAAGAG   2430   CUCUUCGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAACAACA   5830               2357   UAGACGAA G AGGCAGGU   2431   ACCUGCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCGUCUA   5831               2359   GACCAAGA G GCACGUCC   2432   CGACCUGC CGAGCAAACUCC CU UCAACCACAUCGUCCGGG UCUUCCUC   5832               2363   AACACGCA G GUCCCCUA   2433   UACGGGAC GGAGGAAACUCC CU UCAAGGACAUCCUCCGGG UGCCUCUU   5833               2372   GUCCCCUA G AAGAACAA   2434   UUCUUCUU GCAGCAAACUCC CU UCAAGGACAUCCUCCGCG UAGGGGAC   5834               2375   CCCUACAA G AAGAACUC   2435   CAGUUCUU CGAGGAAACUCC CU UCAAGCACAUCCUCCCGG UUCUACGC   5835               2378   UACAAGAA G AACUCCCU   2436   AGGGAGUU GGAGGAAACUCC CU UCAAGGACAUCGUCCCGG UUCUUCUA   5836               2396   GCCUCCCA G ACCAAGGU   2437   ACCUUCCU CCACCAAACUCC CU UCAAGCACAUCGUCCCGC UCCCAGGC   5837               2402   CAGACGAA G GUCUCAAU   2438   AUUGAGAC CGAGGAAACUCC CU UCAAGGACAUCGUCCGGC UUCCUCUG   5838               2423   GCGUCCCA G AAGAUCUC   2439   CAGAUCUU CGAGGAAACUCC CU UCAAGCACAUCCUCCGGG UGCGACGC   5839               2426   UCCCAGAA G AUCUCAAU   2440   AUUGAGAU CGAGCAAACUCC CU UCAAGGACAUCCUCCGCC UUCUCCGA   5840               2438   UCAAUCUC G GGAAUCUC   2441   CAGAUUCC GCACCAAACUCC CU UCAAGCACAUCCUCCGGC GACAUUGA   5841               2439   CAAUCUCG G CAAUCUCA   2442   UGAGAUUC CGAGGAAACUCC CU UCAACGACAUCCUCCGGG CGAGAUUG   5842               2440   AAUCUCGG G AAUCUCAA   2443   UUCACAUU CCAGGAAACUCC CU UCAACGACAUCGUCCCCC CCGAGAUU   5843               2463   UAUUCCUU G GACACAUA   2444   UAUGUGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGGAAUA   5844               2464   AUUCCUUG G ACACAUAA   2445   UUAUGUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAAGGAAU   5845               2473   ACACAUAA G GUGGGAAA   2446   UUUCCCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUAUGUGU   5846               2476   CAUAAGGU G GGAAACUU   2447   AAGUUUCC GCAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCUUAUG   5847               2477   AUAAGGUG G GPAACUUU   2448   AAAGUUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACCUUAU   5848               2478   UAAGGUGG G AAACUUUA   2449   UAAAGUUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCACCUUA   5849               2488   AACUUUAC G GGGCUUUA   2450   UAAAGCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUAAAGUU   5850               2489   ACUUUACG G GGCUUUAU   2451   AUAAAGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGUAAAGU   5851               2490   CUUUACGG G GCUUUAUU   2452   AAUAAAGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCGUAAAG   5852               2506   UCUUCUAC G GUACCCUG   2453   CAAGGUAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GUAGAAGA   5853               2529   UCCUAAAU G GCAAACUC   2454   GAGUUUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUUUAGGA   5854               2563   CAUUUGCA G GAGGACAU   2455   AUGUCCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGCAAAUG   5855               2564   AUUUGCAG G AGGACAUU   2456   AAUGUCCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGCAAAU   5856               2566   UUGCAGGA G GACAUUGU   2457   ACAAUGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUGCAA   5857               2567   UGCAGGAG G ACAUUGUU   2458   AACAAUGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUCCUGCA   5858               2580   UGUUGAUA G AUGUAAGC   2459   GCUUACAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAUCAACA   5859               2596   CAAUUUGU G GGGCCCCU   2460   AGGGGCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACAAAUUG   5860               2597   AAUUUGUG G GGCCCCUU   2461   AAGGGGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACAAAUU   5861               2598   AUUUGUGG G GCCCCUUA   2462   UAAGGGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCACAAAU   5862               2622   UGAAAACA G GAGACUUA   2463   UAAGUCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGUUUUCA   5863               2623   GAAAACAG G AGACUUAA   2464   UUAAGUCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGUUUUC   5864               2625   AAACAGGA G ACUUAAAU   2465   AUUUAAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCUGUUU   5865               2649   GCCUGCUA G GUUUUAUC   2466   GAUAAAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAGCAGGC   5866               2684   UGCCCUUA G AUAAAGGG   2467   CCCUUUAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UAAGGGCA   5867               2690   UAGAUAAA G GGAUCAAA   2468   UUUGAUCC GGAGGAAACUCC CU UCAAGUACAUCGUCCGGG UUUAUCUA   5868               2691   AGAUAAAG G UAUCAAAC   2469   GUUUGAUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUUAUCU   5869               2692   GAUAAAGU G AUCAAACC   2470   GGUUUGAU GGAGUAAACUCC CU UCAAGGACAUCGUCCGGG CCUUUAUC   5870               2711   AUUAUCCA G AGUAUGUA   2471   UACAUACU GGAGGAAACUCC CU UCAAGUACAUCGUCCGGG UGUAUAAU   5871               2737   UACUUCCA G ACGCGACA   2472   UGUCUCGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAAGUA   5872               2763   CACUCUUU G GAAGGCGG   2473   CCGCCUUC GGAGGAAACUCC CU UCAAGUACAUCUUCCGUG AAAGAGUG   5873               2764   ACUCUUUG G AAGUCGUG   2474   CCCGCCUU GUAGUAAACUCC CU UCAAGGACAUCUUCCGGG CAAAGAGU   5874               2767   CUUUGGAA G GCGGGGAU   2475   AUCCCCGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCAAAG   5875               2770   UGGAAGUC G GUUAUCUU   2476   AAGAUCCC GUAGUAAACUCC CU UCAAUGACAUCGUCCGGG GCCUUCCA   5876               2771   GGAAGGCG G UGAUCUUA   2477   UAAUAUCC UUAGUAAACUCC CU UCAAUGACAUCGUCCUUG CGCCUUCC   5877               2772   UAAGUCGU G UAUCUUAU   2478   AUAAGAUC UGAGGAAACUCC CU UCAAGGACAUCUUCCGGU CCUCCUUC   5878               2773   AAUGCUGG G AUCUUAUA   2479   UAUAAUAU UGAGGAAACUCC CU UCAAGGACAUCGUCCUGU CCCGCCUU   5879               2787   AUAUAAAA G AGAGUCCA   2480   UGUACUCU UGAGGAAACUCC CU UCAAGUACAUCGUCCGGG UUUUAUAU   5880               2789   AUAAAAGA G AGUCCACA   2481   UGUGGACU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCUUUUAU   5882               2816   CAUUUUGC G GGUCACCA   2482   UGGUGACC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GCAAAAUG   5882               2817   AUUUUGCG G GUCACCAU   2483   AUGGUGAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGCAAAAU   5883               2832   AUAUUCUU G GGAACAAG   2484   CUUGUUCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AAGAAUAU   5884               2833   UAUUCUUG G GAACAACA   2485   UCUUGUUC GCAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAACAAUA   5885               2834   AUUCUUGG G AACAAGAU   2486   AUCUUGUU GCACGAAACUCC CU UCAAGGACAUCGUCCGGG CCAAGAAU   5886               2840   GGGAACAA G AUCUACAG   2487   CUGUAGAU GGACGAAACUCC CU UCAAGGACAUCGUCCGGG UUGUUCCC   5887               2852   UACACCAU G GGAGGUUG   2488   CAACCUCC GGAGGAAACUCC CU UCAAGCACAUCGUCCGGG AUGCUGUA   5888               2853   ACAGCAUG G GAGGUUCG   2489   CCAACCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGCG CAUGCUGU   5889               2854   CAGCAUCG G ACGUUGGU   2490   ACCAACCU GCAGCAAACUCC CU UCAAGCACAUCGUCCGGG CCAUGCUG   5890               2856   CCAUGGGA G GUUGGUCU   2491   ACACCAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UCCCAUGC   5891               2860   GGGAGGUU G GUCUUCCA   2492   UCGAACAC GGAGGAAACUCC CU UCAAGCACAUCGUCCGGG AACCUCCC   5892               2880   CUCGAAAA G CCAUCCCG   2493   CCCCAUGC GGAGCAAACUCC CU UCAAGGACAUCGUCCGGG UUUUCGAG   5893               2885   AAAGGCAU G GGGACAAA   2494   UUUCUCCC GGAGCAAACUCC CU UCAAGGACAUCGUCCGCG AUGCCUUU   5894               2886   AAGGCAUG G GGACAAAU   2495   AUUUGUCC GGAGCAAACUCC CU UCAAGGACAUCGUCCGGG CAUGCCUU   5895               2887   ACGCAUGC G GACAAAUC   2496   GAUUUCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGCG CCAUGCCU   5896               2888   GGCAUGGG G ACAAAUCU   2497   AGAUUUGU CGAGCAAACUCC CU UCAAGGACAUCGUCCGCG CCCAUGCC   5897               2915   AAUCCCCU G GCAUUCUU   2498   AACAAUCC GGAGCAAACUCC CU UCAAGGACAUCGUCCGCG AGGGGAUU   5898               2916   AUCCCCUG G GAUUCUUC   2499   GAACAAUC GGAGCAAACUCC CU UCAAGGACAUCCUCCGCG CAGGGCAU   5899               2917   UCCCCUGG G AUUCUUCC   2500   GGAACAAU CGACCAAACUCC CU UCAAGGACAUCCUCCGGG CCAGGGGA   5900               2939   CAUCAGUU G CACCCUGC   2501   CCAGCGUC CCAGCAAACUCC CU UCAAGCACAUCCUCCGGC AACUGAUC   5901               2940   AUCAGUUG G ACCCUGCA   2502   UGCACGCU GGAGCAAACUCC CU UCAAGGACAUCCUCCGCG CAACUCAU   5902               2973   UAAAUCCA G AUUGGGAC   2503   GUCCCAAU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGAUUUA   5903               2977   UCCAGAUU G CGACCUCA   2504   UGAGGUCC GCAGGAAACUCC CU UCAAGGACAUCCUCCGGC AAUCUCGA   5904               2978   CCAGAUUG G GACCUCAA   2505   UUCAGGUC GGACCAAACUCC CU UCAACGACAUCGUCCGGG CAAUCUGC   5905               2979   CACAUUCG G ACCUCAAC   2506   GUUCAGCU GCACGAAACUCC CU UCAACGACAUCCUCCGGG CCAAUCUG   5906               2996   CCGCACAA G GACAACUG   2507   CACUUGUC CCACGAAACUCC CU UCAACGACAUCCUCCCGC UUGUGCGC   5907               2997   CCCACAAG G ACAACUCG   2508   CCACUUCU CCACGAAACUCC CU UCAACCACAUCCUCCCGC CUUGUCCC   5908               3004   GGACAACU G GCCGGACG   2509   CCUCCCCC GCACGAAACUCC CU UCAACGACAUCCUCCGGC AGUUGUCC   5909               3008   AACUGCCC G GACCCCAA   2510   UUGCCGUC GCACGAAACUCC CU UCAACGACAUCCUCCCGC GGCCACUU   5910               3009   ACUCGCCC G ACGCCAAC   2511   GUUCGCCU GCACGAAACUCC CU UCAACGACAUCCUCCCGC CGCCCAGU   5911               3020   GCCAACAA G GUCCGAGU   2512   ACUCCCAC GCACGAAACUCC CU UCAACGACAUCCUCCGGG UUCUUCGC   5912               3023   AACAACCU G GCACUCGC   2513   CCCACUCC GCACGAAACUCC CU UCAACGACAUCCUCCCGC ACCUUGUU   5913               3024   ACAACGUC G CACUCCGA   2514   UCCCACUC CCACCAAACUCC CU UCAACGACAUCCUCCCGC CACCUUCU   5914               3025   CAAGGUCG G AGUCCGAC   2515   CUCCCACU CCACCAAACUCC CU UCAAGCACAUCGUCCCGC CCACCUUC   5915               3029   CUCGCACU G CGAGCAUU   2516   AAUCCUCC GGAGCAAACUCC CU UCAACCACAUCGUCCCGC ACUCCCAC   5916               3030   UGCGACUG G GACCAUUC   2517   GAAUGCUC CGAGCAAACUCC CU UCAACCACAUCGUCCCGC CACUCCCA   5917               3031   GGGAGUGG G AGCAUUCG   2518   CGAAUGCU GGAGGAAACUCC CU UCAAGGACAUCCUCCGGC CCACUCCC   5918               3039   GAGCAUUC G GGCCAGGG   2519   CCCUGGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG GAAUGCUC   5919               3040   AGCAUUCG G GCCAGGGU   2520   ACCCUGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CGAAUGCU   5920               3045   UCGGGCCA G GGUUCACC   2521   GGUGAACC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGGCCCGA   5921               3046   CGGGCCAG G GUUCACCC   2522   GGGUGAAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGGCCCG   5922               3063   CUCCCCAU G GGGGACUG   2523   CAGUCCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AUGGGGAG   5923               3064   UCCCCAUG G GGGACUGU   2524   ACAGUCCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAUGGGGA   5924               3065   CCCCAUGG G GGACUGUU   2525   AACAGUCC GGAGGAAACUCC CU UCAAGCACAUCGUCCGGG CCAUGGGG   5925               3066   CCCAUGGG G GACUGUUG   2526   CAACAGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCAUGUG   5926               3067   CCAUGGGG G ACUGUUGG   2527   CCAACAGU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCCCAUGG   5927               3074   GGACUGUU G UGGUGGAG   2528   CUCCACCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG AACAGUCC   5928               3075   GACUGUUG G GGUGGAGC   2529   GCUCCACC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CAACAGUC   5929               3076   ACUGUUGG G GUGGAGCC   2530   GGCUCCAC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CCAACAGU   5930               3079   GUUGGGGU G GAGCCCUC   2531   GAGGGCUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG ACCCCAAC   5931               3080   UUGGGGUG G AGCCCUCA   2532   UGAGGGCU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CACCCCAA   5932               3095   CACGCUCA G GGCCUACU   2533   AGUAGGCC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGAGCGUG   5933               3096   ACUCUCAG G UCCUACUC   2534   GAGUAGGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGAGCGU   5934               3145   CACCAAUC G GCAGUCAG   2535   CUGACUGC GUAGGAAACUCC CU UCAAGGACAUCGUCCGGG GACUGGUG   5935               3153   GGCAGUCA G GAAGGCAG   2536   CUGCCUUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UGACUGCC   5936               3154   GCAGUCAG G AAGGCAUC   2537   GCUUCCUU GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUGACUGC   5937               3157   GUCAGGAA G GCAGCCUA   2538   UAGGCUGC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG UUCCUGAC   5938               3187   ACCUCUAA G UGACACUC   2539   GAGUGUCC GGAGUAAACUCC CU UCAAGGACAUCGUCCGGG UUAGAGGU   5939               3188   CCUCUAAG G GACACUCA   2540   UGAGUGUC GGAGGAAACUCC CU UCAAGGACAUCGUCCGGG CUUAGAGG   5940               3189   CUCUAAGU G ACACUCAU   2541   AUUAGUUU GGAGGAAACUCC CU UCAAUGACAUCUUCCUGG CCUUAUAU   5941               3203   CAUCCUCA G GCCAUUCA   2542   UGCAUUGC GGAGGAAACUCC CU UCAAUGACAUCUUCCGUG UGAUGAUG   5942                               Stem Length = 8.                             
     [0254]               TABLE XI                          Human HBV Enzymatic Nucleic Acid and Target Sequence                                                 SEQ       Enzymatic nucleic       SEQ       Pos   SUBSTRATE   ID   RPI#   acid Alias   ENZYMATIC NUCLEIC ACID   ID                                                     313   CCAAAAU U CGCAGUC   5943   18157   HBV-313 Rz-7 RNA   GACUGCG CUGAUGAGGCCGUUAGGCCGAA AUUUUGG  B     6175                   327   CCCAAAU C UCCAGUC   5944   18158   HBV-327 Rz-7 RNA   GACUGGA CUGAUGAGGCCGUUAGGCCGAA AUUUGGG  B     6176               334   CUCCAGU C ACUCACC   5945   18159   HBV-334 Rz-7 RNA   GGUGAGU CUGAUGAGGCCGUUAGGCCGAA ACUGGAG  B     6177               408   UCUUCCU C UGCAUCC   5946   18160   HBV-408 Rz-7 RNA   GGAUGCA CUGAUGAGGCCGUUAGGCCGAA AGGAAGA  B     6178               557   UCUAUGU U UCCCUCA   5947   18161   HBV-557 Rz-7 RNA   UGAGGGA CUGAUGAGGCCGUUAGGCCGAA ACAUAGA  B     6179               1255   UUUGUGU C UCCUCUG   5948   18162   HBV-1255 Rz-7 RNA   CAGAGGA CUGAUGAGGCCGUUAGGCCGAA ACACAAA  B     6180               1538   CCUCUCU U UACGCGG   5949   18163   HBV-1538 Rz-7 RNA   CCGCGUA CUGAUGAGGCCGUUAGGCCGAA AGAGAGG  B     6181               1756   AGGAGGU U AGGUUAA   5950   18164   HBV-1756 Rz-7 RNA   UUAACCU CUGAUGAGGCCGUUAGGCCGAA ACCUCCU  B     6182               1861   AUGUCCU A CUGUUCA   5951   18165   HBV-1861 Rz-7 RNA   UGAACAG CUGAUGAGGCCGUUAGGCCGAA AGGACAU  B     6183               2504   UUCUUCU A CGGUACC   5952   18166   HBV-2504 Rz-7 RNA   GGUACCG CUGAUGAGGCCGUUAGGCCGAA AGAAGAA  B     6184               10   CUCCACC A CUUUCCA   5953   18197   HBV-10 CHz-7 RNA   UGGAAAG CUGAUGAGGCCGUUAGGCCGAA GGUGGAG  B     6185               335   UCCAGUC A CUCACCA   5954   18198   HBV-335 CHz-7 RNA   UGGUGAG CUGAUGAGGCCGUUAGGCCGAA GACUGGA  B     6186               1258   GUGUCUC C UCUGCCG   5955   18199   HBV-1258 CHz-7 RNA   CGGCAGA CUGAUGAGGCCGUUAGGCCGAA GAGACAC  B     6187               2307   GACCACC A AAUGCCC   5956   18200   HBV-2307 CHz-7 RNA   GGGCAUU CUGAUGAGGCCGUUAGGCCGAA GGUGGUC  B     6188               347   UCACCAACCU G UUGUC   5957   18216   HBV-347 GCl.Rz-5/10   GACAA UGAUGGCAUGCACUAUGCGCG AGGUUGGUGA  B     6189                       RNA               350   CCAACCUGUU G UCCUC   5958   18217   HBV-350 GCl.Rz-5/10   GAGGA UGAUGGCAUGCACUAUGCGCG AACAGGUUGG  B     6190                       RNA               1508   UCCGCCUAUU G UACCG   5959   18218   HBV-1508 GCl.Rz-   CGGUA UGAUGGCAUGCACUAUGCGCG AAUAGGCGGA  B     6191                       5/10 RNA               234   AAUCCU C ACAAUA   5960   18334   HBV-234 Rz-6 allyl   u s a s u s u s gu cUGAuGaggccguuaggccGaa Aggauu  B     6192                       stab1               252   GAGUCU A GACUCG   5961   18335   HBV-252 Rz-6 allyl   c s g s a s g s uc cUGAuGaggccguuaggccGaa Agacuc  B     6193                       stab1               268   UGGACU U CUCUCA   5962   18337   HBV-268 Rz-6 allyl   u s g s a s g s ag cUGAuGaggccguuaggccGaa Agucca  B     6194                       stab1               280   AAUUUU C UAGGGG   5963   18345   HBV-280 Rz-6 allyl   c s c s c s c s ua cUGAuGaggccguuaggccGaa Aaaauu  B     6195                       stab1               313   CAAAAU U CGCAGU   5964   18346   HBV-313 Rz-6 allyl   a s c s u s g s cg cUGAuGaggccguuaggccGaa Auuuug  B     6196                       stab1               395   GGCGUU U UAUCAU   5965   18350   HBV-395 Rz-6 allyl   a s u s g s a s ua cUGAuGaggccguuaggccGaa Aacgcc  B     6197                       stab1               402   UAUCAU C UUCCUC   5966   18351   HBV-402 Rz-6 allyl   g s a s g s g s aa cUGAuGaggccguuaggccGaa Augaua  B     6198                       stab1               607   UGUAUU C CCAUCC   5967   18355   HBV-607 Rz-6 allyl   g s g s a s u s gg cUGAuGaggccguuaggccGaa Aauaca  B     6199                       stab1               697   UUUGUU C AGUGGU   5968   18362   HBV-697 Rz-6 allyl   a s c s c s a s cu cUGAuGaggccguuaggccGaa Aacaaa  B     6200                       stab1               1539   UCUCUU U ACGCGG   5969   18366   HBV-1539 Rz-6 allyl   c s c s g s c s gu cUGAuGaggccguuaggccGaa Aagaga  B     6201                       stab1               1599   UCACCU C UGCACG   5970   18367   HBV-1599 Rz-6 allyl   c s g s u s g s ca cUGAuGaggccguuaggccGaa Agguga  B     6202                       stab1               1607   GCACGU C GCAUGG   5971   18368   HBV-1607 Rz-6 allyl   c s c s a s u s gc cUGAuGaggccguuaggccGaa Acgugc  B     6203                       stab1               1833   UCACCU C UGCCUA   5972   18371   HBV-1833 Rz-6 allyl   u s a s g s g s ca cUGAuGaggccguuaggccGaa Agguga  B     6204                       stab1               2383   AGAACU C CCUCGC   5973   18374   HBV-2383 Rz-6 allyl   g s c s g s a s gg cUGAuGaggccguuaggccGaa Aguucu  B     6205                       stab1               2429   GAAGAU C UCAAUC   5974   18376   HBV-2429 Rz-6 allyl   g s a s u s u s ga cUGAuGaggccguuaggccGaa Aucuuc  B     6206                       stab1               2831   UAUUCU U GGGAAC   5975   18379   HBV-2831 Rz-6 allyl   g s u s u s c s cc cUGAuGaggccguuaggccGaa Agaaua  B     6207                       stab1               430   UGCCUC A UCUUCU   5976   18391   HBV-430 CHz-6 allyl   a s g s a s a s ga cUGAuGaggccguuaggccGaa Iaggca  B     6208                       stab1               676   UGGCUC A GUUUAC   5977   18396   HBV-676 CHz-6 allyl   g s u s a s a s ac cUGAuGaggccguuaggccGaa Iagcca  B     6209                       stab1               683   GUUUAC U AGUGCC   5978   18397   HBV-683 CHz-6 allyl   g s g s c s a s cu cUGAuGaggccguuaggccGaa Iuaaac  B     6210                       stab1               1150   UUUACC C CGUUGC   5979   18402   HBV-1150 CHz-6   g s c s a s a s cg cUGAuGaggccguuaggccGaa Iguaaa  B     6211                       allyl stab1               1200   GCAACC C CCACUG   5980   18403   HBV-1200 CHz-6   c s a s g s u s gg cUGAuGaggccguuaggccGaa Iguugc  B     6212                       allyl stab1               1201   CAACCC C CACUGG   5981   18404   HBV-1201 CHz-6   c s c s a s g s ug cUGAuGaggccguuaggccGaa Igguug  B     6213                       allyl stab1               1444   CGGCGC U GAAUCC   5982   18405   HBV-1444 CHz-6   g s g s a s u s uc cUGAuGaggccguuaggccGaa Icgccg  B     6214                       allyl stab1               1451   GAAUCC C GCGGAC   5983   18406   HBV-1451 CHz-6   g s u s c s c s gc cUGAuGaggccguuaggccGaa Igauuc  B     6215                       allyl stab1               1533   CGCACC U CUCUUU   5984   18407   HBV-1533 CHz-6   a s a s a s g s ag cUGAuGaggccguuaggccGaa Igugcg  B     6216                       allyl stab1               1600   CACCUC U GCACGU   5985   18410   HBV-1600 CHz-6   a s c s g s u s gc cUGAuGaggccguuaggccGaa Iaggug  B     6217                       allyl stab1               1698   CCGACC U UGAGGC   5986   18411   HBV-1698 CHz-6   g s c s c s u s ca cUGAuGaggccguuaggccGaa Igucgg  B     6218                       allyl stab1               1784   GGAGGC U GUAGGC   5987   18412   HBV-1784 CHz-6   g s c s c s u s ac cUGAuGaggccguuaggccGaa Iccucc  B     6219                       allyl stab1               1829   UUUUUC A CCUCUG   5988   18414   HBV-1829 CHz-6   c s a s g s a s gg cUGAuGaggccguuaggccGaa Iaaaaa  B     6220                       allyl stab1               1876   GCCUCC A AGCUGU   5989   18420   HBV-1876 CHz-6   a s c s a s g s cu cUGAuGaggccguuaggccGaa Igaggc  B     6221                       allyl stab1               1880   CCAAGC U GUGCCU   5990   18422   HBV-1880 CHz-6   a s g s g s c s ac cUGAuGaggccguuaggccGaa Icuugg  B     6222                       allyl stab1               218   UUUUUCU U GUUGACA   5991   18333   HBV-218 Rz-7 allyl   u s g s u s c s aac cUGAuGaggccguuaggccGaa Agaaaaa  B     6223                       stab1               257   CUAGACU C GUGGUGG   5992   18336   HBV-257 Rz-7 allyl   c s c s a s c s cac cUGAuGaggccguuaggccGaa Agucuag  B     6224                       stab1               268   GUGGACU U CUCUCAA   5993   18338   HBV-268 Rz-7 allyl   u s u s g s a s gag cUGAuGaggccguuaggccGaa Aguccac  B     6225                       stab1               269   UGGACUU C UCUCAAU   5994   18339   HBV-269 Rz-7 allyl   a s u s u s g s aga cUGAuGaggccguuaggccGaa Aagucca  B     6226                       stab1               271   GACUUCU C UCAAUUU   5995   18340   HBV-271 Rz-7 allyl   a s a s a s u s uga cUGAuGaggccguuaggccGaa Agaaguc  B     6227                       stab1               273   CUUCUCU C AAUUUUC   5996   18341   HBV-273 Rz-7 allyl   g s a s a s a s auu cUGAuGaggccguuaggccGaa Agagaag  B     6228                       stab1               277   UCUCAAU U UUCUAGG   5997   18342   HBV-277 Rz-7 allyl   c s c s u s a s gaa cUGAuGaggccguuaggccGaa Auugaga  B     6229                       stab1               278   CUCAAUU U UCUAGGG   5998   18343   HBV-278 Rz-7 allyl   c s c s c s u s aga cUGAuGaggccguuaggccGaa Aauugag  B     6230                       stab1               279   UCAAUUU U CUAGGGG   5999   18344   HBV-279 Rz-7 allyl   c s c s c s c s uag cUGAuGaggccguuaggccGaa Aaauuga  B     6231                       stab1               314   CAAAAUU C GCAGUCC   6000   18347   HBV-314 Rz-7 allyl   g s g s a s c s ugc cUGAuGaggccguuaggccGaa Aauuuug  B     6232                       stab1               385   GAUGUGU C UGCGGCG   6001   18348   HBV-385 Rz-7 allyl   c s g s c s c s gca cUGAuGaggccguuaggccGaa Acacauc  B     6233                       stab1               394   GCGGCGU U UUAUCAU   6002   18349   HBV-394 Rz-7 allyl   a s u s g s a s uaa cUGAuGaggccguuaggccGaa Acgccgc  B     6234                       stab1               402   UUAUCAU C UUCCUCU   6003   18352   HBV-402 Rz-7 allyl   a s g s a s g s gaa cUGAuGaggccguuaggccGaa Augauaa  B     6235                       stab1               423   UGCUGCU A UGCCUCA   6004   18353   HBV-423 Rz-7 allyl   u s g s a s g s gca cUGAuGaggccguuaggccGaa Agcagca  B     6236                       stab1               429   UAUGCCU C AUCUUCU   6005   18354   HBV-429 Rz-7 allyl   a s g s a s a s gau cUGAuGaggccguuaggccGaa Aggcaua  B     6237                       stab1               679   GCUCAGU U UACUAGU   6006   18356   HBV-679 Rz-7 allyl   a s c s u s a s gua cUGAuGaggccguuaggccGaa Acugagc  B     6238                       stab1               680   CUCAGUU U ACUAGUG   6007   18357   HBV-680 Rz-7 allyl   c s a s c s u s agu cUGAuGaggccguuaggccGaa Aacugag  B     6239                       stab1               681   UCAGUUU A CUAGUGC   6008   18358   HBV-681 Rz-7 allyl   g s c s a s c s uag cUGAuGaggccguuaggccGaa Aaacuga  B     6240                       stab1               684   GUUUACU A GUGCCAU   6009   18359   HBV-684 Rz-7 allyl   a s u s g s g s cac cUGAuGaggccguuaggccGaa Aguaaac  B     6241                       stab1               692   GUGCCAU U UGUUCAG   6010   18360   HBV-692 Rz-7 allyl   c s u s g s a s aca cUGAuGaggccguuaggccGaa Auggcac  B     6242                       stab1               693   UGCCAUU U GUUCAGU   6011   18361   HBV-693 Rz-7 allyl   a s c s u s g s aac cUGAuGaggccguuaggccGaa Aauggca  B     6243                       stab1               1534   CGCACCU C UCUUUAC   6012   18363   HBV-1534 Rz-7 allyl   g s u s a s a s aga cUGAuGaggccguuaggccGaa Aggugcg  B     6244                       stab1               1536   CACCUCU C UUUACGC   6013   18364   HBV-1536 Rz-7 allyl   g s c s g s u s aaa cUGAuGaggccguuaggccGaa Agaggug  B     6245                       stab1               1538   CCUCUCU U UACGCGG   6014   18365   HBV-1538 Rz-7 allyl   c s c s g s c s gua cUGAuGaggccguuaggccGaa Agagagg  B     6246                       stab1               1787   AGGCUGU A GGCAUAA   6015   18369   HBV-1787 Rz-7 allyl   u s u s a s u s gcc cUGAuGaggccguuaggccGaa Acagccu  B     6247                       stab1               1793   UAGGCAU A AAUUGGU   6016   18370   HBV-1793 Rz-7 allyl   a s c s c s a s auu cUGAuGaggccguuaggccGaa Augccua  B     6248                       stab1               1874   CAAGCCU C CAAGCUG   6017   18372   HBV-1874 Rz-7 allyl   c s a s g s c s uug cUGAuGaggccguuaggccGaa Aggcuug  B     6249                       stab1               1887   UGUGCCU U GGGUGGC   6018   18373   HBV-1887 Rz-7 allyl   g s c s c s a s ccc cUGAuGaggccguuaggccGaa Aggcaca  B     6250                       stab1               2383   AAGAACU C CCUCGCC   6019   18375   HBV-2383 Rz-7 allyl   g s g s c s g s agg cUGAuGaggccguuaggccGaa Aguucuu  B     6251                       stab1               2828   ACCAUAU U CUUGGGA   6020   18377   HBV-2828 Rz-7 allyl   u s c s c s c s aag cUGAuGaggccguuaggccGaa Auauggu  B     6252                       stab1               2829   CCAUAUU C UUGGGAA   6021   18378   HBV-2829 Rz-7 allyl   u s u s c s c s caa cUGAuGaggccguuaggccGaa Aauaugg  B     6253                       stab1               2831   AUAUUCU U GGGAACA   6022   18380   HBV-2831 Rz-7 allyl   u s g s u s u s ccc cUGAuGaggccguuaggccGaa Agaauau  B     6254                       stab1               256   UCUAGAC U CGUGGUG   6023   18381   HBV-256 CHz-7 allyl   c s a s c s c s acg cUGAuGaggccguuaggccGaa Iucuaga  B     6255                       stab1               267   GGUGGAC U UCUCUCA   6024   18382   HBV-267 CHz-7 allyl   u s g s a s g s aga cUGAuGaggccguuaggccGaa Iuccacc  B     6256                       stab1               270   GGACUUC U CUCAAUU   6025   18383   HBV-270 CHz-7 allyl   a s a s u s u s gag cUGAuGaggccguuaggccGaa Iaagucc  B     6257                       stab1               272   ACUUCUC U CAAUUUU   6026   18384   HBV-272 CHz-7 allyl   a s a s a s a s uug cUGAuGaggccguuaggccGaa Iagaagu  B     6258                       stab1               274   UUCUCUC A AUUUUCU   6027   18385   HBV-274 CHz-7 allyl   a s g s a s a s aau cUGAuGaggccguuaggccGaa Iagagaa  B     6259                       stab1               386   AUGUGUC U GCGGCGU   6028   18386   HBV-386 CHz-7 allyl   a s c s g s c s cgc cUGAuGaggccguuaggccGaa Iacacau  B     6260                       stab1               419   AUCCUGC U GCUAUGC   6029   18387   HBV-419 CHz-7 allyl   g s c s a s u s agc cUGAuGaggccguuaggccGaa Icaggau  B     6261                       stab1               422   CUGCUGC U AUGCCUC   6030   18388   HBV-422 CHz-7 allyl   g s a s g s g s cau cUGAuGaggccguuaggccGaa Icagcag  B     6262                       stab1               427   GCUAUGC C UCAUCUU   6031   18389   HBV-427 CHz-7 allyl   a s a s g s a s uga cUGAuGaggccguuaggccGaa Icauagc  B     6263                       stab1               428   CUAUGCC U CAUCUUC   6032   18390   HBV-428 CHz-7 allyl   g s a s a s g s aug cUGAuGaggccguuaggccGaa Igcauag  B     6264                       stab1               430   AUGCCUC A UCUUCUU   6033   18392   HBV-430 CHz-7 allyl   a s a s g s a s aga cUGAuGaggccguuaggccGaa Iaggcau  B     6265                       stab1               608   UGUAUUC C CAUCCCA   6034   18393   HBV-608 CHz-7 allyl   u s g s g s g s aug cUGAuGaggccguuaggccGaa Iaauaca  B     6266                       stab1               609   GUAUUCC C AUCCCAU   6035   18394   HBV-609 CHz-7 allyl   a s u s g s g s gau cUGAuGaggccguuaggccGaa Igaauac  B     6267                       stab1               669   GUUUCUC U UGGCUCA   6036   18395   HBV-669 CHz-7 allyl   u s g s a s g s cca cUGAuGaggccguuaggccGaa Iagaaac  B     6268                       stab1               689   CUAGUGC C AUUUGUU   6037   18398   HBV-689 CHz-7 allyl   a s a s c s a s aau cUGAuGaggccguuaggccGaa Icacuag  B     6269                       stab1               690   UAGUGCC A UUUGUUC   6038   18399   HBV-690 CHz-7 aLlyl   g s a s a s c s aaa cUGAuGaggccguuaggccGaa Igcacua  B     6270                       stab1               718   GCUUUCC C CCACUGU   6039   18400   HBV-718 CHz-7 allyl   a s c s a s g s ugg cUGAuGaggccguuaggccGaa Igaaagc  B     6271                       stab1               1149   CCUUUAC C CCGUUGC   6040   18401   HBV-1149 CHz-7   g s c s a s a s cgg cUGAuGaggccguuaggccGaa Iuaaagg  B     6272                       allyl stab1               1535   GCACCUC U CUUUACG   6041   18408   HBV-1535 CHz-7   c s g s u s a s aag cUGAuGaggccguuaggccGaa Iaggugc  B     6273                       allyl stab1               1537   ACCUCUC U UUACGCG   6042   18409   HBV-1537 CHz-7   c s g s c s g s uaa cUGAuGaggccguuaggccGaa Iagaggu  B     6274                       allyl stab1               1791   UGUAGGC A UAAAUUG   6043   18413   HBV-1791 CHz-7   c s a s a s u s uua cUGAuGaggccguuaggccGaa Iccuaca  B     6275                       allyl stab1               1831   UUUUCAC C UCUGCCU   6044   18415   HBV-1831 CHz-7   a s g s g s c s aga cUGAuGaggccguuaggccGaa Iugaaaa  B     6276                       allyl stab1               1832   UUUCACC U CUGCCUA   6045   18416   HBV-1832 CHz-7   u s a s g s g s cag cUGAuGaggccguuaggccGaa Igugaaa  B     6277                       allyl stab1               1872   UUCAAGC C UCCAAGC   6046   18417   HBV-1872 CHz-7   g s c s u s u s gga cUGAuGaggccguuaggccGaa Icuugaa  B     6278                       allyl stab1               1873   UCAAGCC U CCAAGCU   6047   18418   HBV-1873 CHz-7   a s g s c s u s ugg cUGAuGaggccguuaggccGaa Igcuuga  B     6279                       allyl stab1               1875   AAGCCUC C AAGCUGU   6048   18419   HBV-1875 CHz-7   a s c s a s g s cuu cUGAuGaggccguuaggccGaa Iaggcuu  B     6280                       allyl stab1               1876   AGCCUCC A AGCUGUG   6049   18421   HBV-1876 CHz-7   c s a s c s a s gcu cUGAuGaggccguuaggccGaa Igaggcu  B     6281                       allyl stab1               1880   UCCAAGC U GUGCCUU   6050   18423   HBV-1880 CHz-7   a s a s g s g s cac cUGAuGaggccguuaggccGaa Icuugga  B     6282                       allyl stab1               2382   GAAGAAC U CCCUCGC   6051   18424   HBV-2382 CHz-7   g s c s g s a s ggg cUGAuGaggccguuaggccGaa Iuucuuc  B     6283                       allyl stab1               2384   AGAACUC C CUCGCCU   6052   18425   HBV-2384 CHz-7   a s g s g s c s gag cUGAuGaggccguuaggccGaa Iaguucu  B     6284                       allyl stab1               2385   GAACUCC C UCGCCUC   6053   18426   HBV-2385 CHz-7   g s a s g s g s cga cUGAuGaggccguuaggccGaa Igaguuc  B     6285                       allyl stab1               2422   GCGUCGC A GAAGAUC   6054   18427   HBV-2422 CHz-7   g s a s u s c s uuc cUGAuGaggccguuaggccGaa Icgacgc  B     6286                       allyl stab1               2830   CAUAUUC U UGGGAAC   6055   18428   HBV-2830 CHz-7   g s u s u s c s cca cUGAuGaggccguuaggccGaa Iaauaug  B     6287                       allyl stab1               234   AAUCCU C ACAAUA   6056   19179   HBV-234 Rz-6 amino   u s a s u s u s gu c U GA U GaggccguuaggccGaa Aggauu  B     6288                       stab1               252   GAGUCU A GACUCG   6057   19180   HBV-252 Rz-6 amino   c s g s a s g s uc c U GA U GaggccguuaggccGaa Agacuc  B     6289                       stab1               268   UGGACU U CUCUCA   6058   19182   HBV-268 Rz-6 amino   u s g s a s g s ag c U GA U GaggccguuaggccGaa Agucca  B     6290                       stab1               280   AAUUUU C UAGGGG   6059   19190   HBV-280 Rz-6 amino   c s c s c s c s ua c U GA U GaggccguuaggccGaa Aaaauu  B     6291                       stab1               313   CAAAAU U CGCAGU   6060   19191   HBV-313 Rz-6 amino   a s c s u s g s cg c U GA U GaggccguuaggccGaa Auuuug  B     6292                       stab1               395   GGCGUU U UAUCAU   6061   19195   HBV-395 Rz-6 amino   a s u s g s a s ua c U GA U GaggccguuaggccGaa Aacgcc  B     6293                       stab1               402   UAUCAU C UUCCUC   6062   19196   HBV-402 Rz-6 amino   g s a s g s g s aa c U GA U GaggccguuaggccGaa Augaua  B     6294                       stab1               607   UGUAUU C CCAUCC   6063   19200   HBV-607 Rz-6 amino   g s g s a s u s gg c U GA U GaggccguuaggccGaa Aauaca  B     6295                       stab1               697   UUUGUU C AGUGGU   6064   19207   HBV-697 Rz-6 amino   a s c s c s a s cu c U GA U GaggccguuaggccGaa Aacaaa  B     6296                       stab1               1539   UCUCUU U ACGCGG   6065   19211   HBV-1539 Rz-6 amino   c s c s g s c s gu c U GA U GaggccguuaggccGaa Aagaga  B     6297                       stab1               1599   UCACCU C UGCACG   6066   19212   HBV-1599 Rz-6 amino   c s g s u s g s ca c U GA U GaggccguuaggccGaa Agguga  B     6298                       stab1               1607   GCACGU C GCAUGG   6067   19213   HBV-1607 Rz-6 amino   c s c s a s u s gc c U GA U GaggccguuaggccGaa Acgugc  B     6299                       stab1               1833   UCACCU C UGCCUA   6068   19216   HBV-1833 Rz-6 amino   u s a s g s g s ca c U GA U GaggccguuaggccGaa Agguga  B     6300                       stab1               2383   AGAACU C CCUCGC   6069   19219   HBV-2383 Rz-6 amino   g s c s g s a s gg c U GA U GaggccguuaggccGaa Aguucu  B     6301                       stab1               2429   GAAGAU C UCAAUC   6070   19221   HBV-2429 Rz-6 amino   g s a s u s u s ga c U GA U GaggccguuaggccGaa Aucuuc  B     6302                       stab1               2831   UAUUCU U GGGAAC   6071   19224   HBV-2831 Rz-6 amino   g s u s u s c s cc c U GA U GaggccguuaggccGaa Agaaua  B     6303                       stab1               430   UGCCUC A UCUUCU   6072   19236   HBV-430 CHz-6 amino   a s g s a s a s ga c U GA U GaggccguuaggccGaa Iaggca  B     6304                       stab1               676   UGGCUC A GUUUAC   6073   19241   HBV-676 CHz-6 amino   g s u s a s a s ac c U GA U GaggccguuaggccGaa Iagcca  B     6305                       stab1               683   GUUUAC U AGUGCC   6074   19242   HBV-683 CHz-6 amino   g s g s c s a s cu c U GA U GaggccguuaggccGaa Iuaaac  B     6306                       stab1               1150   UUUACC C CGUUGC   6075   19247   HBV-1150 CHz-6   g s c s a s a s cg c U GA U GaggccguuaggccGaa Iguaaa  B     6307                       amino stab1               1200   GCAACC C CCACUG   6076   19248   HBV-1200 CHz-6   c s a s g s u s gg c U GA U GaggccguuaggccGaa Iguugc  B     6308                       amino stab1               1201   CAACCC C CACUGG   6077   19249   HBV-1201 CHz-6   c s c s a s g s ug c U GA U GaggccguuaggccGaa Igguug  B     6309                       amino stab1               1444   CGGCGC U GAAUCC   6078   19250   HBV-1444 CHz-6   g s g s a s u s uc c U GA U GaggccguuaggccGaa Icgccg  B     6310                       amino stab1               1451   GAAUCC C GCGGAC   6079   19251   HBV-1451 CHz-6   g s u s c s c s gc c U GA U GaggccguuaggccGaa Igauuc  B     6311                       amino stab1               1533   CGCACC U CUCUUU   6080   19252   HBV-1533 CHz-6   a s a s a s g s ag c U GA U GaggccguuaggccGaa Igugcg  B     6312                       amino stab1               1600   CACCUC U GCACGU   6081   19255   HBV-1600 CHz-6   a s c s g s u s gc c U GA U GaggccguuaggccGaa Iaggug  B     6313                       amino stab1               1698   CCGACC U UGAGGC   6082   19256   HBV-1698 CHz-6   g s c s c s u s ca c U GA U GaggccguuaggccGaa Igucgg  B     6314                       amino stab1               1784   GGAGGC U GUAGGC   6083   19257   HBV-1784 CHz-6   g s c s c s u s ac c U GA U GaggccguuaggccGaa Iccucc  B     6315                       amino stab1               1829   UUUUUC A CCUCUG   6084   19259   HBV-1829 CHz-6   c s a s g s a s gg c U GA U GaggccguuaggccGaa Iaaaaa  B     6316                       amino stab1               1876   GCCUCC A AGCUGU   6085   19265   HBV-1876 CHz-6   a s c s a s g s cu c U GA U GaggccguuaggccGaa Igaggc  B     6317                       amino stab1               1880   CCAAGC U GUGCCU   6086   19267   HBV-1880 CHz-6   a s g s g s c s ac c U GA U GaggccguuaggccGaa Icuugg  B     6318                       amino stab1               218   UUUUUCU U GUUGACA   6087   19178   HBV-218 Rz-7 amino   u s g s u s c s aac c U GA U GaggccguuaggccGaa Agaaaaa  B     6319                       stab1               257   CUAGACU C GUGGUGG   6088   19181   HBV-257 Rz-7 amino   c s c s a s c s cac c U GA U GaggccguuaggccGaa Agucuag  B     6320                       stab1               268   GUGGACU U CUCUCAA   6089   19183   HBV-268 Rz-7 amino   u s u s g s a s gag c U GA U GaggccguuaggccGaa Aguccac  B     6321                       stab1               269   UGGACUU C UCUCAAU   6090   19184   HBV-269 Rz-7 amino   a s u s u s g s aga c U GA U GaggccguuaggccGaa Aagucca  B     6322                       stab1               271   GACUUCU C UCAAUUU   6091   19185   HBV-271 Rz-7 amino   a s a s a s u s uga c U GA U GaggccguuaggccGaa Agaaguc  B     6323                       stab1               273   CUUCUCU C AAUUUUC   6092   19186   HBV-273 Rz-7 amino   g s a s a s a s auu c U GA U GaggccguuaggccGaa Agagaag  B     6324                       stab1               277   UCUCAAU U UUCUAGG   6093   19187   HBV-277 Rz-7 amino   c s c s u s a s gaa c U GA U GaggccguuaggccGaa Auugaga  B     6325                       stab1               278   CUCAAUU U UCUAGGG   6094   19188   HBV-278 Rz-7 amino   c s c s c s u s aga c U GA U GaggccguuaggccGaa Aauugag  B     6326                       stab1               279   UCAAUUU U CUAGGGG   6095   19189   HBV-279 Rz-7 amino   c s c s c s c s uag c U GA U GaggccguuaggccGaa Aaauuga  B     6327                       stab1               314   CAAAAUU C GCAGUCC   6096   19192   HBV-314 Rz-7 amino   g s g s a s c s ugc c U GA U GaggccguuaggccGaa Aauuuug  B     6328                       stab1               385   GAUGUGU C UGCGGCG   6097   19193   HBV-385 Rz-7 amino   c s g s c s c s gca c U GA U GaggccguuaggccGaa Acacauc  B     6329                       stab1               394   GCGGCGU U UUAUCAU   6098   19194   HBV-394 Rz-7 amino   a s u s g s a s uaa c U GA U GaggccguuaggccGaa Acgccgc  B     6330                       stab1               402   UUAUCAU C UUCCUCU   6099   19197   HBV-402 Rz-7 amino   a s g s a s g s gaa c U GA U GaggccguuaggccGaa Augauaa  B     6331                       stab1               423   UGCUGCU A UGCCUCA   6100   19198   HBV-423 Rz-7 amino   u s g s a s g s gca c U GA U GaggccguuaggccGaa Agcagca  B     6332                       stab1               429   UAUGCCU C AUCUUCU   6101   19199   HBV-429 Rz-7 amino   a s g s a s a s gau c U GA U GaggccguuaggccGaa Aggcaua  B     6333                       stab1               679   GCUCAGU U UACUAGU   6102   19201   HBV-679 Rz-7 amino   a s c s u s a s gua c U GA U GaggccguuaggccGaa Acugagc  B     6334                       stab1               680   CUCAGUU U ACUAGUG   6103   19202   HBV-680 Rz-7 amino   c s a s c s u s agu c U GA U GaggccguuaggccGaa Aacugag  B     6335                       stab1               681   UCAGUUU A CUAGUGC   6104   19203   HBV-681 Rz-7 amino   g s c s a s c s uag c U GA U GaggccguuaggccGaa Aaacuga  B     6336                       stab1               684   GUUUACU A GUGCCAU   6105   19204   HBV-684 Rz-7 amino   a s u s g s g s cac c U GA U GaggccguuaggccGaa Aguaaac  B     6337                       stab1               692   GUGCCAU U UGUUCAG   6106   19205   HBV-692 Rz-7 amino   c s u s g s a s aca c U GA U GaggccguuaggccGaa Auggcac  B     6338                       stab1               693   UGCCAUU U GUUCAGU   6107   19206   HBV-693 Rz-7 amino   a s c s u s g s aac c U GA U GaggccguuaggccGaa Aauggca  B     6339                       stab1               1534   CGCACCU C UCUUUAC   6108   19208   HBV-1534 Rz-7 amino   g s u s a s a s aga c U GA U GaggccguuaggccGaa Aggugcg  B     6340                       stab1               1536   CACCUCU C UUUACGC   6109   19209   HBV-1536 Rz-7 amino   g s c s g s u s aaa c U GA U GaggccguuaggccGaa Agaggug  B     6341                       stab1               1538   CCUCUCU U UACGCGG   6110   19210   HBV-1538 Rz-7 amino   c s c s g s c s gua c U GA U GaggccguuaggccGaa Agagagg  B     6342                       stab1               1787   AGGCUGU A GGCAUAA   6111   19214   HBV-1787 Rz-7 amino   u s u s a s u s gcc c U GA U GaggccguuaggccGaa Acagccu  B     6343                       stab1               1793   UAGGCAU A AAUUGGU   6112   19215   HBV-1793 Rz-7 amino   a s c s c s a s auu c U GA U GaggccguuaggccGaa Augccua  B     6344                       stab1               1874   CAAGCCU C CAAGCUG   6113   19217   HBV-1874 Rz-7 amino   c s a s g s c s uug c U GA U GaggccguuaggccGaa Aggcuug  B     6345                       stab1               1887   UGUGCCU U GGGUGGC   6114   19218   HBV-1887 Rz-7 amino   g s c s c s a s ccc c U GA U GaggccguuaggccGaa Aggcaca  B     6346                       stab1               2383   AAGAACU C CCUCGCC   6115   19220   HBV-2383 Rz-7 amino   g s g s c s g s agg c U GA U GaggccguuaggccGaa Aguucuu  B     6347                       stab1               2828   ACCAUAU U CUUGGGA   6116   19222   HBV-2828 Rz-7 amino   u s c s c s c s aag c U GA U GaggccguuaggccGaa Auauggu  B     6348                       stab1               2829   CCAUAUU C UUGGGAA   6117   19223   HBV-2829 Rz-7 amino   u s u s c s c s caa c U GA U GaggccguuaggccGaa Aauaugg  B     6349                       stab1               2831   AUAUUCU U GGGAACA   6118   19225   HBV-2831 Rz-7 amino   u s g s u s u s ccc c U GA U GaggccguuaggccGaa Agaauau  B     6350                       stab1               256   UCUAGAC U CGUGGUG   6119   19226   HBV-256 CHz-7 amino   c s a s c s c s acg c U GA U GaggccguuaggccGaa Iucuaga  B     6351                       stab1               267   GGUGGAC U UCUCUCA   6120   19227   HBV-267 CHz-7 amino   u s g s a s g s aga c U GA U GaggccguuaggccGaa Iuccacc  B     6352                       stab1               270   GGACUUC U CUCAAUU   6121   19228   HBV-270 CHz-7 amino   a s a s u s u s gag c U GA U GaggccguuaggccGaa Iaagucc  B     6353                       stab1               272   ACUUCUC U CAAUUUU   6122   19229   HBV-272 CHz-7 amino   a s a s a s a s uug c U GA U GaggccguuaggccGaa Iagaagu  B     6354                       stab1               274   UUCUCUC A AUUUUCU   6123   19230   HBV-274 CHz-7 amino   a s g s a s a s aau c U GA U GaggccguuaggccGaa Iagagaa  B     6355                       stab1       386   AUGUGUC U GCGGCGU   6124   19231   HBV-386 CHz-7 amino   a s c s g s c s cgc c U GA U GaggccguuaggccGaa Iacacau  B     6356                       stab1               419   AUCCUGC U GCUAUGC   6125   19232   HBV-419 CHz-7 amino   g s c s a s u s agc c U GA U GaggccguuaggccGaa Icaggau  B     6357                       stab1               422   CUGCUGC U AUGCCUC   6126   19233   HBV-422 CHz-7 amino   g s a s g s g s cau c U GA U GaggccguuaggccGaa Icagcag  B     6358                       stab1               427   GCUAUGC C UCAUCUU   6127   19234   HBV-427 CHz-7 amino   a s a s g s a s uga c U GA U GaggccguuaggccGaa Icauagc  B     6359                       stab1               428   CUAUGCC U CAUCUUC   6128   19235   HBV-428 CHz-7 amino   g s a s a s g s aug c U GA U GaggccguuaggccGaa Igcauag  B     6360                       stab1               430   AUGCCUC A UCUUCUU   6129   19237   HBV-430 CHz-7 amino   a s a s g s a s aga c U GA U GaggccguuaggccGaa Iaggcau  B     6361                       stab1               608   UGUAUUC C CAUCCCA   6130   19238   HBV-608 CHz-7 amino   u s g s g s g s aug c U GA U GaggccguuaggccGaa Iaauaca  B     6362                       stab1               609   GUAUUCC C AUCCCAU   6131   19239   HBV-609 CHz-7 amino   a s u s g s g s gau c U GA U GaggccguuaggccGaa Igaauac  B     6363                       stab1               669   GUUUCUC U UGGCUCA   6132   19240   HBV-669 CHz-7 amino   u s g s a s g s cca c U GA U GaggccguuaggccGaa Iagaaac  B     6364                       stab1               689   CUAGUGC C AUUUGUU   6133   19243   HBV-689 CHz-7 amino   a s a s c s a s aau c U GA U GaggccguuaggccGaa Icacuag  B     6365                       stab1               690   UAGUGCC A UUUGUUC   6134   19244   HBV-690 CHz-7 amino   g s a s a s c s aaa c U GA U GaggccguuaggccGaa Igcacua  B     6366                       stab1               718   GCUUUCC C CCACUGU   6135   19245   HBV-718 CHz-7 amino   a s c s a s g s ugg c U GA U GaggccguuaggccGaa Igaaagc  B     6367                       stab1               1149   CCUUUAC C CCGUUGC   6136   19246   HBV-1149 CHz-7   g s c s a s a s cgg c U GA U GaggccguuaggccGaa Iuaaagg  B     6368                       amino stab1               1535   GCACCUC U CUUUACG   6137   19253   HBV-1535 CHz-7   c s g s u s a s aag c U GA U GaggccguuaggccGaa Iaggugc  B     6369                       amino stab1               1537   ACCUCUC U UUACGCG   6138   19254   HBV-1537 CHz-7   c s g s c s g s uaa c U GA U GaggccguuaggccGaa Iagaggu  B     6370                       amino stab1               1791   UGUAGGC A UAAAUUG   6139   19258   HBV-1791 CHz-7   c s a s a s u s uua c U GA U GaggccguuaggccGaa Iccuaca  B     6371                       amino stab1               1831   UUUUCAC C UCUGCCU   6140   19260   HBV-1831 CHz-7   a s g s g s c s aga c U GA U GaggccguuaggccGaa Iugaaaa  B     6372                       amino stab1               1832   UUUCACC U CUGCCUA   6141   19261   HBV-1832 CHz-7   u s a s g s g s cag c U GA U GaggccguuaggccGaa Igugaaa  B     6373                       amino stab1               1872   UUCAAGC C UCCAAGC   6142   19262   HBV-1872 CHz-7   g s c s u s u s gga c U GA U GaggccguuaggccGaa Icuugaa  B     6374                       amino stab1               1873   UCAAGCC U CCAAGCU   6143   19263   HBV-1873 CHz-7   a s g s c s u s ugg c U GA U GaggccguuaggccGaa Igcuuga  B     6375                       amino stab1       1875   AAGCCUC C AAGCUGU   6144   19264   HBV-1875 CHz-7   a s c s a s g s cuu c U GA U GaggccguuaggccGaa Iaggcuu  B     6376                       amino stab1               1876   AGCCUCC A AGCUGUG   6145   19266   HBV-1876 CHz-7   c s a s c s a s gcu c U GA U GaggccguuaggccGaa Igaggcu  B     6377                       amino stab1               1880   UCCAAGC U GUGCCUU   6146   19268   HBV-1880 CHz-7   a s a s g s g s cac c U GA U GaggccguuaggccGaa Icuugga  B     6378                       amino stab1               2382   GAAGAAC U CCCUCGC   6147   19269   HBV-2382 CHz-7   g s c s g s a s ggg c U GA U GaggccguuaggccGaa Iuucuuc  B     6379                       amino stab1               2384   AGAACUC C CUCGCCU   6148   19270   HBV-2384 CHz-7   a s g s g s c s gag c U GA U GaggccguuaggccGaa Iaguucu  B     6380                       amino stab1               2385   GAACUCC C UCGCCUC   6149   19271   HBV-2385 CHz-7   g s a s g s g s cga c U GA U GaggccguuaggccGaa Igaguuc  B     6381                       amino stab1               2422   GCGUCGC A GAAGAUC   6150   19272   HBV-2422 CHz-7   g s a s u s c s uuc c U GA U GaggccguuaggccGaa Icgacgc  B     6382                       amino stab1               2830   CAUAUUC U UGGGAAC   6151   19273   HBV-2830 CHz-7   g s u s u s c s cca c U GA U GaggccguuaggccGaa Iaauaug  B     6383                       amino stab1               315   GCCAAAAUUC G CAGUC   6152   20079   HBV-315 GCl.Rz-5/10   g s a s c s g uGAU s g gcauGcacuaugc gcg gaauuuuggc  B     6384                       stab2               381   AUCGCUGGAU G UGUCU   6153   20080   HBV-381 GCl.Rz-5/10   a s g s a s a uGAU s g gcauGcacuaugc gcg auccagcgau  B     6385                       stab2               476   UUGCCCGUUU G UCCUC   6154   20081   HBV-476 GCl.Rz-5/10   g s a s g s a uGAU s g gcauGcacuaugc gcg aaacgggcaa  B     6386                       stab2               694   AGUGCCAUUU G UUCAG   6155   20082   HBV-694 GCl.Rz-5/10   c s u s g s a uGAU s g gcauGcacuaugc gcg aaauggcacu  B     6387                       stab2               1265   CUCCUCUGCC G AUCCA   6156   20083   HBV-1265 GCl.Rz-   u s g s g s u uGAU s g gcauGcacuaugc gcg ggcagaggag  B     6388                       5/10 stab2               1601   CUUCACCUCU G CACGU   6157   20084   HBV-1601 GCl.Rz-   a s c s g s g uGAU s g gcauGcacuaugc gcg agaggugaag  B     6389                       5/10 stab2               1881   CCUCCAAGCU G UGCCU   6158   20085   HBV-1881 GCl.Rz-   a s g s g s a uGAU s g gcauGcacuaugc gcg agcuuggagg  B     6390                       5/10 stab2               1883   UCCAAGCUGU G CCUUG   6159   20086   HBV-1883 GCl.Rz-   c s a s a s g uGAU s g gcauGcacuaugc gcg acagcuugga  B     6391                       5/10 stab2               2388   GAACUCCCUC G CCUCG   6160   20087   HBV-2388 GCl.Rz-   c s g s a s g uGAU s g gcauGcacuaugc gcg gagggaguuc  B     6392                       5/10 stab2               381   GCUGGAU G UGUCUGC   6161   20091   HBV-381 Zin.Rz-7   g s c s a s g s aca GccgaaagG C GaGugaGGu C u auccagc  B     6393                       amino stab2               392   CUGCGGC G UUUUAUC   6162   20092   HBV-392 Zin.Rz-7   g s a s u s a s aaa GccgaaagG C GaGugaGGu C u gccgcag  B     6394                       amino stab2               420   UCCUGCU G CUAUGCC   6163   20093   HBV-420 Zin.Rz-7   g s g s c s a s uag GccgaaagG C GaGugaGGu C u agcagga  B     6395                       amino stab2               648   UAUGGGA G UGGGCCU   6164   20094   HBV-648 Zin.Rz-7   a s g s g s c s cca GccgaaagG C GaGugaGGu C u ucccaua  B     6396                       amino stab2               711   UCGUAGG G CUUUCCC   6165   20095   HBV-711 Zin.Rz-7   g s g s g s a s aag GccgaaagG C GaGugaGGu C u ccuacga  B     6397                       amino stab2               1262   CUCCUCU G CCGAUCC   6166   20096   HBV-1262 Zin.Rz-7   g s g s a s u s cgg GccgaaagG C GaGugaGGu C u agaggag  B     6398                       amino stab2               1835   CACCUCU G CCUAAUC   6167   20097   HBV-1835 Zin.Rz-7   g s a s u s u s agg GccgaaagG C GaGugaGGu C u agaggug  B     6399                       amino stab2               2388   CUCCCUC G CCUCGCA   6168   20098   HBV-2388 Zin.Rz-7   u s g s c s g s agg GccgaaagG C GaGugaGGu C u gagggag  B     6400                       amino stab2               192   GACCCCU G CUCGUGU   6169   20099   HBV-192 Zin.Rz-7   a s c s a s c s gag GccgaaagG C GaGugaGGu C u agggguc  B     6401                       amino stab2               198   UGCUCGU G UUACAGG   6170   20100   HBV-198 Zin.Rz-7   c s c s u s g s uaa GccgaaagG C GaGugaGGu C u acgagca  B     6402                       amino stab2               315   AAAUUC G CAGUCC   6171   20101   HBV-315 Zin.Rz-7   g s g s g s a s cug GccgaaagG C GaGugaGGu C u gaauuuu  B     6403                       amino stab2               383   GGAUGU G UCUGCG   6172   20102   HBV-383 Zin.Rz-6   c s g s c s a s ga GccgaaagG C GaGugaGGu C u acaucc  B     6404                       amino stab2               383   UGGAUGU G UCUGCGG   6173   20103   HBV-383 Zin.Rz-7   c s c s g s c s aga GccgaaagG C GaGugaGGu C u acaucca  B     6405                       amino stab2               387   GUGUCU G CGGCGU   6174   20104   HBV-387 Zin.Rz-6   a s c s g s c s cg GccgaaagG C GaGugaGGu C u agacac  B     6406                       amino stab2               390   GUCUGCG G CGUUUUA   6175   20105   HBV-390 Zin.Rz-7   u s a s a s a s acg GccgaaagG C GaGugaGGu C u cgcagac  B     6407                       amino stab2               392   UGCGGC G UUUUAU   6176   20106   HBV-392 Zin.Rz-6   a s u s a s a s aa GccgaaagG C GaGugaGGu C u gccgca  B     6408                       amino stab2               425   UGCUAU G CCUCAU   6177   20107   HBV-425 Zin.Rz-6   a s u s g s a s gg GccgaaagG C GaGugaGGu C u auagca  B     6409                       amino stab2               425   CUGCUAU G CCUCAUC   6178   20108   HBV-425 Zin.Rz-7   g s a s u s g s agg GccgaaagG C GaGugaGGu C u auagcag  B     6410                       amino stab2               468   GUAUGUU G CCCGUUU   6179   20109   HBV-468 Zin.Rz-7   a s a s a s c s agg GccgaaagG C GaGugaGGu C u aacauac  B     6411                       amino stab2               476   CCCGUUU G UCCUCUA   6180   20110   HBV-476 Zin.Rz-7   u s a s g s a s gga GccgaaagG C GaGugaGGu C u aaacggg  B     6412                       amino stab2               648   AUGGGA G UGGGCC   6181   20111   HBV-648 Zin.Rz-6   g s g s c s c s ca GccgaaagG C GaGugaGGu C u ucccau  B     6413                       amino stab2               694   GCCAUUU G UUCAGUG   6182   20112   HBV-694 Zin.Rz-7   c s a s c s u s gaa GccgaaagG C GaGugaGGu C u aaauggc  B     6414                       amino stab2               699   UUGUUCA G UGGUUCG   6183   20113   HBV-699 Zin.Rz-7   c s g s a s a s cca GccgaaagG C GaGugaGGu C u ugaacaa  B     6415                       amino stab2               1262   UCCUCU G CCGAUC   6184   20114   HBV-1262 Zin.Rz-6   g s a s u s c s gg GccgaaagG C GaGugaGGu C u agagga  B     6416                       amino stab2               1440   CCCGUCG G CGCUGAA   6185   20115   HBV-1440 Zin.Rz-7   u s u s c s a s gcg GccgaaagG C GaGugaGGu C u cgacggg  B     6417                       amino stab2               1526   CACGGG G CGCACC   6186   20116   HBV-1526 Zin.Rz-6   g s g s u s g s cg GccgaaagG C GaGugaGGu C u cccgug  B     6418                       amino stab2               1526   CCACGGG G CGCACCU   6187   20117   HBV-1526 Zin.Rz-7   a s g s g s u s gcg GccgaaagG C GaGugaGGu C u cccgugg  B     6419                       amino stab2               1557   CCCGUCU G UGCCUUC   6188   20118   HBV-1557 Zin.Rz-7   g s a s a s g s gca GccgaaagG C GaGugaGGu C u agacggg  B     6420                       amino stab2               1559   CGUCUGU G CCUUCUC   6189   20119   HBV-1559 Zin.Rz-7   g s a s g s a s agg GccgaaagG C GaGugaGGu C u acagacg  B     6421                       amino stab2               1590   GCACUUC G CUUCACC   6190   20120   HBV-1590 Zin.Rz-7   g s g s u s g s aag GccgaaagG C GaGugaGGu C u gaagugc  B     6422                       amino stab2               1835   ACCUCU G CCUAAU   6191   20121   HBV-1835 Zin.Rz-6   a s u s u s a s gg GccgaaagG C GaGugaGGu C u agaggu  B     6423                       amino stab2               2311   ACCAAAU G CCCCUAU   6192   20122   HBV-2311 Zin.Rz-7   a s u s a s g s ggg GccgaaagG C GaGugaGGu C u auuuggu  B     6424                       amino stab2               2420   CCGCGUC G CAGAAGA   6193   20123   HBV-2420 Zin.Rz-7   u s c s u s u s cug GccgaaagG C GaGugaGGu C u gacgcgg  B     6425                       amino stab2               65   CCUGCUG G UGGCUCC   6194   20124   HBV-65 Zin.Rz-7   g s g s a s g s cca GccgaaagG C GaGugaGGu C u cagcagg  B     6426                       amino stab2               192   ACCCCU G CUCGUG   6195   20125   HBV-192 Zin.Rz-6   c s a s c s g s ag GccgaaagG C GaGugaGGu C u aggggu  B     6427                       amino stab2               198   GCUCGU G UUACAG   6196   20126   HBV-198 Zin.Rz-6   c s u s g s u s aa GccgaaagG C GaGugaGGu C u acgagc  B     6428                       amino stab2               258   UAGACUC G UGGUGGA   6197   20127   HBV-258 Zin.Rz-7   u s c s c s a s cca GccgaaagG C GaGugaGGu C u gagucua  B     6429                       amino stab2               261   ACUCGUG G UGGACUU   6198   20128   HBV-261 Zin.Rz-7   a s a s g s u s cca GccgaaagG C GaGugaGGu C u cacgagu  B     6430                       amino stab2               315   AAAUUC G CAGUCC   6199   20129   HBV-315 Zin.Rz-6   g s g s a s c s ug GccgaaagG C GaGugaGGu C u gaauuu  B     6431                       amino stab2               381   CUGGAU G UGUCUG   6200   20130   HBV-381 Zin.Rz-6   c s a s g s a s ca GccgaaagG C GaGugaGGu C u auccag  B     6432                       amino stab2               387   UGUGUCU G CGGCGUU   6201   20131   HBV-387 Zin.Rz-7   a s a s c s g s ccg GccgaaagG C GaGugaGGu C u agacaca  B     6433                       amino stab2               390   UCUGCG G CGUUUU   6202   20132   HBV-390 Zin.Rz-6   a s a s a s a s cg GccgaaagG C GaGugaGGu C u cgcaga  B     6434                       amino stab2               417   CAUCCU G CUGCUA   6203   20133   HBV-417 Zin.Rz-6   u s a s g s c s ag GccgaaagG C GaGugaGGu C u aggaug  B     6435                       amino stab2               420   CCUGCU G CUAUGC   6204   20134   HBV-420 Zin.Rz-6   g s c s a s u s ag GccgaaagG C GaGugaGGu C u agcagg  B     6436                       amino stab2               468   UAUGUU G CCCGUU   6205   20135   HBV-468 Zin.Rz-6   a s a s c s g s gg GccgaaagG C GaGugaGGu C u aacaua  B     6437                       amino stab2               476   CCGUUU G UCCUCU   6206   20136   HBV-476 Zin.Rz-6   a s g s a s g s ga GccgaaagG C GaGugaGGu C u aaacgg  B     6438                       amino stab2               677   GGCUCA G UUUACU   6207   20137   HBV-677 Zin.Rz-6   a s g s u s a s aa GccgaaagG C GaGugaGGu C u ugagcc  B     6439                       amino stab2               677   UGGCUCA G UUUACUA   6209   20138   HBV-677 Zin.Rz-7   u s a s g s u s aaa GccgaaagG C GaGugaGGu C u ugagoca  B     6440                       amino stab2               685   UUACUA G UGCCAU   6209   20139   HBV-685 Zin.Rz-6   a s u s g s g s ca GccgaaagG C GaGugaGGu C u uaguaa  B     6441                       amino stab2               685   UUUACUA G UGCCAUU   6210   20140   HBV-685 Zin.Rz-7   a s a s u s g s gca GccgaaagG C GaGugaGGu C u uaguaaa  B     6442                       amino stab2               687   UACUAGU G CCAUUUG   6211   20141   HBV-687 Zin.Rz-7   c s a s a s a s ugg GccgaaagG C GaGugaGGu C u acuagua  B     6443                       amino stab2               699   UGUUCA G UGGUUC   6212   20142   HBV-699 Zin.Rz-6   g s a s a s c s ca GccgaaagG C GaGugaGGu C u ugaaca  B     6444                       amino stab2               702   UCAGUG G UUCGUA   6213   20143   HBV-702 Zin.Rz-6   u s a s c s g s aa GccgaaagG C GaGugaGGu C u cacuga  B     6445                       amino stab2               702   UUCAGUG G UUCGUAG   6214   20144   HBV-702 Zin.Rz-7   c s u s a s c s gaa GccgaaagG C GaGugaGGu C u cacugaa  B     6446                       amino stab2               711   CGUAGG G CUUUCC   6215   20145   HBV-711 Zin.Rz-6   g s g s a s a s ag GccgaaagG C GaGugaGGu C u ccuacg  B     6447                       amino stab2               1006   UUGUGG G UCUUUU   6216   20146   HBV-1006 Zin.Rz-6   a s a s a s a s ga GccgaaagG C GaGugaGGu C u ccacaa  B     6448                       amino stab2               1103   UUUCUC G CCAACU   6217   20147   HBV-1103 Zin.Rz-6   a s g s u s u s gg GccgaaagG C GaGugaGGu C u gagaaa  B     6449                       amino stab2               1103   CUUUCUC G CCAACUU   6218   20148   HBV-1103 Zin.Rz-7   a s a s g s u s ugg GccgaaagG C GaGugaGGu C u gagaaag  B     6450                       amino stab2               1184   GCCAAGU G UUUGCUG   6219   20149   HBV-1184 Zin.Rz-7   c s a s g s c s aaa GccgaaagG C GaGugaGGu C u acuuggc  B     6451                       amino stab2               1440   CCGUCG G CGCUGA   6220   20150   HBV-1440 Zin.Rz-6   u s c s a s g s cg GccgaaagG C GaGugaGGu C u cgacgg  B     6452                       amino stab2               1442   GUCGGC G CUGAAU   6221   20151   HBV-1442 Zin.Rz-6   a s u s u s c s ag GccgaaagG C GaGugaGGu C u gccgac  B     6453                       amino stab2               1442   CGUCGGC G CUGAAUC   6222   20152   HBV-1442 Zin.Rz-7   g s a s u s u s cag GccgaaagG C GaGugaGGu C u gccgacg  B     6454                       amino stab2               1553   CUCCCC G UCUGUG   6223   20153   HBV-1553 Zin.Rz-6   c s a s c s a s ga GccgaaagG C GaGugaGGu C u ggggag  B     6455                       amino stab2               1557   CCGUCU G UGCCUU   6224   20154   HBV-1557 Zin.Rz-6   a s a s g s g s ca GccgaaagG C GaGugaGGu C u agacgg  B     6456                       amino stab2               1559   GUCUGU G CCUUCU   6225   20155   HBV-1559 Zin.Rz-6   a s g s a s a s gg GccgaaagG C GaGugaGGu C u acagac  B     6457                       amino stab2               1583   CCGUGU G CACUUC   6226   20156   HBV-1583 Zin.Rz-6   g s a s a s g s ug GccgaaagG C GaGugaGGu C u acacgg  B     6458                       amino stab2               1590   CACUUC G CUUCAC   6227   20157   HBV-1590 Zin.Rz-6   g s u s g s a s ag GccgaaagG C GaGugaGGu C u gaagug  B     6459                       amino stab2               1622   ACCACC G UGAACG   6228   20158   HBV-1622 Zin.Rz-6   c s g s u s   u sca GccgaaagG C GaGugaGGu C u gguggu  B     6460                       amino stab2               1870   UGUUCAA G CCUCCAA   6229   20159   HBV-1870 Zin.Rz-7   u s u s g s g s agg GccgaaagG C GaGugaGGu C u uugaaca  B     6461                       amino stab2               1881   CCAAGCU G UGCCUUG   6230   20160   HBV-1881 Zin.Rz-7   c s a s a s g s gca GccgaaagG C GaGugaGGu C u agcuugg  B     6462                       amino stab2               1883   AGCUGU G CCUUGG   6231   20161   HBV-1883 Zin.Rz-6   c s c s a s a s gg GccgaaagG C GaGugaGGu C u acagcu  B     6463                       amino stab2               1883   AAGCUGU G CCUUGGG   6232   20162   HBV-1883 Zin.Rz-7   c s c s c s a s agg GccgaaagG C GaGugaGGu C u acagcuu  B     6464                       amino stab2               2311   CCAAAU G CCCCUA   6233   20163   HBV-2311 Zin.Rz-6   u s a s g s g s gg GccgaaagG C GaGugaGGu C u auuugg  B     6465                       amino stab2               2347   ACUGUU G UUAGAC   6234   20164   HBV-2347 Zin.Rz-6   g s u s c s u s aa GccgaaagG C GaGugaGGu C u aacagu  B     6466                       amino stab2               2364   AGGCAG G UCCCCU   6235   20165   HBV-2364 Zin.Rz-6   a s g s g s g s ga GccgaaagG C GaGugaGGu C u cugccu  B     6467                       amino stab2               2364   GAGGCAG G UCCCCUA   6236   20166   HBV-2364 Zin.Rz-7   u s a s g s g s gga GccgaaagG C GaGugaGGu C u cugccuc  B     6468                       amino stab2               2388   UCCUC G CCUCGC   6237   20167   HBV-2388 Zin.Rz-6   g s c s g s a s gg GccgaaagGCGaGugaGGu C u gaggga  B     6469                       amino stab2               2393   CGCCUC G CAGACG   6238   20168   HBV-2393 Zin.Rz-6   c s g s u s c s ug GccgaaagG C GaGugaGGu C u gaggcg  B     6470                       amino stab2               2417   CGCCGC G UCGCAG   6239   20169   HBV-2417 Zin.Rz-6   c s u s g s c s ga GccgaaagG C GaGugaGGu C u gcggcg  B     6471                       amino stab2               2420   CGCGUC G CAGAAG   6240   20170   HBV-2420 Zin.Rz-6   c s u s u s c s ug GccgaaagG C GaGugaGGu C u gacgcg  B     6472                       amino stab2               2474   CAUAAG G UGGGAA   6241   20171   HBV-2474 Zin.Rz-6   u s u s c s c s ca GccgaaagG C GaGugaGGu C u cuuaug  B     6473                       amino stab2               381   GCUGGAU G UGUCUGC   6242   20172   HBV-381 Amb.Rz-7   g s c s a s g s aca gga L uc CCUUC aagga L uc C GGG   6474                       stab2   auccagc  B                 648   UAUGGGA G UGGGCCU   6243   20173   HBV-648 Amb.Rz-7   a s g s g s c s cca gga L uc CCUUC aagga L uc C GGG   6475                       stab2   ucccaua  B                 198   UGCUCGU G UUACAGG   6244   20174   HBV-198 Amb.Rz-7   c s c s u s g s uaa gga L uc CCUUC aagga L uc C GGG   6476                       stab2   acgagca  B                 377   UAUCGCU G GAUGUGU   6245   20175   HBV-377 Amb.Rz-7   a s c s a s c s auc gga L uc CCUUC aagga L uc C GGG   6477                       stab2   agcgaua  B                 378   AUCGCUG G AUGUGUC   6246   20176   HBV-378 Amb.Rz-7   g s a s c s a s cau gga L uc CCUUC aagga L uc C GGG   6478                       stab2   cagcgau  B                 383   UGGAUGU G UCUGCGG   6247   20177   HBV-383 Amb.Rz-7   c s c s g s c s aga gga L uc CCUUC aagga L uc C GGG   6479                       stab2   acaucca  B                 383   GGAUGU G UCUGCG   6248   20178   HBV-383 Amb.Rz-6   c s g s c s a s ga gga L uc CCUUC aagga L uc C GGG   6480                       stab2   acaucc  B                 648   AUGGGA G UGGGCC   6249   20179   HBV-648 Amb.Rz-6   g s g s c s c s ca gga L uc CCUUC aagga L uc C GGG   6481                       stab2   ucccau  B                 650   UGGGAGU G GGCCUCA   6250   20180   HBV-650 Amb.Rz-7   u s g s a s g s gcc gga L uc CCUUC aagga L uc C GGG   6482                       stab2   acuccca  B                 650   GGGAGU G GGCCUC   6251   20181   HBV-650 Amb.Rz-6   g s a s g s g s cc gga L uc CCUUC aagga L uc C GGG   6483                       stab2   acuccc  B         694   GCCAUUU G UUCAGUG   6252   20182   HBV-694 Amb.Rz-7   c s a s c s u s gaa gga L uc CCUUC aagga L uc C GGG   6484                       stab2   aaauggc  B                 699   UUGUUCA G UGGUUCG   6253   20183   HBV-699 Amb.Rz-7   c s g s a s a s cca gga L uc CCUUC aagga L uc C GGG   6485                       stab2   ugaacaa  B                 701   GUUCAGU G GUUCGUA   6254   20184   HBV-701 Amb.Rz-7   u s a s c s g s aac gga L uc CCUUC aagga L uc C GGG   6486                       stab2   acugaac  B                 710   UUCGUAG G GCUUUCC   6255   20185   HBV-710 Amb.Rz-7   g s g s a s a s agc gga L uc CCUUC aagga L uc C GGG   6487                       stab2   cuacgaa  B                 1525   CCACGG G GCGCAC   6256   20186   HBV-1525 Amb.Rz-6   g s u s g s c s gc gga L uc CCUUC aagga L uc C GGG   6488                       stab2   ccgugg  B                 1624   CACCGU G AACGCC   6257   20187   HBV-1624 Amb.Rz-6   g s g s c s g s uu gga L uc CCUUC aagga L uc C GGG   6489                       stab2   acggug  B                 2069   CACUCA G GCAAGC   6258   20188   HBV-2069 Amb.Rz-6   g s c s u s u s gc gga L uc CCUUC aagga L uc C GGG   6490                       stab2   ugagug  B                 2375   CCUAGAA G AAGAACU   6259   20189   HBV-2375 Amb.Rz-7   a s g s u s u s cuu gga L uc CCUUC aagga L uc C GGG   6491                       stab2   uucuagg  B                 2476   AUAAGGU G GGAAACU   6260   20190   HBV-2476 Amb.Rz-7   a s g s u s u s ucc gga L uc CCUUC aagga L uc C GGG   6492                       stab2   accuuau  B                 65   CCUGCUG G UGGCUCC   6261   20191   HBV-65 Amb.Rz-7   g s g s a s g s cca gga L uc CCUUC aagga L uc C GGG   6493                       stab2   cagcagg  B                 67   GCUGGU G GCUCCA   6262   20192   HBV-67 Amb.Rz-6   u s g s g s a s gc gga L uc CCUUC aagga L uc C GGG   6494                       stab2   accagc  B                 198   GCUCGU G UUACAG   6263   20193   HBV-198 Amb.Rz-6   c s u s g s u s aa gga L uc CCUUC aagga L uc C GGG   6495                       stab2   acgagc  B                 260   GACUCGU G GUGGACU   6264   20194   HBV-260 Amb.Rz-7   a s g s u s c s cac gga L uc CCUUC aagga L uc C GGG   6496                       stab2   acgaguc  B                 263   UCGUGGU G GACUUCU   6265   20195   HBV-263 Amb.Rz-7   a s g s a s a s guc gga L uc CCUUC aagga L uc C GGG   6497                       stab2     B                 377   AUCGCU G GAUGUG   6266   20196   HBV-377 Amb.Rz-6   c s a s c s a s uc gga L uc CCUUC aagga L uc C GGG   6498                       stab2   agcgau  B                 378   UCGCUG G AUGUGU   6267   20197   HBV-378 Amb.Rz-6   a s c s a s c s au gga L uc CCUUC aagga L uc C GGG   6499                       stab2   cagcga  B                 476   CCGUUU G UCCUCU   6268   20198   HBV-476 Amb.Rz-6   a s g s a s g s ga gga L uc CCUUC aagga L uc C GGG   6500                       stab2   aaacgg  B                 651   GGGAGUG G GCCUCAG   6269   20199   HBV-651 Amb.Rz-7   c s u s g s a s ggc gga L uc CCUUC aagga L uc C GGG   6501                       stab2   cacuccc  B                 677   UGGCUCA G UUUACUA   6270   20200   HBV-677 Amb.Rz-7   u s a s g s u s aaa gga L uc CCUUC aagga L uc C GGG   6502                       stab2   ugagcca  B                 685   UUUACUA G UGCCAUU   6271   20201   HBV-685 Amb.Rz-7   a s a s u s g s gca gga L uc CCUUC aagga L uc C GGG   6503                       stab2   uaguaaa  B                 702   UUCAGUG G UUCGUAG   6272   20202   HBV-702 Amb.Rz-7   c s u s a s c s gaa gga L uc CCUUC aagga L uc C GGG   6504                       stab2   cacugaa  B                 709   GUUCGUA G GGCUUUC   6273   20203   HBV-709 Amb.Rz-7   g s a s a s a s gcc gga L uc CCUUC aagga L uc C GGG   6505                       stab2   uacgaac  B                 710   UCGUAG G GCUUUC   6274   20204   HBV-710 Amb.Rz-6   g s a s a s a s gc gga L uc CCUUC aagga L uc C GGG   6506                       stab2   cuacga  B                 747   UAUGGAU G AUGUGGU   6275   20205   HBV-747 Amb.Rz-7   a s c s c s a s cau gga L uc CCUUC aagga L uc C GGG   6507                       stab2   auccaua  B                 1557   CCGUCU G UGCCUU   6276   20206   HBV-1557 Amb.Rz-6   a s a s g s g s ca gga L uc CCUUC aagga L uc C GGG   6508                       stab2   agacgg  B                 1881   CCAAGCU G UGCCUUG   6277   20207   HBV-1881 Amb.Rz-7   c s a s a s g s gca gga L uc CCUUC aagga L uc C GGG   6509                       stab2   agcuugg  B                 2347   ACUGUU G UUAGAC   6278   20208   HBV-2347 Amb.Rz-6   g s u s c s u s aa gga L uc CCUUC aagga L uc C GGG   6510                       stab2   aacagu  B                 2375   CUAGAA G AAGAAC   6279   20209   HBV-2375 Amb.Rz-6   g s u s u s c s uu gga L uc CCUUC aagga L uc C GGG   6511                       stab2   uucuag  B                 2378   GAAGAA G AACUCC   6280   20210   HBV-2378 Amb.Rz-6   g s g s a s g s uu gga L uc CCUUC aagga L uc C GGG   6512                       stab2   uucuuc  B                 2423   CGUCGCA G AAGAUCU   6281   20211   HBV-2423 Amb.Rz-7   a s g s a s u s cuu gga L uc CCUUC aagga L uc C GGG   6513                       stab2   ugcgacg  B                 2426   GCAGAA G AUCUCA   6282   20212   HBV-2426 Amb.Rz-6   u s g s a s g s au gga L uc CCUUC aagga L uc C GGG   6514                       stab2   uucugc  B                 2426   CGCAGAA G AUCUCAA   6283   20213   HBV-2426 Amb.Rz-7   u s u s g s a s gau gga L uc CCUUC aagga L uc C GGG   6515                       stab2   uucugcg  B                 2476   UAAGGU G GGAAAC   6284   20214   HBV-2476 Amb.Rz-6   g s u s u s u s cc gga L uc CCUUC aagga L uc C GGG   6516                       stab2   accuua  B                 2477   UAAGGUG G GAAACUU   6285   20215   HBV-2477 Amb.Rz-7   a s a s g s u s uuc gga L uc CCUUC aagga L uc C GGG   6517                       stab2   caccuua  B                 2477   AAGGUG G GAAACU   6286   20216   HBV-2477 Amb.Rz-6   a s g s u s u s uc gga L uc CCUUC aagga L uc C GGG   6518                       stab2   caccuu  B                 1607   UGCACGU G GCAUGGA   6287   20697   HBV-1607 Rz-7 allyl   u s c s c s a s ugc cUGAuGaggccguuaggccGaa Acgugca  B     6519                       stab1 (7/4)               1887   GUGCCU G GGGUGG   6288   20698   HBV-1887 Rz-6 allyl   c s c s a s c s cc cUGAuGaggccguuaggccGaa Aggcac  B     6520                       stab1 (6/4)               1607   GCACGU G GCAUGG   6289   20699   HBV-1607 Rz-6 allyl   c s c s a s u s gc cUGAuGaggccguuaggccGaa Acgugc  B     6521                       stab1 (6/3)               1607   UGCACGU G GCAUGGA   6290   20700   HBV-1607 Rz-7 allyl   u s c s c s a s ugc cUGAuGaggccguuaggccGaa Acgugca  B     6522                       stab1 (7/3)               1887   GUGCCU G GGGUGG   6291   20701   HBV-1887 Rz-6 allyl   c s c s a s c s cc cUGAuGaggccguuaggccGaa Aggcac  B     6523                       stab1 (6/3)               1887   UGUGCCU G GGGUGGC   6292   20702   HBV-1887 Rz-7 allyl   g s c s c s a s ccc cUGAuGaggccguuaggccGaa Aggcaca  B     6524                       stab1 (7/3)               313   CCAAAAU G CGCAGUC   5943   22798   HBV-313 Rz-7 Ome   gacugcg CUGAUGAggccguuaggccGAA Auuuugg  B     6541                       stab1               408   UCUUCCU G UGCAUCC   5946   22799   HBV-408 Rz-7 Ome   ggaugca CUGAUGAggccguuaggccGAA Aggaaga  B     6542                       stab1               1756   AGGAGGU G AGGUUAA   5950   22800   HBV-1756 Rz-7 Ome   uuaaccu CUGAUGAggccguuaggccGAA Accuccu  B     6543                       stab1               10   CUCCACC A CUUUCCA   5953   22770   HBV-10 CHz-7 Ome   uggaaag CUGAUGAggccguuaggccGAA Iguggag  B     6544                       stab1               335   UCCAGUC A CUCACCA   5954   22771   HBV-335 CHz-7 Ome   uggugag CUGAUGAggccguuaggccGAA Iacugga  B     6545                       stab1               273   CUUCUCU G AAUUUUC   5996   22645   HBV-273 Rz-7 allyl   g s a s a s a s auu cUGAuGagccguuaggcGaa Agagaag  B     6546                       stab1 (7/3-GUUA)               273   CUUCUCU G AAUUUUC   5996   22648   HBV-273 Rz-7 allyl   g s a s a s a s auu cUGAuGagccguuaggcGaa Agagaag  B     6547                       stab1 (7/3-GAAA)               273   CUUCUCU G AAUUUUC   5996   22650   HBV-273 Rz-7 allyl   g s a s a s a s auu cUGAuGagccguuaggcGaa Agagaag  B     6548                       stab1 (7/4-GAAA)               273   UUCUCU G AAUUUU   6643   22644   HBV-273 Rz-6 allyl   a s a s a s a s uu cUGAuGagccguuaggcGaa Agagaa  B     6549                       stab1 (6/3-GUUA)               273   UUCUCU C AAUUUU   6643   22647   HBV-273 RZ-6 allyl   a s a s a s a s uu cUGAuGagccgaaaggcGaa Agagaa  B     6550                       stab1 (6/3-GAAA)               273   UUCUCU C AAUUUU   6643   22649   HBV-273 Rz-6 allyl   a s a s a s a s uu cUGAuGagccguuaggcGaa Agagaa  B     6551                       stab1 (6/4-GAAA)               350   ACCUGUU G UCCUCCA   6644   22714   HBV-350 GCl.Rz-7   uggagga uGAUg gcauGcacuaugc gCg aacaggu  B     6552                       5ribo stab3               1253   CCUUUGU G UCUCCUC   6645   22715   HBV-1 253 GCl.Rz-7   gaggaga uGAUg gcauGcacuaugc gCg acaaagg  B     6553                       5ribo stab3               1856   UGUUCAU G UCCUACU   6646   22716   HBV-1 856 GCl.Rz-7   aguagga uGAUg gcauGcacuaugc gCg augaaca  B     6554                       5ribo stab3               1966   GCCUUCU G ACUUCUU   6647   22717   HBV-1 966 GCl.Rz-7   aagaagu uGAUg gcauGcacuaugc gCg agaaggc  B     6555                       5ribo stab3               3132   UCCUCCU G CCUCCAC   6648   22718   HBV-3132 GCl.Rz-7   guggagg uGAUg gcauGcacuaugc gCg aggagga  B     6556                       5ribo stab3               332   AUCUCCA G UCACUCA   6649   22742   HBV-332 Zin.Rz-7   ugaguga gccgaaagg C gagugaGGu C u uggagau  B     6557                       amino stab4               350   ACCUGUU G UCCUCCA   6644   22743   HBV-350 Zin.Rz-7   uggagga gccgaaagg C gagugaGGu C u aacaggu  B     6558                       amino stab4               410   UUCCUCU G CAUCCUG   6650   22744   HBV-410 Zin.Rz-7   caggaug gccgaaagg C gagugaGGu C u agaggaa  B     6559                       amino stab4               1253   CCUUUGU G UCUCCUC   6645   22745   HBV-1253 Zin.Rz-7   gaggaga gccgaaagg C gagugaGGu C u acaaagg  B     6560                       amino stab4               1754   GGAGGAG G UUAGGUU   6651   22746   HBV-1754 Zin.Rz-7   aaccuaa gccgaaagg C gagugaGGu C u cuccucc  B     6561                       amino stab4               407   AUCUUCC U CUGCAUC   6652   22772   HBV-407 CHz-7 Ome   gaugcag CUGAUGAggccguuaggccGAA Igaagau  B     6562                       stab1               1848   UCAUCUC A UGUUCAU   6653   22773   HBV-1848 CHz-7 Ome   augaaca CUGAUGAggccguuaggccGAA Iagauga  B     6563                       stab1               3124   GCAGCUC C UCCUCCU   6654   22774   HBV-3124 CHz-7 Ome   aggagga CUGAUGAggccguuaggccGAA Iagcugc  B     6564                       stab1               2165   GUCAGCU A UGUCAAC   6655   22801   HBV-2165 Rz-7 Ome   guugaca CUGAUGAggccguuaggccGAA Agcugac  B     6565                       stab1               2706   CCGUAUU A UCCAGAG   6656   22802   HBV-2706 Rz-7 Ome   cucugga CUGAUGAggccguuaggccGAA Aauacgg  B     6566                       stab1               350   ACCUGUU G UCCUCCA   6644   22966   HBV-350 Dz-7 stab3   uggagga  GGCTAGCTACAACGA aacaggu  B     6567               332   AUCUCCA G UCACUCA   6649   22967   HBV-332 Dz-7 stab3   ugaguga  GGCTAGCTACAACGA uggagau  B     6568               1840   CUGCCUA A UCAUCUC   6657   22968   HBV-1840 Dz-7 stab3   gagauga  GGCTAGCTACAACGA uaggcag  B     6569               358   UCCUCCA A UUUGUCC   6658   22969   HBV-358 Dz-7 stab3   ggacaaa  GGCTAGCTACAACGA uggagga  B     6570               1253   CCUUUGU G UCUCCUC   6645   22970   HBV-1253 Dz-7 stab3   gaggaga  GGCTAGCTACAACGA acaaagg  B     6571                   20599   SAC   c s g s a s u s gu CUAGuGacccgaaagggGaa Aagagg B     6572               273   CUUCUCU C AAUUUUC   5996   25516   HBV-273 UH.Rz-7 mod   g s a s a s a s auu cUgaugaggccguuaggccgaa agagaag  B     6589                       R18341 all r &gt;                       Ome active               273   CUUCUCU C AAUUUUC   5996   25535   HBV-273 UH.Rz-7 mod   g s a s a s a s auu cUagugacgccguuaggcggaa agagaag  B     6590                       R18341 all r &gt;                       Ome BAC                           25536   HBV-273 UH.Rz-7 mod   a s a s u s g s agg cUagugacgccguuaggcggaa aaaugaa  B     6591                       R24588 all r &gt;                       Ome SAC                           24588   HBV-273 UH.Rz-7   a s a s u s g s agg cUAGuGacgccguuaggcgGaa Aaaugaa  B     6592                       allyl stab1 inact3                       scram1 (GUUA SAC)                                                                                                    
     [0255]               TABLE XII                          Group Designation and Dosage levels for HBV transgenic mouse study                                             Number of   Duration of       Group   Compound   Dose   Mice   Treatment               1   RPI.18341   100 mg/kg/day*   10 F   14 days           (site 273)       2   RPI.18371   100 mg/kg/day*   10 F   14 days           (site 1833)       3   RPI.18418   100 mg/kg/day*   10 F   14 days           (site 1873)       4   RPI.18372   100 mg/kg/day*   10 F   14 days           (site 1874)       5   Saline control   100 mg/kg/day*   10 F   14 days       6   Untreated       10 F    0 days                            
     [0256]               TABLE XIII                          GROUP DESIGNATION AND DOSAGE LEVELS FOR HBV       TRANSGENIC MOUSE STUDY                                                 Duration                   Number of   of Treat-       Group   Compound   Dose   Mice   ment                                             1   RPI.18341   100   mg/kg/day*   15 (M or F)   14 days           (site 273)       2   RPI.18341   30   mg/kg/day*   15 (M or F)   14 days           (site 273)       3   RPI.18341   10   mg/kg/day*   15 (M or F)   14 days           (site 273)       4   RPI.18371   100   mg/kg/day*   15 (M or F)   14 days           site 1833       5   RPI.18371   30   mg/kg/day*   15 (M or F)   14 days           site 1833       6   RPI.18371   10   mg/kg/day*   15 (M or F)   14 days           site 1833       7   SAC   100   mg/kg/day*   15 (M or F)   14 days           (RPI.20599)       8   SAC   30   mg/kg/day*   15 (M or F)   14 days           (RPI.20599)       9   SAC   10   mg/kg/day*   15 (M or F)   14 days           (RPI.20599)       10   Saline   12   μl/day*   15 (M or F)   14 days           control       11   3TC ®   50   mg/kg/day, PO   15 (M or F)   14 days           control                            
     [0257] 
    
     
       
         0 
         
           
               
            
               
                   
               
               
                   
               
               
                 SEQUENCE LISTING 
               
            
           
           
               
            
               
                 The patent application contains a lengthy “Sequence Listing” section. A copy of the “Sequence Listing” is available in electronic form from the USPTO 
               
               
                 web site (http://seqdata.uspto.gov/sequence.html?DocID=20040054156). An electronic copy of the “Sequence Listing” will also be available from the 
               
               
                 USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).